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Abstract 
Skeletal muscle contains a large number of mitochondria, known for their production 
of ATP via oxidative phosphorylation, which is of vital importance for energy-
demanding muscle contraction. However, the mitochondria also have a plethora of 
other functions such as; calcium ion homeostasis, iron-sulphur cluster formation, 
redox signalling and apoptotic signalling, which are of similarly high importance to 
skeletal muscle function. As such, it is of little surprise that mitochondrial dysfunction 
has been linked to a large number of neuromuscular conditions as well as healthy 
skeletal muscle ageing and sarcopenia. However, the mechanisms by which the 
dysfunction occurs and its pathological and clinical relevance remains to be 
understood. This thesis therefore aims to advance the understanding of mechanisms 
and pathological significance of mitochondrial dysfunction in mitochondrial disease, 
myofibrillar myopathy, dysferlin myopathy and skeletal muscle ageing. 
The project was approached from three very different angles. Firstly, by exploring 
mitochondrial dysfunction in myofibrillar myopathy, dysferlinopathy and looking for 
potential links to disease pathology. Secondly, by attempting to understand 
mechanisms and factors effecting clonal expansion of mitochondrial DNA (mtDNA) 
mutations, which accumulate with age in post mitotic tissues in both healthy 
individuals and those affected by neuromuscular and neurodegenerative disorders. 
Both of these approaches were investigated using histochemical, 
immunocytochemical and single cell genetic methodologies. Finally, possible links 
between mitochondrial morphology, ultrastructure and function were investigated 
using electron microscopy techniques. 
This work provides novel insights into mitochondrial involvement in neuromuscular 
disease pathology.  Key findings include; the reduction of mitochondrial mass in 
myofibrillar myopathy, increased respiratory chain deficiency in some patients with 
dysferlinopathy, the spectrum of mitochondrial ultrastructural defects in mitochondrial 
myopathy, the anisotropic nature of the skeletal muscle mitochondria, the perinuclear 
origins of mtDNA deletions and their clonal expansion due to retrograde signalling 
and mitochondrial biogenesis. 
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Chapter 1. Introduction 
1.1 Mitochondrial origins 
Mitochondria reside in almost every eukaryotic cell and produce adenosine 
triphosphate (ATP) to power normal cellular function. Mitochondrial origins within 
eukaryotic cells are thought to have arisen due to an endosymbiotic relationship 
(Sagan, 1967). 
There are two potential theories proposed to explain eukaryotic origins. One 
hypothesis suggests that nucleated Archeazoa diverged from prokaryotes, with 
Archeazoa including the host for the mitochondrial endosymbiont (Cavalier-Smith, 
1987; Moreira and Lopez-Garcia, 1998). This hypothesis is based on the small 
subunit ribosomal RNA (rRNA) phylogenetic tree. The alternative suggests that the 
endosymbiotic event occurred before the diversion of eukaryotes from prokaryotes, 
with the subsequent diversion and development of a nucleus forming the eukaryotic 
cell (Martin and Muller, 1998). This second theory is now thought to be more 
plausible, since many genes in eukaryotic nuclei are more closely related to 
eubacteria homologues than archaebacterial homologues. 
Although there is debate over the host cell, the endosymbiont has been easier to 
trace phylogenetically. The endosymbiont is thought to be an α-proteobacteria, due 
to the similarities between present day mitochondrial DNA (mtDNA) and some of the 
genes encoded by the α-proteobacteria genome (Esser et al., 2004). Phylogenetic 
analysis of cytochrome b oxidase and cytochrome c oxidase genes of Rickettsia 
prowazekii confirmed the ancestor of mitochondria to be α-proteobacteria of the 
Rickettsiaceae family (Sicheritz-Ponten et al., 1998).  
 
1.2 Mitochondrial structure 
Mitochondria are double membrane organelles, with the inner mitochondrial 
membrane (IMM) enclosing the matrix and the outer mitochondrial membrane (OMM) 
enclosing the intermembrane space (IMS). Early work on mitochondrial structure 
produced the baffle model of cristae structure (Palade, 1953), suggesting that the 
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IMM forms wide invaginations. This has been found to be inaccurate with the cristae 
actually being connected to the IMS by tubular cristae junctions (Daems and Wisse, 
1966). In addition to this, regular cristae structure are known to take two formations; 
tubular and lamella-like, which are both connected to the IMS by 30 nm tubular 
connections (Mannella et al., 1997; Perkins et al., 1997; Frey and Mannella, 2000; 
Nicastro et al., 2000).  Figure 1.1 shows a schematic representation of mitochondrial 
structure along-side an electron micrograph.  
 
 
Figure 1.1 Normal mitochondrial ultrastructure. Electron micrograph (left) and 
schematic (right) showing normal mitochondrial ultrastructure. Scale bar; 200 nm.
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The double membrane provides strict transport regulation for metabolites and ions 
both into and out of the mitochondria. The OMM is similar in composition to that of 
the cell membrane, thus allowing lipid soluble molecules to diffuse into the IMS. In 
comparison, proteins and hydrophilic molecules are transported across the OMM 
through protein channels such as the voltage-dependent anion channel (VDAC) 
(Ponnalagu and Singh, 2016). 
The IMM is less permeable than the OMM, providing the stringency of mitochondrial 
transport into and out of the mitochondria, which is necessary for oxidative 
phosphorylation. In comparison to the OMM, the IMM has a greater ratio of protein to 
phospholipid, 70% protein to 30% lipid (Fleischer et al., 1961), due to the large 
number of proteins required for metabolic pathways and high levels of cardiolipin. 
The IMM forms a series of invaginations, and consists of three topologically different 
regions.  The inner boundary membrane is situated closest to the OMM, a large 
percentage of respiratory chain complex II are localised to the inner boundary 
membrane (Wilkens et al., 2013; Cogliati et al., 2016). The inner boundary 
membrane bends inwards at regular intervals forming cristae junctions; tubular 
structures, which are tightly regulated by the mitochondrial cristae organising system 
(MICOS) proteins. The final region is the cristae membrane, which delves into the 
mitochondrial matrix space. Respiratory chain complexes I, III and IV as well as ATP 
synthase localise to the cristae membrane (Wilkens et al., 2013; Cogliati et al., 2016). 
ATP synthase is known to form dimers at the apex of the cristae (Paumard et al., 
2002; Dudkina et al., 2005; Strauss et al., 2008). ATP synthase dimerisation and 
cristae morphology is described in detail in 6.1.2. 
The matrix is a continuous regulated environment where many mitochondrial 
biochemical processes, such as iron-sulphur (Fe-S) cluster formation and the 
tricarboxylic acid (TCA) cycle, occur. Multiple copies of the nucleoid packaged 
mtDNA are found in the matrix along with the machinery required for transcription 
and translation. 
Nuclear encoded proteins, possessing a mitochondrial targeting sequence, can enter 
the mitochondria via the outer (TOM) and inner (TIM) mitochondrial translocases 
(Herrmann and Neupert, 2000; Rehling et al., 2004). Depending on the protein 
function and its targeting sequence, these can be targeted to the matrix, IMS or be 
inserted into the OMM or IMM (Rehling et al., 2004). Further detail on the 
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organisation and regulation of normal mitochondrial structure can be found in 
Chapter 6, along with analysis and discussion of abnormal mitochondrial 
ultrastructure. 
 
1.3  Mitochondrial dynamics and morphology 
Mitochondria were originally considered to be discrete, bean shaped organelles and 
are still commonly depicted in this way in scientific textbooks. However, it has now be 
known for some time that the mitochondria are in fact highly dynamic organelles, 
constantly undergoing fission and fusion (Bereiter-Hahn, 1978; Bereiter-Hahn and 
Voth, 1994). The balance of these determines their morphology and subsequently 
function. The frequency of these events alters mitochondrial morphology and in turn 
mitochondrial morphology can be used to predict the likelihood of fission or fusion 
events (Westrate et al., 2014). Maintaining the balance is crucial and may shift 
dependent on cellular requirements. With increased mitochondrial fusion increasing 
mtDNA stability (Chen et al., 2010) but allowing functional complementation to 
mitigate cellular stress and fission allowing selective removal of damaged 
mitochondria (Youle and van der Bliek, 2012). Defects in fission and fusion have 
been associated with numerous human diseases e.g. Parkinson’s disease (Van Laar 
and Berman, 2009), Alzheimer’s disease (Santos et al., 2010) and Charcot-Marie-
Tooth (CMT) disease (Palau et al., 2009).  
Mitochondrial dynamics have been found to vary substantially between different cell 
types (Kuznetsov et al., 2009), with some cell types such as neurons having highly 
dynamic mitochondria while skeletal and cardiac mitochondria are less so. To date, 
the understanding of how frequently fission and fusion events occur in intact 
myofibres is limited and cultured myoblasts and myotubes do not have the regular 
lattice-like structure of mitochondrial arrangement found in fully developed muscle so 
are unlikely to be representative of in vivo mitochondrial dynamics. So far, the best 
models of mitochondria dynamics in skeletal muscle are live cell imaging of intact 
mouse muscle (Pham et al., 2012), demonstrating that mitochondria are dynamic and 
fusion competent despite their static appearance. 
  Chapter 1 
5 
 
1.1.1 Fission 
Fission is the process by which one mitochondrion divides to form two mitochondria 
(Figure 1.2). Early work to identify the fission machinery was completed in yeast 
where Dnm1 and Fis1 were identified (Bleazard et al., 1999; Mozdy et al., 2000). 
Mammalian homologues of these proteins, dynamin related protein 1 (Drp1) and 
mitochondrial fission 1 protein (Fis1), were subsequently identified (Smirnova et al., 
2001; James et al., 2003). Functional studies have demonstrated that knockdown of 
either protein causes mitochondria to elongate and become hyperfused whilst over 
expression fragments the mitochondrial network (Lee et al., 2004).  
 
Figure 1.2 Mitochondrial fission. Schematic representing mitochondrial fission and 
demonstrating the localisation of Dynamin related protein 1(Drp1) and mitochondrial 
fission 1 protein (Fis1). Fis1 is found to be evenly distributed across the full OMM and 
may play a role in Drp1 recruitment. Drp1 forms a helix around the mitochondrion. 
Contraction of this helix septates the membranes forming two mitochondria. 
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In mammals, Drp1 is recruited from the cytosol and oligomerises forming a helix 
which, through the process of GTP hydrolysis constricts the mitochondrion ultimately 
resulting in membrane scission (Legesse-Miller et al., 2003; Mears et al., 2011). Drp1 
recruitment and function are highly regulated by a number of post translational 
modifications (Chang and Blackstone, 2010). Furthermore, numerous proteins have 
been found to interact with Drp1 and are thus thought to play a role in its recruitment. 
These include Mff, Fis1, MID49 and MID51 (Mozdy et al., 2000; Loson et al., 2013). 
Recently, Septin 2 was found to localise to fission sites and interact with Drp1, 
depletion of Septin 2 significantly decreases the recruitment of Drp1 thus confirming 
its importance (Pagliuso et al., 2016). The exact mechanism and roles that all of the 
proteins mentioned above play is not yet completely resolved. 
Mitochondrial fission is important for the isolation and selective degradation of 
damaged mitochondria by mitophagy. A reduction in membrane potential results in 
fission, if the membrane potential remains low the mitochondrion cannot fuse back 
into the mitochondrial network and is targeted for mitophagy (Twig et al., 2008), as 
described in 1.4.2. 
Due to the double membrane of the mitochondria, the fission process is a two-step 
process, requiring independent fission of the inner and outer membranes. Although 
the mechanism of mitochondrial fission is not yet completely understood, the proteins 
involved are well characterised. 
 
1.1.2 Fusion 
Fusion is the process by which two mitochondria combine to form a single 
mitochondrion with continuous inner and outer membranes (Figure 1.3). OMM fusion 
is regulated by GTPases MFN1 and MFN2, which form homo- or heterodimers (Chen 
et al., 2003), that are all competent for fusion (Chen et al., 2005). Both MFN1 and 
MFN2 perform similar roles but are both required for successful fusion, though they 
have differential importance in different tissues (Chen et al., 2003; Chen et al., 2005). 
MFN2 has also been demonstrated to perform a number of additional roles for which 
MFN1 cannot compensate e.g. tethering of mitochondria to the endoplasmic 
reticulum (de Brito and Scorrano, 2008) and normal glucose homeostasis (Sebastian 
et al., 2012). The process of OMM fusion requires hydrolysis of GTP by the GTPase 
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domain, which induces a conformational change allowing the membranes to fuse 
(Chan, 2006). 
IMM fusion is thought to be mediated by OPA1 (Cipolat et al., 2004), which localises 
to the IMM. OPA1 undergoes alternative splicing and thus can exist in a number of 
functionally different isoforms (Delettre et al., 2001). Upon low membrane potential or 
low ATP levels, Oma1 is activated leading to the proteolytic cleavage of Opa1 and 
preventing fusion (Head et al., 2009).  
Loss of the fusion machinery has been associated with disease in a number of 
tissues including heart (Papanicolaou et al., 2011), brain (Chen et al., 2007)  and 
muscle (Chen et al., 2010). However, the importance of the fusion machinery varies 
in a tissue specific manner, as such some defects, such as knockout of MFN2 in 
kidney, only result in a phenotype when the mitochondria are stressed (Gall et al., 
2012). 
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Figure 1.3 Mitchondrial fusion. Schematic representing mitochondrial fusion and 
demonstrating the localisation of Opa1 and Mfn1/2. Binding of Mfn1/2 to the 
membrane and dimerisation is necessary for tethering of the two mitochondria prior 
to GTP hydrolysis and fusion of the outer mitochondrial membrane. Opa1 mediates 
fusion of the inner mitochondrial membrane.HR1 and HR2; heptad repeat region 1 
and 2. 
 
1.1.3 Mitochondrial transport 
Along with fission and fusion, mitochondrial dynamics also include small Brownian-
like movements and transport over longer distances within the cell. However, the 
degree of motility varies on a tissue-specific basis, in some cells such as neurons 
and pancreatic cells, mitochondria can move quickly and continuously (Boldogh and 
Pon, 2007). Mitochondrial transport is particularly important in neurons, where it is 
used to balance changing energy needs of the subcellular locations (Hollenbeck and 
Saxton, 2005). 
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In neurons anterograde mitochondrial transport takes mitochondria from the cell body 
into the axon towards the synapse and is generated by Kinesin-1 (Hurd and Saxton, 
1996; Glater et al., 2006), which interacts with Miro through adapter protein Milton 
(Stowers et al., 2002; Glater et al., 2006), in a calcium dependent manner (Wang and 
Schwarz, 2009). Retrograde transport of mitochondria back to the cell body is 
achieved by a dynein motor (Martin et al., 1999). 
However, in mature, cardiac and skeletal muscle, mitochondrial transport is not 
observed. In mice with photoactivatable mitochondria the mitochondrial appear 
immotile (Eisner et al., 2014) and in rat cardiomyocytes it has been demonstrated 
that mitochondria do not make large scale movements, only Brownian-like vibrations 
(Beraud et al., 2009). This may largely be due to the dependence of mitochondria on 
interactions with the cytoskeleton which gives the skeletal muscle mitochondria a 
crystal-like organisation (Vendelin et al., 2005). Specifically, mitochondria are known 
to be localised to the z-band in skeletal muscle and are tethered here by a protein 
complex containing desmin and plectin (described in more detail in 1.8.1), other 
members of this complex have yet to be identified.  
Work in cultured myoblasts has demonstrated that many of the proteins required for 
transport of mitochondria in other cell types are also expressed in myoblasts, 
although some kinesin heavy chain isoforms are not expressed (Iqbal and Hood, 
2014). To date, this is the only work that has looked at mitochondrial transport in 
muscle and due to the change in cell architecture and mitochondrial positioning 
during myoblast differentiation and skeletal muscle development, the extent of 
mitochondrial transport in skeletal muscle in vivo is largely unknown.  
 
1.4 Oxidative phosphorylation and ATP production 
1.2.1 TCA cycle 
The generation of ATP for cellular energy is a multi-step process starting with the 
anaerobic glycolysis, which feeds into the tricarboxylic acid cycle (TCA) or Kreb’s 
cycle in the mitochondrial matrix, before reaching the respiratory chain and oxidative 
phosphorylation. Anaerobic glycolysis Equation 1.1, which occurs in the cytosol, 
produces two molecules of pyruvate (Berg et al., 2012b). Pyruvate is either imported 
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into mitochondria, to the Kreb’s cycle, or used to restore cytoplasmic NAD+ pools for 
further glycolysis. The process of creating NAD+ is either via fermentation in yeast or 
reduction of pyruvate to lactate by lactate dehydrogenase. 
 
Glucose + 2[NAD+] + 2[ADP] + 2[Pi] → 2 [pyruvate] 2[NADH] + 2[H+] + 2[ATP] + 
2[H2O] 
Equation 1.1 Glycolysis reaction (Berg et al., 2012a). 
 
NADH molecules created by glycolysis cannot cross the IMM as such electrons are 
transferred via the glycerol 3-phosphate shuttle (Berg et al., 2012a). NADH donates 
2e- to dihydroxyacetone in the cytosol, producing NAD and glycerol 3-phophate. 
Glycerol 3-phosphate dehydrogenase oxidises glycerol 3-phophate back to 
dihydroxyacetone and the 2e- are transferred to flavin adenine dinucleotide (FAD) to 
produce FADH2. FADH2 is oxidised and ubiquinone (Q) reduced to ubiqinol (QH2) in 
the matrix (Berg et al., 2012a). 
The Kreb’s cycle or tricarboylic acid (TCA) cycle occurs in the mitochondrial matrix. 
The initial reaction is a conversion of pyruvate to acetyl CoA, catalysed by pyruvate 
dehydrogenase (Equation 1.2) (Berg et al., 2012c). Acetyl CoA for the Kreb’s cycle 
can also be produced via β-oxidation of fatty acids. 
 
Pyruvate + CoA + NAD+ → Acetyl-CoA + NADH + H+ + CO2 
Equation 1.2 Pyruvate decarboxylation reaction catalysed by pyruvate 
dehydrogenase (Berg et al., 2012c).  
 
The Kreb’s cycle (Krebs and Johnson, 1937) is a series of reactions that produces 
one molecule of ATP and CO2 plus three NADH and two FADH2 electron carriers that 
are subsequently involved in oxidative phosphorylation (Equation 1.3) (Berg et al., 
2012c). Oxaloacetate and Acetyl-CoA are converted to citrate catalysed by citrate 
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synthesis. A series of reactions then produces NADH, FADH2 and ATP and returns 
citrate to oxaloacetate (Berg et al., 2012c). 
 
Acetyl-CoA + 3[NAD+ + FAD + ADP + Pi + 2[H2O] → CoA + 3[NADH] + 2[H+] + 
FADH2 + ATP + 2[CO2] 
Equation 1.3 The Kreb's cycle overall reaction 
 
1.2.2 Oxidative phosphorylation 
The final stage of respiration is oxidative phosphorylation which couples the transport 
of electrons along the respiratory chain complexes I to IV with the translocation of 
protons across the IMM (Figure 1.4). Thus producing a chemiosmotic gradient, which 
results in the flow of electron back through ATP synthase, generating the energy 
required to produce ATP. This coupling of electron transport and ATP production was 
first described by Mitchell in 1961 and is termed the chemisomotic theory (Mitchell, 
1961). 
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Figure 1.4 Oxidative phosphorylation. Respiratory chain complexes I-IV are 
embedded into the inner mitochondrial membrane (IMM). Oxidative phosphorylation 
couples electron transport and proton translocation to ATP generation. Electrons can 
enter the electron transport chain at complex I or complex II and are shuttled to 
complex IV via cytochrome c. The transfer of electrons provides the energy to 
translocate protons from the matrix to the intermembrane space. Complex V or ATP 
synthase uses the proton gradient to produce ATP. 
 
1.2.3 Complex I or NADH: Ubiquinone Oxidoreductase 
Complex I was first isolated in 1961 (Hatefi et al., 1961). Composed of 45 subunits 
(of which seven are mitochondrial-encoded), complex I is the largest respiratory 
chain complex (almost 1000 kDa) (Zhu et al., 2016). Fully assembled, complex I is L 
shaped, with a hydrophobic arm embedded in the IMM and one arm protruding into 
the matrix. 
Complex I, schematically represented in Figure 1.5, can be subdivided into three 
functional modules (Brandt, 2006); the N-module, Q-module and P-module. The N-
module is located in the matrix arm and binds NADH oxidising it, transferring two 
electrons to a flavin mononucleotide (FMN) to form FMNH2. The electrons are then 
transferred to Q via a chain of Fe-S clusters in the Q modules, also located in the 
matrix arm (Sazanov, 2007). Within the Fe-S clusters, electrons transiently reduce 
Fe3+ to Fe2+ prior to oxidation back to Fe3+. Transfer of electrons to QH2 also requires 
2H+ from the matrix (Sazanov, 2007), the product QH2 is released into the IMS. The 
  Chapter 1 
13 
 
reduction of Q is coupled to proton translocation and can be inhibited for 
experimental purposes by rotenone, piericidin A, barbiturates (e.g. Amytal), Demerol 
and mercuricals. The overall reaction catalysed by complex I, is presented below 
(Equation 1.4). The final module is the P-module, which is IMM embedded and 
contains the seven mtDNA encoded subunits (Anderson et al., 1981), acts as a 
proton pump. The transfer of electrons in the matrix arm, causes a conformational 
change in both arms, opening the channel and permitting the translocation of protons 
out of the matrix and across the IMM (Efremov et al., 2010; Efremov and Sazanov, 
2011). 
 
 
Figure 1.5 Complex I. The schematic shows a simplified structure of respiratory 
chain complex I. Electrons are accepted from NADH and transferred to FMN. They 
are shuttled along a chain of iron sulphur clusters (Fe-S) and transferred to 
ubiquinone (Q). This shuttling of electrons is coupled to the transfer of a proton from 
the matrix to the intermembrane space across the inner mitochondrial membrane. 
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NADH + Q + 5[H+]matrix → NAD+ + QH2 + 4[H+]cytoplasm 
Equation 1.4 Complex I reaction (Berg et al., 2012b).  
 
Recently, complexasome profiling was implemented to study the assembly of 
complex I (Guerrero-Castillo et al., 2016) and demonstrated a stepwise assembly. 
PP-b is the central building block to which Q/PP-a and PD-a are added. However, data 
so far is inconclusive as to the order these join the complex. Subsequently, PD-b is 
attached completing the Q and P modules. The final addition is the N-module, along 
with a few remaining accessory subunits. Of note, NDUFB8 belonging to PD-b is a 
commonly targeted subunit when assaying complex I levels via immunofluorescent 
protocols(Grünewald et al., 2014; Rocha et al., 2015) or western blotting (Lopez-
Fabuel et al., 2016). 
 
1.2.4 Complex II or succinate:ubiquinone oxidoreductase dehydrogenase 
Complex II (124kDa), was initially discovered by Thunberg in 1909, solubilised by 
Morton in 1950 and purified in 1971 (Davis and Hatefi, 1971; Hatefi, 1985). The 
enzymatic component is called succinate dehydrogenase or (SDH). Complex II 
consists of only four subunits (Figure 1.6), which are completely encoded by the 
nuclear genome. SDHC and SDHD are embedded in the IMM and SDHA and SDHB 
which are in the matrix and form the catalytic core (Hagerhall, 1997; Sun et al., 
2005). Complex II is not involved in the transfer of H+ across the IMM, but catalyses 
the oxidation of succinate to fumarate and transfer of the electrons to ubiquinone via 
FAD and Fe-S clusters in SDHB (Hagerhall, 1997), thus acting as the second and 
last point of entry for electrons into the respiratory chain. The generation of fumarate 
is important for the TCA cycle.  
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Figure 1.6 Complex II. Schematic shows a simplified structure of complex II including 
pathway of electron transport. Complex II is the second point of entry for electrons 
into the oxidative phosphorylation system. Electrons are transferred from succinate to 
FAD, reducing it to FADH2. Electrons are then shuttled along Fe-S clusters to 
ubiquinone. 
 
 
Succinate +FAD +2[H+] +Q → Fumerate +FADH2 + Q → fumerate +FAD +QH2 
Equation 1.5 Complex II reaction (Berg et al., 2012b). 
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1.2.5 Complex III or Ubiquinol cytochrome c oxidoreductase 
Complex III, was first purified from bovine heart mitochondria in 1961 (Hatefi, 1976) 
and subsequent crystallisation showed that it consists of 11 subunits (Xia et al., 
1997; Iwata et al., 1998), a simplified schematic is presented in Figure 1.7. Of the 11 
subunits only cytochrome b is mitochondrially encoded. 
Complex III catalyses the transfer of electrons from ubihydroquinone (QH2) to 
cytochrome c as part of the Q cycle (Mitchell, 1976), which processes two QH2 
molecules in succession (Equation 1.4). For each QH2, 2H+ are released into the 
IMS, and the electrons diverge down different routes. One electron is passed to 
cyctochrome c via the Riske Fe-S cluster and cytochrome c1 and the second to 
cytochrome b where it binds to first low affinity haem (bL), then high affinity haem (bH) 
before reducing ubiquinone to a semiquinone intermediate. The process is repeated 
again and semiubiquione is reduced to QH2. 
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Figure 1.7 Complex III. Schematic demonstrates a simplified structure of complex II, 
electron pathway and translocation of protons. Electrons are shuttled from 
ubihydroquinone via sulphur clusters and haem to ubiquinone and cytochrome c. 
This shuttling of electrons is coupled with the translocation of protons from the matrix 
to the intermembrane space. 
 
 
2[QH2] + Q + 2[Cyt c]ox + 2[H+]matrix → 2 [Q] +QH2 + 2[Cyt c]red +4[H+]cytoplasm 
Equation 1.6 Complex III reaction (Berg et al., 2012b). 
 
1.2.6 Complex IV or cytochrome c oxidase (COX)  
Complex IV or cytochrome c oxidase (COX) is the final complex of the electron 
transport chain and is responsible for the reduction of oxygen to water. COX is 
comprised of 13 subunits (Figure 1.8), of which three (MTCOI, MTCOII and MTCOIII) 
are mitochondrially encoded (Tsukihara et al., 1996).  
Electrons from cytochrome c are transferred via two haem groups and two copper 
centres (CuA and CuB) to O2. Overall, four cytochrome c molecules are oxidised, 
donating four electrons. One passes via CuA and haem a to haem a3 before reducing 
CuB. The next passes via CuA to haem a, allowing O2 to bind to CuB and haem a 
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generating a peroxide bridge (Faxen et al., 2005). The same process happens with 
the next two electrons, but this time 2H+ binding cleaves the peroxide bridge and a 
further two 2H+ to complete the reduction of O2 to H2O (Faxen et al., 2005). 
 
 
Figure 1.8 Complex IV. Schematic demonstrates simplified structure transport of 
electrons and translocation of protons. Electrons from cytochrome c are transferred 
via two heam groups and two copper centres, allowing the binding of molecular 
oxygen and hydrogen atoms to form water. The shuttling of electrons is also couples 
to the translocation of protons from the matrix to the intermembrane space. 
 
 
4[Cyt c]red + 8[H+]matrix +O2 → 4[Cyt c]ox + 2H2O + 4[H+]cytoplasm 
Equation 1.7 Complex IV reaction (Berg et al., 2012b). 
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1.2.7 Complex V or ATP synthase  
ATP synthase catalyses the final step in the synthesis of ATP. ATP synthase uses 
the electrochemical gradient generated by complexes I, III and IV to drive rotation of 
the F0 rotary ring phosphorylating ADP to form ATP. ATP synthase consists of the F0 
portion which is situated in the IMM and the F1 portion which protrudes into the matrix 
space (Figure 1.9). F0 is made up of a c-ring and subunits a, b, d, F6 and oligomycin 
sensitivity-conferring protein (OSCP), in addition subunits e, f, g and A6L are all 
associated with F0 (Jonckheere et al., 2012). Subunits a and A6L are the only two 
ATP synthase subunits to be encoded for by the mtDNA genes, ATP6 and ATP8 
respectively (Anderson et al., 1981). F1 consists of three alternating α and β subunits 
plus one γ, one δ and one ε subunit. 
 
Figure 1.9 Complex V or ATP Synthase. Schematic shows subunit arrangement, 
translocation of protons and generation of ATP. ATP synthase catalyses the 
synthesis of ATP from ADP and inorganic phosphate. This reaction is powered by the 
transport of protons through ATP synthase from the intermembrane space to the 
matrix. This flow occurs due to an electrochemical gradient generated by complexes I 
to IV. The silhouette to the left demonstrates the F1 and F0 portions. 
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The proton gradient establishes a proton motive forces, and movement of protons 
through the c-ring is coupled with the rotation of two rotary motors; the c-ring (F0) and 
γ, δ and ε subunit. As F1 rotates, the β subunits to which ADP and Pi are bound 
undergoes a conformational change (Noji et al., 1997). Thus, the turning generates 
the energy required to phosphorylate ADP and release ATP. A full 360° rotation is 
coupled to the transfer of eight protons and produces three ATP molecules (Watt et 
al., 2010). ATP synthase can also reverse this process hydrolysing ATP, when 
mitochondrial membrane potential falls and pumping protons across the IMM to 
restore membrane potential. 
ATP synthase has been demonstrated by electron cryo-tomography to dimerise at 
the apex of the cristae (Strauss et al., 2008), such a dimersation induces a bend in 
the IMM. The cristae acts as a proton trap and ATP synthase dimerisation increases 
the electron-gradient, creating a proton sink at the apex of the cristae. Thus, leading 
to efficient ATP synthesis under proton limiting conditions. 
 
1.2.8 Supercomplexes  
Respiratory chain complexes I, II and IV, assemble into supercomplexes which 
improves complex stability and it has been hypothesised may reduce ROS 
production and lead to more efficient substrate channelling. Initially, a solid state 
model was proposed, suggesting that the complexes were organised in a large 
particle called the oxasome (Chance et al., 1963). However, later findings of isolated 
complexes and the diffusion couples process of electron transport weaken this 
hypothesis. Subsequently, a fluid-state model was proposed (Hackenbrock et al., 
1986), before the proposition of supercomplexes, for which there is now substantial 
experimental support (Schagger and Pfeiffer, 2000). Thus, it is now believed that 
majority of complex I, is found bound as a complex II dimer and complex IV (known 
as the respirasome), with a smaller proportion just bound to a complex III dimer. 
There is also another supercomplex with dimerised complex III bound to complex IV 
(Schagger and Pfeiffer, 2000; Schägger and Pfeiffer, 2001). In addition, use of 
cryoEM has demonstrated that the respirasome is found in two structural 
conformations ‘tight’ and ‘loose’, for which it is unclear whether there is a transition 
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between the two states or if these are structurally different conformations (Gu et al., 
2016; Letts et al., 2016). 
 
1.5 Mitochondrial functions 
Mitochondria are commonly referred to as ‘the powerhouse of the cell’ however 
mitochondria have long been known to perform functions, aside from ATP, 
production that are just as important to cell survival. These functions include calcium 
homeostasis, iron sulphur (Fe-S) cluster formation and a role in apoptotic signalling 
each of which is described in more detail below. 
 
1.3.1 Calcium ion buffering 
Calcium (Ca2+) is an important cellular signal and as such cytosolic Ca2+ 
concentration is fundamental to numerous cellular processes. Ca2+ buffering in the 
cell is regulated by modulating translocation of Ca2+ into and out of the mitochondria. 
Ca2+ uptake by the mitochondria is achieved via the Ca2+ uniporter in the IMM in an 
electrochemical gradient dependent manner (Baughman et al., 2011; De Stefani et 
al., 2011) and release is via an ion exchange with Na+ (Palty et al., 2010). Findings 
suggest this occurs in a 3Na+/1Ca2+ ratio (Boyman et al., 2013), with the 
mitochondrial membrane potential and Na+ concentration gradient driving calcium 
release. 
Control of intracellular Ca2+ concentration in muscle is critically important for 
controlling muscle contraction. Motor neurons innervate muscle forming 
neuromuscular junctions at which an action potential opens Ca2+ channels causing 
an influx of extracellular Ca2+ into the neuron triggering release of acetylcholine into 
the synaptic cleft. Acetylcholine binds to receptors on the post-synaptic cleft and 
induces Na+ and K+ channel opening and depolarisation of the sarcolemmal 
membrane and opening of L-type Ca2+ channels in the sarcoplasmic reticulum (SR) 
triggering the release of Ca2+ into the cytosol. This cytosolic Ca2+ is increased which 
initiates actin/myosin cross bridging and movement of the myosin head to cause 
muscle contraction (Gehlert et al., 2015). As the depolarisation spreads across the 
sarcolemma, it reduces the voltage dependent activation of L-type Ca2+ channels and 
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conformational change closes the channel. Muscle relaxation requires reuptake of 
calcium by the SR via ATP-dependent Ca2+ pumps, sarcoplasmic/endoplasmic 
reticulum calcium ATPase (SERCA) 1 and 2 (Brini and Carafoli, 2009). 
 
1.3.2 Iron Sulphur cluster formation 
Iron Sulphur clusters are an essential cofactor for OXPHOS and are present in 
oxidative phosphorylation complexes I-IV. Within the complexes iron sulphur clusters 
facilitate the transfer of electrons by repeated redox reactions. Reduced iron is 
transported into the matrix by mitoferrins (Zhu et al., 2016). Following this, iron is 
donated to Isu1 and Nfu scaffold proteins via frataxin and an iron sulphur cluster is 
formed (Tong et al., 2003; Yoon and Cowan, 2003). The sulphur for the cluster is 
provided in the form of sulphide ions generated from the release of sulphur from 
cysteine by cysteine dysulphurase (Tong and Rouault, 2000). 
 
1.3.3 Apoptosis 
Apoptosis is the process of controlled cell death which was initially expected to be a 
fully nuclear driven event (Kerr et al., 1972). Contrary to this, it is now known that the 
mitochondria have a significant role in the control of this process (Estaquier et al., 
2012). A reduction in mitochondrial membrane potential and mitochondrial fission is 
temporally coupled to apoptosis with mitochondrial network fragmentation occurring 
prior to apoptosis, and Dnmp1 (yeast DRP1 homologue) has been found to mediate 
fragmentation and apoptosis like cell death in yeast (Fannjiang et al., 2004). 
Furthermore, Drp-deficient cells with hyperfused mitochondria have been found to be 
resistant to apoptosis (Frank et al., 2001). 
Apoptosis is regulated in part by the Bcl-2 family of proteins, specifically pro-
apoptotic (e.g. Bax and Bak) and anti-apoptotic (e.g. Bcl-2) which interact at the 
mitochondrial IMM (Cory and Adams, 2002). Activation of Bax and Bak or inhibition 
of Bcl-2 by the Bh3 family of proteins regulates the release of pro-apoptotic factors 
including cytochrome c from the IMS into the cytosol (Zong et al., 2001). 
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Factors including cytochrome c interact with apoptosis proteinase-1 activating factor 
(Aparf-1) and caspase-9 in an ‘apoptosome’, which induces the caspase cascade 
(Wang and Youle, 2009). Apoptosis can be inhibited at the apoptosome level but 
inhibition can be relieved by proteins such as Smac and DIABLO which are also 
mitochondrially derived (Srinivasula et al., 2001). Furthermore, apoptosis inducing 
factor which is responsible for chromatin condensation and degradation of nuclear 
DNA is also released by the mitochondria (Candé et al., 2002). 
The exact route by which apoptotic factors are released from the IMS is a topic of 
some debate. Loss of Opa1 oligomers during apoptosis releases the cristae junctions 
to facilitate release of IMS proteins (Scorrano et al., 2002; Frezza et al., 2006). This 
process is regulated by Oma1 which inhibits AAA protease YME1L cleavage of Opa1 
(Head et al., 2009). Prior to this, suggestions include a change in membrane 
permeabilisation (Kroemer et al., 1995), due to opening of the mitochondrial 
permeability transition pore (PTP) which conists of; VDAC (Shimizu et al., 1999) and 
ANT (Marzo et al., 1998) or via Bax generated openings (Kuwana et al., 2002). 
 
1.3.4 Reactive oxygen species (ROS) 
Reactive nitrogen and oxygen species cause damage to both protein and DNA (Cui 
et al., 2012). The close proximity of the mitochondrial proteins and mtDNA to the 
respiratory chain, which produces ROS, makes them highly susceptible to ROS 
induced damage (Turrens, 2003). 
The most common ROS produced is superoxide (O2-). Superoxide is produced by an 
electron leak from the respiratory chain which results in electrons being accepted 
directly by molecular oxygen (Turrens, 2003). Superoxide dismutase in the cell is 
able buffer superoxide by converting it to hydrogen peroxide (H2O2), which is more 
stable but still highly toxic. Hydrogen peroxide can be broken down to water and 
oxygen by catalase. 
Although ROS are highly damaging, they play important functional roles in cell 
signalling (Droge, 2002). ROS signalling has been demonstrated to be important for 
cell adaptations to hypoxia (Chandel et al., 1998), regulation of autophagy (Scherz-
Shouval et al., 2007), immunity (West et al., 2011) and apoptosis (Pierce et al., 
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1991). Interestingly, it has also been linked to upregulation of mitochondrial 
biogenesis and mitophagy promoting mitochondrial turnover in the heart (Bartz et al., 
2015). 
 
1.6 Mitochondrial turnover 
Mitochondrial turnover occurs at a tissue specific rate. For instance, mitochondrial 
half-life in the mouse heart has been found to be around 17 days compared to 
around four days for the mouse liver (Kim et al., 2012).  Mitochondrial turnover can 
be considered to be the result of a fine balance between mitochondrial biogenesis 
and mitophagy. The turnover of mitochondria occurs independently of the cell cycle 
and thus still occurs in post-mitotic tissues. 
 
1.4.1 Mitochondrial biogenesis 
Mitochondrial biogenesis is the process by which cells increase their mitochondrial 
mass and mtDNA copy number. This is particularly important in skeletal muscle 
where periods of contractile activity, in the form of exercise, induce mitochondrial 
biogenesis and lead to an increase in mitochondrial mass and oxidative capacity 
(Holt et al., 1989). Central to mitochondrial biogenesis is peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α), a transcriptional co-
activator which upregulates expression of nuclear respiratory factor-1 (NRF-1), 
estrogen related receptor alpha (ERRα) and peroxisome proliferator-activated 
receptor alpha (PPARα) (Figure 1.10). Muscle specific knockout of PGC-1α in mice 
has been found to cause a reduction in mitochondrial mass and a fibre type shift from 
slow type I to fast IIx/IIb (Handschin et al., 2007). PGC-1α is activated by AMPK 
mediated phosphorylation and SIRT1 mediated deacetylation in response to energy 
deprivation signalled by increasing AMP/ATP ratio and NAD+/NADH ratios, 
respectively (Canto et al., 2009). 
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Figure 1.10 Signalling pathway for mitochondrial biogenesis. Peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) governs 
mitochondrial biogenesis. PGC-1α is regulated in response to AMP/ATP and 
NAD+/NADH levels which are indicators of energetic status. PGC-1α functions 
through its transcriptional regulation of nuclear respiratory factor 1 (NRF1), estrogen 
related receptor alpha (ERRα) and peroxisome proliferator-activated receptor alpha 
(PPARα). NRF1 transcriptionally activates TFAM, which regulates mtDNA 
transcription and replication. Adapted from Scarpulla (2011). 
 
ERRα activates transcription of NRF-2, which along with NRF-1 and ERRα drives 
transcription of mitochondrial mtDNA (Schreiber et al., 2004). ERRα also stimulates 
RIPI40 expression (Nichol et al., 2006), suggesting a possible negative feedback 
mechanism inhibiting PGC-1α activity and thus tightly regulating mitochondrial 
biogenesis. NRF-1 is responsible for the activation of transcription factor A, 
mitochondrial (TFAM) which is a transcriptional activator for the mtDNA (Virbasius 
and Scarpulla, 1994). 
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1.4.2 Mitophagy 
Mitophagy is the selective degradation of damaged mitochondria (Kanki and 
Klionsky, 2008) and is proceeded by fission of the damaged mitochondrion (Twig et 
al., 2008) (Figure 1.11). The dysfunctional mitochondrion has a loss of membrane 
potential, which activates Oma1 cleaving Opa1 and preventing re-fusion into the 
mitochondrial network (Duvezin-Caubet et al., 2006). 
 
 
Figure 1.11 Signalling pathway for mitophagy and autophagasome formation. 
Damaged mitochondria are separated from the mitochondrial network due to low 
membrane potential. The low membrane potential prevents presenilins-associated 
rhomboid-like protein (PARL) cleavage of PTEN-induced putative kinase 1 (PINK1), 
which accumulates on the outer mitochondrial membrane and recruits parkin. Parkin 
mediates the ubiquitination of the outer membrane proteins which leads to 
recruitment of p62 and autophagasome formation. 
 
Mitophagy involves two key proteins; PINK1 and Parkin which when mutated cause 
familial Parkinson’s disease (Kitada et al., 1998; Valente et al., 2004). Under normal 
cellular conditions PINK1 is imported into the IMS by the TOM transporter and is 
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cleaved by PARL (Meissner et al., 2011). However, when a mitochondrion becomes 
dysfunctional and the membrane potential is reduced PINK1 import and cleavage by 
PARL is blocked and instead it locates to the OMM and recruits Parkin (Narendra et 
al., 2008). Parkin mediates the ubiquitination of OMM proteins and p62 is recruited to 
the OMM (Narendra et al., 2010). Interaction of p62 with the ubiquitinated proteins 
and also with LC3 recruits lysosomes containing hydrolytic enzymes and forms an 
autophagasome for mitochondrial degradation. 
 
1.7  Mitochondrial stress response 
Mitochondria are involved in apoptotic cell death and as such their response to 
cellular stress is essential in deciding whether a cell survives and recovers or 
undergoes apoptosis. Mitochondria respond to cellular stresses in a number of ways 
including changes in morphology, release of damage associated mitochondrial 
proteins (DAMPs) and possibly activation of the mitochondrial unfolded protein 
response (UPRmt). Each of these responses will be specific to dealing with the stress 
to which the cell has been exposed and each is described in more detail below. 
 
1.5.1 Morphology and dynamics 
It has been demonstrated that under low levels of cellular stress, mitochondria fuse 
to become a connected network (Tondera et al., 2009; Shutt and McBride, 2013; 
Picard et al., 2014; Leduc-Gaudet et al., 2015), likely allowing functional 
complementation and increasing the ability of mitochondria to cope with the stress. 
However, at higher levels of mitochondrial stress the mitochondrial network 
fragments and mitochondria swell. Mitochondrial swelling appears to occur due to an 
influx of water caused by higher ion concentrations in the matrix over the cytosol as a 
result of mitochondrial permeability transition pore (PTP) opening (Di Lisa et al., 
2001) due to calcium overload (Halestrap et al., 1986) and depolarisation of the 
mitochondria (Minamikawa et al., 1999).  
An alternative to mitochondrial swelling, is the formation of donut or toroid shaped 
mitochondria (Long et al., 2015). Toroid mitochondria have an increase in 
mitochondrial volume but also have an advantage over swollen mitochondria since 
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return to normal mitochondria is easier upon removal of mitochondrial stress (Liu and 
Hajnoczky, 2011). 
 
1.5.2 Mitochondrial derived vesicles 
Mitochondrial derived vesicles have been found to be an early response to oxidative 
stress occurring prior to mitochondrial depolarisation (Soubannier et al., 2012a; 
Soubannier et al., 2012b) and are thus form an essential housekeeping and quality 
control mechanism. Targeting of HeLa cells with a subtoxic dose of ROS, produced 
MDVs detectable by electron microscopy and confocal microscopy, prior to 
mitochondrial fragmentation which are targeted to lysosomes (Soubannier et al., 
2012a). There are two species of MDVs which differ based on their subcellular 
destination and protein composition, with peroxisome targeted MDVs containing 
MAPL and lysosomal targeted MDVs containing TOM20 (Neuspiel et al., 2008; 
Soubannier et al., 2012a). Electron microscopy has demonstrated MDVs to be of a 
regular spherical shape around 80 to 120 nm in size (Neuspiel et al., 2008). 
Mechanistic studies suggest GTP hydrolysis is not essential for MDV formation 
suggesting the process to be independent of DRP1 (Soubannier et al., 2012b). More 
recently, treatment of HeLa cells transfected with GFP-parkin with antimycin A lead to 
parkin recruitment to the OMM (McLelland et al., 2014). Furthermore, parkin mutants 
did not generate MDVs and MDV formation was found to require PINK1 similar to 
mitophagy (McLelland et al., 2014). The involvement of PINK1 and parkin, in both 
quality control processes, has led to the suggestion that when mitochondrial damage 
exceeds a threshold level, the membrane potential dissipates and PINK1 detects this 
change and orchestrates the switch from MDV formation to mitophagy (McLelland et 
al., 2014). 
 
1.5.3 The mitochondrial unfolded protein response 
The mitochondrial unfolded protein response is a mechanism for dealing with 
proteotoxic stress specifically in the mitochondria. Although originally identified in 
cultured rat hepatoma cells (Martinus et al., 1996), the molecular mechanisms 
involved in the UPRmt have mainly been investigated in Caenorhabditis elegans (C. 
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elegans) (Pellegrino et al., 2013), as such the mammalian UPRmt has not yet been 
fully elucidated. 
The mitochondrion, as a double membrane organelle, presents a proteostasis risk for 
the cell since they require import of numerous proteins to specific locations within the 
mitochondrion. Thus, the mitochondria are equipped with numerous chaperone 
proteins that aid in the correct folding and localisation of the imported mitochondrial 
proteins (Bukau et al., 2006). In addition to this, a number of proteases (e.g. Lon 
protease, ClpXP, YME1L and paraplegin) are also found within the mitochondria and 
degrade those proteins that are misfolded (Tatsuta and Langer, 2009). 
To date, the established signalling pathway (Figure 1.12), for the induction of the 
UPRmt in C. elegans, is initiated by ClpP which degrades misfolded proteins to 
peptides, which are pumped across the IMM and detected by ATFS-1 (Pellegrino et 
al., 2013). ATFS-1 is a transcription factor and upon activation localises to the 
nucleus activating UPRmt genes including chaperone proteins mtHsp70 and Hsp60. 
In comparison, the mammalian UPRmt (Figure 1.13) is not completely characterised 
but appears to have two signalling pathways one for the matrix and one for the IMS. 
The matrix UPRmt functions by activating the JNK2 signalling pathway which 
activates the transcription factor CHOP, which upregulates UPRmt genes including 
Hsp60, mtDnaJ, ClpP and CHOP (Zhao et al., 2002). The IMS UPRmt functions via 
the AKT signalling pathway which activates ERα increasing expression of Htra2, 
NRF1 and activating proteasome activity (Papa and Germain, 2011). No mammalian 
homologue of ATFS-1 has been identified. 
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Figure 1.12 The mitochondrial unfolded protein response (UPRmt) signalling pathway 
in C. elegans. Unfolded proteins are degraded by ClpP protease and undergo HAF-1 
mediated export from the mitochondria. HAF-1 mediated peptide release leads to the 
nuclear accumulation of ATFS-1, UBL-5 and DVE-1 in the nucleus. This leads to the 
transcriptional activation of Hsp60 and mtHsp70 to restore correct protein folding. 
Figure adapted from. Figure adapted from Pellegrino et al. (2013). 
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Figure 1.13 The mitochondrial unfolded protein response (UPRmt) signalling 
pathway in mammals. The pathway has not been fully elucidated, however it is 
thought that there are two branches a matrix stress specific and an intermyofibrillar 
space (IMF) specific. Accumulation of unfolded proteins in the matrix signals the 
upregulation of CHOP via JNK and c-Jun. CHOP transcriptionally activates the 
expression of ClpP protease, Hsp60 chaperone protein and mtDnaJ. Accumulation of 
unfolded protein in the IMS leads to AKT dependent phosphorylation of ERα. Which 
transcriptionally activates Htra2 protease and Nrf1 transcription factor expression. 
Figure adapted from Pellegrino et al. (2013). 
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1.8  Mitochondrial genetics 
1.5.4 Mitochondrial genome 
The mitochondrial genome is a double stranded, negatively-coiled, 16569bp circular 
genome encoding 22 tRNAs, two rRNAs and 13 subunits of the oxidative 
phosphorylation complexes (Figure 1.14). The mtDNA was originally sequenced by 
Anderson et al. (1981) and later revised by Andrews et al. (1999). Compared to the 
organisation of the nuclear genome, the amount of non-coding DNA is extremely low, 
with tRNAs typically punctuating the coding regions of the respiratory chain subunits 
and rRNA (Ojala et al., 1981). The majority of these genes (both rRNAs, 14 tRNAs 
and 12 proteins) are transcribed from the heavy strand, named as such due to it 
being guanine rich, the remaining genes are transcribed from the light strand. In 
addition, to the mentioned genes the mtDNA also has a non-coding region (NCR), 
which has two hypervariable regions (HSV1 and HSV2) and three conserved 
sequence blocks (CSB1-3) (Walberg and Clayton, 1981). It is here in the NCR, where 
the displacement loop (D-Loop) is found. The D-loop is a displaced region of heavy 
strand DNA with 7S DNA bound to the light strand (Figure 1.14). 
The mitochondrial genome exists in numerous copies per cell, with the number of 
copies varying on a cell-type specific basis e.g. approximately 100000 in the mature 
oocyte (Shoubridge and Wai, 2007), 7000 in cardiomyocytes and 3600 skeletal 
muscle fibres (Miller et al., 2003).The mtDNA has been demonstrated to be 
packaged in a nucleoprotein complex called a nucleoid which is found to interact with 
the IMM (Wang and Bogenhagen, 2006). Super resolution microscopy has been 
used to elucidate that some of the protein machinery necessary for replication and 
transcription of the mtDNA including mitochondrial transcription factor A (TFAM) 
single stranded binding protein and the twinkle helicase (Garrido et al., 2003; Brown 
et al., 2011). 
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Figure 1.14 Mitochondrial genome organisation. The protein encoded genes are 
colour coded for: complex I, purple; complex III, red; complex IV, yellow and complex 
IV, blue. Ribosomal RNA genes are in orange and the tRNAs in green. The origins of 
replication; OH (heavy strand) and OL (light strand) are also shown. The non-coding 
region (NCR) also contains the displacement loop (D-loop), which is shown in greater 
detail. The NCR includes three conserved sequence blocks (CSB) and two 
hypervariable sequences (HVS), as well as the heavy strand promotor (HSP), light 
strand promotor (LSP) and origin of heavy strand replication (OH). Binding of 7S DNA 
sometimes displaces a region of the heavy strand leading to a region of the D-loop 
being triple stranded. Adapted from Nicholls and Minczuk (2014). 
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1.5.5 Mitochondrial DNA Replication 
Replication of the mtDNA requires a small repertoire of proteins. These proteins 
include; Polymerase gamma (POLG) which replicates the mtDNA, Twinkle (TWNK) 
the mtDNA helicase which is involved in the unwinding of the mtDNA, mitochondrial 
DNA ligase III mitochondrial single strand binding protein (mtSSB) which stabilises 
the single stranded mtDNA, POLRMT which synthesises the RNA primer, RNaseH1 
which removes the RNA primer and topoisomerase which unwinds the DNA as the 
replication fork progresses (Figure 1.15) (Wanrooij and Falkenberg, 2010; Young 
and Copeland, 2016). 
 
Figure 1.15 Mitochondrial DNA replication fork. The mtDNA is replicated by 
polymerase gamma (POLG). POLG is assisted by a number of proteins including the 
twinkle helicase which unwinds the DNA at the replication fork and single strand 
binding protein (mtSSB) which binds the single stranded mtDNA protecting it.  
 
Replication is initiated at the H-strand origin of replication (OH) located within in the 
D-Loop and requires RNA primers produced during transcription originating at the 
LSP (Chang and Clayton, 1984). As such, initiation of replication is dependent on the 
premature termination of transcription from the LSP thus transcription and replication 
the mtDNA is linked (Bonawitz et al., 2006). 
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Replication of the mitochondrial DNA occurs via relaxed replication, that is it occurs 
independently from the cell cycle (Bogenhagen and Clayton, 1977) and is proposed 
to occur by one of two models; asynchronous or synchronous. 
Strand asynchronous replication (Figure 1.16) was first proposed by (Clayton, 1982) 
and suggests that replication initiates at OH, then after two thirds of the heavy strand 
is replicated the OL is exposed and light strand replication is initiated. Heavy strand 
replication then continues in a clockwise direction and light strand replication in a 
counter-clockwise direction. The replication of the light strand lags behind that of the 
heavy strand thus the strands can also be termed lagging and leading strands. Once 
replication is complete, the mtDNA is circularised and becomes supercoiled. Finally, 
the D-loop is replicated and it is hypothesised that this serves as a template for its 
replication (Clayton, 1982). 
The synchronous model of replication (Figure 1.16) was originally proposed by 
(Robberson et al., 1972) and further developed and supported by data from (Holt et 
al., 2000). This theory suggests that replication of the heavy strand is initiated at OH 
and light strand replication occurs simultaneously through priming of replication by 
short oligonucleotide Okazaki fragments (Holt et al., 2000). However, the presence of 
the okazaki fragments has yet to be demonstrated (Wanrooij and Falkenberg, 2010). 
ChIP-seq used to map the binding of mtSSB to the D-loop and the retention of 
primers at the origins of replication in RNaseH1 deficient cell lines is suggestive that 
mtDNA replication is more likely to occur via a strand-displacement mechanism 
(Miralles Fusté et al., 2014; Young and Copeland, 2016). 
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Figure 1.16 Models of mtDNA replication. Strand asynchronous replication (top), 
starts at the heavy strand origin of replication OH and replicates the heavy strand until 
the origin of light strand of replication is reached and light strand replication is 
imitated from OL. Strand synchronous replication (bottom), also starts at OH however 
priming and replication of the light strand starts prior to the OL being reached by 
generation of a series of short okazaki fragments. 
 
1.5.6 Transcription 
Transcription of the light strand is imitated at the light strand promotor (LSP) and 
transcription of the heavy strand at the heavy strand promotor (HSP) from two sites 
(H1 and H2) (Montoya et al., 1983). Initiation at H1 generates a short transcript for 
the two rRNAs. Whereas initiation at H2 generates a transcript for the majority of the 
mtDNA (Chang and Clayton, 1984; Zollo et al., 2012). Due to the lack of non-coding 
DNA the mtDNA is transcribed as polycistronic mRNAs, which is subsequently 
cleaved into different transcripts aided by folding of the transcripts at the tRNA coding 
regions, creating a site for RNA processing enzymes (Ojala et al., 1981). 
Mitochondrial transcription is performed by mitochondrial RNA polymerase 
(POLMRT) which also requires a number of transcription factors; TFAM, transcription 
  Chapter 1 
37 
 
factors B2 (TFB2M) (Falkenberg et al., 2002; Litonin et al., 2010). Initially, POLRMT 
and TFAM bind to the promotor forming a transcription-incompetent pre-initiation 
complex in which the elements of POLRMT that bind and melt the promoter are not 
in a position to interact with the DNA (Morozov et al., 2014). Following this, TFB2M 
binds causing the promoter to melt and the pre-initiation complex to convert into a 
transcription competent initiation complex (Morozov et al., 2015). 
Transcription initiated at HSP1 is terminated downstream of the 16sRNA gene, which 
is regulated by mitochondrial termination factor (mTERF). In addition, mTERF has 
been found by Martin et al. (2005) to have a role in transcription initiation from HSP1 
and HSP2 by allowing recycling of the initiation machinery, and to play a role in 
termination of transcripts initiated at the LSP. However, termination of heavy strand 
transcripts at the distal site within the D-loop is not understood (Guja and Garcia-
Diaz, 2012).  
 
1.5.7 Translation  
Mitochondrial translation differs from the cytosolic translation first since the ribosome 
is much smaller, with a sedimentation coefficient of 55S and secondly since it only 
requires 22 tRNAs. The smaller requirement of tRNAs is explained by the “Wobble 
hypothesis” which proposes that the first base of the tRNA can form non Watson-
Crick pairing and thus recognise multiple codons (Crick, 1966; Barrell et al., 1980).   
Prior to translation, all mitochondrially encoded mRNA transcripts with the exception 
of MTND6 are processed, mainly at the tRNA sites (Ojala et al., 1981), and matured 
by the addition of a poly-A tail by the mitochondrial poly (A) polymerase (mtPAP) 
(Tomecki et al., 2004; Slomovic et al., 2005).  
Translation can be broken down into initiation, elongation termination and recycling 
(Figure 1.17). The first step in initiation is the recruitment of mt-mRNA to the 
mitochondrial small subunit (mt-SSU) and binding to initiation factor mtIF3 thus 
preventing premature association with large subunit (mt-LSU). Following this, mtIF2 
facilitates the binding of tRNAfmet and GTP at the ribosome P-site (Ma and Spremulli, 
1996), tRNAfmet is only used during initiation, during elongation non-formylated 
tRNAmet is used (Takeuchi et al., 1998). Following the binding of tRNAfmet, the mt-LSU 
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can bind to complete the ribosome, triggering hydrolysis of the GTP and the release 
of initiation factors IF2/3 (Mai et al., 2016). 
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Figure 1.17 Mitochondrial translation. Mitochondrial translation can be broken down 
into initiation, elongation and termination and recycling. Details of each step are 
described in section 1.5.7, along with abbreviations. Figure was adapted from Mai et 
al. (2016).  
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The next step is elongation which requires the elongation factor mtEFTu, GTP and a 
charged mt-tRNA forming a ternary complex which can enter the ribosomal A-site. 
The presence of the correct codon:anticodon pairing results in GTP hydrolysis, the 
release and recycling of mtEF-Tu (Jeppesen et al., 2005) and the subsequent 
formation of a peptide bond at the peptidyl transferase centre in the mt-LSU. The P-
site of the mitoribosome now contains a deacetylated mt-tRNA and the di-peptidyl-
tRNA is present at the A-site. Interaction of elongation factor mtEF-G1 causes a 
conformational change that results in movement of the tRNA in the A-site to the E-
site and the di-peptidyl-tRNA to the A-site (Katunin et al., 2002). This process cycles 
and the newly synthesised polypeptide moves through the ribosome to the matrix 
where it is folded (Smits et al., 2010). 
When the mitoribosome receives a stop codon at the A-site termination occurs and 
mitochondrial translation release factor mtRF1a (Soleimanpour-Lichaei et al., 2007), 
enters the ribosome hydrolysing the ester bond holding the peptide in the P-site 
causing its release (Martin Schmeing et al., 2005). Following peptide release, two 
ribosome recycling factors mtRRF-1 and mtEF-G2 promote the disassociation of the 
mito-ribosome and release of the mRNA and tRNA (Rorbach et al., 2008; Tsuboi et 
al., 2009). The human mitoribosome has been found to invoke a -1 frameshift at rare 
arginine codons AGA or AGG triplets, which are termed “hungry codons” (Temperley 
et al., 2010). 
 
1.5.8 Mitochondrial DNA repair 
Mitochondria were originally thought to have no mechanism of DNA repair, based on 
evidence that no mechanism for pyrimidine dimer repair existed in mammalian 
mitochondria (Clayton et al., 1974). However, since then a number of repair 
mechanisms have been identified. 
Base excision repair (BER) has been found to occur in mitochondria in a similar 
manner to BER in the nucleus and repair alkylation and oxidative DNA lesions. Most 
importantly in the mitochondria, BER can be used to repair damage caused by ROS 
which includes thymine glycol (TG) and 8-oxoguanine (8-oxoG) lesions. BER can 
proceed via two pathways. Both require recognition and cleavage of the damaged 
site by a glycosylase specific for the damage leaving an abasic site. The abasic site 
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is cleaved at the 5’ end by an AP endonuclease generating a nick with a 
5’deoxyribose phosphate (5’dRP) flap. For single nucleotide BER the POLG can then 
fill the gap and cleave the 5‘dRP flap before ligation (Longley et al., 1998). However, 
some oxidative damage cannot be repaired in this way since it inhibits replication and 
thus interferes with POLG performing short-patch BER. Alternatively, long patch BER 
requires the endonucleases FEN1 and DNA2 (Liu et al., 2008; Zheng et al., 2008) to 
displace the 5’ flap structure prior to ligation by ligase III. 
Single strand breaks (SSB) can form in mtDNA due to ROS damage, collision of 
topoisomerase with RNA polymerase during transcription or failed BER. The repair of 
SSB follows a similar process to BER and it is generally suspected that the same 
machinery is used (Kazak et al., 2012). In comparison, double strand breaks have 
also been found to occur in the mtDNA and there has been a lot of debate as to 
whether the mitochondria are able to repair these by recombination as in the nucleus. 
However, the presence of repeat sequences at many break points reported in 
MitoBreak (Damas et al., 2014a), provides potential evidence for homologous 
recombination. Furthermore, use of a mitochondrially targeted ScaI restriction 
endonuclease in mice demonstrated evidence for recombination (Bacman et al., 
2009) and a mouse model expressing an inducible restriction endonuclease provided 
evidence for both homologous and non-homologous recombination by as yet 
undefined mechanisms (Fukui and Moraes, 2009). 
 
1.5.9 Mitochondrial DNA copy number regulation 
Studies in cultured mouse and human cells have estimated the mitochondrial copy 
number to be highly variable and by approximately 1000 to 5000 copies per cell 
(Shmookler Reis and Goldstein, 1983; Alexander et al., 2000). Furthermore, 
evidence suggests that mitochondrial DNA copy number is tightly regulated and 
varies in a tissue specific manner, dependent on the energy demands of the tissue. 
In most instances, the mtDNA copy number appears to be linked to mitochondrial 
mass. However, the mechanism by which mitochondrial DNA copy number is 
regulated has not been conclusively shown and a number of hypotheses have been 
proposed. 
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Tang et al. (2000), proposed that mtDNA copy number is regulated indirectly by 
controlling the size of dNTP pools, meaning that the number of mtDNA copies will 
increase if the genome size is smaller. Another hypothesis suggests that TFAM 
regulates copy number by switching the mode of replication, evidence for this 
includes the depletion of mtDNA in TFAM knockout mice (Pohjoismaki et al., 2006). 
However, changes in mtDNA packaging due to lack of TFAM could also be argued to 
cause this. Clay Montier et al. (2009), proposed that copy number is regulated 
dependent on the current ATP requirement for the cell. However, so far no evidence 
supporting this has been found. This model however, does fit with tissue specific 
variances in energy demands and mtDNA copy number.  
More recently, investigation of CpG island methylation around the POLG gene has 
indicated a role for epigenetic regulation of the mtDNA maintenance machinery in the 
regulation of mtDNA copy number (Kelly et al., 2012). This work finds a correlation 
between mtDNA copy number and POLG CpG island methylation. However, previous 
data indicates that the mtDNA replication factors increase significantly when mtDNA 
copy number decreases (Schultz et al., 1998). Thus, epigenetic regulation of POLG 
would appear to be a long term mechanism for tissue specific copy number 
regulation rather than a homeostatic mechanism for short term fluctuations in mtDNA 
copy number. 
 
1.5.10 Heteroplasmy and the threshold effect 
The mitochondrial DNA exists as multiple copies within an individual cell, as such it is 
possible that some but not all of these will contain polymorphic or even pathogenic 
variants. If all copies of the mtDNA are identical the cell is said to be homoplasmic, 
however if more than one mtDNA species is present within a single cell the cell is 
said to be heteroplasmy (Figure 1.18). Heteroplasmy is measured as a percentage 
of the total copy number and percentage heteroplasmy can vary between 0 - 100%. 
Since the mtDNA is regularly replicated a mutated molecule may replicate increasing 
in heteroplasmy until it out numbers the wild type copy number, this process is known 
as clonal expansion. 
The effect that a mutation will have on the function of the mitochondria is based on a 
principle known as the threshold effect (Figure 1.18) (Rossignol et al., 2003). Low 
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level heteroplasmy typically does not cause a biochemical deficiency and thus does 
not affect the cell phenotype due to the compensatory effect of the wild type mtDNA. 
However, if the mutational heteroplasmy exceeds the phenotypic threshold, the 
mutation can no longer be compensated for and thus a biochemical deficiency and 
cell phenotype becomes apparent (Rossignol et al., 2003). 
 
Figure 1.18 Heteroplasmy and the threshold effect. Mitochondrial DNA exists in 
numerous copies per mitochondrion as such an mtDNA mutation can exist at 
anywhere between 0 and 100% heteroplasmy. At low levels of heteroplasmy a 
mitochondrion may be biochemically normal, due to the presence of wild type 
mtDNA. However, above a functional threshold (red dotted line) the oxidative 
phosphorylation chain enzyme activity is diminished. 
 
The threshold effect has been found to vary both between mutation types and also 
between tissues. Mitochondrial DNA deletions in skeletal muscle are reported to 
have a threshold anywhere between 50% (Porteous et al., 1998) and 90% (Sciacco 
et al., 1994). This large variability in threshold is likely to be due to the substantial 
variation in deletion size and location, therefore affecting the impact the deletion is 
likely to have on the respiratory chain. Point mutations show an even greater 
variation in threshold with the m.8344A>G tRNALys mutation reported to have a 
threshold of 97% (Moslemi et al., 1997) and the m.3243A>G tRNALeu(UUR) mutation a 
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threshold of 50% (Jeppesen et al., 2006) in skeletal muscle. The higher threshold for 
some mt-tRNA mutations may be due to the fact that these are generally accepted to 
be functionally recessive (Al-Dosary et al., 2009; Tuppen et al., 2010), however 
findings of dominant mt-tRNA mutations challenges this assumption (Sacconi et al., 
2008). Interestingly, in skeletal muscle the mutational heteroplasmy can vary along 
the length of a myofibre as well as between fibres.  
One of the complications when investigating mitochondrial disease pathogenesis is 
the lack of correlation between mutational heteroplasmy and disease severity 
(Morgan-Hughes et al., 1995). Furthermore, identical mutations can have different 
phenotypic presentations, for example patients with the m.3243A>G tRNALys 
mutation may present with mitochondrial encephalomyopathy, lactic acidosis, and 
stroke-like episodes (MELAS), maternally inherited diabetes and deafness (MIDD) 
and CPEO as well as additional symptoms (Nesbitt and McFarland, 2011).  
 
1.5.11 Maternal inheritance and the mitochondrial bottle neck 
Unlike the nuclear genome, the mtDNA is inherited solely down the maternal lineage 
(Giles et al., 1980), with the mitochondria from the sperm being selectively degraded. 
Pathogenic variants in the mtDNA are therefore passed from the mother to her 
offspring, however there can a large amount of variability in the number of mutated 
mtDNA molecules passed on and siblings can end up with very different 
heteroplasmy levels (Taylor and Turnbull, 2005). This variation is attributed to a 
phenomena termed the mitochondrial bottle neck (Howell et al., 2000). The 
mitochondrial bottleneck is the result of rapid replication after fertilisation (Cree et al., 
2008), with variation in heteroplasmy of an mtDNA variant in an embryo resulting 
from random genetic drift during replication (Brown et al., 2001). 
 
 
1.9  Mitochondrial DNA mutations 
The mtDNA is prone to high levels of mutagenesis, with a mutation rate 
approximately 10 times higher than that of the nuclear genome (Brown et al., 1979). 
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The high mutation rate may be due to a number of factors and more than likely to a 
combination of these factors. The first to consider is the close proximity of the mtDNA 
to the respiratory chain complex and thus the exposure to damaging ROS produced 
by the respiratory chain. A second issue is that the mtDNA polymerase POLG has a 
much lower fidelity than that of the nuclear polymerase (Kunkel and Loeb, 1981). 
Further to this, the mitochondrial DNA is replicated much more frequently than the 
nuclear genome (Bogenhagen and Clayton, 1977) and therefore the probability of an 
error during replication that is incorrectly repaired is much more likely. In addition to 
the high mutation rate, since the mitochondrial genome consists almost entirely of 
coding regions mutations are much more likely to occur in a coding region and as 
such be pathogenic. 
 
1.6.1 Point mutations 
Point mutations are a single base substitution and occurrence in the mitochondrial 
genome is highest in the tRNA genes, with 50% of all point mutations occurring here 
(Schaefer et al., 2008). Pathogenic point mutations are known to cause a number of 
mitochondrial diseases and can be maternally inherited or sporadic. The most 
common and thus most well characterised point mutations are the m.3243A>G 
tRNALeu(UUR) and the m.8344A>G tRNALys (Gorman et al., 2015). 
The m.3243A>G mutation is the most common cause of MELAS causing 
approximately 80% of all cases (Urata et al., 2004). However, the phenotypic 
spectrum of m.3243A>G mutations is very variable. MIDD is most common but 
patients also present with Leigh’s syndrome and CPEO, and isolated symptoms are 
also reported (Nesbitt and McFarland, 2011; Mancuso et al., 2014). The m.8344A>G 
point mutations has been reported to cause 80-90% of all myoclonic epilepsy with 
ragged red fibres (MERRF) cases (Wu et al., 2010). However, m.8344A>G, similar to 
m.3243A>G, also causes a wider variety of symptoms including migraine, psychiatric 
disorders, hearing impairment, respiratory and gastrointestinal symptoms (Mancuso 
et al., 2013; Altmann et al., 2016). 
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1.6.2 Single large-scale mtDNA deletions 
Large-scale single mtDNA deletions arise sporadically during embryogenesis due to 
errors in either mtDNA replication or repair (Shoffner et al., 1989; Krishnan et al., 
2008; Dong et al., 2014) and the same deletion species is found at variable 
heteroplasmy in each cell. Clinically these account for 12% of adult mitochondrial 
disease cases (Gorman et al., 2015). Patients can present with chronic progressive 
external ophthalmoplegia (CPEO), Kearns-Sayre Syndrome and Pearson Syndrome 
as well as non-syndromic disease symptoms, with the most common symptoms 
being ptosis, ophthalmoparesis and muscle weakness (Mancuso et al., 2015). The 
most common single, large-scale mtDNA deletion is the 4977bp common deletion 
between nucleotides 8482 and 13460 of the mtDNA, and typically has a 13bp repeat 
either side of the breakpoint as reported in MitoBreak (Damas et al., 2014a). The 
common deletion has been reported to account for approximately one third of all 
single mtDNA deletions (Pitceathly et al., 2012a), but also commonly accumulates 
with age (Williams et al., 2013).  
Early investigations into single, large-scale mtDNA deletions found there to be a lack 
of relationship between mtDNA genetics, biochemical function and clinical phenotype 
(Zeviani et al., 1988; Holt et al., 1989; Moraes et al., 1989). However, more recently 
reports have found relationships between mtDNA deletion heteroplasmy, age of 
onset and disease phenotype i.e. larger deletions lead to a more severe phenotype 
(Yamashita et al., 2008; Lopez-Gallardo et al., 2009). However, mtDNA deletion size 
is found to both have a correlation with disease phenotype (Yamashita et al., 2008) 
and not to have a relationship (Lopez-Gallardo et al., 2009). Furthermore, both of the 
above studies found that deletion location can impact disease severity. (Yamashita et 
al., 2008), find that a deletion affecting MT-COI, MT-COII, MT-COIII, MT-ATP6 or 
MT-ATP8 have significantly earlier onset, while (Lopez-Gallardo et al., 2009) found 
that deletions affecting MT-CYB are associated with a severe KSS phenotype.  
 
1.6.3 Disorders of mtDNA maintenance 
Mitochondrial DNA deletions have been associated secondary mitochondrial 
diseases due to nuclear mutations and also with a number of neuromuscular (Oldfors 
et al., 2006; Rygiel et al., 2016) and neurodegenerative disorders (Bender et al., 
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2006), as well as accumulating with age in healthy post-mitotic tissues (Muller-
Hocker et al., 1993; Brierley et al., 1998; Kraytsberg et al., 2006; Meissner et al., 
2006). 
They most commonly occur in the major arc of the mtDNA, however the frequency at 
which deletions are detected in the minor arc has increased in recent years. They are 
typically found to accumulate throughout life, with the highest levels identified in the 
post-mitotic tissues e.g. neurons and myofibres (Bender et al., 2006). Mitochondrial 
DNA deletions which typically arise secondary to a nuclear mutations in a gene 
involved in the maintenance or replication of the mtDNA, but are also associated with 
neuromuscular and neurodegenerative diseases and healthy ageing. Genes 
associated with mtDNA deletions encode proteins involved in replication (e.g. POLG 
(Van Goethem et al., 2001), TWNK (Spelbrink et al., 2001)), synthesis of dNTPs (e.g. 
RRM2B (Tyynismaa et al., 2009)) and mitochondrial fission and fusion (e.g. OPA1 
and MFN2 (Amati-Bonneau et al., 2008; Rouzier et al., 2012)). Additional genes that 
cause multiple mtDNA deletions are continually being identified. Phenotypically 
mtDNA deletions range from isolated progressive external opthalmoplegia (PEO) to 
fatal multi-systemic PEO-plus syndromes. The other symptoms encompassed in the 
PEO-plus category can be very diverse, and disease onset ranges from infantile to 
late adulthood. Accumulation of deletions with age is termed clonal expansion, 
theories of how this occurs and the process by which deletions are expected to form 
is explored in more detail in Chapter 4. 
 
1.10 Mitochondrial disease 
1.7.1 Disease prevalence  
Mitochondrial diseases are multi-systemic disorders that typically present with 
symptoms affecting some of the most energetically demanding organs such as the 
central and peripheral nervous systems and the skeletal muscle. The prevalence of 
mitochondrial disease is difficult to accurately assess, due to the clinical and genetic 
heterogeneity. The most recent assessment in the North East of England finds the 
prevalence of mitochondrial disease caused by mutations of both the mitochondrial 
and nuclear genomes to be approximately 1 in 4300 (Gorman et al., 2015). In 
comparison, the minimum prevalence of mtDNA mutations is reported to be 1 in 
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5000. The study finds the m.3243A>G mutation to be the most prevalent pathogenic 
point mutation with a prevalence of 7.8 per 1000000. Although, single deletions are 
still the most common cause of mitochondrial disease (minimum prevalence = 1.5 × 
10−5). 
 
1.11 Skeletal muscle structure 
Skeletal muscle is a highly structured tissue, consisting of a hierarchical structure. 
Each myofibre consists of repeats of contractile units called sarcomeres and is 
composed of a bundle of myofibrils surrounded by the sarcolemma and endomysium 
(Leiber, 2010). Myofibres are then bundled together into ‘fascicles’, which are held 
together by perimysium, which also provides entry for the capillary bed and motor 
neurons to innervate the myofibres. Finally, the entire muscle is surrounded by the 
epimysium. 
 
1.8.1 The sarcomere 
Within each myofibre, 85-90% of the volume is occupied by myofibrils arranged in 
parallel. The myofibrils are composed of series of repeating units called sarcomeres 
of approximately 2.5-3 µm in length (Figure 1.19). Each sarcomere is made up of 
thick and thin filaments. The thick filament is anchored to the z-band by elastic 
protein titin, which regulates the spatial relationship between the thick and thin 
filaments (Dubowitz, 2007). 
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Figure 1.19 Skeletal muscle structure and structure of the sarcomere. Mitochondria 
are located at the z-band. 
 
A number of the proteins localised to the z-band are associated with Myofibrillar 
myopathy, which has been reported to have changes to mitochondrial function and 
positioning. These proteins are discussed below in the context of sarcomeric 
structure.  
Desmin is found at the z-band and inserts into the costamere, linking adjacent 
myofibrils (Dubowitz, 2007), and synchronizes contraction of the myofibres. Desmin 
also interacts with the heat shock protein αB-crystallin, which is involved in desmin 
polymerization and plectin which, together with desmin, anchors the mitochondria in 
pairs at the z-band (Reipert et al., 1999). Both αB-crystallin and plectin gene 
mutations are associated with aggregation of desmin protein as seen in MFM (Vicart 
et al., 1998; Schroder et al., 2002). Due to the role of desmin in mitochondrial 
localisation, mutations in desmin have been suggested and reported to have an 
impact on mitochondrial positioning and function. Myotilin also localises to the z-band 
as part of a complex of actin cross-linking proteins, which control myofibril assembly 
and help to stabilise the Z-band (Salmikangas et al., 2003). Mutations in the MYOT 
gene lead to protein aggregates which typically label for the presence of both myotilin 
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and desmin. Z-band alternatively spiced protein (Zasp) or LIM domain binding 3 
(LDB3), is also located at the Z-band. Proteins with LIM domains and PDZ motifs 
typically interact with other proteins often guiding them to multiprotein complexes 
(Faulkner et al., 1999). Zasp is thought to play a role in protein kinase C-mediated 
signalling. Mutations in the ZASP gene lead to protein aggregates positive for the 
presence of myotilin, desmin or both. 
 
1.8.2 Myogenesis  
Skeletal myofibres formed during embryogenesis at regions along the embryo from 
small clusters or somites of mesoderm progenitor cells called myoblasts (Yusuf and 
Brand-Saberi, 2012). Initially, clusters of myoblasts fuse to form multinucleated 
myotubes. Subsequently, a secondary myotube will arise beneath the basal lamina of 
the primary myotube, using the primary myotube as a scaffold for support. Continued 
fusion of myotubes both radially and longitudinally forms the myofibre beneath the 
basal lamina and myonuclei from the fused cells will migrate to below the 
sarcolemma membrane (Leiber, 2010). A small portion of myoblasts will remain 
unfused and become satellite cells, which are the stem cells of the muscle and 
remain for purpose of myofibre regeneration. As the myofibres mature, primary and 
secondary myotubes will separate, each contained in a basal lamina with myonuclei 
and satellite cells (Leiber, 2010). Myoblast differentiation and formation of myofibres 
is transcriptionally regulated by four myogenic regulatory factors (MRFs). Early 
differentiation is regulated by MYOD and MYF5 and terminal differentiation is 
regulated by myogenin (Braun and Gautel, 2011). The final MRF, MRF4 appears to 
have a dual role in both terminal differentiation but also in determination of embryonic 
cells to mesoderm progenitor cells (Kassar-Duchossoy et al., 2004). 
Once a muscle fibre is fully differentiated, although post-mitotic, it can undergo 
regeneration through a process of satellite cell fusion. Satellite cells are the 
progenitor cells of the skeletal muscle, which retain proliferative capacity. Upon 
muscle fibre damage and necrosis a satellite cell can fuse with a muscle fibre and 
allow regeneration of the muscle fibre (Charge and Rudnicki, 2004). Evidence 
demonstrates that satellite cells harbour similar levels of mtDNA mutations as muscle 
fibres in mitochondrial myopathy patients (Spendiff et al., 2013).  
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A fully differentiated muscle fibre will have multiple peripherally located nuclei. Each 
nucleus will have a nuclear domain, which is defined as a region of the muscle fibre 
cytoplasm for which the nucleus is transcriptionally responsible. The size of the 
nuclear domain has been found to vary between muscle fibre types (Mishra et al., 
2015). 
 
1.8.3 Muscle fibre types 
Skeletal muscles typically consist of a mixture of muscle fibre types, with the 
proportions of each fibre type influencing the oxidative capacity of that muscle. The 
growth and differentiation of these muscle fibres is transcriptionally regulated based 
on electrical impulses from the nervous system. Discharge rates of 10 and 100Hz 
influence the pattern of gene expression and thus the development of fast and slow 
fibre types (Schiaffino et al., 1999). 
Grouping of muscle fibre types is based on morphological, contractile and metabolic 
characteristics (Burke et al., 1971; Peter et al., 1972; Reiser et al., 1985). Type I 
muscle fibres are the most oxidative, have a higher mitochondrial content but low 
ATP consumption due to their slow contraction rate. Type IIA fibres are defined as 
fast oxidative glycolytic have a high mitochondrial content, high ATP consumption 
and a fast contraction rate. Finally, type IIB fibres are fast glycolytic with a low 
mitochondrial content, high ATP consumption and fast contraction rate (Leiber, 
2010). 
 
1.8.4 Skeletal muscle mitochondria   
In skeletal muscle mitochondria can be found in two subcellular populations, the 
intermyofibrillar (IMF) mitochondria and the subsarcolemmal (SS) mitochondria. The 
two populations are topologically, morphologically and functionally different. The 
intermyofibrillar mitochondria are located in pairs either side of the z-band and are 
held here by a z-band protein complex known to contain desmin and plectin proteins 
among others (Milner et al., 2000). As such, the intermyofibrillar mitochondria form a 
rigid lattice structure and are relatively immotile compared to mitochondria described 
in other cells such as the neurons (Huang et al., 2013). The subsarcolemmal 
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mitochondria can usually be found in a small, perinuclear cluster just below the 
sarcolemma of the myofibre.  
Proteomic and biochemical comparison in rats finds the IMF mitochondria to have 
higher level of respiratory chain activity, consistent with their location between the 
myofibrils to power muscle contraction (Ferreira et al., 2010). This is consistent with 
structural findings in rat cardiomyocytes, that SS mitochondrial cristae are more 
lamella and IMF more tubular, which may provide an increased proton gradient due 
to smaller intracristae space (Riva et al., 2005). In comparison to IMF mitochondria, 
SS mitochondria are thought to produce ATP mainly for the function of the 
membrane and nuclei (Hood, 2001). The different proteomic composition also leads 
to IMF mitochondria being more susceptible to apoptotic stimuli, likely due to their 
large numbers and importance in sensing and triggering apoptosis (Adhihetty et al., 
2005). 
 
1.8.5 COX-deficiency in skeletal muscle 
When examined in transverse orientation, skeletal muscle can be seen to present 
with a mosaic pattern of COX-deficiency (Johnson et al., 1983; Sciacco et al., 1994). 
In addition, when the muscle is examined longitudinally the COX-deficiency is found 
to be segmental. Bua et al. (2006), reported that at 49 years ~6% of myofibres will 
have a COX-deficient segment somewhere along the length. Furthermore, this was 
found to increase to ~22% at 67 years and reach ~31% by 92 years.  
A number of studies in humans and animal models have found the segmental 
deficiency to be concomitant with high levels of mtDNA deletion (Lee et al., 1998; 
Wanagat et al., 2001; Bua et al., 2006; Herbst et al., 2007; Campbell et al., 2014). 
Many studies have also found increased skeletal muscle fibre atrophy and breakage 
in regions with segmental deficiency, suggesting a possible link (Wanagat et al., 
2001; Herbst et al., 2007). 
Although it is now widely accepted that mtDNA deletions are causative of respiratory 
chain deficiency in skeletal muscle. The mechanisms by which these arise and lead 
to a biochemical defect are not fully understood. Another puzzling question is what 
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restricts the longitudinal spread along the myofibre and whether this is a defensive 
mechanism to protect the myofibre from the spread of damage? 
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1.12 Overall aims and objectives 
The overall aim of this project was to improve the understanding of mitochondrial 
pathogenesis in skeletal muscle and more specifically to explore the mechanisms by 
which mtDNA mutations accumulate in skeletal muscle fibres and segmental 
respiratory chain deficiency arises. This included three aims: 
1) To investigate two neuromuscular conditions, myofibrillar myopathy and 
dysferlinopathy, for which mitochondrial dysfunction was suspected. The 
hypothesis was that protein aggregates in myofibrillar myopathy would cause 
aberrations in mitochondrial positioning and dynamics and that Dysferlin 
myopathy due, to its inflammatory nature, may present with similar 
mitochondrial pathology to inclusion body myositis.  
2) To assessed a range of muscle biopsies for the presence of small regions of 
respiratory chain deficiency that may represent the earliest stages of 
respiratory chain deficiency in a muscle fibre and thus the initial events of 
mtDNA deletion clonal expansion. The purpose of this was to find and 
investigate the early stages of mutation accumulation and thus the spread of 
respiratory chain deficiency through the muscle fibre. 
3)  To develop mechanisms to assess the variability of the mitochondrial network 
in human skeletal muscle of the control population, to contrast this with cases 
of mitochondrial myopathy and potentially gain an insight into the importance 
of mitochondrial morphology in skeletal muscle pathogenesis. 
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Chapter 2. Materials and methods 
2.1 Reagents, equipment, solutions and consumables: 
2.1.1 Equipment and software 
Equipment or Software Supplier 
ABI Step one software v2.0 Applied Biosystems 
ABI Step-one Plus Real Time PCR system Applied Biosystems 
ABI verti-96 well Thermo Cycler Applied Biosystems 
Autoclave Prior Clave 
Axiovison Zeiss 
Biorad Chemidoc Biorad 
Corning LSE Vortex mixer Sigma Alderich 
Cryostat Bright OTF 5000 
Digital Micrograph v2.31.734.0 Gatan 
Eppendorf Thermomixer Eppendorf 
GeneAmp PCR system 9700 Applied Biosystems 
Image lab v4 Biorad 
Imaris v7.7.2 Bitplane 
IMOD v4.7.15 Boulder Lab 
Laminar flow hood Jencons-PLS 
Leica Laser microdissection system Leica 
Microflow biological safety hood J. Marston engineers 
Minitab 17 Minitab 
Nanodrop ND-1000 Spectrophotometer Labtech International 
NANOpurell Water Purification System Barnstead 
ND-1000 software Labtech International 
Palm Robo v4.6 Zeiss 
Pipette boy Integra 
Prism v7.0 Graph pad 
Serial block face scanning electron 
microscope Gatan 3-view 
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R v3.3.0 R  
R Studio v0.99.896 R Studio 
Stereo Investigator MBF Bioscience 
Stereology microscope Olympus BX51 
Sterilizing oven 
Laboratory Thermal Equipment 
Ltd. 
Transmission Electron Microscope Philips CM100 
UV hood (PCR clean room) Astec 
UV hood (UV room) Bioair 
Vortex genie 2 Scientific Industries 
Zeiss axioimager Zeiss 
ZEN blue Zeiss 
Table 2.1 Equipment and software 
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2.2 Reagents 
2.2.1 Molecular genetics 
Reagent Supplier 
Agilent Bioanalyzer DNA High Sensitivity kit Agilent 
DEPC treated water Ambion 
DNA Away Thermo Fisher 
dNTPS  TaKaRa 
QIAmp DNA Blood Mini Kit Qiagen 
Ethylenediaminetetraacetic acid (EDTA) GIBCO 
Expand Long template PCR kit Roche 
LA Taq TaKaRa 
Nuclease free water Ambion 
Prime STAR GXL TaKaRa 
Primers Eurofinns 
Proteinase K solution Fisher Scientific 
Real Time PCR primers Applied biosystems 
Tamra labelled probes (ND1, ND4, Dloop) Applied biosystems 
Taqman mastermix Applied biosystems 
Tris-EDTA Fluka analytic 
Table 2.2 Molecular genetics reagents 
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2.2.2 Chemicals 
Chemical Supplier 
Liquid Nitrogen BOC 
3,3' Diaminobenzidine Tetrahydrochloride Sigma 
Catalase Sigma 
Cytochrome C Sigma 
DAPI Sigma 
DPX BDH 
Eosin CellPath 
Ethanol Analar Merck 
Haemotoxylin TCS Biosciences Ltd. 
Histoclear National diagnostics 
Methanol Merck 
Nitro Blue Tetrazolium Sigma 
Normal Goat Serum Sigma 
Paraformaldehyde (4%) (PFA) Santa Cruz Biotech 
Paraformaldehyde (16%) (EM grade) Agar Scientific 
Phosphate Buffered Saline tablets Sigma 
Prolong Gold Life Technolodies 
Sodium Azide Sigma 
Sodium Cacodylate Sigma 
Sodium Dodecycl Sulphate (SDS) BDH 
Sodium succinate Sigma 
TAE buffer (10x) Sigma 
Trizma base Sigma 
Tween-20 Sigma 
 Table 2.3 Chemicals and supplier 
  
  Chapter 2 
59 
 
2.3 Solutions 
Solution  Recipe 
5x TBST pH 7.4 (2L) 121 g Trizma Base 
 
90 g NaCl 
 
5 ml Tween 
 
Concentrated HCl 
COX-EM fixative 2% Glutaraldehyde 
 
0.1 M Sorrenson's buffer (pH7.4) 
DNA Loading buffer 0.25% (w/v) Bromophenol blue 
 
0.25% (w/v) Xylene Cyanol 
 
30% (v/v) Glycerol 
DNA electrophoresis gel 
buffer (1L) 
100 ml 10x TAE (0.4 M Tris-acetate, 10 mM EDTA, 
pH 8.3) 
 
900ml Nanopure water 
DNA electrophoresis running 
buffer (1L) 
100 ml 10x TAE (0.4 M Tris-acetate, 10 mM EDTA, 
pH 8.3) 
 
900ml Nanopure water 
smPCR lysis buffer (1ml) 5 ml SDS 
 
945 ml 10mM EDTA 
 
50 µl proteinase K 
Single cell lysis buffer (500µl) 250 µl 1% Tween 20 
 
50 µl 0.5M TrisHCl pH 98.5 
 
195 µl dH2O 
 
5 µl proteinase K 
Phosphate Buffered Saline 
(PBS) 1 tablet in 100ml dH2O 
TEM fixative (pH 7) 2% Glutaraldehyde 
 
0.1 M Sodium Cacodylate 
Table 2.4 Buffers and recipes 
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2.4  Consumables 
 
 Table 2.5 Consumables 
 
Consumables Supplier 
0.2ml Thin-walled PCR tubes Star Lab 
0.5ml Thin-walled PCR tubes Star Lab 
1.5ml Eppendorf Eppendorf 
2ml Eppendorf Eppendorf 
5ml Eppendorf Eppendorf 
96 Well Fast Optical Reaction Plates Applied Biosystems 
96 Well semi-skirted Plate, with raiser rim Starlab 
Electronic pipettes Ranin 
Gilson pipette (P2, P10, P20, P100, P200, P1000) Anachem 
Glass slides Thermo Scientific 
Gloves Starlab 
PEN slides Leica 
QIAmp DNA micro kit Qiagen 
Scalples Swann Morton 
Serological pipettes Cellstar 
SlideRita 5 Mailer CellPath 
Starseal advanced Polyelfin film Thermo scientific 
Weigh boats VWR 
Filter pipette tips Tip One 
QIAamp DNA midi kit Qiagen 
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2.5 Patient cohort 
2.5.1 Controls 
Controls fell in to either “healthy disease controls” (those referred to the NGS 
mitochondrial disease diagnostic service but were found not to have mitochondrial 
disease) or “healthy control” groups (muscle donated during routine ligament 
surgery.) All controls are selected to be age matched for the required study and 
relevant information for these can be found in Table 2.6. In addition a single disease 
control with pathogenic, recessively inherited RRM2B variants, previously reported 
by Pitceathly et al. (2012b), was also used in Chapter 3 and Chapter 4. Patient 
details are provided in Table 2.6. Control blood (previously tested for mtDNA 
deletions) was also provided by NGS mitochondrial disease diagnostic service for 
DNA extraction. 
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Control Classification Age/years Gender Chapters  
C1 Healthy disease 18 F 3 
C2 Healthy disease 34 F 3 
C3 Healthy disease 52 F 4,3 
C4 Healthy disease 63 F 4 
C5 Healthy 23 M 7 
C6 Healthy 33 M 7 
C7 Healthy 28 M 7 
C8 Healthy 27 M 7 
C9 Healthy 25 F 7 
C10 Healthy 25 M 7 
C11 Healthy 35 F 7 
C12 Healthy 45 F 7 
     
Table 2.6 Control case information. Healthy disease controls were referred to the 
NGS mitochondrial disease diagnostic service but found not to have mitochondrial 
disease. Healthy controls agreed to donate muscle during routine anterior cruciate 
ligament surgery. M; male, F; female. 
 
 
2.5.2 Dysferlinopathy patients 
Dysferlinopathy (n = 8) patients were identified through the Rare Diseases Advisory 
Group Service for Neuromuscular Diseases. Selection was based on 
immunohistochemistry using anti-Ham1/3 antibody against the C-terminus of 
Dysferlin as well as a genetic diagnosis. Patient details including clinical and 
pathological findings are summarised in Table 2.7, these patients are investigated in 
Chapter 3.
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Table 2.7 Dysferlinopathy patient information. Patients are organised in age order and all mutation nomenclature uses the primary 
transcript (NM_003494.3). All biopsies were taken from the Quadriceps via needle biopsy.  N/K; not known, M; male, F; female, Hom.; 
homozygous, LGMD2B; Limb girdle muscular dystrophy type 2B, MM; Myoshi myopathy. Adapted from Vincent et al. (2016c). 
 
Patient  Gender Age at onset (if 
known) 
Age at 
biopsy 
Mutation CK Phenotype 
P1 F 10 (distal 
myopathy) 
15.7 c.855+1delG; c.3031G>C, p.(Gly1011Arg)  3012 MM 
P2 F 26 20.5 c.2434dup p.(His812Profs*53); c.1745G>T p.(Arg582Leu)  7586 LGMD2B 
P3 F 26 21.9 Hom. c.2163-1G>T 13000 LGMD2B 
P4 M Birth 24.7 Hom. c.1480+18T>C; c.4999G>A, p.(Glu1667Lys)  400-700 LGMD2B 
P5 M 9 28.9 exon 5-10 deletion; c.757C>T, p.(Arg253Trp) 5000 LGMD2B 
P6 M Late teens (distal 
myopathy) 
30.4 Hom. c.3059dupC, p.(Glu1021Glyfs*10)  20000 MM 
P7 F N/K 47.1 c. 5509G>A, p.(Asp1837Asn); c.6124C>T, 
p.(Arg2042Cys) 
5110 LGMD2B 
P8 M 13 52.5 c.3512_3513delCT, p.(Ser1171Phefs*3); c.5908C>T, 
p.(Pro19070Ser)  
6000 LGMD2B 
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2.5.3 Myofibrillar myopathy patients 
Myofibrillar myopathy patients (n = 9) were identified through the Rare Diseases 
Advisory Group Service for Neuromuscular Diseases. Selection was based on the 
presence of protein aggregates in skeletal muscle cryosections labelled for myotilin 
and desmin immunohistochemistry as well as a genetic diagnosis. Patient details 
including clinical and pathological findings are summarised in Table 2.8, these 
patients are investigated in Chapter 4. 
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Table 2.8 Clinical and diagnostic information for Myofibrillar myopathy patients examine in Chapter 4 (n = 9). Patients are organised by 
gene then age order and all mutation nomenclature uses the primary transcripts for DES (NM_001927) and MYOT (NM_006790) and for 
LDB3 or ZASP transcript variant 2 (NM_001080114.1). DES; desmin, MYOT; myotilin, Hom.; homozygous, Het.; heterozygous, MA; 
minor allele frequency, CK; creatine kinase, NK; not known. Adapted from Vincent et al. (2016a). 
 
 
Patient Gender Mutated gene  Mutation CK Biopsy Site Age at biopsy Age at 
onset (if 
known) 
P9 M DES Het. c.1069G>C, p.(Ala357Pro) 480 Quadriceps 31.2 29 
        
P10 M DES Het. c.1069G>C,  p.(Ala357Pro) NK NK 32.1 NK 
P11 M DES Hom. c.46C>T, p.(Arg16Cys) 450 Quadriceps 33.8 20's 
P12 F DES Het. c.735+20C>T  (MAF=0.01);  
c.638C>T, p.(Ala213Val) 
NK Quadriceps 51.3 Early 
childhood 
P13 F DES Het. c.638 C>T,  p.(Ala213Val)  74 Quadriceps 53 40's 
P14 F DES Het. c.1346A>C , p.(Lys449Thr) 287 NK 64.3 46 
P15 M MYOT Het. c.179C>G, p.(Ser60Cys) 446 Quadriceps 60.5 55 
P16 M MYOT c.179C>G, p.(Ser60Cys) 400-500 Tibialis Anterior 65.7 NK 
P17 F LDB3 or ZASP Het. c.494C>T, p.(Ala165Val); 
Het. c.728C>T, p.(Pro243Leu) 
300 Quadriceps 69.6 
 
60’s 
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2.5.4 Patients for clonal expansion experiments (Chapter 5) 
A cohort of mitochondrial disease patients has been selected for investigation 
throughout this thesis. In Chapter 5, a range of patients including; multiple mtDNA 
deletions (n = 7), single, large-scale mtDNA deletions (n = 4), inclusion body myositis 
(IBM) (n = 5), are used to investigate mechanisms of clonal expansion. Relevant 
clinical information for these patients is presented in Table 2.9. Patient 28 is also 
investigated in Chapter 6. All patients mentioned above were identified through the 
NGS mitochondrial disease diagnostic service.
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Patient Gender Age at 
onset 
Age at 
biopsy 
Gene Mutations 
(c.DNA; amino acid) 
% COX 
deficiency 
% RRF Clinical 
phenotype 
Reported 
previously? 
P18 F N/A 31 TWNK c.1121G>A, 
p.(Arg374Gln) 
10% 1% adPEO nr 
P19 M 14 37 RRM2B c.431 C>T; p.(Thr141Ile) 
and 
c.817G>A; 
p.(Gly273Ser) 
>40% 20% arPEO, muscle 
weakness 
Pitceathly et 
al. Brain 
(2012), 
Patient 19  
P20 F 11 43 RRM2B c.556A>G; 
p.(Arg186Gly) and 
c.653C>T; p.(Thr218Ile) 
30%  5% arPEO plus Pitceathly et 
al. Brain 
(2012), 
Patient 20  
P21 F 38 64 RRM2B c.208G4A; p.(Asp70Asn) 8% 3%  adPEO, ptosis, 
ataxia 
Pitceathly et 
al. Brain 
(2012), 
Patient 5 
P22 F N/A 66 POLG c.1399G>A, 
p.(Ala467Thr); 
c.2799T>G 
p.(Ser933Arg) 
24% 6% arPEO, ataxia nr 
P23 F N/A 69 TWNK c.907c>T, p.(Arg303Trp) 30% 8% adPEO, ptosis nr 
P24 M N/A 80 POLG c.752C>T, p.(Thr251Ile); 
c.1760C>T, p.(Pro587 
Leu); c.1399G>A 
p.(Ala467Thr) 
20% 4% arPEO nr 
P25 M N/A 27 mtDNA single deletion 25% 5% CPEO, ptosis nr 
P26 F N/A 32 mtDNA single deletion 40% 1% CPEO nr 
P27 F N/A 35 mtDNA single deletion 25% 1% CPEO, 
proximal 
nr 
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muscle 
weakness 
P28 F N/A 47 mtDNA single deletion 20% 10% CPEO nr 
P29 F 20 66 mtDNA single deletion 20% 1% CPEO, ptosis nr 
P30 M 44 48 N/A N/A 79% 0% IBM Rygiel et al. 
Nucl Acid Res 
(2016)  
Patient 7 
P31 F 44 47 N/A N/A 10% 0% IBM Rygiel et al. 
Nucl Acid Res 
(2016)  
Patient 9  
P32 F 61 64 N/A N/A 23% 0% IBM Rygiel et al. 
Nucl Acid Res 
(2016)  
Patient 5  
P33 F 69 79 N/A N/A 24% 0% IBM Rygiel et al. 
Nucl Acid Res 
(2016)  
Patient 4 
P34 M 78 81 N/A N/A 5% 0% IBM Rygiel et al. 
Nucl Acid Res 
(2016)  
Patient 8  
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Table 2.9 Case information for patients examined in Chapter 5 for clonal expansion experiments, including patients with; Multiple mtDNA 
deletions (n = 7), Single, large-scale mtDNA deletions (n = 4), Inclusion body myositis (IBM) (n = 5). adPEO, autosomal dominant 
progressive external ophthalmoplegia; arPEO, autosomal recessive progressive external ophthamoplegia; CPEO, chronic progressive 
external ophthalmoplegia; nr, not reported. 
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2.5.5 Patients for electron microscopy studies (Chapter 6 and Chapter 7) 
In Chapter 6 a group of seven patients are examined; m.8344A>G (n = 3), 
m.3243A>G (n = 1), single, large-scale mtDNA deletions (n = 3). Of the patients 
examined in Chapter 6 all but one single deletion patient (P28) is also examined in 
Chapter 7. The relevant clinical information for these patients is presented in Table 
2.10. Patient 28 was also investigated in Chapter 5. All patients mentioned above 
were identified through the NGS mitochondrial disease diagnostic service. 
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Patient 
# 
Sex Age at 
biopsy 
Genetic 
diagnosis 
Heteroplasmy 
(if applicable) 
% COX 
deficiency 
% 
RRF 
CK  
(IU/L) 
Lactate 
(mmol/L) 
Clinical 
phenotype 
Diagnostic 
notes 
P28 F 47 Large-scale 
single mtDNA 
deletion 
N/A 20 10 226 2.4 CPEO, 
proximal 
myopathy 
- 
P35 F 62 Large-scale 
single mtDNA 
deletion 
34 20 15 122-
197 
2.1-3.1 CPEO, 
proximal 
myopathy 
- 
P36 F 70 Large-scale 
single mtDNA 
deletion 
22 18 9 318-
1238 
1.4-2 CPEO, 
proximal 
myopathy 
Asymmetric 
myopathy 
P37 F 22 m.8344A>G 97 97 10 145-
291 
7.4 Axial, proximal 
myopathy, 
lactic acidosis 
- 
P38 F 50 m.8344A>G 63 22 7 43 1.6 Mild myopathy Mother of 
Patient 7.4 
P39 F 20 m.8344A>G 40 COX 
intermediate 
0 267 1.2 Asymptomatic Sister of 
Patient 7.4 
P40 F 69 m.3243A>G 21 3 2 180-
375 
1.3 Diabetes 
mellitus, 
deafness, gut 
dysmotility 
- 
  Chapter 2 
72 
 
Table 2.10 Patient information for the biopsies examined in electron microscopy investigations in Chapter 6 (P28, 35-40) and Chapter 7 
(P34-40). N/A: non-available; % COX: proportion of muscle fibres with cytochrome c oxidase deficiency; RRF: ragged red fibres; CK: 
creatine kinase; CPEO: chronic progressive external opthalmoplegia; HCM: hypertrophic cardiomyopathy; OA: optic atrophy; MERRF: 
myoclonic epilepsy with ragged red fibres. Deletions position and sizes for P28: N/A; P35: m.8482-13460, 4978bp; P36: m.8576-12968, 
4392bp. Normal clinical range for CK: 25-200 IU/L; lactate: <2.2 mmol/L. All biopsies from the tibialis anterior muscle, none of these 
patients were previously reported.
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2.6  Ethical guidelines 
All work presented here was previously approved by the Newcastle and North 
Tyneside Local Research Ethics Committees (reference 2002/205) and is now 
approved under Newcastle and North Tyneside Local Research Ethics Committees 
(reference 16NE/0267). Control biopsies from routine ACL surgery were approved by 
Newcastle and North Tyneside Local Research Ethics Committees (reference 
12/NE/0395, project number 42). Prior informed consent was obtained from all 
participants and all experiments were carried out in accordance with the approved 
guidelines. 
 
2.7 Newcastle Mitochondrial Disease Adult Scale (NMDAS) 
Due to the multi-systemic nature of mitochondrial disease and the large degree of 
clinical severity observed in mitochondrial disease, standardisation of clinical 
assessment is invaluable. Clinicians at the Wellcome Trust Centre for Mitochondrial 
research developed the Newcastle Mitochondrial Disease Adult Scale (NMDAS) in 
order to provide a standardised assessment (Schaefer et al., 2006). The NMDAS 
consists of a number of sections with the first portion being a questionnaire filled in 
by the patients and the second portion consisting of more clinical measurements. 
Thus for each clinical assessment a patient will receive a score for each symptom 
specific sub-section (e.g. myopathy or diabetes) and an overall NMDAS score. The 
NMDAS is a valuable tool to both standardise assessment within the centre and 
externally and has proven to be a good means of assessing patient disease 
progression. An example of the NMDAS questionnaire is included in Appendix 1. 
 
2.8 Histochemistry 
2.8.1 Haematoxylin and eosin 
Tissue sections were removed from -80 °C storage and air dried on the bench for 
one hour. Slides were immersed in Haemotoxylin for 10 minutes and subsequently 
washed in tap water until the water turns clear. A drop of ammonia was added for 
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blueing and the slides were rinsed again. Slides were immersed in eosin for one 
minute and washed with tap water until the water turns clear. Sections were rapidly 
dehydrated in an ascending ethanol gradient (70%, 90%, 100%, 100%) and cleared 
in two washes of histoclear before mounting in DPX medium. 
 
2.8.2 COX histochemistry 
Tissue sections were removed from -80 °C storage and air dried on the bench for 
one hour, during which time they were encircled with a hydrophobic pen. Sections 
were rinsed briefly in 1 M PBS whilst the COX incubation medium was prepared. 
COX reagents were defrosted at 55 °C and combined in the following quantities; 200 
µl cytochrome C, 800 µl DAB and a pinch of catalase. Sufficient reaction medium 
was applied to each section (roughly 200 µl). Sections were incubated for 45 minutes 
at 37 °C, after which they were washed for three five minute intervals in 1 M PBS. 
Slides were dehydrated in an ascending ethanol gradient by placing for 10 minutes 
in each ethanol (70%, 90%, 100% and 100%) and cleared in two pots of histoclear 
for 10 minutes each before mounting in DPX. 
 
2.8.3 SDH histochemistry 
Tissue sections were removed from -80 °C storage and air dried on the bench for 
one hour, during which time they were encircled with a hydrophobic pen. Sections 
were rinsed briefly in 1 M PBS. Reagents for SDH reaction medium were defrosted 
at 55 °C and combined in the following quantities; 100 µl sodium succinate, 100 µl 
PMS, 10 µl sodium azide and 800 µl NBT. Sufficient reaction medium was applied to 
each section (roughly 200 µl). Sections were incubated for 40 minutes at 37 °C. 
Sections were incubated for 45 minutes at 37 °C, after which they were washed for 
three five minute intervals in 1 M PBS. Slides were dehydrated in an ethanol gradient 
by placing for 10 minutes in each ethanol (70%, 90%, 100% and 100%) and cleared 
in two pots of histoclear for 10 minutes each before mounting in DPX. 
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2.8.4 Sequential COX/SDH histochemistry 
Tissue sections were removed from -80 °C storage and air dried on the bench for 
one hour, during which time they were encircled with a hydrophobic pen. Sections 
were rinsed briefly in 1 M PBS whilst the COX incubation medium was prepared. 
COX reagents were defrosted at 55 °C and combined in the following quantities; 200 
µl cytochrome C, 800 µl DAB and a pinch of catalase. Sufficient reaction medium 
was applied to each section (roughly 200 µl). Sections were incubated for 45 minutes 
at 37 °C, after which they were washed for three five minute intervals in 1 M PBS. 
Reagents for SDH reaction medium were defrosted at 55 °C and combined in the 
following quantities; 100 µl sodium succinate, 100 µl PMS, 10 µl sodium azide and 
800 µl NBT. Sufficient reaction medium was applied to each section (roughly 200 µl). 
Sections were incubated for 40 minutes at 37 °C, after which they were washed for 
three five minute intervals in 1 M PBS. Slides were dehydrated in an ethanol 
gradient, with 10 minutes in each ethanol (70%, 95%, 100% and 100%) and cleared 
in two pots of histoclear for 10 minutes each before mounting in DPX. 
 
2.9 Immunofluorescence 
2.9.1 Quadruple immunofluorescence 
Tissue sections were removed from -80 °C storage and air dried for one hour during 
which the slides were labelled as either primary antibody or no primary control (NPC) 
and each section encircled using a hydrophobic pen. Sections were fixed in 4% cold 
PFA over a period of three minutes. Slides were rinsed quickly twice with TBST, 
followed by 10 minutes in 1X TBST. Sections were dehydrated and rehydrated in a 
methanol series; 70% (10 minutes), 95% (10 minutes), 100% (20 minutes), 95% (10 
minutes), 70% (10 minutes), followed by three five minute washes in 1X TBST. 
Sections were then blocked for one hour at room temperature with 10% NGS in 
TBST. Approximately 200 µl primary antibody cocktail was applied to one section 
from each patient and a no primary control (NPC) cocktail applied to a corresponding 
NPC section. Both cocktails were made in 10% NGS and all primary antibody 
concentrations can be found in Table 2.11.  Sections were placed at 4 °C overnight. 
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Sections were washed for three five minute washes in 1X TBST. Approximately 
200µl secondary antibody cocktail was added to all sections and sections incubated 
at 4 °C for two hours. Secondary antibody concentrations can be found in Table 
2.12. 
Sections were washed for three five minute periods in 1X TBST. If a streptavidin 
conjugated secondary antibody was being used this was added next. Approximately 
200 µl was applied to each section and sections incubated for 2 hours at 4 °C. Slides 
were washed for three periods of five minutes in 1X TBST, mount in Prolong Gold 
mounting medium for fluorescence (Life Tech) and encircled with nail varnish. 
 
Antibody Supplier Product 
number 
Dilution 
Mouse anti-desmin (IgG1) Dako M076029-2 1:400 
Rabbit anti-laminin 
(polyclonal) 
Sigma L9393 1:50 
Mouse anti-MTCOI (IgG2a)  Abcam ab14705 1:100 
Mouse anti-myotilin (IgG2a) Santa Cruz 
Biotechnologies 
sc-393958 1:100 
Mouse anti-NDUFB8 (IgG1) Abcam ab110242 1:100 
Mouse anti-SDHA (IgG1) Abcam Ab14715 1:100 
Mouse anti-VDAC1 IgG2b Abcam ab14734 1:100 
Table 2.11 Primary antibodies used in immunofluorescence and dilutions used. 
 
 
Antibody Supplier Serial 
number 
Dilution 
Anti-IgG1-biotinylated Life Technologies S32357 1:200 
Anti-IgG2a-Alexa Fluor 488 Life Technologies S21131 1:200 
Anti-IgG2b-Alex Fluor 546 Life Technologies A21143 1:200 
Anti-Rabbit-Alexa Fluor 405 Life Technologies A31556 1:200 
Streptavidin-Alex Fluor 647 Life Technologies S21374 1:100 
Table 2.12 Secondary antibodies used for immunofluorescence and dilutions used. 
 
  Chapter 2 
77 
 
2.9.2 Counterstaining of COX/SDH histochemistry or immunofluorescence with 
DAPI. 
Counterstaining with DAPI was completed following incubation with SDH reaction 
medium and PBS washes for COX/SDH histochemistry and following TBST washes 
after the final secondary antibody incubation for immunofluorescence. Sections were 
washed thoroughly in either PBS (histochemistry) or TBST (immunofluorescence) 
before counterstaining with DAPI at a concentration of 2 μg/ml in PBS for 5 minutes. 
Sections were washed again and mounted in ProLong Gold. 
 
2.9.3 Fluorescence microscopy 
Fluorescent images were captured at either 10x, 20x or 40x magnification using a 
Zeiss axioimager M1 and either axiovision or ZEN blue software with a monochrome 
digital camera (AxioCam MRm) and filter cubes for dyes at 405 nm, 488 nm, 546 nm 
and 647 nm. A motorised stage and software tiling function allowed automated 
scanning of full muscle biopsy sections. Exposure times for each channel were 
chosen to avoid over exposure and minimise background detected on primary 
controls. Exposure times were used for all cases and controls within an experiment. 
Following imaging .zvi files were stitched to generate a .czi file for image analysis. 
 
2.9.4 Imaris image analysis 
Imaris version v7.7.2 was used to quantify mean fluorescent intensity per fibre for 
each channel. Individual fibres were isolated using the membrane marker laminin to 
create surface one. Surface one was masked and a second surface created over 
each fibre. Unwanted areas were removed either by thresholding of the analysis or 
manually removed at the end. The mean optical density for the 488, 546 and 647 
channels was automatically measured. 
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2.9.5 R statistical analysis of quantitative immunofluorescence 
Data generated by analysis of quadruple immunofluorescence in Imaris was 
statistically analyzed using an R-script written by Dr John Grady. The R script first 
corrected for background in each channel by subtracting the average optical density 
(OD) for each channel in the no primary control from the values generated from the 
section labelled with all primary antibodies. Background corrected values were log 
transformed to normalise data and the VDAC distribution was checked to confirm 
that it was normally distributed. Mean and standard deviation of the control 
population were obtained and z-scores determined for VDAC, complex I and IV 
based on the expected level of each calculated using the VDAC level as a 
mitochondrial mass marker. A z-score for each control and patient fibre is generated 
for each channel. This z-score allows each fibre to be classified as positive, 
intermediate positive, intermediate negative or negative for complex I and IV and 
very low, low, normal, high or very high for VDAC. The boundaries of categories 
were tested and validated by Rocha et al. (2015), and further details of statistical 
analysis are also described. 
 
2.10 DNA extraction and cell lysis 
2.10.1 Laser microdissection 
Individual cells were captured by laser microdissection using a Zeiss Laser Capture 
Microdissection microscope with Palm Robo v4.6. Single muscle fibres were traced 
using the RoboLPC function and with cut settings; energy = 33 and focus =71 and 
LPC settings; energy = 15 and delta = 1. Two 0.2 ml eppendorfs were inserted into 
the tube collection holder and 15 µl of lysis buffer appropriate for the downstream 
application (2.10.2 or 2.10.3) added to each cap. Cell traces were selected and 
assigned to Tube 1 or Tube 2 and upon initiation the laser cut around the cell and 
fired it into the target cap.  After cutting tubes containing cells were kept on ice and 
then were centrifuged briefly using the “short spin” function to bring lysis buffer and 
cell to the bottom prior to incubating for the appropriate lysis protocol (2.10.2 or 
2.10.3). 
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2.10.2 Tris-Tween single cell lysis 
Tris-Tween-Protinase K lysis buffer (0.5 M Tris-HCl, 0.5% Tween 20, 1% Proteinase 
K, pH 8.5) is made up in a UV hood. Cells were captured into 15µl lysis buffer, 
centrifuged briefly and incubated at 55°C for three hours, followed by 10 minutes at 
95 °C. 
 
2.10.3 SDS-EDTA single cell lysis 
SDS-EDTA-Protinase K lysis buffer (0.5% SDS, 10 mM EDTA, 5% proteinase K) is 
made up in a clean room with a laminar flow hood. Cells were captured into 15 µl 
lysis buffer, vortexed for 30 seconds, centrifuged briefly and incubated at 37 °C for 
two hours. 
 
2.10.4 DNA extraction from blood homogenate 
10 ml of anonymised frozen control blood was provided by NGS mitochondrial 
disease diagnostic service for DNA extraction. DNA extraction was completed using 
a QIAGEN Mini extraction kit following the manufacturer’s instructions. The blood 
was split and processed in 10 x 1 ml samples. Columns were left to stand for 5 
minutes in AE buffer to increase DNA yield and samples were eluted into 50 µl of 
nuclease free water rather than TE buffer in case of incompatibility with any 
downstream applications. DNA was quantified using the Nanodrop with the lowest 
concentration being 63 ng/µl.  
 
2.11 PCRs and sequencing 
2.11.1 D-loop/MT-ND1/MT-ND4 triplex real rime PCR deletion assay 
A triplex real time PCR assay was used to quantify mtDNA deletion level as 
described previously (Rygiel et al., 2015a). This method quantifies relative levels of 
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MT-ND4 (commonly deleted) and MT-ND1 (rarely deleted) and D-Loop (rarely 
deleted), using TaqMan chemistry.  Primers and TaqMan MGB probes to detect MT-
ND1, MT-ND4 and D-Loop used have been previously reported (Rygiel et al., 
2015a). MT-ND1, MT-ND4 and D-Loop probes were coupled with VIC, FAM and 
NED fluorophores, respectively.  PCR amplification was carried out as described 
previously (Rygiel et al., 2015a), in a 25 µl reaction in triplicate for each sample, with 
each plate containing a serial dilution of p7D1 plasmid for standard curve generation. 
Real time primer details can be found in Table 2.13 and probe details in Table 2.14. 
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Primer 
pair 
Primer 
name 
Primer 
position 
Sequence 
D-Loop D-Loop 
forward 
chrM:16536-
16557 
5′-CCCACACGTTCCCCTTAAATAA-3′ 
D-Loop 
reverse 
chrM:34-9 5′-CGTGAGTGGTTAATAGGGTGATAGAC-
3′  
MT-ND1 MT-ND1 
forward 
chrM:3485-
3504 
5’-CCCTAAAACCCGCCACATCT-3’ 
MT-ND1 
reverse 
chrM:3532-
3553 
5’-GAGCGATGGTGAGAGCTAAGGT-3’ 
MT-ND4  MT-ND4 
forward 
chrM:12087-
12109 
5’-CCATTCTCCTCCTATCCCTCAAC-3 
MT-ND4 
reverse 
chrM:12170-
12140 
5’–
CACAATCTGATGTTTTGGTTAAACTATAT
TT-3’ 
Table 2.13 Real time PCR primer positions and sequences. All primer sequences 
are based on the revised Cambridge reference sequence (NC_012920.1). 
 
 
Probe Primer position Sequence 
D-Loop chrM:16559–6 NED-5′-ACATCACGATGGATCAC-3′-MGB 
ND1 chrM:3506-3529 VIC-5’-CCATCACCCTCTACATCACCGCCC-3’-
MGB 
ND4 chrM:12111-
12138 
FAM-5’-
CCGACATCATTACCGGGTTTTCCTCTTG-3’-
MGB 
Table 2.14 Real time probe positions and sequences. All probe sequences are 
based on the revised Cambridge reference sequence (NC_012920.1). 
 
 
2.11.2 Long range PCR primer design and selection (work by Dr. Georgia Cambell) 
A large number of primer pairs were designed to amplify roughly 16 Kb amplicons 
from the mitochondrial genome. Primers were designed using the PrimerBLAST 
(NCBI) web programme and based on the Revised Cambridge reference sequence 
(rCRS), GenBank accession number NC_012920.1 for human mtDNA.  These 
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primer sets were then grouped dependent by size, melting temperature (Tm) and 
location in the mtDNA. Following this the primers were narrowed down. Primers were 
required to have a one or two base pair (bp) GC-clamp (primers with a 3’ Guanine or 
Cysteine bind more efficiently and greater than 2 bp GC-clamp have an increased 
risk of non-specific binding) and not have a greater than 4 bp repeat of a single 
nucleotide (poly X repeat). 
Finally, one primer pair for each set of reaction conditions and mtDNA location was 
selected to order and test. The final 16 Kb primer pairs selected can be found in 
Table 2.15. In addition, when working with single cell lysates it sometimes become 
necessary to implement a second round of amplification, which is commonly more 
successful using nested primers, as such 30 second round (three per first round pair, 
Table 2.16) were designed and ordered also. 
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Primer 
pair 
Primer Primer position Primer 
Length 
(bp) 
Amplicon 
size (bp) 
Tm 
(°C) 
Gene 
located 
in 
1 
 
1F chrM:3-27 25 16358 60 D-Loop 
1R chrM:16360-16336 25 
2 
 
2F chrM:2700-2724 25 15876 63 16S 
2R chrM:1956-1932 25 
3 
 
3F chrM:2699-2724 26 15822 67 16S 
3R chrM:2006-1982 25 
4 4F chrM:3086-3115 30 15882 60 16S 
4R chrM:2339-2310 30 
5 5F chrM:2862-2891 30 16070 63 16s 
5R chrM:2362-2333 30 
6 6F chrM:122-150 29 16188 63 D-Loop 
6R chrM:16309-6281 29 
7 7F chrM:2180-2209 30 16178 67 12S 
7R chrM:1789-1760 30 
8 8F chrM:458-490 34 15848 63 D-Loop 
8R chrM:16305-16273 33 
9 9F chrM:1371-1405 35 16306 67 12S 
9R chrM:1108-1074 35 
10 10F chrM:442-476 35 16090 67 D-loop 
10R chrM:16531-16497 35 
 
Table 2.15 16 Kb long range PCR first round primer pairs selected for optimisation. 
Primer pairs were selected to have a range of melting temperatures (Tm) and primer 
lengths as well as for the gene in which they bind. Primers are designed using the 
revised Cambridge reference sequence (rCRS), GenBank accession number 
NC_012920.1, for human mtDNA. 
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First 
round 
primer 
pair 
Second 
round 
primer 
pair 
Primer Primer position Primer 
Length 
(bp) 
Amplicon 
size (bp) 
Tm 
(°C) 
1 
 
1A 1AF chrM:116-140 25 16131 60 
1AR chrM:16246-16222 25 
1B 1BF chrM:261-285 25 16031 60 
1BR chrM:16291-16267 25 
1C 1CF chrM:126-150 25 16179 60 
1CR chrM:16304-16281 24 
2 
 
2A 2AF chrM:2768-2793 26 15534 63 
2AR chrM:1733-1758 26 
2B 2BF chrM:2860-2884 25 15480 63 
2BR chrM:1771-1749 24 
2C 2CF chrM:2939-2967 29 15488 63 
2CR chrM:1858-1830 29 
3 
 
3A 3AF chrM:2974-3001 28 15512 67 
3AR chrM:1917-1893 25 
3B 3BF chrM:3015-3040 26 15505 67 
3BR chrM:1951-1926 26 
3C 3CF chrM:2769-2794 26 15752 67 
3CR chrM:1952-1926 27 
4 4A 4AF chrM:3269-3297 29 15534 60 
4AR chrM:2260-2234 27 
4B 4BF chrM:3273-3302 30 15561 60 
4BR chrM:2265-2239 27 
4C 4CF chrM:3210-3236 27 15445 60 
4CR chrM:2086-2060 27 
5 5A 5AF chrM:3039-3068 30 15793 63 
5AR chrM:2263-2235 29 
5B 5BF chrM:3087-3116 30 15744 63 
5BR chrM:2262-2234 29 
5C 5CF chrM:2939-2967 29 15846 63 
5CR chrM:2216-2188 29 
6 6A 6AF chrM:333-362 30 15900 63 
6AR chrM:16233-16204 30 
6B 6BF chrM:358-386 29 15874 63 
6BR chrM:16232-16204 29 
6C 6CF chrM:448-476 29 15802 63 
6CR chrM:16250-16222 29 
7 7A 7AF chrM:2330-2359 30 15951 67 
7AR chrM:1712-1683 30 
7B 7BF chrM:2328-2412 30 15967 67 
7BR chrM:1726-1697 30 
7C 7CF chrM:2331-2359 29 15883 67 
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7CR chrM:1645-1616 30 
8 8A 8AF chrM:648-677 30 15522 63 
8AR chrM:16170-16141 30 
8B 8BF chrM:580-309 30 15532 63 
8BR chrM:16112-16084 29 
8C 8CF chrM:720-748 29 15512 63 
8CR chrM:16232-16204 29 
9 9A 9AF chrM:1413-1442 30 16186 65 
9AR chrM:1030-1001 30 
9B 9BF chrM:1530-1559 30 16071 65 
9BR chrM:1032-1003 30 
9C 9CF chrM:1560-1588 29 15980 65 
9CR chrM:971-944 28 
10 10A 10AF chrM:719-748 30 15703 65 
10AR chrM:16422-16394 29 
10B 10BF chrM:608-635 28 15703 65 
10BR chrM:16311-16281 31 
10C 10CF chrM:582-609 28 15711 65 
10CR chrM:16293-16267 27 
Table 2.16 16 Kb long range PCR second round primer. For each first round primer 
three second round primer pairs were designed and these have been labelled using 
the number of the first round primer pair they correspond to and the letters A to C. 
For each primer pair the Tm (meting temperature) and length is generally similar to 
the first round primer pair. Primers are designed using the revised Cambridge 
reference sequenc (rCRS) GenBank accession number NC_012920.1 for human 
mtDNA. 
 
2.11.3 Optimisation of long range PCR 
All twenty primer pairs were trialed with LA Taq and PrimeSTAR taq polymerase 
using two sets of cycling conditions for each taq polymerase. Initial testing was 
completed using 50 µl reaction volumes for both polymerases and 1x mastermix 
(Table 2.17) volumes were decided based on the manufacturer’s guidance. Cycling 
conditions are summarised in Table 2.18. 
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Table 2.17 1x reaction master mix for PrimeSTAR GXL and LA Taq. 
 
 
Polymerase Cycling protocol 1 Cycling protocol 2 
PrimeSTAR GXL 40 cycles of 98 °C for 10 
seconds followed by 68 °C 
for 16 minutes. Hold at 4°C 
35 cycles of 98 °C for 10 
seconds followed by 68 
°C for 11 minutes. Hold at 
4 °C 
LA Taq Initial denaturation at 94 °C 
for 30 seconds followed by 
35 cycles of 94 °C for 30 
second, 58 °C for 30 
seconds and 68 °C for 11 
minutes. Then a final 
extension of 72 °C for 10 
minutes and hold at 4 °C. 
Initial denaturation at 94 
°C for 30 seconds 
followed by 35 cycles of 
94 °C for 30 second and 
68 °C for 15 minutes. 
Then a final extension of 
72 °C for 10 minutes and 
hold at 4 °C. 
Table 2.18 Cycling conditions trialled for PrimeSTAR GXL and LA Taq 
 
 
Results of initial trials for 16 Kb primer pairs can be found in Figure 2.1. Primer pairs 
that successfully amplified a product from the 1 in 10 (10-1) dilution of wild type blood 
homogenate were carried forward and tested on serial dilutions from 10-1 to 10-5 to 
test which primers work best at lower concentrations of blood homogenate (Figure 
2.2), which would be similar to that achieved from a single cell lysate. 
PrimeSTAR GXL 1x mastermix LA Taq 1x mastermix 
Nuclease free water 32 µl Nuclease free water 33.5 µl 
5x PrimeSTAR GXL buffer 10 µl 10x LA Taq buffer 5 µl 
dNTPs (2.5 µm) 4 µl dNTPs (2.5 µm) 8 µl 
Forward primer (10 µm) 1 µl Forward primer (10 
µm) 
1 µl 
Reverse primer (10 µm) 1 µl Reverse primer (10 
µm) 
1 µl 
PrimeSTAR GXL 
polymerase 
1 µl LA Taq polymerase 0.5 µl 
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Following this the best conditions were selected for each polymerase, this was the 3-
temperature cycling protocol (protocol 1) for LA taq and the 11 minutes extension 
time and 35 cycles (protocol 2) for PrimeSTAR GXL to be carried forward for trial on 
single cell lysates. 
Interestingly, for the primers for 16 Kb long range PCR ranking of primer pair for 
each of LA taq and PrimeSTAR GXL demonstrates that the best primers are 30 bp in 
length and melting temperature varies substantially. Whereas for LA Taq the best 
primer pairs have a high Tm of 66 or 67 °C but vary in length. Therefore, it appeared 
that primer length was most important for successful amplification with PrimeSTAR 
GXL whereas Tm is important for LA taq. 
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Figure 2.1 16 Kb Long range PCR testing primer pairs (PP) 1 to 10 on wild type 
blood homogenate DNA. (a) PrimerSTAR GXL taq polymerase with 16 minute 
extension time and 40 cycles. (b) PrimerSTAR GXL taq polymerase with 11 minute 
extension time and 35 cycles. (c) LA taq polymerase using the two temperature step 
protocol. (d) LA taq polymerase using a three temperature step protocol. L; 1Kb 
ladder (Promega), N; neat, 10-1; 1 in 10 dilution of N and NTC; no template control. 
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Figure 2.2 16Kb Long range PCR testing for primer pairs down to 10-5. (a) 
PrimerSTAR GXL taq polymerase with primer pairs 1 to 5, 7 and 8 (b) LA taq 
polymerase with primer pairs 1-5 and 7 to 9. Ladder; 1 Kb ladder (Promega), 10-2; 1 
in 100, 10-3; 1 in 10 dilution of 10-2, 10-4; 1 in 10 dilution of 10-3, 10-5; 1 in 10 dilution 
of 10-4, and NTC; no template control. 
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Based on serial dilution success the two most successful primers for each 
polymerase were selected for trial on multiple deletion single cell lysates. Single cells 
were laser microdissected from a SDH stained muscle section of a patient 20, with 
RRM2B variants. Previous work using single cell lysates for long range PCR and real 
time PCR demonstrated a difference in success of different lysis methods e.g. SDS-
EDTA-proteinase K lysis is not successful with real time PCR. As such two lysis 
methods were trialed; 10 fibres were captured into a tris-tween proteinase K lysis 
buffer and 10 fibres captured into a SDS-EDTA-proteinase K lysis buffer and 
incubated as stated in 2.10.2 and 2.10.3. A 10-3 wild type blood homogenate was run 
as a positive control on every PCR plate alongside the no template control. 
This demonstrated better amplification with SDS-EDTA-proteinase K lysis buffer than 
tris-tween-proteinase K lysis buffer with both LA taq and PrimeSTAR for the selected 
primer pairs. For 16 Kb long range on single cell lysates it was often the case that a 
product would not be detectable following the first round therefore a set of three 
second round nested primers were designed for each of the 16 Kb first round primer 
pairs. After an unsuccessful or partially successful first round of PCR second round 
primers were then trialed to see if this boosted amplification, which it often did. 
Successful primer pairs were trialed for reduced reaction volumes including 25 µl 
and 10 µl as this is necessary in order to be cost effective when preforming both long 
range and most importantly single molecule PCR.  Figure 2.3 demonstrates 
amplification of wild type and deletion molecules from COX negative fibres from 
patient 20 with RRM2B variants and multiple mtDNA deletions. This was completed 
in 10 µl reaction volumes in quadruplicate and the gel presented is a second round 
reaction. 
The most successful 16 Kb primer, taq and cycling condition combination for 
amplification of single cell lysates was PrimeSTAR GXL, using 11 minutes extension 
and 35 cycles with primer pair number six (122F/16309R) and second round primer 
pair 6A (333F/16233R). These were trialed unsuccessfully for single molecule PCR, 
This would require further optimisation to use in future. Subsequently primer pair 6 
was no longer viable, therefore primer pair 7 (2180F/1789R) with PrimeSTAR GXL 
was subsequently used for long range PCR in 2.11.4 and Chapters 3 and 4. 
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Figure 2.3 16 Kb Long range PCR using primer pair 6 (122F/16309R) and second 
round primer pair 6B (333F/16233R) on single fibre lysates. COX negative fibres 1 to 
10 from patient 20 with RRM2B variants and multiple mtDNA deletions and blood 
homogenate and no template. 
 
2.11.4 Final Long range PCR protocol 
Two rounds of PCR were employed to screen single muscle fibre lysates for large-
scale mtDNA rearrangements using PrimeSTAR GXL (TaKaRa, Clonetech). The 
reaction was prepared as follows: 1 μl cell lysate, 1x PrimeSTAR GXL reaction 
buffer, 0.2 μM dNTPs, 0.2 μM forward and reverse primers and 0.625 unit 
polymerase, in a total volume of 50 μl. The first round of PCR amplified a 16179 bp 
region using primer pair 7 (2180F/1789R) (Table 2.15) and the second round 
reaction amplified a 16029bp region using the reverse primer from primer pair 7 and 
the forward primer from primer pair 7A (2330F/1789R) (Table 2.16). Cycling 
conditions were: 35 cycles of 10 seconds at 98 °C and 11 minutes at 68 °C.  PCR 
products were separated through a 0.7% agarose gel with a 1 Kb ladder used to size 
amplicons. 
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2.11.5 Agarose gel electrophoresis 
Agarose was dissolved in 1 x TAE by heating in a microwave until boiling. For long 
range and smPCR products which were in excess of 10 Kb in length 0.7% agarose 
gel was used. 4 µl of gel red was added per 100 ml for DNA visualisation. This was 
emptied into a gel cassette and a well comb inserted. The gel was allowed to set 
before transfer to an electrophoresis tank filled with 1 x TAE running buffer. 1 µl of 
loading dye was added to each well of the plate and 5 µl of each sample was loaded 
on to the gel. 5 µl of an appropriately sized DNA ladder was also loaded for sizing of 
products. The gel was run out at 140 volts until the PCR products were sufficiently 
separated. PCR products were visualised and imaged using the BioRad ChemiDoc. 
 
2.12 Electron microscopy techniques 
2.12.1 Transmission electron microscopy 
Muscle fibre bundles were teased from a fresh biopsy and lightly fixed overnight in 
2% glutaradehyde (in Sorenson’s buffer (0.1M, pH7.4)) at 4 °C. All subsequent 
processing of samples was completed by Drs Kathryn White and Tracey Davey in 
Electron Microscopy Research Services (EMRS). Fibres were post fixed in 1% 
osmium tetroxide for one hour. Samples are dehydrated in a graded series of 
acetone (25%, 50%, 75%, 100%) before being embedded in epoxy resin (TAAB 
medium grade) and polymerised at 60 °C. Sections are cut on an ultramicrotome, 
firstly semi-thin sections (0.5 µm) are stained with toluidine blue for LM to identify the 
area of interest/confirm orientation of tissue. Ultrathin sections (70 nm) are then cut 
and picked up onto copper grids. Sections were stained with uranyl acetate and lead 
citrate before being viewed on the TEM (Philips CM100). Images were captured 
using an AMT CCD camera (Deben). Scanning for regions of interest 5800x and 
initial images were captured at 7900x, more detailed images were captured at 
13500x. Fibres selected for analysis had to have no more than two z-lines separated 
by a minimum of 10–15 μm in order to be deemed optimally transverse in orientation. 
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2.12.2 Serial block face scanning electron microscopy 
Processing of samples was completed by Drs Kathryn White and Tracey Davey in 
EMRS. Tissue was fixed in 2% glutaraldehyde in 0.1 M cacodylate buffer. It is then 
treated with a series of heavy metals as described previously (Deerinck T et al., 
2010). Briefly, tissue was immersed in 3% potassium ferrocyanide + 2% osmium 
tetroxide, followed by 0.1% thiocarbohydrazide, then 2% osmium tetroxide and finally 
left overnight in 1% uranyl acetate (with water washes between each step). The next 
day the samples were immersed in 0.6% lead aspartate solution and then 
dehydrated in graded acetone and embedded in epoxy tab 812 hard resin. After 
polymerisation the block was trimmed and sectioned for TEM to identify the area of 
interest before performing serial block face SEM. Fibres with a high mitochondrial 
content were selected, from cases with specific mitochondrial pathology detected via 
TEM and a z- stack was captured using the Gatan 3view system and digital 
micrograph software to allow further analysis of mitochondrial pathology. 
 
2.13 Statistical analyses 
Graphs were produced in Prism v7.0 and statistical analysis was performed in a 
combination of R v3.3.0, Prism v7.0 and Mini tab 17. Normality tests and histograms 
were performed to assess normality where appropriate and then data normalised (if 
possible) prior to selecting the appropriate parametric or non-parametric statistical 
test. Specific tests area specified in the methods and results sections of individual 
chapters. 
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Chapter 3. Dysferlinopathy and mitochondrial dysfunction 
3.1 Introduction: 
3.1.1 Dysferlin and ferlin proteins 
The ferlin protein group to which dysferlin belongs all have Ca2+ sensitive C2 
domains (Lek et al., 2010), dysferlin itself has seven C2 domains with variable 
affinities for Ca2+ (Abdullah et al., 2014).  As a group ferlin proteins play roles in 
vesicle and membrane fusion events. 
Dysferlin is encoded by the DYSF gene, the loci for which is 2p13 (MIM*603009). 
Dysferlin localises to the sarcolemmal membrane (Figure 3.1) and is a membrane 
resealing protein which repairs damage to the sarcolemmal membrane caused by the 
mechanical stress due to muscle contraction. It has previously been demonstrated 
that an influx of Ca2+ through the site of membrane injury binds to the C2 domains of 
dysferlin and triggers dysferlin-mediated membrane repair (Bansal et al., 2003). 
Membrane rupture results in an influx of Ca2+ which binds to dysferlin, this triggers 
fusion of cytosolic vesicles and localisation to the site of membrane resealing where 
the vesicles fuse with the membrane repairing the damage. Figure 3.2 is a schematic 
showing how membrane resealing occurs. Patients with dysferlin mutations often 
have impaired membrane resealing, this is of particular importance in skeletal muscle 
where Ca2+ concentration is highly important. 
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Figure 3.1 Dystroglycan complex and localisation of dysferlin in the sarcolemma. 
 
 
Figure 3.2 Schematic demonstrating the mechanism of dysferlin mediated 
membrane repair. (a) Before membrane damage, (b) membrane damage and influx 
of calcium which binds to annexin A1/A2 and dysferlin. (c) Cytoplasmic vesicles fuse 
and (d) move to the site of membrane damage. (e) Vesicles fuse with the membrane 
sealing the hole. 
 
  Chapter 3 
96 
 
3.1.2 Dysferlinopathy 
Mutations of the DYSF gene generate a heterogeneous clinical phenotype presenting 
as; limb girdle muscular dystrophy type 2B (LGMD2B), Miyoshi Myopathy (MM) 
(Bashir et al., 1998; Liu et al., 1998), distal myopathy with anterior tibialis onset 
(DMAT) (Bansal and Campbell, 2004) or muscular dystrophy with congenital onset 
(Paradas et al., 2009). MM (MIM*254130) is typically autosomal recessive in 
inheritance, with onset during young adult hood. Although MM is caused by 
mutations in DYSF, it is genetically heterogeneous and mutations in ANO5 are also 
known to cause MM. LGMD2B (MIM*253601), also fits an autosomal recessive 
pattern of inheritance, with typical onset between 15 and 25 years (Bashir et al., 
1994). DMAT (MIM*606768) has an autosomal recessive pattern of inheritance and 
has reported onset between 14 and 28 years.  
 
3.1.3 Inflammatory myopathies and mitochondria 
Inflammatory myopathies are a group of conditions characterised by inflammation 
and inflammatory infiltrates. These include; polymyositis, dermatomyosistis and 
inclusion body myositis (IBM) (Dubowitz, 2007). A proportion of these have been 
found to be associated with skeletal muscle mitochondrial abnormalities (Oldfors et 
al., 1993; Levine and Pestronk, 1998), these are most prominent in sporadic IBM. In 
sporadic IBM, percentage COX-deficiency of up to 5% (Oldfors et al., 1995) has been 
reported and around 50% of these COX-deficient fibres have been shown to have 
one or more large-scale mtDNA rearrangements (Rygiel et al., 2016).  Interestingly, 
inflammatory infiltrates also correlate with the level of respiratory chain deficiency and 
myofibre atrophy (Rygiel et al., 2015b). Mutations in the DYSF gene have been 
associated with inflammatory myopathy (Fanin and Angelini, 2002; Yin et al., 2015) 
and it is due to this commonality between sporadic IBM and dysferlinopathy 
researchers have become interested in how mitochondria function in patients with 
DYSF mutations. 
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3.1.4 Dysferlin and mitochondria 
In addition to the inflammatory nature of both IBM and dysferlinopathies, 
mitochondria have been demonstrated to accumulate at the site of membrane 
damage and inhibition of mitochondrial function inhibits healing of injured myofibres 
in intact myofibres (Sharma et al., 2012). This further suggest that mitochondria may 
be pathologically involved in disease pathology of patients with DYSF mutations.  
Two reports have so far demonstrated mitochondrial abnormalities in patients with 
dysferlin variants.  The first report found an accumulation of subsarcolemmal 
mitochondria in some patients’ myofibres including one patient with COX or complex 
IV deficient ragged red fibres (RRF) and paracrystalline inclusions (Gayathri et al., 
2011).  The second investigation reported up to 10% of myofibres to be COX-
deficient, and some of these fibres have increased mitochondrial mass (Liu et al., 
2016).  The same study also observed a decreased complex IV and complex III 
levels of activity in some patients, whilst others showed a significant reduction of 
complex I and complex IV and a mild decrease in complex III activities.  
Recent work looking at membrane repair in mdx mice which have a C>T transition in 
exon 23 of the dystrophin gene and are a disease model for Duchenne muscular 
dystrophy has found mitochondria to be important in dysferlin mediated membrane 
repair (Vila et al., 2016). They report that in mdx mice mitochondrial accumulation at 
the site of injury and mitochondrial mass is significantly reduced compared to wild 
type mice and dysferlin protein levels are increased. This increase in dysferlin 
relieves the cellular stress induced by membrane rupture but is not sufficient to repair 
the fibre. Furthermore, in dysferlin and dystrophin double knock out mice they find 
that this increases severity of disease when DYSF knockout alone causes no 
phenotype at the same age. The underlying mechanism was not demonstrated, 
however they hypothesise this may be due to reduced muscle fibre bioenergetics and 
calcium handling. 
The findings presented here have been published (Vincent et al., 2016c), this paper 
can be found in Appendix 2. 
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3.2 Aims of this investigation: 
This study aimed to characterise the degree of mitochondrial dysfunction in a cohort 
of dysferlinopathy patients and determine the mechanisms of mitochondrial 
involvement in DYSF mutation pathogenesis. 
3.3 Methodology: 
3.3.1 Patient cohort: 
Muscle biopsies were taken for diagnostic purposes from patients (n = 8), with a 
suspected neuromuscular condition; all patients consented to the use of the sample 
for research.  Diagnostic immunohistochemistry and western blotting showed an 
absence of dysferlin protein and sequencing of the DYSF gene identified pathogenic 
mutations confirming a diagnosis of dysferlinopathy. Relevant clinical and diagnostic 
details for all eight patients included in this study can be found in Table 2.7. Six were 
diagnosed with LGMD2B and the remaining two with MM.  A previously reported 
patient with recessive Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) 
variants (Patient 20,  
Table 2.9) (Pitceathly et al., 2012b), mtDNA maintenance disorder and multiple 
mtDNA deletions was used as a positive control. This patient has multiple mtDNA 
deletions due to an imbalance in the dNTP pools caused by the mutation in RRM2B, 
the product for which is involved in dNTP synthesis. In addition three healthy control 
biopsies were also used; Controls 1, 2 and 3 which were 18, 35 and 52 years 
respectively. The healthy disease control information can be found in Table 2.6. 
Ethical approval was granted by the Newcastle and North Tyneside Local Research 
Ethics Committees (reference 2002/205). 
 
3.3.2 Histochemistry: 
Three serial cryosections (10 μm) were reacted for COX, SDH and sequential 
COX/SDH histochemistry as described in 2.8.2, 2.8.3 and 2.8.4. A serial section was 
stained with haematoxylin and eosin (H&E) (as described in 2.8.1) to examine 
muscle morphology. 
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3.3.3 Stereology 
Numbers of COX-deficient fibres were counted in a defined area for each section 
using the meander scan function in Stereo Investigator and a Stereology microscope.  
Sections were assessed independently by two investigators (myself and Hannah 
Rosa), due to the subjectivity of assessment by eye. Myofibres were classified as 
COX-negative (blue), intermediate-negative (blue-grey), Intermediate-positive 
(brown-grey) and positive (brown) (Figure 3.3), in order to be more comparable with 
quantitative immunofluorescent assessment. 
 
Figure 3.3 Guide to classification of fibres as COX-negative, intermediate negative, 
intermediate positive and positive, for comparison to the quadruple 
immunofluorescence assay. 
 
3.3.4  Laser microdissection and cell lysis 
Three serial cryosections (15 μm) were cut and the first and last muscle sections 
underwent sequential COX/SDH histochemistry (as described in 2.8.4) and were 
used to assess COX deficiency of myofibres. The second tissue section underwent 
SDH histochemistry (as described in 2.8.3) only and was used for mtDNA analysis.  
Single myofibres were laser microdissected as described in 2.10.1 and captured into 
15 µl SDS-EDTA-Proteinase K lysis buffer as described in 2.10.3. 
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3.3.5 Long Range PCR 
Long range PCR was performed on single cell lysates of 20 fibres per patient as 
described in 2.10.4. Primer information is detailed in Table 2.15 and Table 2.16. 
PCR products were separated through a 0.7 % agarose gel with a 1 Kb ladder used 
to size amplicons. 
 
3.3.6 Immunofluorescent analysis of respiratory chain protein expression profiles 
A quantitative  immunofluorescent assay was used to assess levels of complex I and 
complex IV relative to mitochondrial mass (Rocha et al., 2015). Immunofluorescence 
was completed as described in 2.9.1 with primary antibodies being anti-MTCOI, anti-
NDUFB8, anti-VDAC and laminin and secondary antibodies, anti-IgG2a Alexa Fluor 
488, anti-IgG2b Alexa Fluor 546, Biotinylated IgG1 and Streptavidin conjugated 
Alexa Fluor 647. All antibody dilutions can be found in Table 2.11 and Table 2.12.  
Images were captured on a Zeiss Axioimager and AxioCam MRm with Axiovision and 
then stitched using ZEN (blue edition). Image analysis using Imaris (v.7.7.2) and 
statistical analysis as described in 2.9.4 and 2.9.5. 
 
3.4 Results: 
3.4.1 Histochemistry 
H&E staining demonstrated fibre size variability (Figure 3.4a), muscle fibre necrosis 
(Figure 3.4b), internal nuclei (Figure 3.4c), inflammatory fibres (Figure 3.4d) and in 
some muscle biopsies inflammatory infiltrates. Inflammatory infiltrates were mostly 
associated with (but not limited to) necrotic fibres (Figure 3.5, left column).  
Sequential COX/SDH histochemistry showed a small number (typically less than 1%) 
of COX-deficient fibres (Figure 3.5, right column).  However, many biopsies had a 
large number of fibres that appeared to have intermediate levels of COX deficiency, 
which was difficult to assess by eye (Figure 3.5, Patient 3). Stereo Investigator and a 
stereology microscope were used to count the number of COX positive, intermediate-
positive, intermediate-negative and negative fibres in a defined region (Table 3.1).  
Due to very small numbers of completely COX-deficient fibres and larger numbers of 
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COX-intermediate myofibres, percentage deficiency was likely to be under- or 
overestimated.  Furthermore, counts were completed by two investigators and inter-
investigator variability substantial, due to a large number of fibres intermediate for 
COX activity. This demonstrated the necessity of using quantitative 
immunofluorescence (Rocha et al., 2015) for objective classification of complex I and 
IV deficiency. 
 
 
Figure 3.4 H and E for dysferlin patients. H and E showed (a) muscle fibre size 
variation, (b) necrotic fibres (occasionally with inflammatory infiltrates), (c) internal 
nuclei and (d) inflammatory fibres with vacuoles.  
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Figure 3.5 Histochemical analysis of Dysferlin patient muscle. Serial muscle sections 
from P3, P6 and P8, for H&E, COX, SDH and sequential COX/SDH histochemistry.  
H&E demonstrates large variation in fibre size, with occasional internal nuclei and 
inflammation. Only P6 shows a clear cut COX negative fibre but all three biopsies 
show evidence of intermediate fibres. Adapted from Vincent et al. (2016c). 
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Table 3.1 COX deficiency for dysferlin patients (n = 8) as assessed by sequential 
COX/SDH histochemistry.  Fibres were classified as COX-positive, COX-intermediate 
positive, COX-intermediate negative or COX-negative for comparison with 
immunofluorescent assessment. Adapted from Vincent et al. (2016c). 
 
 
Investigator Patient Total 
fibers 
% COX 
positive 
% 
Intermediate 
positive 
% 
Intermediate 
negative 
% COX 
negative 
1 P1 1491 98.2% 1.8% 0.0% 0.0% 
P2 577 75.4% 18.4% 6.1% 0.1% 
P3 963 65.5% 21.9% 11.9% 0.6% 
P4 1774 97.7% 5.0% 0.1% 0.0% 
P5 397 86.9% 12.8% 0.3% 0.0% 
P6 563 80.8% 17.9% 0.9% 0.4% 
P7 132 69.7% 30.3% 0.0% 0.0% 
P8 453 92.5% 4.9% 2.0% 0.7% 
2 P1 1357 83.6% 16.3% 0.07% 0.0% 
P2 382 71.7% 26.9% 1.5% 0.0% 
P3 328 65.9% 30.4% 3.7% 0.0% 
P4 1131 97.1% 2.6% 0.2% 0.1% 
P5 395 77.7% 22.0% 0.3% 0.0% 
P6 726 70.4% 27.1% 1.9% 0.6% 
P7 135 58.5% 31.1% 10.4% 0.0% 
P8 463 78.2% 20.3% 1.2% 0.4% 
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3.4.2 Immunofluorescent analysis 
Quadruple immunofluorescence allowed objective quantification of complex I and 
complex IV protein abundance.  A summary of results can be found in Table 3.2. 
Representative immunofluorescent images for all patients are presented in Figure 
3.6, these show complex I and complex IV deficient fibres in a small number of 
patients (patients 2, 4, 5, 6 and 8). Controls 1 (18 years) and 2 (34 years) had no 
complex I deficiency, but the control 3 (52 years) had approximately 0.5% complex I 
deficiency.  In comparison, percentage complex I deficiency ranged from 0% in two 
patients up to 29.4% in patient 3.  Complex I deficiency detected was higher than 
expected in age matched healthy individuals but lower than levels detected in the 
patient with recessive RRM2B variants (36.2%). 
 
 
Patient Age/years Complex I 
negative/% 
Complex I 
deficient/% 
Complex IV 
negative/% 
Complex IV 
deficient/% 
P1 15.7 2.03 12.26 0.58 6.62 
C1 18.0 0.00 0.00 0.00 0.00 
P2 20.5 0.00 0.00 0.00 0.05 
P3 21.9 26.10 29.4 0.00 11.10 
P4 24.7 0.09 0.85 1.13 4.70 
P5 28.9 0.15 0.48 0.12 0.33 
P6 30.4 1.78 7.43 1.24 3.05 
C2 34.0 0.18 0.60 0.18 0.30 
P7 47.1 0.00 0.00 0.00 5.05 
C3 52.0 0.00 0.00 0.00 0.00 
P8 52.5 1.96 10.79 0.44 1.31 
Table 3.2 Immunofluorescent analysis of respiratory chain protein expression in 
Dysferlin patients.  For each fibre a z_score for complex I and complex IV described 
variation from the control population. The z-scores allowed fibres to be classified into 
positive, intermediate positive, intermediate negative and negative groupings for 
complex I and IV. These groups were validated by Rocha et al. (2015). Summary of 
percentage of fibres classified as complex I and complex IV negative or deficient 
(negative and intermediate positive and intermediate negative categories combined).  
Controls and patients are organised in age order for easy comparison and controls 
are shaded grey. Adapted from Vincent et al. (2016c). 
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Figure 3.6 Quadruple immunofluorescent analysis of mitochondrial respiratory chain 
deficiency in Dysferlin patients, control 3 and patient 20 with RRM2B variants.  
Representative images of NDUFB8 (complex I) (purple), VDAC1 (red) and COX-I 
(complex IV) (red).  Immunofluorescent staining in a Control 3 (52 years) negative 
control and patients 1-8. Fibres deficient for; both complex I and complex IV (x in P4 
and P8), complex IV only (# in P8) and complex I only (arrow head in P5 and P8) can 
be seen. Scale bar 100 µm. Adapted from Vincent et al. (2016c). 
 
Muscle biopsies from control 1 (18 years) and control 2 (35 years) had no complex IV 
deficient fibres and the muscle biopsy of control 3 (52 years) had approximately 0.5% 
complex IV deficiency.  In comparison to this, 0.1-11.1% of DYSF patients’ muscle 
fibres had evidence of complex IV deficiency. A higher percentage of myofibres were 
complex IV deficient than in the age-matched controls tested here and previous 
reports of age-related complex IV deficiency (Bua et al., 2006).  However, in 
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comparison to the patient 20, with RRM2B variants, whose biopsy harboured 23.2% 
complex IV deficient fibres, the degree of deficiency in the dysferlin patient is low. 
The respiratory expression profiles in Figure 3.7 show three patterns of mitochondrial 
respiratory chain protein levels.  Dysferlin patients 1, 3 and 6 (Figure 3.7 a, c and f 
respectively) present with a large number of complex I deficient myofibres.  Dysferlin 
patient 4 (Figure 3.7d) showed a greater number of complex IV deficient fibres than 
complex I deficient fibres.  DYSF patients, 2, 5, 7 and 8 (Figure 3.7 b, e, g and h 
respectively) demonstrated very little deficiency affecting either respiratory chain 
complex.  All DYSF patients had lower levels of complex I and complex IV deficiency 
than the patient 20, with RRM2B variants (Figure 3.7i). At 43 years of age, this 
disease control is older than the majority of dysferlin patients (many of whom are 
below the age of 35 years), however the RRM2B variants rather than age is likely to 
explain the difference in deficiency. 
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Figure 3.7 Mitochondrial respiratory chain expression profiles displaying complex I, 
complex IV and VDAC1 levels in patients with DYSF mutations and an RRM2B 
mutation as a mitochondrial disease control.  (a) patient 1, (b) patient 2, (c) patient 3, 
(d) patient 4, (e) patient 5, (f) patient 6, (g) patient 7, (h) patient 8 and (i) patient 20 
(RRM2B patient) positive control.  Each point gives the complex I and complex IV z-
scores for a single fibre and is colour coded to indicate the VDAC1 category of the 
fibre (very low, dark blue; low, light blue; normal, beige; high, orange; or very high, 
red).  Bars next to the X and Y-axes indicate category of complex I or complex IV 
levels (dark blue, negative; light blue, intermediate negative; light beige, intermediate 
positive and beige, normal). Adapted from Vincent et al. (2016c). 
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3.4.3 Mitochondrial DNA deletions 
Patients 4, 6 and 8 were selected for genetic analysis, based on the presence of 
COX-deficient fibres in sections reacted for sequential COX/SDH histochemistry.  
Long-range PCR indicated a lack of deletions in all fibres for which a product was 
successfully amplified for each patient (Figure 3.8a) whilst the positive control, 
patient 20, with compound RRM2B variants showed multiple clonally-expanded 
mtDNA deletions (Figure 3.8b). For each case examined a small number of fibres 
failed to amplify, which is common in single cell long range PCR. This was less 
frequently seen for patient 20 and can likely be attributed to the fact that fibres 
selected from the RRM2B patient were more commonly ragged red and therefore the 
mtDNA concentration was higher.
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Figure 3.8 Long range PCR analysis of mtDNA.  Long range analysis of dysferlin patient 6 (representative). Red arrows on all gels 
indicates wild type mitochondrial DNA size. 1 Kb ladder (Promega) run on every agarose gel to size bands and a non-deleted, wild type 
DNA sample and a no template were included as controls. (a) Long range PCR results for 20 single fibre lysates from patient 6 showed 
no deletions to be present whilst (b) patient 20, the RRM2B positive controls, long-range PCR results showed multiple large-scale mtDNA 
deletions detected(*). Adapted from Vincent et al. (2016c).
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3.5 Discussion 
This study has demonstrated that the levels of complex IV (COX) and complex I 
deficiency are higher in some DYSF patients examined than in age-matched 
controls.  The majority of fibres that were deficient were classified as intermediate-
positive or intermediate-negative rather than completely negative. Additionally, the 
percentage of complex I-deficient fibres were commonly higher than the percentage 
of complex IV deficient fibres. 
Long range PCR analysis of mtDNA from three patients, with a high percentage of 
complex I and complex IV deficient fibres, produced full length mtDNA amplicons. 
Despite an absence of large-scale mtDNA deletions detected, it is still possible that 
the respiratory chain dysfunction may be due to either deletions smaller than the 
resolution of the technique or duplications which are unlikely to be detected here 
(due to the larger amplicon size). It is also possible that the respiratory chain 
deficiency is due to point mutations, however I believe deletions or dupications to be 
more-likely given the inflammatory nature of dysferlin myopathy.  
As there is a larger percentage of complex I and complex IV deficiency in patients 
than observed in controls and since mutations in the DYSF gene cause a defect in 
membrane resealing causing an increase in intracellular Ca2+ this could also have an 
impact on the mitochondria. If so mitochondrial respiratory chain dysfunction may be 
secondary to a change in mitochondrial morphology in response to increased 
cytosolic Ca2+.  Dysferlin, which has ferlin Ca2+ binding domains with variable 
affinities for Ca2+, functions to regulate cytosolic Ca2+ by repairing membrane 
damage (Gayathri et al., 2011).  In the absence of normal levels of functional 
dysferlin, myofibre cytosolic Ca2+ levels increase to abnormal levels.  Since Ca2+ 
homeostasis is also a role of the mitochondria, a shift in Ca2+ concentration will alter 
mitochondrial function. Increased cytosolic Ca2+ results in increased mitochondrial 
fission, fragmenting the mitochondrial network (Han et al., 2010).  Mitochondrial 
fusion is important for stability of the mtDNA and tolerance of mtDNA mutations, 
since it allows dilution of mutated mtDNA reducing the impact on mitochondrial 
function and equilibration of mtDNA maintenance machinery (Chen et al., 2010).  
Therefore, mutations in the DYSF gene impairing Ca2+ homeostatic ability of the 
muscle, result in an increase in cytosolic Ca2+, fragmentation of the mitochondrial 
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network and thus allows mitochondrial dysfunction to accrue and have a negative 
impact on muscle function.  
In addition, mitochondria are also known to accumulate at the site of membrane 
injury in wild-type mice and therefore this suggests they play a role in membrane 
resealing (Sharma et al., 2012; Vila et al., 2016). Increased dysfunction of 
mitochondria may therefore cause a negative feedback further perturbing membrane 
resealing. Given that perturbed membrane resealing following injury related muscle 
damage is likely to lead to an immune response and increased inflammation, this 
could also be causative of mitochondrial damage. 
 
3.5.1 Limitations 
Here no mtDNA deletions were detected however fibres for genetic analysis were 
selected based on COX/SDH histochemistry. Given that the majority of fibres with 
complex IV deficiency fell into the intermediate complex IV categories when 
assessed by immunofluorescence and the fact that complex I deficiency was more 
prominent it would have been better to use the immunofluorescent sections for 
selection of fibres. 
Tissue culture and assessment of patient myoblasts for calcium handling defects and 
mitochondrial morphology, would have been valuable. Unfotunately no myoblasts 
were available for any patients reported here. 
 
3.5.2 Future work 
Since patients 1, 3 and 6 showed a trend towards more complex I deficiency than 
COX deficiency and patient 4 more complex IV deficiency than complex I, it would be 
interesting to investigate deficient pools of fibres from these patients for both mtDNA 
deletions and point mutations. Previous findings using this immunofluorescent assay 
has demonstrated a correlation between the pattern of deficiency observed and the 
genetic cause which would be interesting to investigate here. Furthermore given that 
a correlation between inflammatory infiltrates and mitochondrial dysfunction is noted 
in IBM it may be interesting to look for a similar correlation in dysferlin patients. 
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Due to the relevance of calcium in these patients, investigating calcium homeostasis 
by fluorescence imaging of DYSF patient myoblasts to detect fluorescence intensity 
of Rhod2/AM (mitochondrial Ca2+ concentration) and Fluo3 (Cytoplasmic Ca2+ 
concentration), as previously described (Csordás and Hajnóczky, 2003), may be very 
interesting. However, this would need to be approached in a new cohort of patients 
since myoblasts are not available for the patients included here. Although this is 
unlikely to be an ideal model given the difference in cytoarchitecture and 
mitochondrial arrangement in myoblasts and myotubes from full differentiated muscle 
this may shed some light on the pathogenic mechanisms. 
 
3.5.3 Conclusion 
The results presented here demonstrate that percentage of complex I and complex 
IV deficient myofibres is higher in patients with DYSF mutations than in age-matched 
controls. This can be explained if calcium homeostasis is disrupted due to the 
mutation in Dysferlin and defect in membrane resealing. Further testing is required to 
test this hypothesis and to understand what role the mitochondria play in membrane 
resealing since they are found to relocate to the site of injury, however it could 
provide a potential therapeutic target.  
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Chapter 4. Myofibrillar myopathy and mitochondrial 
dysfunction 
 
4.1 Introduction: 
4.1.1 Myofibrillar myopathy 
Myofibrillar myopathies (MFMs) are a group of myopathies characterised by 
focal myofibrillar destruction and aggregation of z-disk proteins. MFMs are 
clinically and genetically heterogeneous and age of onset is most commonly 
between 10 and 61 years. However, incidents of infantile presentation have 
been recorded (Piñol-Ripoll et al., 2009). 
Muscle weakness can present as proximal or distal but is usually progressive 
(Ferrer and Olive, 2008; Olivé et al., 2011), cardiomyopathy and isolated 
cardiomyopathy are also common. Mutations causing MFM have been identified 
in genes encoding a range of cytoskeletal proteins including; desmin (DES) 
(Goldfarb et al., 1998), αB-crystallin (CryAB) (Vicart et al., 1998), myotilin 
(MYOT) (Selcen and Engel, 2004), filamin C  (FLNC) (Vorgerd et al., 2005), 
LDB3 or ZASP (Selcen and Engel, 2005) and BAG3 (Selcen et al., 2009). The 
function of each of these proteins, cellular location and disease association are 
presented in Table 4.1.  
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Protein Loci Cellular location Function Disease 
DES 2q35 Cytoplasm, z-disk Desmin forms 
filaments tethering 
myofibrils to each 
other and to the 
plasma membrane. 
Anchors mitochondria 
at the Z-disk. 
MFM1, dilated cardiomyopathy 1, Limb-girdle muscular 
dystrophy type 2R, neurogenic scapuloperoneal syndrome 
CRYAB 11q23.1
  
Cytoplasm, Nucleus Protein chaperone MFM2, fatal infantile hypertonic myofibrillar myopathy 
MYOT 5q31.2 z-line Actin cross-linking 
proteins. 
MFM3, Limb-girdle muscular dystrophy 1A, Spheroid body 
myopathy 
LDB3 or 
ZASP 
10q23.2 Localized to the 
cytoplasm around 
nuclei. Colocalises 
with ACTN2 at the z-
lines. 
Protein kinase C-
mediated signalling 
Dilated cardiomyopathy 1C, Left ventricular non-compaction 
3, MFM4 
TTN 2q31.2  
  
Cytoplasm, Nucleus Contributes to the fine 
balance of forces 
between the two 
halves of the 
sarcomere. 
Hereditary myopathy with early onset respiratory failure 
(HMERF), MFM, dilated cardiomyopathy 1G, Familial 
hypertrophic cardiomyopathy 9, LGMD2J, early onset 
myopathy with fatal cardiomyopathy, tibial muscular 
dystrophy, proximal myopathy with early respiratory muscle 
involvement 
Table 4.1 Genes mutated in myofibrillar myopathy, their protein functions, cellular location and clinical disease associated with mutations 
in the gene presentation.
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Reports of desmin protein aggregates and fibres with reduced COX and SDH 
on sequential histochemistry, indicative of reduced mitochondrial mass and 
abnormal mitochondrial morphology and positioning in a patient with a plectin 
related Epidermolysis Bullosa Simplex and muscular dystrophy (Schroder et al., 
2002), may indicate that plectin is involved also. To date, only 50% of MFM 
causing mutations have been identified and large-scale proteomic studies are 
being pursued to identify novel candidate genes (Kley, 2014).  
 
4.1.2 Myofibrillar myopathy and mitochondrial dysfunction 
Interest in understanding mitochondrial dysfunction in myofibrillar myopathies 
stems from the role of desmin in localisation of the mitochondria at the z-band, 
where they are required to meet the energy demands of muscle contraction. As 
such, it was of great interest when a number of studies discovered that 
mitochondria are often relocated in patients with MFM and that respiratory chain 
deficiency also appears to be more common. However, this presents an 
intriguing question: why do mutations in other MFM genes cause mitochondrial 
dysfunction? It could be hypothesised that this is likely due to secondary effects 
of Desmin aggregation in many MFM cases. 
Investigations into mitochondrial dysfunction, positioning and dynamics in 
myofibrillar myopathies are limited to desminopathy, αB-crystallinopathy, 
zaspopathy, and myotilinopathy. Henderson et al. (2013), examined a 12 year 
old male and his 11 year old sister. Both proband and sister were heterozygous 
for two DES variants; c.266delA (p.Thr76fs*21) and c.322G>T (p.Glu108*). The 
proband showed 5% COX deficiency but lacked signs of any mtDNA copy 
number variation, rearrangements or deletions. There were no mitochondrial 
structural abnormalities reported however the size and distribution of 
mitochondria varied. 
Dold et al. (2012), examined three patients with mutations in DES. The first two 
patients showed COX-negative fibres, as well as fibres with diminished or 
irregular COX activities, mtDNA deletions and histochemical and biochemical 
mitochondrial dysfunction. One of these also presented with mitochondrial 
proliferation and a reduction in respiratory chain activity, while the other and the 
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third patient had changes in mitochondrial morphology. The third patient 
showed no mtDNA deletions or biochemical or histochemical abnormalities. No 
mitochondrial positional rearrangements were reported. 
Claeys et al. (2008), examined mitochondrial positioning in muscle biopsy 
sections from genetically confirmed MFM patients with; DES (n = 9), CRYAB (n 
= 5), LDB3 (n = 3) and MYOT (n = 2) mutations. Seven of the desminopathy 
patients showed mitochondria in a sandwich-like formation around protein 
deposits, which were located parallel to the z-line. The majority of desminopathy 
patients had a normal mitochondrial structure and size. One patient presented 
with paracrystalline inclusions. However there was nothing else remarkable 
noted about this patient.  For αB-crystallinopathy they found that, although 
mitochondria were structurally normal they were accumulated in the 
subsarcolemmal region of the fibres and were depleted in areas of intraplasmic 
granulofilamentous masses. One CRYAB patient also had a few mitochondria 
with paracrystalline inclusions. For patients with LDB3 mutations, they found 
that the mitochondria had a normal structure but were completely absent from 
filamentous bundles and areas of filamentous accumulation and aggregated 
around filamentous bundles. Finally, for patients with MYOT mutations they 
found no mitochondria present within tubulofilamentous or filamentous bundles 
but an accumulation of mitochondria on the periphery of myofibres. 
A study of five patients with a histopathalogical diagnosis of MFM but without 
genetic confirmation was also completed (Reimann et al., 2003). Ages ranged 
from 50 to 78 years. Of these four patients presented with 0.7%, 0.6%, 3.8% 
and 1.8%, COX-deficient fibres respectively and the majority of COX deficiency 
was due to myofibrillar pathology. All five had higher subsarcolemmal COX and 
SDH activity relative to the intermyofibrillar region. Two patients had low 
complex I activity and one had low complex IV activity. No decrease in complex 
II or III activities were demonstrated. Uneven COX, NADH and SDH 
histochemical activity across the fibres indicated changes in mitochondrial 
positioning. No mtDNA deletions were found and screening for m.8344A>G 
tRNALys and m.3243A>G tRNALeu(UUR) point mutations was negative. However 
the authors do not provide details of nuclear DNA screening, so a confirmed 
MFM diagnosis is not given; contacting the author confirmed that a genetic 
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diagnosis was never completed and is no longer possible (J. Reimann – 
personal communication). 
Schroder et al. (2003), examined one 40 year old, male patient with slowly 
progressive muscle weakness since the age of 18. Sequencing of the full DES 
gene showed a c.5141_5143insA (p.Lys239fs*4). This caused a frame shift and 
premature stop codon, 4 codons downstream of the insertion and resulted in a 
truncated protein. Muscle analysis showed an increase in fibre diameter and 
basophilic inclusions. Mitochondria were depleted in some regions but a focal 
increase found in others. COX-deficient fibres were present at less than 2%, 
and there were no ragged red fibres. Mitochondrial foci co-localised with protein 
aggregates and depletion of mitochondria was found to co-localise with 
granulofilamentous inclusions. Respiratory chain analysis showed normal levels 
of complex I, complex IV and citrate synthase activity and normal COX/citrate 
synthase and complex I/citrate synthase ratios. However isolated saponin-
permeabilized cells, which are more representative of the in vivo state, 
demonstrated reduced maximal respiratory rates and higher amytal sensitivity, 
Since amytal is an inhibitor of respiration, that blocks electron transport between 
complex I and coenzyme Q, this indicates complex I inhibition. 
In addition, Winter et al. (2016) examined muscle biopsies from three desmin 
patients in conjunction with studies of the heterozygous and homozygous DES 
knock-in mice carrying c.1045_1047delAGG>insCCC (p.Arg349Pro) mutation. 
They report few COX-deficient fibres but a large number of ‘rubbed-out’, which 
are fibres with little COX or SDH staining on sequential histochemistry, 
indicative of reduced mitochondrial mass. Electron microscopy on patient 
muscle showed subsarcolemmal accumulation of mitochondria, in association 
with protein aggregates. Long range PCR demonstrated large-scale mtDNA 
deletions in two of three patients and heterozygous mice. Interestingly, where 
patients and heterozygous mice both had wild type products, with additional 
mtDNA deletion products, homozygous mice displayed prominent mtDNA 
deletion products with only a few wild type products. They also examined 
mtDNA copy number and found a reduction of mtDNA copy number in their 
oldest patient, homozygous knock-in and homozygous knock-out mice. 
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This chapter investigates a cohort of eight MFM patients and has previously 
been reported (Vincent et al., 2016a). This paper can also be found in 
Appendix 3. 
 
4.2 Aims of this investigation: 
This work aimed to characterise the degree of mitochondrial dysfunction in a 
cohort of myofibrillar myopathy patients and determine what role if any 
mitochondrial dysfunction has in the pathogenesis of mitochondrial myopathy. 
 
 
4.3 Methodology: 
4.3.1 Patient cohort 
Myofibrillar myopathy patients (n = 9) were identified through the Rare Diseases 
Advisory Group Service for Neuromuscular Diseases. Selection was based on 
the presence of protein aggregates in myotilin and desmin 
immunohistochemistry as well as a genetic diagnosis. A previously reported 
patient with recessive Ribonucleoside-diphosphate reductase subunit M2 B 
(RRM2B) variants (Patient 20,  
Table 2.9) (Pitceathly et al., 2012b), mtDNA maintenance disorder and multiple 
mtDNA deletions was used as a positive control. This patient has multiple 
mtDNA deletions due to an imbalance in the dNTP pools caused by the 
mutation in RRM2B, the product for which is involved in dNTP synthesis. 
Control 3 (52 years) and control 4 (63 years) were used as age matched 
controls. Patient details including clinical and pathological findings (where 
appropriate) are summarised in Table 2.8. Ethical approval was previously 
approved by the Newcastle and North Tyneside Local Research Ethics 
Committees (reference 2002/205). 
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4.3.2 Histology 
Serial muscle cryosections (10 µm) were stained for Haematoxyin and Eosin or 
treated for COX, SDH and sequential COX/SDH histochemistry as described in 
sections 2.8.1, 2.8.2, 2.8.3 and 2.8.4. 
 
4.3.3 Stereology 
COX/SDH histochemistry sections were analysed by outlining the full biopsy 
section and using the meander scan function in Stereo Investigator and a 
stereology microscope. The minimum number of fibres counted was 127 in 
patient 11. Fibres were classified by eye with brown fibres categorised as COX 
positive, grey-brown as COX intermediate positive, blue-grey as COX 
intermediate negative and blue as COX negative. These categories were used 
to make the stereology results comparable with the immunofluorescent 
quantification. 
 
 
Figure 4.1 Guide to classification of fibres in COX/SDH histochemistry. Fibres 
can be classified as; COX-negative, intermediate negative, intermediate positive 
and positive, for comparison to the quadruple immunofluorescence assay.
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4.3.4 Cryosectioning and histochemistry for single cell genetic analysis 
Four serial muscle sections were cryosectioned the first and last were 10 µm 
sections and were treated for sequential COX/SDH histochemistry before being 
dehydrated and mounted as a reference for COX efficiency of the fibres. The 
second and third were 15 µm sections, cut on to membrane slides for laser 
microdissection and were treated for SDH histochemistry only. These sections 
were dehydrated prior to laser microdissection. 
 
4.3.5 Laser microdissection 
Individual cells were captured by laser microdissection into 15 µl of lysis buffer 
as in 2.10.1. The same fibre from serial sections was captured into different 
lysis buffers for two downstream applications. Tris-Tween-Proteinase K lysis (as 
in 2.10.2) was used for real time PCR and SDS-EDTA-proteinase K (as in 
2.10.3) for long range PCR. Tubes were centrifuged briefly to bring lysis buffer 
and cell to the bottom prior to incubating for the appropriate lysis protocols 
(2.10.2 and 2.10.3). 
 
4.3.6 Long Range PCR and agarose gel 
Two round of long range PCR were performed using PrimesStar GXL as 
described in 2.11.4. The first round used primer pair 7 (2180F/1789R) and the 
second round the reverse primer from primer pair 7 and the forward primer of 
primer pair 7A (2330F/1789R). Primer details can be found in Table 2.15 and 
Table 2.16. PCR products were separated through a 0.7 % agarose gel with a 1 
Kb ladder used to size amplicons, as in 2.11.5. 
 
4.3.7 D-loop/MT-ND1/MT-ND4 triplex real time PCR 
A triplex real time PCR assay, targeting D-Loop, MT-ND1 and MT-ND4, to 
quantify deletion level was used as described in 2.11.1. All primer details are 
provided in Table 2.13 and probe details in Table 2.14 of Chapter 2. 
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4.3.8 Immunofluorescent analysis of respiratory chain protein expression 
profiles 
An immunofluorescent assay was used to assess levels of complex I and 
complex IV relative to mitochondrial mass (Rocha et al., 2015). 
Immunofluorescence was completed as described in 2.9.1 with primary 
antibodies being anti-MTCOI, anti-NDUFB8, anti-VDAC and laminin and 
secondary antibodies, anti-IgG2a Alexa Fluor 488, anti-IgG2b Alexa Fluor 546, 
Biotinylated IgG1, streptavidin conjugated Alexa Fluor 647. All antibody dilutions 
can be found in Table 2.11 and Table 2.12.  Images were captured on a Zeiss 
axioimager (microscope details) using Axiovision and then stitched using ZEN 
(blue edition). Analysis was completed in Imaris (v7.7.2) software and statistical 
analysis was completed as described in 2.9.4 and 2.9.5 and also by (Rocha et 
al., 2015).  
 
4.3.9 Measurement of mitochondrial mass across myofibres 
A total pool of normal (n = 10), low (n = 10) and very low VDAC (n = 10) fibres 
were selected to assess VDAC level across the myofibre. The profile tab in ZEN 
(blue edition) was used to draw a segmenting line across the full myofibre and 
generate a graph of fluorescent intensity in each channel across the fibre 
 
4.3.10 Assessment of mitochondrial mass 
To assess mitochondrial mass, expression of a second marker, succinate 
dehydrogenase subunit A (SDHA) was compared to VDAC1. Cryosectioned 
muscle (10 µm) was stained following a similar protocol, as in 4.3.8 but without 
anti-MTCOI and replacing anti-NDUFB8 with anti-SDHA (1:100). Imaging and 
image analysis was completed as in 4.3.8. 
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4.3.11 Analysis of MFM protein aggregates and mitochondrial mass 
Muscle sections were co-stained with antibodies for laminin, desmin (Dako), 
myotilin (Leica Biosystems) and VDAC1.  Image were capture, processed and 
analysed as in 4.3.8. Myofibres that contained very low (n = 436), low (n = 338) 
and normal VDAC1 (n = 150) content (across all patients) were analysed in turn 
and grouped as either being positive or negative for the presence of desmin 
and/or myotilin aggregates. Following this, fibres with or without aggregates 
were plotted against z-score for VDAC1 protein level as an indicator of 
mitochondrial mass. Imaging and image analysis were completed as described 
in 4.3.8. 
 
4.3.12 Analysis and statistics 
For quantitative immunofluorescence, an R script written by Dr. John Grady was 
used to generate z-scores for each patient fibre to describe deviation from the 
control population and classify the fibre as normal, intermediate positive, 
intermediate negative or negative for each protein (complex I, complex IV and 
VDAC1). The average OD for each channel from the negative (no primary 
antibody) control for each case was subtracted from that of the sections stained 
with primary antibodies to correct for non-specific background. NDUFB8 and 
COX-1 intensity was normalised to VDAC1 intensity as a mitochondrial mass 
marker. Control values then created a “normal population” for which the patient 
fibres were assigned a z-score describing their deviation from the normal 
population. Statistical analysis is described in 2.9.5 and by Rocha et al. (2015). 
Total fibres analysed was dependent on section size and ranged from n = 111 to 
n = 1883 in patients and controls. 
Percentage classification of fibres for complex I, complex IV and VDAC1 were 
compared between the patient group and control group, using a Wilcoxen 
Signed-Rank test. Spearman’s rank correlation (src) was used to assess the 
relationship between fibre area and complex I, complex IV and VDAC1 protein 
levels. 
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4.4 Results: 
4.4.1 Histochemistry 
Haematoxylin and eosin (H&E) staining revealed a variety of pathological 
features, consistent with a diagnosis of myofibrillar myopathy including; fibre 
size variation, rimmed vacuoles, internal nuclei, nuclear bags, basophilic and 
eosinophilic inclusions, fibre splitting and necrotic and regenerating fibres.  
Sequential COX/SDH histochemistry showed a small number of COX-deficient 
fibres (typically not more than 5%) (Table 4.2).  Often fibres that had decreased 
COX activity also had decreased SDH activity, indicating low mitochondrial 
content rather than COX deficiency (Figure 4.2). Core-like lesions, which is 
defined as reduction of COX and SDH activity in the centre of the fibre, was 
also observed (e.g. patient 10, Figure 4.2). Fibre type distribution was not 
assessed, as it is generally not affected in MFM patients, except where signs of 
peripheral neuropathy are present. However in these cases grouping of atrophic 
fibres of both types is present (Dubowitz, 2007). 
 
 
 
Table 4.2 COX deficiency counts for myofibrillar myopathy patients based on 
sequential COX/SDH histochemistry. Adapted from Vincent et al. (2016a). 
 
Patient Total 
fibres 
COX 
positive 
Intermediate 
positive 
Intermediate 
negtative 
COX 
negative 
P9 494 94.3 4.45 1.01 0.202 
P10 611 87.7 10.3 1.80 0.164 
P11 127 81.9 18.1 0.0 0.0 
P12 863 95.6 4.06 0.348 0.0 
P13 1086 93.6 5.06 0.829 0.552 
P14 248 45.16 39.1 12.9 2.82 
P15 848 96.6 2.48 0.943 0.0 
P16 697 91.1 5.67 3.73 0.0 
P17 835 99.4 0.479 0.120 0.0 
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Figure 4.2 Histochemistry for serial muscle sections from myofibrillar myopathy 
patients.  Images of sections from P10, P13, P15 and P17 treated for H&E 
staining, COX histochemistry, SDH histochemistry and sequential COX/SDH 
histochemistry. H&E staining demonstrates morphological changes compatible 
with diagnosis.  Many fibres appear COX-deficient but also demonstrate low 
SDH reactivity, indicative of a reduction in mitochondrial mass.  X indicates 
COX-deficient fibres and asterisks fibres that are core-like or have low 
mitochondrial mass. Scale bar 200 µm. Adapted from Vincent et al. (2016a). 
 
4.4.1 Mitochondrial DNA deletions 
Six patients with DES (n = 3), MYOT (n = 1) and LDB3 (n = 1) were selected for 
further mtDNA genetic analysis. Selection was based on the percentage of 
COX-deficient fibres as assessed by sequential COX/SDH histochemistry. For 
every single fibre analysed, both long range PCR and real time PCR were 
implemented to search for clonally-expanded mtDNA deletions. For each MFM 
patient, 20 single fibre lysates were analysed, 20 fibres were also analysed from 
patient 20 (recessive RRM2B variants,  
Table 2.9), as a positive control.  
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Long range PCR analysis of 20 fibres from patient 20 demonstrated full length 
wild type amplicons and products of varying size indicative of different sized 
mtDNA deletions (Figure 4.3 a).  In comparison to the patient 20, only five 
fibres (P12: n = 1, P13: n = 1 and P17: n = 3) from the six MFM patients (total 
fibres n=120) had an mtDNA deletion detected (Figure 4.3 b-d).  
Failure to amplify a product is common in long range PCR from single cell 
lysates, since the concentration of DNA is low and this also occurred in two 
fibres from patient 20.  The percentage of fibres that did not amplify is lower in 
the patient 20. I hypothesise that this is due to a difference in mtDNA content of 
MFM patient myofibres and those patient 20, which is based on the observation 
of ragged-red fibres indicative of high mitochondrial mass in the patient 20 and 
core-like fibres suggesting low mitochondrial mass in the MFM patients. 
Real time PCR analysis is presented in Figure 4.4, as MT-ND4 to MT-ND1 ratio 
and MT-ND1 to D-Loop ratio. Due to the potential for the D-Loop region to be 
triple stranded, when assessing MT-ND1 to D-Loop, a percentage deletion was 
required to be above 33% in order to confirm an MT-ND1 deletion (red box), as 
highlighted by Rygiel et al. (2015a). However, it is interesting to note that some 
of the potential MT-ND1 deletions highlighted by the blue box appear to be 
confirmed as true low level deletions by the MT-ND4/MT-ND1 results. Similar to 
the long range PCR results, the real time PCR shows the greatest number of 
deletions in patient 17, with the level of MT-ND4 deletions and the number of 
fibres affected, close to that of the patient 20.
 Chapter 4 
128 
 
 
 
Figure 4.3 Long range PCR results for single fibre lysates of MFM patients. In long range PCR gels (a-d) red arrows indicate size of wild 
type mtDNA product, red asterisk (*) indicates deletion products. (a) Long range PCR results for 10 single fibre lysates relative to a wild 
type blood homogenate (WT BH), no template control (NTC) and 1 Kb ladder (Promega), multiple and single deletions present due to 
variants in P20.  (b) Long range PCR results for 20 single fibre lysates from P17 demonstrating three fibres with a single deletion.  (c) 
Long range PCR results for 20 single fibre lysates from P13 demonstrating one fibre with an mtDNA deletion.  (d) Long range PCR 
results for 20 single fibre lysates from demonstrating one fibre with an mtDNA deletion. Adapted from Vincent et al. (2016a). 
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Figure 4.4 Real time PCR results for MFM patients P12, P13, P14, P15 and P17. Graphs show ratios of MT-ND4 to MT-ND1 (left) and 
ND1 to D-Loop (right). Since the D-Loop region is likely to be partially triple stranded quantification of MT-ND1 deletion cannot be exact 
as such the red box indicates a definite deletion and blue box a potential deletion. In addition, there are a small number of fibres for which 
MT-ND1 is present in a greater proportion than D-Loop, which could be explained by an MT-ND1 duplication which would not have been 
detected by long range PCR. The dashed line at 100 (left) represents 0% deletion of MTND4. In both graphs, mean and standard error of 
the mean (SEM) are plotted for each case. Fibres circled in red (graph left) are those for which a deletion was detected on real time but 
not long range. Adapted from Vincent et al. (2016a). 
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Out of the 120 fibres, on which both long range PCR and real time PCR were 
completed, a deletion was found by both methods in five fibres. A further seven 
fibres were shown to have a deletion by real time PCR alone. In these seven 
fibres, unfortunately no long range product was amplified. Inclusion of the D-
loop allowed confirmation that MFM patient fibres did not contain any deletions 
affecting MT-ND1 (Figure 4.4). This was in agreement with long range PCR. 
 
4.4.2 Immunofluorescent analysis of respiratory chain protein expression 
Based on lack of genetic defect and histochemistry results, a quantitative 
immunofluorescence approach was used to explore the nature of the respiratory 
chain protein expression further. Quantitative analysis allowed comparison of 
the protein expression levels of VDAC1, NDUFB8 (complex I) and COX-I 
(complex IV) in patients and controls. 
Immunofluorescent analysis allowed comparison of the myofibrillar myopathy 
patients to age matched controls and a patient with compound heterozygous 
RRM2B variants.  Immunofluorescent images showed a number of complex I, 
complex IV deficient fibres and combined complex I and IV deficiency as well as 
fibres with reduced mitochondrial mass (Figure 4.5).  A summary of results can 
be found in Table 4.3 and protein expression profiles for all MFM patients and 
patient 20 are presented in Figure 4.6. 
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Figure 4.5 Representative immunofluorescence images for NDUFB8 (complex 
I), VDAC1 and COX-I (complex IV) in C3 and P9 to P17. Complex I and 
complex IV deficient fibres, complex IV deficient fibres and complex I deficient 
fibres can be seen.  Most strikingly fibres with low VDAC1, complex I and 
complex IV can be seen in a number of patients, most pronounced in P17(*).  
Arrow head; complex I negative, hash; complex IV deficient, cross; complex I 
and IV deficient, asterisk; low complex I, IV and VDAC1. Scale bar 100 µm. 
Adapted from Vincent et al. (2016a). 
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Figure 4.6 Immunofluorescence results for MFM patients and RRM2B patient 
positive control.  Graphs demonstrate distribution of z-scores for complex I and 
complex IV with each point colour coded for VDAC1 category.  (a) P9, (b) P10, 
(c) P11, (d) P12 , (e) P13, (f) P14, (g) P15, (h)P16, (i) P17, (j) P20. Each point 
gives the COX and complex I z-scores for a single fibre and is colour coded to 
indicate the VDAC1 category of the fibre (very low; dark blue, low; light blue, 
normal; beige, high; orange or very high; red).  Bars next to the X and Y-axes 
indicate category of COX or complex I levels (dark blue; negative, light blue; 
intermediate negative, light beige; Intermediate positive and beige; normal.) 
Additionally solid and dashed lines running vertically and horizontally also mark 
the boundaries between each category of complex I and complex IV. Adapted 
from Vincent et al. (2016a). 
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Controls 3 and 4 showed no complex I or complex IV deficiency (Figure 4.6 k 
and l).  In comparison, desmin patients showed higher levels of complex I and 
complex IV deficiency (Figure 4.6 a-f), reaching 6.5% and 4.2% deficient fibres 
for complex I and complex IV respectively.  The myotilin patients exhibited even 
higher levels of deficiency, with one patient reaching deficiency of 45.5% for 
complex I and 24.7% for complex IV.  Finally, the LDB3 patient (P17) had 
11.5% complex I deficient fibres and 9% complex IV deficient fibres. 
When these patients are compared with the RRM2B patient with 32.6% 
complex I and 23% complex IV deficiency, it is apparent that the patient 15 and 
17 in particular exhibit levels of deficiency similar to that of a mitochondrial 
disease patient. 
 
Patient Age/years Complex 
I 
negative
/% 
Complex 
I 
deficient
/% 
Complex 
IV 
negative
/% 
Complex 
IV 
deficient/
% 
Total 
fibres 
analyse
d 
P9 31.2 0.00 0.00 0.00 0.00 111 
P10 32.1 0.12 6.48 0.12 3.62 174 
P11 33.8 0.00 0.00 0.58 4.18 162 
P12 51.3 0.00 0.00 0.00 0.00 224 
C3 52.0 0.00 0.00 0.00 0.00 581 
P13 53.0 0.79 1.41 0.8 1.63 1883 
C4 60.0 0.00 0.73 0.07 0.07 395 
P14 60.5 0.18 0.18 0.12 0.44 669 
P15 64.3 1.91 2.50 3.52 4.99 149 
P16 65.7 38.5 45.51 13.57 24.73 177 
P17 69.6 6.43 11.47 5.34 8.96 1348 
 
 
Table 4.3 Immunofluorescent analysis of respiratory chain protein expression in 
MFM patinets.  Summary of percentage of fibres classified as complex I and 
complex IV negative or deficient (negative and intermediate categories). 
Controls and patients are organised in age order for easy comparison. Adapted 
from Vincent et al. (2016a). 
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4.4.3 Immunofluorescent analysis of mitochondrial mass 
MFM patients have between 11% and 51.4% very low VDAC1 fibres. Low and 
very low VDAC1 fibres are presented by light blue and dark blue circles in the 
respiratory chain expression profiles in (Figure 4.6).  There is a significant 
difference in percentage of normal (p = 0.03), low (p = 0.03) and very low (p = 
0.04) VDAC1 fibres between patients and controls.   
During the image analysis process, the surface created in Imaris does not cover 
the full area within the laminin membrane staining.  Previous reports and 
findings presented here suggest core-like depletion of mitochondria in the 
intermyofibrillar regions and aggregation in the subsarcolemmal regions. If this 
is the case, it is possible the image analysis process may miss some of the 
mitochondria, explaining the low VDAC1 fibres. This was tested by analysis 
across the full diameter of the fibre, using the plot profile function in Zen, 
described in section 4.4.4.  
  
4.4.4 Investigating reduction in mitochondrial mass 
In order to test whether this is the case the fluorescent signal intensity was 
analysed across a pool of normal, low and very low VDAC1 fibres.  This showed 
that low and very low VDAC1 fibres have a lower fluorescent intensity across 
the full width of the fibre (Figure 4.7).   
To validate mitochondrial mass reduction, sections were labelled for VDAC1 
and SDHA, a subunit of complex II, which is nuclearly encoded and therefore a 
good marker of mitochondrial mass.  When SDHA is linearly regressed against 
VDAC1, the r2 values suggest a strong positive relationship in the cases with the 
largest range of VDAC1 and SDHA levels. For those cases with a smaller range 
the relationship was still apparent but the r2 value was smaller due to the spread 
of the data points. This indicates that mitochondrial mass is reduced in a higher 
percentage of myofibrillar myopathy patient fibres compared to controls (2.6% 
and 6.4%). 
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Figure 4.7 Representative examples of analysis of VDAC1 fluorescent intensity 
across the myofibres of MFM patients. Indicated that in very low VDAC1 fibres 
VDAC1 fluorescent intensity is lower across the full fibre. Adapted from Vincent 
et al. (2016a). 
 
4.4.5 Relation of respiratory chain deficiencies, mitochondrial mass and fibre 
size 
To determine whether levels of VDAC1, complex I and complex IV could be 
related to fibre atrophy we compared fluorescent intensity for each channel with 
fibre area. Correlation was examined using Spearman’s rank correlation (src) 
coefficient (summarised in Table 4.4).  Regression of myofibre area against 
complex I level (Figure 4.8) demonstrated a positive correlations for patients 
P13 (src = 0.2600, p < 0.0001) and P11 (src = 0.4389, p = < 0.0001) but a 
negative correlation for P14 (src = −0.4817, p < 0.0001). For myofibre area and 
complex IV levels (Figure 4.9), only very weak to no correlation was 
demonstrated. In addition, a negative correlation between myofibre area and 
VDAC1 level (Figure 4.10) for P17 (src = −0.4487, p < 0.0001) and P14 (src = 
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−0.4583, p < 0.0001) was noted. Spearman’s rank correlations were also 
significant for P10, P13, P14, P15 and P16; it should be noted however, the 
correlation between VDAC1 and myofibre area was weak in these patients 
(Table 4.4). VDAC1 level plotted against myofibre area, for patient P17, in 
particular, shows that large myofibres all have a low VDAC1 level whilst smaller 
myofibres have a range of high to low VDAC1. Low Spearman’s rank 
correlations in some patients appear to be due to the smaller range of fibre 
area. 
 
Table 4.4 Analysis of myofibre area and respiratory chain expression profiles in 
MFM patients. Summary of Spearman’s rank correlation (src) analysis of 
myofibre area against levels of VDAC1, complex I and complex IV. Adapted 
from Vincent et al. (2016a). 
 
Patient VDAC1 Complex I Complex IV 
 src p value src p value src p value 
P9 -0.0564 0.5546 0.1389 0.144 0.09819 0.303 
P10 -0.2492 0.0009 0.1161 0.1261 -0.1738 0.0214 
P11 0.3776 < 0.0001 0.4389 < 0.0001 0.2808 0.0003 
P12 0.06009 0.3707 0.1249 0.0619 0.05067 0.4504 
P13 -0.1733 < 0.0001 0.2600 < 0.0001 0.2933 < 0.0001 
P14 -0.4583 < 0.0001 -0.4817 < 0.0001 -0.3073 0.0001 
P15 -0.2093 < 0.0001 -0.09169 0.0187 -0.2006 < 0.0001 
P16 0.1302 0.1064 0.2428 0.0023 0.0483 0.5506 
P17 -0.4487 < 0.0001 -0.1716 < 0.0001 -0.1634 < 0.0001 
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Figure 4.8 Complex I z score (Complex I_z) against fibre area z score (Area_z) 
for: (a) P9, (b) P10, (c) P11, (d) P12, (e) P13, (f) P14, (g) P15, (h) P16 and (i) 
P17.  Spearman rank correlation and p values in Table 4. Adapted from Vincent 
et al. (2016a). 
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Figure 4.9. Plots of Complex IV z score (Complex IV_z) against fibre area z 
score (Area_z) for: (a) P9, (b) P10, (c) P11, (d) P12, (e) P13, (f) P14, (g) P15, 
(h) P16 and (i) P17.  Spearman rank correlation and p values in Table 4. 
Adapted from Vincent et al. (2016a). 
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Figure 4.10 VDAC1 z score (VDAC1_z) against fibre area z score (Area_z) for: 
(a) P9, (b) P10, (c) P11, (d) P12, (e) P13, (f) P14, (g) P15, (h) P16 and (i) P17.  
Spearman rank correlation and p values in Table 4. Adapted from Vincent et al. 
(2016a). 
 
 
4.4.6 Analysis of low mitochondrial mass and protein aggregates: 
As the hallmark of myofibrillar myopathy, aggregates may be mechanistically 
linked to the low VDAC1 fibres.  Analysis of sections co-stained with antibodies 
for myotilin, desmin, VDAC1 and laminin demonstrated a similar percentage of 
low and very low VDAC1 fibres relative to controls as previously shown.  Very 
low and low VDAC1 fibres were analysed for the presence of myotilin and 
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desmin aggregates.  This analysis demonstrates no significant relationship 
between presence of protein aggregates and mitochondrial mass (Figure 4.11). 
Furthermore, in fibres with aggregates in patient 7 (the patient with the highest 
percentage of low VDAC1 fibres), only 22.9 % had very low mitochondrial mass.  
Throughout the analysis however, it became apparent that in cases where large 
aggregates are present, there is a lack of VDAC1 and therefore reduction of 
mitochondrial mass.  Mitochondria are accumulated in the subsarcolemmal 
regions or other myofibrillar regions of the fibres, which agrees with previous 
studies using electron microscopy. 
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Figure 4.11 Immunofluorescent analysis of mitochondrial mass and MFM 
aggregates.  P17 as a representative example of analysis of desmin and 
myotilin protein aggregation and mitochondrial mass. (a) P17 fibres classified as 
very low (pink), low (yellow) or normal (green) VDAC1 fibres analysed for 
presence of aggregates.  No clear relationship detected.  Very low VDAC1 
fibres accounted for 22.9% of all fibres with aggregates.  (b) Immunofluorescent 
images from P17 showing individual channel images (desmin, myotilin, VDAC1) 
and merged.  The staining demonstrates a lack of VDAC1 in regions with large 
aggregates (regions within dashed lines). Adapted from Vincent et al. (2016a). 
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4.5 Discussion 
Skeletal muscle from patients with myofibrillar myopathy has previously been 
shown to accumulate mitochondrial respiratory chain deficiency (Schroder et al., 
2003; Dold et al., 2012; Henderson et al., 2013) and clonally-expanded mtDNA 
deletions (Dold et al., 2012; Joshi et al., 2014) and show changes in 
mitochondrial positioning (Claeys et al., 2008). It could be hypothesised that, 
the mutation of DES or other MFM causative genes, which cause protein 
aggregates containing desmin protein, may result in the mislocalisation of 
mitochondria within skeletal muscle. As such, the aim of this investigation was 
to examine a cohort of myofibrillar myopathy patients for the presence of 
mitochondrial dysfunction and attempt to understand what correlation, if any, 
this has with disease pathology.  
Here, clonally expanded mtDNA deletions are identified in a small number of 
fibres from MFM patients by both long range PCR and real time PCR. A further 
seven fibres were found to have deletion real time PCR but failed to amplify a 
product with long range PCR, a common problem with single cell long range 
PCR especially if mtDNA content is low as in MFM myofibres.  Based on the 
age of the patients and the propensity for sporadic mtDNA deletions to 
accumulate with age (McKenzie et al., 2002) it is concluded that these deletions 
arise, at least in part due to age in addition to disease pathogenesis. In 
particular patient 17 where the most deletions were detected, is the oldest 
patient. However, due to the fact that only one ZASP patient was investigated, it 
is difficult to conclude to what extent this is due to genotype or ageing. 
In COX-deficient fibres, where no clonally-expanded mtDNA deletion was 
detected, it is possible that deficiency has arisen due to an mtDNA point 
mutation or mtDNA depletion, both of which can cause respiratory chain 
deficiency. Evidence from immunofluorescence would suggest it is more likely 
to be mtDNA depletion since mitochondrial mass is reduced. Copy number 
comparison between COX positive and COX negative fibres would be required 
to test this. It should be noted, that based on COX/SDH and immunofluorescent 
analysis COX-deficient fibres are less frequent than those with reduced 
mitochondrial mass. Both quantification of mtDNA copy number and deep 
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sequencing would be a valuable addition to this work to assess these 
possibilities. 
Immunofluorescent analysis demonstrated a higher percentage of complex I 
and complex IV deficiency than would be expected in age matched controls for 
four out of six desmin patients one of two MYOT patients (P15) and a ZASP 
patient (P17).  More interestingly, VDAC1 is often reduced in a significantly high 
percentage of fibres relative to controls in all patients, indicating a reduction in 
mitochondrial mass.  This reduction in mitochondrial mass may simply be due to 
the depletion of mitochondria in the intermyofibrillar space and aggregation in 
the subsarcolemmal space, as previously described in myofibrillar myopathy 
patients (Schroder et al., 2003; Claeys et al., 2008; Henderson et al., 2013).  
Careful analysis of low VDAC1 fibres, for labelling intensity across the fibre to 
assess if this is in fact an artefact of the method, revealed that this is not the 
case.  Furthermore, there is no correlation between the presence of desmin and 
myotilin protein aggregates and the reduction in VDAC1. This is in agreement 
with recent work by Winter et al. (2016), who reported that presence of ‘rubbed 
out’ or core-like areas are independent of protein aggregates. Throughout the 
analysis however, it was noted that in some fibres where large protein 
aggregates are present mitochondria are depleted in this area (Figure 4.11b), 
which may explain the core-like findings on COX/SDH histochemistry. These 
fibres also show an accumulation of subsarcolemmal mitochondria, which 
agrees with previous studies using electron microscopy.  
It has been demonstrated that aggregate prone desmin mutations alter Ca2+ 
homeostatic ability, due to a change in mitochondrial positioning further from the 
sarcoplasmic reticulum (Smolina et al., 2014).  Therefore, it may be that 
aggregate prone mutations in MFM related genes, including MYOT and ZASP 
have the same outcome, also leading to increased cytoplasmic Ca2+.  An 
increase in cytoplasmic Ca2+ concentration in the neurons, causes an increase 
in mitochondrial fission and therefore fragmentation of the mitochondrial 
network (Han et al., 2008). Since, mitochondrial fusion and interaction of the 
mitochondrial network is necessary for mitochondrial DNA stability and ability to 
cope with mtDNA mutation (Chen et al., 2010) this might give rise to clonally-
expanded mtDNA deletions.   
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Comparison of complex I and complex IV levels with myofibre cross sectional 
area yielded mixed relationships, this makes it hard to determine whether 
complex I and complex IV levels may be linked to myofibre atrophy or 
hypertrophy.  In contrast to this, comparison of myofibre area with mitochondrial 
mass showed a negative relationship in the majority of patients.  This 
relationship suggests that hypertrophic myofibres with a greater area typically 
have a lower level of VDAC1 than atrophic fibres with a smaller area which 
have more variable levels of VDAC1. This seems to indicate that mitochondrial 
mass is not involved in the process of muscle atrophy but may indicate either a 
lack of mitochondrial biogenesis or increased mitophagy during myofibre 
hypertrophy. It seems the most likely explanation is that a lack of mitochondrial 
biogenesis is responsible for the low levels of VDAC1, leading to a dilution of 
mitochondrial mass during myofibre hypertrophy. However, further testing would 
be needed to confirm this. 
The low occurrence of clonally-expanded mtDNA deletions, lack of relationship 
between complex I and IV deficiency and myofibre cross sectional area and 
between pathological protein aggregates and mitochondrial dysfunction, found 
here, are very different to previous findings in sporadic inclusion body myositis 
(IBM). In sporadic IBM, ~50% of COX-deficient fibres were found to have one or 
more large-scale mtDNA rearrangements (Rygiel et al., 2016). Additionally, 
inflammatory infiltrates were directly correlated with mitochondrial respiratory 
chain deficiency and myofibre atrophy (Rygiel et al., 2015b). Therefore, in 
comparison to sporadic IBM, where it can be concluded that mitochondrial 
dysfunction is pathologically important, and to mitochondrial myopathies where 
clear mechanistic links exist between mutations in mtDNA maintenance genes, 
mtDNA deletions and mitochondrial respiratory chain deficiency, additional work 
needs to be undertaken to determine the pathological relevance of 
mitochondrial dysfunction in MFM. Nevertheless, the decrease in mitochondrial 
mass and weak relationship between mitochondrial mass and myofibre cross 
sectional area, infers that mitochondrial dysfunction may be both 
mechanistically and pathologically relevant. 
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4.5.1 Limitations 
In this study fibres were selected for genetic analysis based on sequential 
COX/SDH histochemistry. This is both subjective and in many MFM patients 
misleading, as to the level of respiratory chain deficiency. It may have been 
more informative to subsequently revisit the genetic analysis using quadruple 
immunofluorescence to assess respiratory chain deficiency and select muscle 
fibres. 
Since the cohort consist of six DES patients, two MYOT and one LDB3, with the 
MYOT and LDB3 patients being the oldest, it is difficult to differentiate between 
ageing and genotype as factors affecting levels of mitochondrial respiratory 
chain deficiency and mtDNA deletions. Furthermore, for the DES patients the 
variability in age and mutations within the gene, with mutations in different 
domains known to have different effects of protein and disease phenotype, it 
means it is difficult to make conclusions linking disease pathogenesis to 
mitochondrial dysfunction. 
Due to the fact that all experiments are completed in skeletal muscle 
cryosections, this work also only examines a static time point. Tissue culture 
and live cell imaging for patient myoblasts may have been more informative for 
gaining mechanistic insight into disease pathogenesis and potential relevance 
of mitochondrial dysfunctions. 
 
4.5.2 Future work 
Since it is hypothesised that the reason for reduced mitochondrial mass is a 
reduction in mitochondrial biogenesis it would be interesting to assess the levels 
of the proteins involved in the mitochondrial biogenesis pathway (e.g. PGC1α, 
TFAM, NRF-1 and NRF-2) (Scarpulla, 2011). 
Furthermore since mitochondria are likely to be repositioned within the 
myofibres, Calcium homeostasis and mitochondrial dynamics may be altered. 
As such, it would be interesting to both examine mitochondrial location, 
ultrastructure and morphology but also Calcium homeostasis in cultured patient 
myotubes. Furthermore, culturing myotubes would have allowed a more 
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dynamic visualisation of mitochondrial morphology and turnover using live cell 
imaging. Although this was intended for the future of the project, only two DES 
mutant cell lines were obtained, of these cell lines one failed to differentiate, as 
such these experiments were not completed. 
An alternative and better model to assess the effects of Desmin mutants in vivo  
could be crossing a DES mutant mouse such as that used by Winter et al. 
(2016) with the mito-Dendra2 mice (Pham et al., 2012) with photoactivatable 
mitochondria and live-tissue imaging as performed by Pham et al. (2012). This 
would have been a better model for the in vivo situation since the 
cytoarchitecture and thus mitochondrial positioning is not full formed until 
muscle is completely differentiated, as such even differentiated myotubes are 
far from the in vivo organisation. 
 
4.6 Conclusions 
In conclusion, this work demonstrates clonally-expanded mtDNA deletions in a 
small number of single myofibre lysates, similar to previous findings in muscle 
homogenate DNA from MFM patients.  It is further noted that the frequency of 
these deletions is highest in the oldest patient (P17) with a LDB3 mutation.  
Given this and previous work it is concluded that mtDNA deletions likely arise 
due to the combined effect of sarcopenia and disease pathogenesis. The 
reason for this conclusion is that the two most severely affected patients are the 
oldest, however they also have the most severe mitochondrial dysfunction and 
MFM muscle pathology both of which are reported to be causative of  mtDNA 
deletions.  Evidence that myofibrillar myopathies can manifest depletion of 
mitochondria and respiratory chain deficiency of varying degrees among 
patients, is also presented.  Previous reports show a core-like reduction of 
mitochondria, which is confirmed here.  Such a depletion of mitochondria may 
be a contributing factor to overall disease pathogenesis and could be linked to 
hypertrophy of the myofibres.  
When taken with previous findings, the involvement of mitochondria in MFM 
disease pathology still appears to be very heterogeneous and mechanistically 
unclear. Furthermore, it seems likely that the extent of mitochondrial 
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involvement is altered depending on the mutation and which gene is affected, 
whether the mutation is heterozygous or homozygous and the age of the 
patient. As such, the small scale studies and studies with a large mixture of 
genotypes, including the work presented here are not sufficient to identify 
patterns and determine the pathological importance of each of these factors.
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Chapter 5. Clonal expansion of mitochondrial DNA deletions 
 
5.1 Introduction: 
Clonal expansion is the term used to describe the accumulation of a single mutant 
species mtDNA to higher levels of heteroplasmy. Eventually, the number of mutant 
mtDNA molecules will outnumber the number of wild type mtDNA molecules and 
subsequently exceed the mutational threshold required to cause a biochemical defect 
(described in more detail in 1.7). This process is highly relevant to the pathogenesis 
of both inherited and sporadic mtDNA mutations and equally applicable to both 
mtDNA deletions and mtDNA point mutations. Furthermore, due to the prevalence of 
mtDNA mutations in neuromuscular and neurodegenerative diseases, as well as in 
normal tissue ageing, this is mechanistically-relevant to a variety of disease and non-
disease pathologies. 
 
5.1.1 mtDNA deletion formation 
Mitochondrial DNA deletions have been proposed to form either during replication or 
mtDNA repair. The first model proposed that deletions form during replication due to 
a slip-replication mechanism (Shoffner et al., 1989) (Figure 5.1), this model assumes 
that mtDNA is replicated by the strand-asynchronous mechanism (See 1.5.5). If a 
slipped strand were to occur, the light strand would misalign so that the 3’ repeat of 
the light strand anneals to the 5’ end of the heavy strand, generating a single strand 
loop which would be susceptible to a single strand break and degradation. Continued 
replication would generate a wild type molecule from the heavy strand and a deleted 
molecules from the light strand (Shoffner et al., 1989). 
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Figure 5.1 Deletion formation by a slippage replication mechanism. Replication of 
the 3’ repeat occurs after which the displaced 3’ repeat misaligns with the 5’ repeat. 
This forms a displaced look and subsequently a strand break. The loop is degraded 
by endonucleases and the ends ligated before replication continues. This generates 
a wild type and a deleted mtDNA molecule (ΔmtDNA). Figure based on (Shoffner et 
al., 1989; Krishnan et al. (2008)). 
 
However, this necessitates the 3’ and 5’ repeats coming together to form a single 
stranded loop that is subsequently degraded when the mtDNA break occurs 
(Krishnan et al., 2008). Based on this an alternative hypothesis was proposed, that 
suggests mtDNA deletions are formed during mtDNA repair of double strand breaks, 
by the annealing of homologous regions created by exonuclease activity at double 
strand breaks (Krishnan et al., 2008). The problem with this hypothesis is that it only 
accounts for homology dependent recombination, whereas there are deletions 
reported, for example in in the substantia nigra (Reeve et al., 2008), which have no 
repeats. 
Findings in a mouse model with an inducible mitochondrially-targeted restriction 
endonuclease (Fukui and Moraes, 2009) lead to the suggestion that mtDNA deletions 
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are formed during mtDNA repair of double-strand breaks by both homology-
dependent and homology-independent mechanisms. In these mice double-strand 
breaks were induced in adult neurons and resulted in deleted mtDNA molecules 
resembling those naturally occurring with age and in neurodegenerative diseases 
such as Parkinson’s disease. The spectrum of mtDNA deletions observed was 
consistent with a mixture of both homologous recombination and non-homologous 
end-joining. 
 
5.1.2 Theories of clonal expansion 
Mitochondrial DNA deletions and point mutations have been found to accumulate to 
high levels in ageing and disease. Many theories have been proposed to explain 
clonal expansion of mtDNA mutations, but to date no one theory explains all of the 
biological data reported. Wallace (1989), proposed the ‘survival of the smallest’ 
hypothesis which suggests that there is a replicative advantage for mtDNA with a 
larger deletion, since the time taken to replicate the mtDNA is reduced. Thus smaller 
genomes can replicate faster and out compete the wild type mtDNA to exceed a 
threshold level (1.5.10), within a cell.  
However, since this hypothesis was proposed numerous papers have questioned its 
validity. In particular, this theory only explains clonal expansion of mtDNA deletions 
and would not fit for point mutations which do not significantly alter the size of the 
mtDNA molecule and yet are found to clonally expand through-out life. For instance 
the m.12320A<G mutation was reported to increase from 70 to 90% over a 12 year 
period in four consecutive muscle biopsies of a patient with isolated mitochondrial 
myopathy (Weber et al., 1997). Similarly mtDNA point mutations were found to be 
present in early adulthood at low levels and higher clonally expanded levels and to 
increase with age (Greaves et al., 2014). 
Furthermore, Campbell et al. (2014) investigated the possibility of a replicative 
advantage by analysing mtDNA deletion size and size of respiratory chain deficient 
segments, as a measure of rate of clonal expansion. By sequencing the breakpoints 
of 62 small COX-deficient segments and 60 large COX-deficient segments they 
concluded that no replicative advantage was apparent. Also, recent data looking at 
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two mtDNA deletions in Caenorhabditis elegans finds that both smaller and larger 
genomes accumulate to similar levels (Gitschlag et al., 2016). 
In contrast to these findings, an in vitro study of mtDNA repopulation following 
mtDNA deletion by Diaz et al. (2002), found that mitochondria were predominantly 
repopulated with smaller mtDNA molecules under relaxed copy number control 
conditions. Furthermore, they demonstrate the hybrid cells containing two mtDNA 
deletion species tend to retain the smallest genomes. In keeping with these 
observations, cell lines containing homoplasmic mtDNA deletions also repopulate 
their mtDNA copy number faster than wild type cell lines (Moraes et al., 1999). 
However, under tight copy number control which constitutes normal non-selective 
conditions, a decrease of deleted mtDNA genomes is demonstrated over time, likely 
due to the faster growth of cells with higher levels of wild type mtDNA. Other studies 
have also demonstrated that cell doubling time is highest in cells with higher levels of 
mtDNA deletion (Hayashi et al., 1991). Thus the evidence for or against replicative 
advantage of deleted mtDNA molecules to date is inconclusive and results are 
dependent on cellular conditions. 
A second hypothesis, often referred to as the “survival of the slowest” hypothesis was 
proposed by de Grey (1997). This suggested that the mtDNA mutation lowers the 
respiratory capacity of the mitochondria, resulting in a reduction in damage caused 
by free radicals. As such these mitochondria are not targeted for mitophagy but 
instead undergo preferential replication. In comparison, otherwise normal 
mitochondria produce high levels of ROS leading to damage to the mitochondrial 
membrane proteins, depolarisation of the IMM and selective degradation (Kim et al., 
2007). The main problem with this theory is that it requires mitochondrial respiratory 
deficiency and therefore only explains the clonal expansion of an already established 
deletion species. 
Both of the above hypotheses suggest a selective advantage of mitochondria 
containing mutant mtDNA. In contrast to this a third hypothesis, termed ‘random 
genetic drift’, was proposed by Elson et al. (2001) which suggests that no selective 
advantage is required. This hypothesis is based on the theory of relaxed replication, 
which describes the regular turnover of mtDNA independently of the nuclear DNA 
which is replicated with each new cell cycle (Bogenhagen and Clayton, 1977). Elson 
et al. (2001), modelled replication based on replicative dynamics previously 
  Chapter 5 
154 
 
demonstrated (Shadel and Clayton, 1997) and found that relaxed replication is 
sufficient to explain the clonal expansion of mtDNA deletions. The model 
demonstrated that clonal expansion to high levels of heteroplasmy, required the vast 
majority of mtDNA mutation events to occur before 30 years of age with 30% 
occurring before 15 years of age. Mutation events that happened after this, according 
to the model, would not have sufficient time to accumulate. 
Another study modelled the accumulation of mtDNA mutations in cancerous epithelial 
stem cell to mutational homoplasmy (Coller et al., 2001). The model assumed that 
the mtDNA was mutated, replicated and segregated during cell divisions randomly 
and found that after only 70 generations a mutation can reach homoplasmy. 
This is further supported by data from the colon of the mtDNA mutator mouse 
(Baines et al., 2014), however does not predict the same levels of mitochondrial 
respiratory chain deficiency and levels of heteroplasmy as observed in human 
biological ageing data. The model by Elson et al. (2001), predicts 4% of post-mitotic 
cells would be COX-deficient over an 80 year period, however 40% of substantia 
nigra neurons are found to be COX-deficient at 80 years with up to 90% deletional 
heteroplasmy (Itoh et al., 1996; Kraytsberg et al., 2006). 
Kowald and Kirkwood (2014), proposed another alternative hypothesis which 
suggested that the driving mechanism is the link between transcription and 
replication of mtDNA. This was supported by in silico data, with these authors 
proposing that MT-ND4, MT-ND5 and MT-ND6 are potential candidates for this 
feedback mechanism. While it is true that these proposed genes are more commonly 
absent in clonally expanded deletion species, they are not always deleted. 
Furthermore their increased frequency could simply be due to their location relative 
to mtDNA mutation hotspots (Damas et al., 2014b), rather than them driving a 
feedback mechanism. Certainly there are clonally expanded deletions reported via 
MitoBreak (Damas et al., 2014a), that only affect the minor arc whilst many more 
reported that only affect the major arc. As such, a single candidate gene that could 
theoretically provide this feedback mechanism seems unlikely. 
Finally, two recent publications have used C. elegans as a model organism to 
investigate the importance of the mitochondrial unfolded protein response (UPRmt) 
(Gitschlag et al., 2016; Lin et al., 2016) in clonal expansion of mtDNA deletions. Both 
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papers show that wild type mtDNA copy number is tightly regulated in C. elegans, 
furthermore according to data in both papers, the expansion of mtDNA deletions 
involves retrograde mito-nuclear signalling to upregulate the UPRmt and increase 
total mtDNA copy number. Lin et al. (2016), demonstrate that activating transcription 
factor associated with stress-1 (ATFS-1) fails to be imported into depolarised 
mitochondria and its cytosolic location activates the UPRmt. Although, similar in 
approach these studies reach different conclusions. Gitschlag et al. (2016) present 
data that shows the UPRmt reduces mitophagy and it is this that allows the mtDNA 
deletions to accumulate. In contrast, Lin et al. (2016) demonstrate that the UPRmt 
induces mitochondrial biogenesis and promotes mitochondrial fission and fusion. 
Although the UPRmt has not been characterised in humans and to date no equivalent 
to ATFS-1 has been identified, these studies raise questions of whether there is a 
similar mito-nuclear signalling mechanism in humans.  
 
5.1.3 The proliferative perinuclear niche hypothesis 
Based on these data and the previous theories presented above a novel hypothesis 
to explain the clonal expansion of mtDNA deletion in skeletal muscle was proposed 
and termed the ‘proliferative perinuclear niche’ hypothesis. The mtDNA would need 
to be actively replicating in order for the mtDNA deletions to clonally expand a 
process which requires nuclear encoded replication machinery. As such the 
perinuclear niche hypothesis proposes that the initial events of clonal expansion 
would be perinuclear. This further makes sense if we consider previous data which 
suggests that mitochondria closest to the nuclei are replicating faster (Davis and 
Clayton, 1996), that signaling is limited by diffusion distance and that mechanisms 
previously reported in C. elegans involve retrograde signaling to changes in 
mitochondrial biogenesis, mitophagy and mitochondrial dynamics (Gitschlag et al., 
2016; Lin et al., 2016). Furthermore, it was hypothesised that in a tissue with the 
highly organised cytoskeletal such as the skeletal muscle, limited mitochondrial 
movement should make the initial events of clonal expansion easily traceable. 
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5.2 Aims of this investigation: 
This investigation aimed to; identify the smallest region of COX deficiency and thus 
the earliest visible signs of clonal expansion in skeletal muscle. Subsequently, the 
investigation was intended to characterise the frequency at which they occur, the 
level of mtDNA deletion in regions of focal COX-deficiency relative to the remainder 
of the fibre and the effect of mitochondrial morphology on the spread of mtDNA 
deletions through the myofibre.  
 
5.3 Methodology: 
5.3.1 Patient cohort 
Muscle biopsies from patients with single, large-scale mtDNA deletions and inclusion 
body myositis (IBM) were selected from large cohorts of recently diagnosed patients, 
by screening for good muscle morphology and a reasonable degree of COX 
deficiency (>5%). Patients with multiple mtDNA deletions were similarly selected from 
a larger cohort of cases with confirmed genetic diagnoses. Cases included those with 
inherited variants in TWNK, RRM2B and POLG genes. Normal human ageing 
samples were obtained from the Hertfordshire cohort, these samples were used to 
screen for the presence of COX negative foci in a non-quantiative manner, to assess 
if these were observed in aged samples also.  Relevant patient information is 
detailed in Table 2.9. 
Ethical approval was previously granted by the Newcastle and North Tyneside Local 
Research Ethics Committees (reference 2002/205) and is now approved under 
Newcastle and North Tyneside Local Research Ethics Committees (reference 
16NE/0267). Prior informed consent was obtained from each participant. All 
experiments were carried out in accordance with the approved guidelines. 
 
5.3.2 Sequential COX/SDH histochemistry  
Cryosections (10 µm) were treated for sequential COX/SDH histochemistry as 
described in 2.8.4 for initial screening of foci and stereological assessment. For 
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analysis of foci proximity to nuclei, 8 µm serial cryosections were cut to allow 
reconstruction of myofibres for three dimensional assessment of nuclear proximity. 
These were treated for COX/SDH histochemistry as described in 2.8.4 and then 
counter stained with DAPI as described below in 5.3.3. 
 
5.3.3 Counterstaining of COX/SDH histochemistry or immunofluorescence with DAPI 
Counterstaining with DAPI was completed following incubation with SDH reaction 
medium and 1x PBS washes for COX/SDH histochemistry and following 1x TBST 
washes after the final secondary antibody incubation for immunofluorescence. 
Sections were washed thoroughly in either 1x PBS (histochemistry) or 1x TBST 
(immunofluorescence) before counterstaining with DAPI at a concentration of 2 μg/ml 
in PBS for 5 minutes. Sections were washed again and mounted in ProLong Gold. 
 
5.3.4 Immunofluorescence for quantitative analysis of foci 
This experiment was completed in collaboration with Hannah Rosa with both parties 
contributing equally (Hannah Rosa completed the immunofluorescent staining, we 
both imaged the sections and stitched the images and I performed the image 
analysis). 
Serial cryosections (8 µm) were obtained from patient 24 with POLG variants. The 
first and last section were treated as no primary controls with 16 serial section in the 
middle treated for full immunofluorescence. Sections were treated for 
immunofluorescence as described in 2.9.1 using anti-MTCOI (1:100), anti-SDHA 
(1:100) and anti-laminin (1:50) primary antibodies and anti-mouse IgG2a Alexa Fluor 
488 (1:200), biotinylated anti-mouse IgG1 (1:200), anti-rabbit Alexa Fluor 405 (1:200) 
and Streptavidin conjugated Alexa Fluor 647 (1:100). No primary controls were 
labelled with anti-laminin as the only primary antibody and all secondary antibodies. 
Imaging was completed as described in 2.9.3. Images were stitched before analysis 
using the profile function in Zen (Blue edition) to plot fluorescent intensity across the 
myofibre.  
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5.3.5 Stereology 
Cryosectioned skeletal muscle from patients with large scale single mtDNA deletions 
(n = 5), IBM (n = 4) and multiple mtDNA deletions (n = 7) were reacted for COX/SDH 
histochemistry (performed by Gavin Falkous, Dr Karolina Rygiel and Dr Georgia 
Cambell, respectively). Prior to assessment both investigators assessed one section 
together and agreed on assessment criteria. It was decided that all fibres that were 
not fully COX-negative (blue) (Figure 5.2) or containing foci, would be classified as 
“other” (Figure 5.2). In order for a fibre to be classified as containing a foci it had to 
have a small clearly defined foci of COX deficiency with the remainder of the fibre 
being COX-positive (Figure 5.2). Finally, the remainder of the fibres which were 
classified as COX-positive were counted to give a total number of fibres assessed. 
The methodology was designed to capture only the earliest events of COX deficiency 
and subsequently allow us to compare frequency of these to fully deficient fibres to 
infer how quickly COX deficiency spreads from the foci across the full myofibre. 
Counts were made in Stereo investigator using the meander scan function and using 
an Olympus BX51 Stereology microscope. It was agreed that I would assess each 
section first, defining a region using the meander scan function in Stereo investigator 
and capturing an image of the annotated region. The annotated image was then used 
by Hannah Rosa to assess the same region independently.  
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Figure 5.2 Guide to classification of fibres by stereology for the purpose of assessing 
the frequency of full COX-negative muscle fibres and muscle fibres with early stage 
focal COX deficiency. 
 
5.3.6 Laser microdissection and cell lysis for triplex real time PCR 
Three patients with mtDNA maintenance disorders and multiple mitochondrial 
deletions were selected for genetic assessment, these patients had variants in 
RRM2B (n = 2, patient 20) and POLG (n = 2, patients 22 and 24). Eight serial 
cryosections (15 µm) were cut and treated for COX/SDH histochemistry as described 
in section.  
Foci from myofibres were laser capture microdissected (2.10.1), along with identically 
sized COX-positive regions from the same myofibre. Full COX-positive and COX-
negative fibres were captured for comparison and all samples were captured into 
Tris-tween-proteinase K lysis buffer (2.10.2). Triplex real time PCR with amplicons in 
the D-Loop (rarely deleted), MT-ND1 (occasionally deleted) and MT-ND4 (commonly 
deleted), was run as described in 2.11.1. For each plate a standard curve of plasmid 
p7D1 and at least two fully COX-negative and fully COX-positive fibres were included 
on each plate. All samples were analyzed in triplicate and each foci were compared 
to two identically sized regions of the same fibre. 
 
5.3.7 Statistical analysis 
For clonal expansion experiments statistical significance was tested using a 
combination of two-tailed unpaired (whole myofibre) and paired (matched sub-cellular 
regions) T-tests. Statistical significance was set at 0.05. All analyses were performed 
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in Prism v7.0 (Graph Pad). 
 
5.4 Results: 
5.4.1 Initial screen 
An initial screen of previously prepared cryosections that had been treated for 
COX/SDH histochemistry were surveyed to assess if focal regions of deficiency were 
present, which may represent the origin of clonally expanded mtDNA deletions and 
thus COX deficiency. Once identified examination of a variety of biopsies from 
patients with multiple mtDNA deletions, single large scale mtDNA deletions, IBM, 
myofibrillar myopathy and aging confirmed that it is a wide spread observation 
(Figure 5.3). In addition, to the frequently reported fully COX-negative (Figure 5.3b) 
and COX-intermediate myofibres observed in both transverse and longitudinally 
orientated myofibres subsarcolemmal foci of COX-deficiency and fibres with larger 
segments of COX deficiency in cross section were also observed (Figure 5.3).  
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Figure 5.3 Sequential COX/SDH for the localisation of COX deficiency in human 
skeletal muscle. (a) Three myofibres in longitudinal orientation from a case of 
inclusion body myositis (IBM), note segmental COX deficiency in the central fibre. (b) 
Fully COX-deficient myofibre in transverse orientation. (c) Focal COX deficiency in a 
case of single, large-scale mtDNA deletion, and (d) multiple mtDNA deletions in 
transverse orientation. (e) Focal COX deficiency in a case of multiple mtDNA 
deletions in longitudinal orientation. Note the restricted nature of deficiency. (f) Focal 
COX deficiency in cross-section from cases of IBM; (g) mechanically-ventilated 
diaphragm; and (h) normal aging. Examples shown in A and B are commonly 
observed in both disease and aging, whereas examples shown in C-H (encircled in 
red dashed line) are rarer. Exact prevalence of myofibres with complete and focal 
COX deficiency is listed in Table 5.1. Scale bars, 25 μm. 
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5.4.2 Quantifying frequency of focal COX deficiency 
Stereological assessment of skeletal muscle biopsies, was performed in order to 
assess; the frequency of COX-deficient foci, whether the frequency is higher in a 
specific patient group or with increased percentage COX deficiency of the overall 
biopsy. Counts were performed by myself and Hannah Rosa and averages are 
presented in Table 5.1. Intra-investigator variability was noted, however, this was 
mainly due to how we classified fibres with low levels of intermediate deficiency. Of 
the total fibres analysed (n = 20595, averaging n = 1373 fibres per patient), 47 fibres 
contained foci and 1644 were COX-deficient. Therefore, on average muscle biopsies 
contained on average 9.7% (range 0.8 – 30.5%) fully COX-deficient fibres, compared 
to 0.16% (range 0 – 0.57%) COX-negative foci. This demonstrated the frequency of 
COX-negative foci to be 1:807 of all myofibres analysed, or 1:64 fully COX-deficient 
myofibres. 
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Table 5.1 Quantification of cytochrome c oxidase (COX) deficient myofibres and foci 
in muscle biopsies from; multiple mtDNA deletions (n = 6), single, large-scale mtDNA 
deletions (n = 5) and inclusion body myositis (IBM) (n = 4). Counts presented here 
are averages of two investigators (Hannah Rosa and myself). 
 
 
5.4.3 Subcellular localization of focal deficiency 
Analysis of approximately 94,000 myofibres from 16 skeletal muscle biopsies of 
patients described in Chapter 2 Table 2.9, demonstrated that partial respiratory 
chain deficiency is always restricted to the subsarcolemmal region of the myofibre 
and never the centre or intermyofibrillar region (dotted line, Figure 5.3b-f). Similar 
subsarcolemmal deficiency was also identified by Martin Picard in mechanically-
ventilated diaphragm where COX deficiency is associated with mtDNA deletions 
(Figure 5.3d) (Picard et al., 2012). In addition to diseased muscle biopsies, muscle of 
healthy adults 68 - 77 years of age (n = 79, Figure 5.3h), were also analysed and 
confirmed the previously observed pattern of subsarcolemmal focal deficiency. As 
such it would appear this pattern is conserved across numerous neuromuscular 
disorders and healthy ageing. 
Patient # Diagnosis Total 
counted 
% COX 
negative 
% 
Foci 
% Foci 
/ COX 
negative 
P18 multiple mtDNA deletions 469 8.53 0.00 0.00 
P19 multiple mtDNA deletions 719 30.48 0.14 0.23 
P20 multiple mtDNA deletions 2421 16.20 0.33 2.04 
P21 multiple mtDNA deletions 1658 0.78 0.12 15.38 
P23 multiple mtDNA deletions 1251 9.52 0.16 1.26 
P24 multiple mtDNA deletions 2615 5.66 0.15 2.71 
P25 single mtDNA deletion 788 19.16 0.38 1.66 
P26 single mtDNA deletion 1364 5.79 0.15 2.55 
P27 single mtDNA deletion 1221 8.52 0.08 0.48 
P28 single mtDNA deletion 349 12.34 0.57 3.53 
P29 single mtDNA deletion 2430 3.29 0.08 1.88 
P30 IBM 626 15.02 0.16 1.06 
P31 IBM 1319 4.78 0.00 0.00 
P32 IBM 1745 4.70 0.06 0.61 
P34 IBM 1620 1.05 0.00 0.00 
 Average 1373 9.72  0.16  1.43  
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Immunofluorescent labelling of nuclear encoded SDHA and mtDNA encoded MTCOI 
further confirmed this pattern (Figure 5.4a). More interestingly, when serial sections 
reacted for COX/SDH histochemistry and immunofluorescence were counter-stained 
with DAPI the foci are always associated to a nucleus (Figure 5.4b and c). 
Quantitative assessment of fluorescently stained sections demonstrated that 97% of 
all identified foci contained a nucleus within the foci either on the same section or on 
a serial section. Figure 5.4d shows a COX deficiency surface map which allowed 
visualisation of level of focal deficiency in Figure 5.4a. Using electron microscopy we 
found close proximity of mitochondria to the nuclear pores facilitating mito-nuclear 
signaling (Figure 5.4e), furthermore close proximity to capillaries providing nutrients 
and oxygen for mitochondrial biogenesis was also observed (Figure 5.4f). 
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Figure 5.4 Foci of respiratory chain deficient mitochondria are located in the 
subsarcolemmal region and colocalise with nuclei. (a) Magnified area showing 
selective absence of MTCOI staining in the perinuclear niche area outlined. (b) Serial 
cryosections reacted for sequential COX/SDH histochemistry and DAPI. Note the foci 
of COX deficiency in the outlined cell restricted to the middle section (red arrow), 
indicating that the foci is less than 8µm in length. (c) Serial cryosections labelled by 
triple immunofluorescence for MTCOI, SDHA, and DAPI for nuclei, showing focal 
COX deficiency restricted to the middle section (red arrow). (d) Intensity profile for 
[1/(MTCOI/SDHA)] ratio for the myofibre region shown in (a) (created by Martin 
Picard). Regions of high COX deficiency are marked by high peaks of red, orange 
and yellow and no deficiency shows no peak. (e) Pseudocoloured transmission 
electron micrograph (TEM) showing a mitochondrion in close proximity to nuclear 
pores within the nuclear envelope (arrows), representing a window onto the 
euchromatin and heterochromatin (*) where transcriptional regulation occurs.(f) 
Pseudocoloured TEM electron micrograph showing subsarcolemmal mitochondria in 
proximity to a capillary and two nuclei, which provide resources for increased 
mitochondrial biogenesis. Example from skeletal muscle of m.8344A>G tRNALys 
skeletal muscle. 
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5.4.4 Quantitative analysis of COX deficiency across the myofibre 
From the immunofluorescently labelled serial sections MTCOI/SDHA intensity profiles 
were generated to precisely map and quantitatively assess the distribution of 
complex IV deficiency with sub-cellular resolution. A range of MTCOI deficiency was 
noted from no deficiency (Figure 5.5a), to small foci confined to the perinuclear 
region (Figure 5.5b), to partially deficient (Figure 5.5c) to completely deficient 
(Figure 5.5d).  
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Figure 5.5 Foci distribution of COX deficiency and mitochondrial content by immunofluorescence in human myofibres. (a) MTCOI and 
SDHA immunofluorescent labelling and quantification of a normal COX-positive myofibre (left), with fluorescence intensity plotted along 
the profile denoted by the arrow (middle), and COX:SDH ratio (right). (b) Myofibre with a niche of focal COX deficiency denoted in red in 
fluorescence intensity plots. (c) Myofibre with segmental COX deficiency spread through approximately 70% of the cell’s longest 
diameter. (d) Myofibre with complete COX deficiency.(e) Quantification of mitochondrial content based on SDHA fluorescence intensity in 
COX- foci and in matched COX+ subsarcolemmal regions within individual myofibres (n = 15, two-tailed paired T test). Data is plotted 
relative to COX+ regions. Scale bars, 50 µm. 
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This pattern would be consistent with spread of mtDNA deletions and respiratory 
chain deficiency from an initial subsarcolemmal foci across the transvers myofibre. 
Comparison of SDHA fluorescent intensity in the COX-deficient foci and the COX-
positive remainder of the same fibre showed higher SDHA fluorescent intensity in the 
COX-deficient foci (Figure 5.5e). This is consistent with an increase in mitochondrial 
mass in areas of respiratory chain deficiency and is also comparable to COX-positive 
and COX-negative fibres. 
 
 
5.4.5 Quantification of deletion level in COX-deficient foci 
Genetic analysis was performed in patients with mtDNA maintenance disorders due 
to mutations in either RRM2B (n = 1) or POLG (n = 2) (patients 6.3, 6.5 and 6.7). 
Laser microdissection of COX-deficient foci and equivalently sized regions of the 
remainder of the fibre (Figure 5.6a) were compared to assess whether the focal 
deficiency observed, was due to a higher mtDNA deletion level in the focal region of 
deficiency than observed in the COX-positive portion of the fibre. 
As expected triplex real time PCR showed that the majority of COX-deficient foci 
contained MT-ND4 deletions with a smaller proportion also containing MT-ND1 
deletions. In comparison the COX-positive regions of the same fibre contained either 
no mtDNA deletion or lower levels of deletion (Figure 5.6b). On average deletion 
level (as assessed by MT-ND4/MT-ND1 relative abundance) was significantly higher 
in COX-deficient foci than in the corresponding COX-positive regions (Figure 5.6c). 
When this is compared to COX positive and negative fibres analysed here and 
previously the deletion pattern is comparable (Figure 5.6d). 
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Figure 5.6 Deletion level is higher in COX-negative foci than the COX-positive region 
of the same fibre. (a) Fibre before and after laser microdissection of COX- and two 
COX+ control regions. (b) MT-ND4/MT-ND1 as an indicator of deletion level in COX- 
foci and matched sub-cellular regions from single fibres. Matched sub-cellular 
regions are connected by a line and colour-coded with the same scheme. (c) 
Averages of data from (b), data are means ± SEM. Three patients, n=18, two-tailed 
paired T-tests. (d) MT-ND4/MT-ND4 in COX+ and COX- fibres. Each data point 
corresponds to a single fibre. Bars indicate mean values. Data points represent 
single fibres (n = 22, 3 patients, two-tailed T tests). 
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5.4.6 Quantification of mtDNA copy number 
Quantification of mtDNA copy number was completed using an optimised standard 
curve method (Rygiel et al., 2015a) for quantification of absolute copy number of the 
real time PCR D-Loop amplicon, since MT-ND1 and MT-ND4 are both found to be 
deleted in some samples. As expected, mtDNA copy number was increased in the 
majority of foci, with some foci showing a greater than three-fold increase in mtDNA 
copy number when compared to COX-positive regions of the same fibre (Figure 
5.7a). COX negative foci relative to COX positive regions shows a mean 1.8-fold 
(range 1.1 - 5.7, P < 0.001) higher mtDNA copy number (Figure 5.7b). In 
comparison, COX-negative fibres have a 1.4-fold (range 1.0 - 4.3, P = 0.03) higher 
mtDNA copy number than COX-positive fibres (Figure 5.7c). When taken in 
conjunction with the increased SDHA protein level (patient 24, Figure 5.5e), this 
implies increased mitochondrial biogenesis in both the focal regions of COX-
deficiency and fully COX-deficient fibres. 
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Figure 5.7 Total mtDNA copy number is increased in foci. (a) Total mtDNA copy 
number in COX- foci and matched sub-cellular regions from single fibres. Matched 
sub-cellular regions are connected by a line and colour-coded with the same 
scheme. (b) Averages of fibres presented in (a), data are means ± SEM, 3 patients, 
n=18, two-tailed T-test. (c) Total mtDNA copy number in COX+ and COX- fibres. 
Each data point corresponds to a single fibre. Bars indicate mean values. Data points 
represent single fibres (n = 22, 3 patients, two-tailed T test). 
 
 
5.4.7 Assessing direction of spreading of respiratory chain deficiency 
COX/SDH histochemistry and mitochondrial morphology as assessed by electron 
microscopy suggest that mtDNA deletions and respiratory chain deficiency are likely 
to spread quicker across the transverse plane of a myofibre than along the 
longitudinal. If this is the case we see segmental COX deficiency as in the 
mitochondrial network model rather than the shape created in a random spread 
model where deficiency spreads equally in both directions (Figure 5.8a). This is 
supported by the number of small segments if COX deficiency observed in the 
longitudinal myofibres (Figure 5.8b). In the fibres shown the aspect ratio (length y / 
width z) is 2 – 2.5, indicating that spread in the transverse plane is at least twice as 
high. Furthermore, electron microscopy of mitochondria in the transverse and 
longitudinal planes shows increased mitochondrial network connectivity in the 
transvers plane (Figure 5.8c and d). This is explored further and quantitatively 
assessed in Chapter 7. 
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Figure 5.8 Skeletal muscle anisotropy in mitochondrial network connectivity. (a) Hypothetical models illustrating potential distributions of 
COX- niches at early stage of clonal expansion. In the random spread model (top), biochemical deficiency covers an equal distance (x) in 
both transverse and longitudinal orientations. In the mitochondrial network model (bottom), biochemical deficiency can cover the width of 
the myofibre, a distance (y) that is greater than the distance covered in the longitudinal axis of the fibre (z). Dotted green boxes denote 
edges of biochemical deficiency. (b) Images of thin longitudinal regions of COX- segments support the mitochondrial network model. (c) 
Schematic demonstrating differences in mitochondrial network connectivity when examining a myofibre in transverse or longitudinal 
orientation. (d) Results from serial block face scanning electron microscopy (SBFSEM) showing that in the transverse orientation (green), 
mitochondria form an interconnected network. In the longitudinal orientation (blue), mitochondria appear round and isolated, with few 
connections across sarcomeres. Each continuous mitochondrion is pseudocoloured, and Z-lines are denoted by dotted lines. Scale bars 
histochemistry (b), 50 μm; scale bars electron microscopy (d), 1 μm. 
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5.5 Discussion: 
Since the late 90s, several theories have been suggested to account for the clonal 
expansion of mtDNA deletions in post mitotic tissues. However, many of these do not 
fully explain the biological data and leave several questions unanswered. Some such 
questions include; i) where do mtDNA deletion originate in the cell? ii) What allows 
deleted mtDNA to accumulate such that it becomes present in higher levels than wild 
type mtDNA and is this driven by a selective advantage? iii) Why do we see 
segmental COX deficiency in longitudinal myofibres, and what dictates the directional 
spread of respiratory chain deficiency? The aim of this study is to attempt to answer 
some of these questions. 
A combination of in-depth imaging and molecular investigations were performed to 
investigate human skeletal muscle biopsies across a number of disease conditions 
as well as ageing. By doing so the work aimed to identify and investigate a 
conserved principle simultaneously accounting for the origin, expansion, and 
directional spread of mtDNA deletions within myofibres. It was hypothesised that 
there is a proliferative perinuclear niche (Figure 5.9), where proximity of mtDNA 
deletions to the nucleus is a key factor which allows retrograde mito-nuclear 
signalling from respiratory chain-deficient mitochondria to initiate local mitochondrial 
biogenesis. Findings presented here suggest that SS perinuclear mitochondria 
acquire an mtDNA deletion and proliferate by driving mitochondrial biogenesis, and 
expand through the sarcomeric planes across the z-band via the path of least 
resistance and subsequently along the myofibre. 
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Figure 5.9 Proliferative perinuclear niche model for clonal expansion of mitochondrial DNA deletions in skeletal muscle. Stages of clonal 
expansion from a single deleted mtDNA clone to a completely COX-deficient myofibre. Sporadic mtDNA deletion (ΔmtDNA) events that 
occur in close proximity to the nucleus expand by random genetic drift until biochemical deficiency develops. This engages “retrograde” 
signalling to the nucleus where it triggers compensatory mitochondrial biogenesis and mtDNA replication, driving proliferation of the 
perinuclear niche. Proliferating SS mitochondria with mtDNA deletions physically interact with IMF mitochondria via fusion and/or 
migration and spread through the path of least resistance (i.e., transversely) in a wave-like manner, creating myofibres with segmental 
COX deficiency. Constant mitochondrial turnover (red crosses) leads to the “replacement” of wild-type mtDNA by deleted mtDNA under 
the force of the proliferative niche. IMF mitochondria that acquire a spontaneous mtDNA deletion are likely degraded without having the 
capacity to drive biogenesis and replicate (red crosses), explaining why COX-deficient foci always arise from the SS compartment.
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Identifying the site of origin for mtDNA deletions could improve the understanding of 
clonal expansion. Myofibres contain two mitochondrial subpopulations, 
subsarcolemmal and intermyofibrillar, with distinct topological, morphological and 
functional differences (Ferreira et al., 2010; Picard et al., 2013). With this in mind 
several thousand myofibres were analysed and the smallest possible foci of COX 
deficiency identified. It was noted that the subsarcolemmal mitochondria are always 
implicated but never the IMF in isolation. 
There are two possible explaination for the perinuclear localization of focal 
deficiency. Deletion events may occur sporadically with an equal probability of 
occurring in SS or IMF mitochondria. In this case the data here suggests that the 
mtDNA deletions in the IMF mitochondria either do not clonally expand or are 
eliminated through mitophagy. A factor in this failure to expand may be the distance 
from the nuclei (Davis and Clayton, 1996), situated in the subsarcolemmal area, 
which would allow biogenesis to be triggered through retrograde signaling due to 
respiratory chain deficiency. Diffusion of signaling molecules declines exponentially 
with distance, therefore distance from nuclei alone could determine the probability of 
a deleted mtDNA expanding. Since IMF mitochondria can be positioned tens of 
microns from a nuclei while SS mitochondria can be only hundreds of nanometers 
from a nuclear pore (Figure 5.4), the difference in probability of an mtDNA deletion 
expanding could be substantial. The proximity of SS mitochondria overcomes 
possible diffusion barriers between the mitochondria and nucleus, therefore giving 
the SS mitochondria a retrograde signaling advantage over their IMF counterparts. 
Another explanation for the perinuclear location of focal deficiency, is that deletion 
evens occur more commonly in the perinuclear mitochondria. If the perinuclear 
mitochondria are the actively replicating mitochondria, then deletion events may 
occur more frequently here due to errors in replication. Similar to the above 
hypothesis mtDNA replication requires nuclear encoded proteins and given the fact 
that diffusion declines over distance this may also be true for nuclear derived mRNA 
or proteins. Even so the increase in mtDNA copy number and mitochondrial mass, 
suggests that mito-nuclear retrograde signaling and upregulation of mitochondrial 
biogenesis is still likely to play an important role. 
The pathogenesis of mtDNA deletions is dependent on their accumulation to levels 
exceeding the mutational threshold. Some previous models of clonal expansion have 
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assumed that a change in mtDNA replication rate e.g. replicative advantage 
(Wallace, 1989) or survival of the slowest (de Grey, 1997) is required to give 
mitochondria with an mtDNA deletion the capability to expand and outnumber the 
wild type mitochondria. The debate over whether a replicate advantage is necessary 
or whether random genetic drift due to relaxed replication is sufficient to allow a 
deletion expand continues to date. Evidence both for (Diaz et al., 2002; Fukui and 
Moraes, 2009; Samuels et al., 2013; Kowald and Kirkwood, 2014) and against 
(Campbell et al., 2014; Gitschlag et al., 2016) a selective advantage has been 
reported. Whilst the proliferative perinuclear niche model presented here neither 
confirms nor disproves the need for a replicative advantage, it demonstrates that 
when a deleted mtDNA clone exceeds the threshold for biochemical deficiency, then 
a nuclear dependent proliferative mechanism is activated. This therefore gives the 
perinuclear niche a proliferative advantage and drives replication of the proximal 
mitochondria including those with deleted mtDNA. Notably, the data presented here 
suggests that the mtDNA size itself does not confer a replicative advantage of the 
deleted mtDNA (Campbell et al., 2014; Gitschlag et al., 2016), however the level of 
respiratory chain deficiency caused by the deletion could indeed influence the 
strength of the signals driving mitochondrial biogenesis. The magnitude of the 
proliferative drive may be dependent on the location and size of the deletion and thus 
the number of structural and tRNA genes which are affected. Mutations in tRNA 
genes are associated with a greater proliferative drive than mutations in structural 
genes as evidenced by RRF formation being more common in patients with tRNA 
point mutations versus patients with point mutations in structural genes (Montoya et 
al., 2009). This is likely due to the fact that tRNA mutations impact on translation of 
multiple mtDNA encoded structural subunits and thus have a greater impact on 
respiratory chain dysfunction.  
Increasing levels of mtDNA heteroplasmy activate nuclear transcriptional 
reprogramming, altering the transcription levels of thousands of genes (Picard et al., 
2014; Maeda et al., 2016). Nuclear transcriptional reprogramming triggers an 
increase in mitochondrial mass and mtDNA copy number (Petruzzella et al., 1994; Yu 
Wai Man et al., 2010; Giordano et al., 2014). In C. elegans, mtDNA deletions activate 
the unfolded protein response (UPRmt) in order to promote mitochondrial biogenesis 
and mitochondrial dynamics (Gitschlag et al., 2016; Lin et al., 2016). This process 
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drives the mtDNA heteroplasmy up at a whole organism level. A UPRmt has been 
identifed in mammals and is proposed to involve the AKT or JNK signaling pathways, 
however this is not well characterised and homologues of the key regulatory proteins 
identified in C. elegans have not been found (Pellegrino et al., 2013). The 
proliferative perinuclear niche model presented here, suggests a conserved 
mechanism for clonal expansion across species, however the key effector pathways 
may vary from species to species and possibly from tissue to tissue. 
Indeed there are a number of possible signaling pathways that could lead to the 
increased mtDNA heteroplasmy and mitochondrial mass. Firstly, a reduction in the 
ATP/ADP ratio or increased ROS due to respiratory chain dysfunction may 
upregulate mitochondrial biogenesis. Alternatively, mitochondrial biogenesis may 
upregulated through the mammalian UPRmt, since evidence suggests that the AKT 
signaling pathway can transcriptionally upregulate Nrf1 (Pellegrino et al., 2013). This 
would be in agreement with findings by Lin et al. (2016) who find that the UPRmt in C. 
elegans increases mitochondrial biogenesis and mitochondrial dynamics. An 
alternative to the proposed upregulation of mitochondrial biogenesis is a reduction in 
mitophagy, again this has been found by Gitschlag et al. (2016) to result from UPRmt 
activation in C. elegans. Each of these possibilities needs to be considered and 
investigated further. 
In addition to the proposed perinuclear niche hypothesis, it could be proposed that 
the perinuclear foci of COX-deficiency arises not from increased mitochondrial 
biogenesis, but from a deficiency in trafficking of dysfunctional mitochondria away 
from the nucleus or active trafficking of dysfunctional mitochondria back to the 
nucleus. While this should not be completely discounted, considering recently 
published findings in mice with photoactivatable mitochondria (Eisner et al., 2014; 
Mishra et al., 2015) and data reported in the present manuscript, neither of these 
hypotheses would accurately account for the observations. 
First, although there is fusion between skeletal muscle mitochondria, there is very 
little movement or trafficking of mitochondria in mature myofibres (Eisner et al., 2014; 
Mishra et al., 2015). Mouse models with photoactivatable mitochondria find frequent 
fusion events between adjacent mitochondria, without apparent mitochondrial 
movement. This is in contrast to cultured cells and undifferentiated tissues. So 
trafficking is very unlikely to contribute to this process. There is also no reason to 
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suspect that mitochondria would be trafficked in the direction of the nucleus, since  
autophagosomes are observed by EM in the IMF space and autophagic removal of 
mitochondria takes place here (Masiero et al., 2009). 
Second, the correct model also needs to explain why mutant mitochondria originate 
as a very small area and accumulate around a single nucleus and not all the nuclei in 
a fibre. Mitochondrial biogenesis requires nuclear products and it is therefore unlikely 
that mitochondria would proliferate to a substantial degree away from nuclei. The 
proliferative perinuclear niche model does not stipulate that mtDNA deletions and 
mutations do not occur outside the perinuclear space. Rather, it stipulates that only 
those that do occur in the perinuclear niche eventually have the opportunity to recruit 
nuclear resources, replicate, and expand to pathogenic levels. 
Finally, data presented here and the proliferative perinuclear niche model is entirely 
consistent with robust data published recently (Mishra et al., 2015). The authors 
show how mitochondrial fluorescent proteins arising from a single nucleus propagate 
from the nucleus towards the middle of the cell. The pattern of propagation from this 
single myonuclear domain parallels findings presented here.  
Following the formation of focal deficiency, an important process to consider in clonal 
expansion is the spread of COX-deficient mitochondria from one perinuclear niche to 
neighboring nuclear domains, thus allowing the propagation of the mitochondrial 
deficiency along the length of the myofibre. In isolated myofibres the average length 
of COX-deficient segments correlates with muscle homogenate mtDNA heteroplasmy 
(Matsuoka et al., 1992), which may suggest that the longitudinal spread and thus 
involvement of more nuclei drives the rise in mtDNA deletion heteroplasmy over time. 
If the spread of COX deficiency were to occur at an equal speed the longitudinal and 
transverse orientations it would be expected that the frequency at which segmental 
COX deficiency is observed in cross section would be relatively high. However this is 
not the case, COX-negative foci are rarely seen in comparison to fully COX negative 
fibres and as such must transition from the former to the latter relatively rapidly. 
Furthermore, when longitudinal myofibres are examined segments of deficiency are 
often very small with the longitudinal length of the deficient segment being smaller 
than the width of the myofibre (Figure 5.8). This suggests that myofibres transition 
from focal COX deficiency to fully COX-deficient fibre in transverse before deficiency 
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then spreads along the longitudinal axis. This is explored more in more depth and 
quantitatively assessed in Chapter 7. 
A possible hypothesis to explain this, is that mitochondria may be more networked or 
branched in the transverse plane than the longitudinal, thus providing less resistance 
to spread. Serial block face scanning electron microscopy demonstrated substantially 
more mitochondrial connections in the transverse plane across the Z-band (or I- band 
(Glancy et al., 2015)), compared to those observed in the longitudinal (Figure 5.8), 
thus supporting this hypothesis. 
However, a number of questions remain unanswered. Firstly, how the SS COX-
negative mitochondria interact with the IMF mitochondria, allowing the spread of 
COX deficiency. Occasional connections between SS and IMF mitochondria have 
been reported (Picard et al., 2013; Dahl et al., 2015; Glancy et al., 2015), indicating 
that both populations can physically interact, likely via fusion. Further to this low 
levels of mtDNA heteroplasmy can promote mitochondrial elongation (Picard et al., 
2014), likely to allow functional complementation (Nakada et al., 2001; Chen et al., 
2010), a caveat of this may be that it contributes to the spread of mtDNA deletions 
into the IMF area. 
Secondly, how it is that wild type mtDNA is lost and replaced by the deleted mtDNA?  
Mitochondria have been reported to have a half-life of days to weeks (Jaleel et al., 
2008; Poovathingal et al., 2012). One of the signaling pathways promoting 
degradation of mitochondria is reactive oxygen species (ROS) (Chen et al., 2009). Of 
interest, the IMF mitochondria have a 2-3 fold higher production of ROS than the SS 
mitochondria (Servais et al., 2003; Adhihetty et al., 2005). Furthermore the low 
oxygen tension in the IMF compartment may promote mitophagy in the IMF region, 
while mitochondrial biogenesis is occurring preferentially in the SS mitochondria 
(Pathi et al., 2012). The combination of the proliferative perinuclear niche, selective 
degradation of IMF mitochondria and occasional interaction of SS and IMF 
mitochondria would result in a “wave-like” flow of deleted mtDNA from the SS 
mitochondria across the myofibre. Therefore, mitochondrial biogenesis, fission and 
fusion and mitophagy are likely to be factors in the overall process of clonal 
expansion. 
Finally, the same focal deficiency is observed in acquired mtDNA mutations (e.g. 
mitochondrial DNA maintenance disorders with multiple deletions and ageing) as with 
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mtDNA mutations that are present since embryogenesis (e.g. single, large-scale 
mtDNA deletions.)  Why is this, since the single mtDNA deletion must already have 
been present at low levels within an affected muscle fibre? One possibility is that the 
increase in mitochondrial DNA replication in the perinuclear area means that it is this 
region that accumulates a high level of the mutation first and thus this region that 
becomes COX-deficient first. However, this will warrant further investigation. 
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5.5.1 Limitations 
The work presented here is a convincing hypothesis and tests a number of key 
assumptions for the hypothesis including the close proximity of focal COX-deficiency 
to nuclei and the higher level of mtDNA deletions in foci compared to the remainder 
of the fibre. However, repeats of these experiments and quantitative analysis of the 
proximity of foci to nuceli should be completed and more patients analysed. 
Furthermore, although close proximity to the nucleus and the increase in mtDNA 
copy number and SDH labelling in the foci is indicative of an upregulation of 
mitochondrial biogenesis the exact signaling pathway has not been identified. 
One of the biggest advantages of this study is the use of human skeletal muscle, 
which provides insight into disease pathogenesis without the limitations of using a 
‘disease model’, which may fall short of accurately representing the human disease 
state. However, the disadvantage of this is the inability to manipulate experimental 
conditions in order to gain mechanistic insight. 
In addition, to this although the data provided is able to identify a conserved pattern 
across numerous diseases and ageing, only a small number of mtDNA deletion 
patients were analysed genetically (n=3). This could be increased to include more 
nuclear genes and more disease groups, however the reason that this was only 
completed in patients with mtDNA maintenance disorders causing mtDNA deletions 
was due to the high rate at which foci are observed in these patients. 
Finally, this hypothesis is only relevant to skeletal muscle where mitochondrial 
movement is relatively restricted. Similar COX-deficient regions are unlikely to arise 
in the neurons where mitochondria are highly dynamic. 
 
5.5.2 Further work 
This work leaves a number of questions unanswered including the mito-nuclear 
signaling mechanism involved in the clonal expansion of mtDNA deletions. As such it 
would be interesting to look at expression levels of key mitochondrial biogenesis 
proteins such as PGC-1α, NRF1/2 and TFAM. Furthermore, is there a mitochondrial 
unfolded protein response in humans that plays a role in clonal expansion similar to 
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that observed in C. elegans? Investigation of this may yield insight into how 
conserved the mechanisms are between species. Given that findings indicate the 
mammalian UPRmt may function through the JNK and AKT signaling pathways 
antibodies for phosphorylated and unphosphorylated forms of these proteins may be 
used to investigate this possibility. If there is a UPRmt, the findings by Gitschlag et al. 
(2016) imply that the mechanism for accumulation may be a change in mitophagy 
rather than biogenesis. This possibility should be investigated also by looking at 
expression of proteins involved in mitophagy such as p62 and LC3.  
Furthermore, the experiments to date have been restricted to mtDNA deletion clonal 
expansion and do not investigate whether the mechanism is conserved for mtDNA 
point mutations. As such, repeating the above investigation in a cohort of patients 
with mtDNA point mutations would be interesting to investigate this. 
Finally, this mechanism does not explain is why mtDNA deletions accumulate in post-
mitotic rather than mitotic tissues since it is specific to muscle fibres. It also does not 
yield insight into the mechanism of mtDNA deletion formation. As such, it would be 
interesting after elucidating the exact signaling mechanism by which clonal 
expansion of mtDNA deletions occurs in skeletal muscle to compare these pathways 
in other post-mitotic cells such as neurons and mitotic tissues such as the colon. 
Furthermore, it will be important to determine whether deletions arise during 
replication or repair. 
 
5.5.3 Conclusions: 
In conclusion, data presented here indicates that in human skeletal muscle 
mitochondrial respiratory chain deficiency starts as a proliferative perinuclear niche. 
Furthermore, the findings suggest mito-nuclear signaling triggering mitochondrial 
biogenesis is a key driver of clonal expansion in human disease and that anisotropy 
of the skeletal muscle mitochondrial network may dictate the spread of mtDNA 
deletions through the myofibres. High resolution subcellular imaging combined with 
methods allowing us to target selected nuclear domains (Mishra et al., 2015), will be 
necessary to understand the signaling pathways implicated in the different stages of 
clonal expansion and how these relate to human disease pathology. 
  Chapter 6 
184 
 
Chapter 6. Mitochondrial ultrastructure in human skeletal muscle 
of mitochondrial disease patients 
6.1 Introduction 
6.1.1 Electron microscopy  
Electron microscopy as a technique was first developed by German physicist 
Ernest Ruska in 1931. In 1945, isolated mitochondria were first examined using 
electron microscopy (Claude and Fullam, 1945). The earliest papers that report 
ultrastructural changes in the mitochondria were published prior to the advent of 
genomics and the advances in molecular biology that have occurred over recent 
decades and as a consequence the functional and genetic context of many of the 
early observations is lacking. Furthermore, advances in genomics and molecular 
biology seem to have occurred in a period where the majority of electron 
microscopy reports were patient case studies or small cohorts, with few attempts to 
link structural observation with functional investigations. 
Although a comparatively old technique, the frequency of reports using EM has not 
declined in recent years, quite the contrary. The mitochondrial genome was first 
sequenced in 1981 (Anderson et al., 1981) and the first draft of the human nuclear 
genome was published by two groups almost simultaneously in 2001 (Lander et 
al., 2001; Venter et al., 2001).  In the 15 years that followed (2001 -2015), 64 
papers (mean 4.3 per year) were published that used EM to look at mitochondria in 
skeletal muscle of mitochondrial disease patients. In the previous 15 years (1986 - 
2000) only 45 papers (mean 3 per year) were published doing the same (literature 
review in Appendix 1). As such it appears that newer technologies and molecular 
techniques have not reduced the applicability of EM. However very few studies link 
structural findings to functional studies and approximately 30% of reports since 
2001 were reporting patients without a genetic diagnosis (literature review in 
Appendix 1).  Therefore, so far many ultrastructural changes are regarded merely 
as non-specific pathological changes. 
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In recent years, advances in technology have seen an increase in the imaging 
options for electron microscopy. From improving resolution and imaging quality of 
scanning electron microscopes and transmission electron microscopes to EM 
tomography and serial block face techniques for three-dimensional reconstruction 
(discussed in detail in Chapter 7). As such there is now an opportunity to 
characterise mitochondrial ultrastructure in the context of recent advances in 
mitochondrial biology, particularly those in model organisms. 
 
6.1.2 Regulating normal cristae structure 
Normal mitochondrial ultrastructure is described in 1.2, here further detail on the 
regulation of cristae structure is provided. The cristae are regularly spaced 
invaginations along the inner mitochondria membrane the structure of which is 
organised by a number of proteins (Pfanner et al., 2014). The mitochondrial 
contact site and cristae organizing system (MICOS) (Harner et al., 2011), also 
termed the mitochondrial inner membrane organising system (MINOS) (von der 
Malsburg et al., 2011; van der Laan et al., 2012) or mitochondrial organising 
structure (MitOS) (Hoppins et al., 2011) due to its simultaneous discovery by a 
number of groups, has been demonstrated to regulate normal cristae junction 
structure. The nomenclature used here is a uniform nomenclature proposed later 
by Pfanner et al. (2014). The MICOS complex consists of six proteins of which 
Mic60 (previously Mitofilin) and Mic10 (previously Mio10) are core components 
(van der Laan et al., 2012). The remaining subunits are Mic19, Mic26, Mic12 and 
Mic28 (Figure 6.1). Numerous experiments interfering with expression of MICOS 
components in HeLa cells, yeast and C. elegans have demonstrated abnormal 
cristae morphology. Some examples include the knockdown of mitofiln in HeLa 
cells using RNAi (John et al., 2005) and knockdown of the Mic19 homologue by 
RNAi in C. elegans (Head et al., 2011), which have both been found to cause 
membrane stacking or concentrically organised cristae or stacked cristae 
membranes . However, in knock-out Mic60 yeast strains, generated by PCR based 
targeted homologous recombination, cristae junctions are not completely absent 
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(Hoppins et al., 2011; von der Malsburg et al., 2011), therefore Mic60 must not be 
essential for the formation of cristae junctions. 
 
 
Figure 6.1 Mitochondrial cristae structure regulation. The mitochondrial cristae 
organising system (MICOS) proteins regulate the size of cristae junctions and the 
bending of the inner mitochondrial membrane (IMM) between the inner boundary 
membrane and cristae membrane. Six proteins have been identified to be part of 
the MICOS complex so far. At the apex of the cristae ATP synthase dimerizes 
causing the IMM to bend. Figure based on Pfanner et al. (2014). 
 
 
Opa1 is also thought to be important in the regulation of normal cristae structure, 
since it remodels the cristae junction during apoptosis (Scorrano et al., 2002; 
Frezza et al., 2006), for more information see 1.3.3. Yeast in which Mgm1 (the 
Opa1 homologue) is mutated show abnormal cristae structure (Meeusen et al., 
2006).  
ATP synthase is located at the apex of the cristae membrane, where it dimerises at 
an angle of 70 ± 5° and causes the IMM to bend (Figure 6.1) (Dudkina et al., 
2005). ATP synthase subunits e and g are not necessary for ATP synthesis but for 
dimerisation and yeast lacking either subunit are found to have concentric cristae 
structures (Giraud et al., 2002; Paumard et al., 2002; Bornhovd et al., 2006). 
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Electron tomogrophy in Podospora anserine, which is commonly used as an 
ageing model also demonstrates a reduction in ATP synthase dimerisation with 
ageing, which causes vesicularisation of the IMM (Daum et al., 2013). 
Finally, cardiolipin is also thought to play a role in IMM ultrastructure, since 
cardiolipin mutant hamster ovary cells with a drop of 30% in cardiolipin, had a 
swollen appearance with disorganised cristae and an electron dense matrix 
(Ohtsuka et al., 1993). It has been demonstrated by NMR spectroscopy that 
cardiolipin interacts with ATP synthase (Eble et al., 1990). It also has stabilising 
effects on respiratory chain supercomplexes (Bottinger et al., 2012) and increases 
membrane fluidity and curvature of membranes (Phan and Shin, 2015). As such, it 
seems plausible that cardiolipin may interact with ATP synthase and aid in the 
curvature of the membrane at the apex of the cristae. 
 
6.1.3 Literature review of mitochondrial ultrastructure in muscle of patients with 
mitochondrial disease 
A systematic review of the literature for reports of electron microscopy in skeletal 
muscle of patients with clinically or genetically diagnosed mitochondrial disease 
resulted in 131 primary articles and 4 reviews.  A summary of findings including; 
patient age, biopsy site, genetic and/or clinical diagnosis where available and a 
description of ultrastructural defect, can be found in Appendix 1.  
Screening of these for specific mitochondrial ultrastructure revealed 69 reports of 
paracrystalline inclusions (including 2 reviews), a number of the reports also call 
these parking-lot mitochondria or parking-lot type inclusions (Mierau et al., 2004; 
Thajeb et al., 2006). Paracrystalline inclusions (See 6.4.2 and Figure 6.4 for 
examples) have been found to label with antibodies for creatine kinase in rat 
cardiomyocytes cultured in creatine-deficient medium (Eppenberger-Eberhardt et 
al., 1991). Creatine is the substrate for creatine kinase and when cells are cultured 
in medium containing creatine, paracrystalline inclusions are not observed. As 
such it is hypothesised that a deficiency in the creatine kinase shuttle (Figure 6.2), 
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which is responsible for the exchange of ATP in the mitochondrial matrix with ADP 
in the cytosol, leads to accumulation of creatine kinase as paracrystalline 
inclusions. Interestingly, these PCIs come in two structurally and topologically 
different types (Hammersen et al., 1980; Stadhouders et al., 1994),  type-I are 
made of stacked sheets forming identical rectangular structures and found in the 
matrix and type-II PCIs are electron dense and found in the IMS. The precise 
reason for these structural and locational differences is unknown however reports 
suggest they may be mutually exclusive (Hammersen et al., 1980). 
 
Figure 6.2 Creatine phosphate shuttle. The creatine phosphate shuttle is 
responsible for the exchange of ATP in the mitochondrial matrix with ADP in the 
cytosol, thus removing the product of ATP synthase and providing more substrate. 
This exchange is mediated by creatine kinase via the sequential phosphorylation 
and dephosphorylation of creatine. 
 
Of the papers screened there were 35 reports of concentric cristae (including 1 
review). There was however some degree of variability in the terminology used to 
describe these structures, which all appeared to be structurally identical. Terms 
used included; circular cristae, “onionoid”, concentric cristae, whorl mitochondria 
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and mitochondria with concentric lamellae. Similar structures have been reported 
in yeast where the mitochondrial cristae organising system (MICOS) proteins have 
been knocked down (see 1.2). 
In addition to this, the literature review highlighted some commonly used terms to 
describe mitochondrial appearance in mitochondrial myopathy which included; 
electron lucent (not very electron dense), giant and swollen. Furthermore, they also 
identified a number of inclusions other than PCIs described previously. The first is 
osmophilic bodies, which appear to be matrix located objects heavily stained with 
osmium. Granular inclusions according to (Munn, 1974), are not well characterised 
but have been suggested to be cation binding sites, areas with accumulation of 
calcium, strontium and barium and present at the sites for calcium binding and 
glycogen among other things (Munn, 1974). Filamentous inclusions or electron 
dense inclusions also appear to be poorly characterised and very variable in 
appearance but commonly described. Other than paracrystalline inclusions and 
concentric cristae, the remaining features reported and analysed below are the first 
report in human skeletal muscle (Vincent et al., 2016b). This has been previously 
published and the paper is available in Appendix 4. 
 
6.2 Aims of this study: 
The aim of this study was to complete an in depth literature review for 
mitochondrial ultrastructure in human skeletal muscle and to document 
mitochondrial ultrastructural abnormalities found in mitochondrial patient skeletal 
muscle. Following this, the objective was to put these ultrastructural abnormalities 
into the context of recent literature in order to better understand the link between 
structure and function and the mechanism by which these structures form. 
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6.3 Methodology: 
6.3.1 Patient cohort: 
Patients were identified via the mitochondrial disease clinic in Newcastle over 12 
consecutive weeks and consented for part of their muscle biopsy to be used for 
research. All work presented here was previously approved by the Newcastle and 
North Tyneside Local Research Ethics Committees (reference 2002/205) and is 
now approved under Newcastle and North Tyneside Local Research Ethics 
Committees (reference 16NE/0267). Patient details including genetic diagnosis 
plus relevant diagnostic and clinical information can be found in Table 2.10. 
 
6.3.2 Transmission electron microscopy 
Transmission microscopy was performed as described in 2.12.1. 
 
6.3.3 Serial block face scanning electron microscopy (SBFSEM) 
SBFSEM was performed as described in 2.12.2. 
 
6.3.4 Image J analysis 
Quantitative measurement of two-dimensional features e.g. nanotunnel diameter, 
intracristae and intercristae distance, intermembrane were performed in Image J 
(NIH, version 1.47v).  For nanotunnel measurements, the narrowest and widest 
regions of each nanotunnel were averaged, yielding a mean diameter for each 
nanotunnel. Segments used for analysis were defined on the basis of lacking 
cristae and being of constant width.  
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6.3.5 IMOD reconstruction 
3 view image stacks were converted to MRC files in Digital Micrograph (Gatan, 
v2.31.734.0) and 25 to 50 mitochondria reconstructed using IMOD (Boulder lab, 
v4.7.15) image analysis software. Mitochondria were manually traced using the 
‘sculpt’ drawing tool, after which a mesh and cap were applied using 1.5 as the flat 
criteria. Following this surface area and volume inside the mesh were extracted. 
 
6.3.6 Systematic review of the literature 
Scopus, Embase and Medline were searched using the following search terms: 
“electron microscop* AND muscle AND human AND mitochondria*”. Filtering these 
for “full text” and “human” yielded 1549 results from scopus, 1670 results from 
embase and 922 results from medline. Duplicates were removed, and search 
results screened on the basis of the following criteria: full text availability, English 
language, human, skeletal muscle, mitochondrial disease, any publication date up 
to the end of 2015. All included studies reported on patients with either a clinical or 
genetic diagnosis of mitochondrial disease; publications including cases where a 
diagnosis could not be reached have not been included. This resulted in 131 
primary articles and four reviews. All articles were screened for the specific 
mitochondrial pathology reported, and for the diagnostic methodology used, which 
included restriction site mutation (RSM) assay, southern blotting, PCR, Sanger 
sequencing, restriction fragment length polymorphism (RFLP), solid phase mini 
sequencing, sequencing (general), next generation sequencing, or method not 
specified. Appendix 5 is a table of results in chronological order including the 
biopsied muscle, age of subjects, clinical features, genetic diagnosis, and a 
summary of mitochondrial ultrastructural and morphological feature(s). 
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6.4 Results: 
Initially a systematic review of the literature for electron microscopy in human 
skeletal muscle of patients with mitochondrial disease was performed (presented in 
the introduction for this chapter). Following this TEM and SBFSEM on skeletal 
muscle from seven genetically diagnosed mitochondrial disease patients was 
completed. This allowed demonstration and analyses of six mitochondrial 
ultrastructural abnormalities which, apart from paracrystalline inclusions (PCIs) and 
concentric cristae had not previously been reported in skeletal muscle of 
mitochondrial disease patients. A semi quantitative summary of these can be found 
in Table 6.1. 
 
6.4.1 Normal mitochondrial ultrastructure 
Normal mitochondrial ultrastructure is extensively characterised in the literature to 
date. Further to this an aged muscle biopsy and a muscle biopsy of a 21 year old 
with hypertrophic cardiomyopathy and normal skeletal muscle were also examined 
(Figure 6.3). Normal ultrastructure was found in some muscle fibres of patient 
biopsies. Fibres with abnormal and normal mitochondrial ultrastructure were found 
in a mosaic pattern similar to that observed for COX positive and negative fibres in 
muscle sections treated for COX/SDH histochemistry. 
Mitochondria are double membrane organelles with the IMM and OMM encasing 
the matrix. (Figure 6.3).  The curved IMM bends inwards and can be subdivided 
into three sections; inner boundary membrane, the crista junction, and the cristae 
membrane (Figure 6.3b) (Pfanner et al., 2014).  In normal mitochondria, the matrix 
is a continuous space containing enzymes for biochemical reactions, as well as 
multiple copies of the mitochondrial genome (mtDNA). Although frequently 
depicted as bean-shaped, mitochondrial shape is dynamic and through continuous 
fission and fusion, switches between tubular and spherical morphology which also 
affect their size (Friedman and Nunnari, 2014). 
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Figure 6.3 Normal mitochondrial ultrastructure. (a) Transmission electron 
micrograph of normal mitochondria in human skeletal muscle. The mitochondria 
have typical tubular cristae and cristae junctions. (b) Schematic of cristae junctions, 
associated structures and parameters measured in this chapter. (c) Three 
dimensional schematic of a normal tubular cristae structure. The outer 
mitochondrial membrane (OMM, red), and three functionally distinct regions of the 
inner mitochondrial membrane (IMM): inner boundary membrane (blue), Cristae 
junction (orange) and crista membrane (green). (d) Electron micrograph from A 
with pseudocoloured adjacent mitochondria and lines to highlight cristae co-
ordination as previously reported by Picard et al. (2015). (e) Unprocessed and (f) 
pseudcoloured transmission electron micrograph of normal Human skeletal muscle 
demonstrating normal mitochondrial shape and size. These mitochondria have 
electron dense curvilinear cristae, with some exhibiting trans-mitochondrial cristae 
co-ordination. Adapted from Vincent et al. (2016b). 
 
To date the literature describes what is considered normal mitochondrial 
morphology in skeletal muscle of humans and mice (Payne et al., 1975; Larsen et 
al., 2012; Picard et al., 2013; Pfanner et al., 2014). Comparable mitochondrial 
morphology is seen in a 78 year old healthy control and a 21 year old with 
hypertrophic cardiomyopathy but normal skeletal muscle mitochondrial 
histochemistry, validating the electron microscopy preparation used here. 
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Furthermore, normal mitochondrial morphology is found in some muscle fibers of 
mitochondrial disease patients examined. The normal morphology and 
ultrastructural defects presented here were present in a mosaic pattern of 
myofibres, comparable to that reported for mitochondrial respiratory chain 
deficiency by COX/SDH histochemistry. 
Here, the aim was to document deviations from the normal mitochondrial 
ultrastructure described above, in genetically-defined cases of mitochondrial 
disease. This chapter looks at muscle biopsies from seven patients with a primary 
mtDNA mutation: single, large-scale mtDNA deletion (n = 3), m.8344A>G tRNALys 
(n = 3), or m.3243A>G tRNALeu(UUR) (n = 1). Six mitochondrial ultrastructural 
abnormalities were identified as possible features linked to myopathy and are 
described below. A semi-quantitative summary of ultrastructural findings for all 
patients can be found in Table 6.1. Each ultrastructural finding is presented below 
and then discussed in the context of recent findings in mitochondrial biology. 
The frequency at which each ultrastructural abnormality is observed varies 
between patients. This could be due to nuclear background, severity of 
mitochondrial dysfunction and cellular environment, along with other environmental 
factors such as diet and activity levels. 
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Table 6.1 Summary of mitochondrial ultrastructural abnormalities identified in patient skeletal muscle biopsies (n = 7). Patients 
coloured based on genetic diagnosis; blue: single, large scale mtDNA deletions; orange: m.8344A>G; green: m.3243A>G. PCI: 
Paracrystalline inclusion; + : Few; ++ : Frequent; +++ : Very frequent; - : none 
 
Patient Type 
I PCI 
Type 
II PCI 
Linearization 
and 
geometrical 
features 
Concentric 
cristae 
Compartmentalisation Nanotunnel Hyperfusion 
and 
branching 
Projections 
P28 +++ - - - - - ++ - 
P35 - - - - - + + - 
P36 - - - - +++ + - +++ 
P37 - + +++ ++ - - - - 
P38 + - - - ++ - - + 
P39 - - - + - - ++ + 
P40 - - - - - +++ +++ +++ 
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6.4.2 Paracrystalline inclusions 
PCIs were observed in a patient with a single, large-scale mtDNA deletion (Patient 
28) and chronic progressive external opthalmoplegia (CPEO) and in two patients 
with myopathy due to the m.8344A>G tRNALys point mutation (Patients 37 and 28). 
Paracrystalline inclusions (PCIs) are rigid rectangular crystals of approximately 250 
nm x 50 nm. They comprise stacked sheets that either run obliquely (Figure 6.4, a 
and d) or parallel (Figure 6.4, b and c) to the length of the paracrystal. The rigidity 
is assumed based on their occasional distortion or damage of mitochondrial 
membranes (Figure 6.4 c). As with other ultrastructural abnormalities discussed 
below, considerable heterogeneity existed in the distribution of PCIs within single 
myofibres, with some mitochondria having normal ultrastructure, and adjacent 
mitochondria containing PCIs of various types and sizes. Although PCIs were 
observed in both SS and IMF mitochondria, they were typically more common in 
SS mitochondria (Figure 6.4, e and f). 
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Figure 6.4 Paracrystalline inclusions (PCIs). (a) Type I PCIs occupying the majority of a mitochondrion’s volume in skeletal 
muscle from a patient with a single mtDNA deletion (patient 28) (b) Linear Type I PCIs in a mitochondrion from a case of 
m.8344A>G (patient 38). (c) Disruption of the IMM and OMM (arrow head) by a rigid type II PCI, and (d) other examples of type 
II PCIs from a case of m.8344A>G (patient 37). (e) Subsarcolemmal region of a myofibre showing extracellular space (EC, 
yellow) and sarcolemmal, Profile of nucleus (N, blue), myofibrils (MF), mitochondria with PCI (red) and normal mitochondria 
(green), with (f) Pseudocoloured mask (patient 28). Note the greater abundance of PCI-containing mitochondria in the 
perinuclear SS compartment relative to the intermyofibrillar compartment. This is consistent with the requirement for de novo 
protein synthesis for PCI formation. Adapted from Vincent et al. (2016b).
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PCIs fall into two classifications based on structure, size, and location within the 
mitochondria. Type-I PCIs consist of stacked sheets forming rectangular inclusions 
located in the intracristal space (Figure 6.4, a and b) and type-II PCIs are electron 
dense without layers and residing in the intracristal and intermembrane space 
(Figure 6.4 d). Both type I and II were observed here and consistent with previous 
observations (Hammersen et al., 1980), were found to be mutually exclusive within 
individual patients, i.e. type-I PCIs were identified in patients 28 and 38, whereas 
type-II PCIs were observed in patient 37. 
 
1.8.6 Cristae linearization and angular features 
In contrast to the normal cristae invaginations of the IMM (Figure 6.3), linearisation 
of cristae IMM with angular (i.e., geometrical) features were observed in Patient 37 
(Figure 6.5, a-d). These structures included rigid linear membranes at angles of 
124.7 ± 7.4o (Figure 6.5, a and b) and are often observed in association with 
electron dense inclusions (Figure 6.5, c and d). Linear membrane segments show 
enhanced electron density, which may be due to the presence of large molecular 
weight proteins and/or substantial change in membrane lipid or protein 
composition. SBFSEM and three-dimensional reconstruction demonstrated that the 
linearised membranes actually formed sheets rather than isolated tubular 
structures as would be expected given normal cristae structure (Figure 6.5, e and 
f). 
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Figure 6.5 Linearization and geometrical cristae features. (a, b) Enlarged mitochondria containing linearized cristae juxtaposed 
at nearly identical angles, and (c) linearized cristae forming various geometrical shapes, and (d) linearized IMM segments 
(arrows) joined by curved segments from a case of m.8344A>G (patient 37). (e) SBFSEM image with example of linearized 
cristae and geometrical shapes and (f) IMOD reconstruction of mitochondrion in (e) (patient 37). Adapted from Vincent et al. 
(2016b).
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6.4.3 Concentric “onion-like’’ cristae 
The IMM bends at regular intervals forming cristae and the connected cristae 
junction forms a pore. In contrast to the normal cristae invaginations TEM images 
from patients 37 and 39 who both have m.8344A>G tRNALys mutations have a 
large proportion of mitochondria with concentric “onion-like” cristae (Figure 6.6, a 
and b) which appear to be completely lacking cristae junctions. SBFSEM and 
three-dimensional reconstruction of one such onion-like mitochondria confirmed 
the tight layers of discontinuous membrane sheets (Figure 6.6, c and d). 
The width of the IMS and intracristal space are known to be tightly regulated by 
specific proteins. Measurement of the IMS and intracristal space demonstrated that 
the IMS width was similar between mitochondria with concentric (7.1 ± 1.6 nm) and 
normal cristae structure (7.9 ± 1.2 nm, P = 0.45). However, the intracristae space 
was reduced by ~15% in mitochondria with concentric cristae (7.78 ± 1.2nm) when 
compared to normal cristae (9.20 ± 1.0nm, P < 0.05), possibly due to compaction 
of the cristae membranes in onion-like mitochondria. Furthermore the intercristal 
space (space between two adjacent cristae), was also significantly reduced in 
mitochondria with concentric cristae (22.2 ± 4.5nm) compared to normal 
mitochondria (60.2 ± 9.9nm, P<0.001). Together this suggests tightly packed 
membranes in dysfunctional mitochondria and implies a loss of regulation of the 
width of the intracristae space.  
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Figure 6.6 Concentric “onion-shaped” cristae. (a) Multiple layers of double OMM and IMM membranes forming two major 
compartments in a case of m.8344A>G (patient 37), and (b) two-dimensional reconstruction of membrane structures. (c) 
Example pf concentric cristae compartments in patient 37, imaged with SBFSEM, with (d) corresponding three-dimensional 
reconstruction. Adapted from Vincent et al. (2016b). 
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6.4.4 Compartmentalisation 
Normal mitochondria have two compartments: a continuous mitochondrial matrix 
compartment, and the intermembranal space. In contrast, patient 36 with a single, 
large-scale mtDNA deletion and CPEO and patient 38 with an m.8344A>G tRNALys 
mutation and mild myopathy had abnormal matrix compartments surrounded by a 
single or double membrane and with a different electron density (Figure 6.7, a and 
b). This difference in electron density may indicate a difference in ionic content. 
Other examples showed dense amorphous material (Figure 6.7c) or were found in 
association with linearised electron dense membranes (Figure 6.7d). This extra 
compartmentalisation appeared in conjunction with complete absence of cristae 
junctions or normal cristae structures. SBFSEM and three-dimensional 
reconstruction of mitochondria with apparent compartmentalisation in cross-section 
showed the complete spatial insolation of individual compartments (Figure 6.7, e 
and f). 
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Figure 6.7 Mitochondrial compartmentalisation. (a) Example of membrane-bound sub-mitochondrial compartments located 
centrally and (b) peripherally in contact with the inner boundary membrane, from cases of m.8344A>G mutation (patient 38) and 
single mtDNA deletion (patient 36), respectively. (c) Electron-dense round compartments, distributed in the mitochondrial matrix 
in a case of single mtDNA deletion (patient 36). (d) Compartment bund by linear electron dense membranes in a case of 
m.8344A>G (patient 37). (e) Cross sectional image of a mitochondrion with two distinct compartments of different electron 
densities and (f) corresponding three-dimensional reconstruction from SBFSEM. (g,h) Examples of OMM protrusion  and 
distension consistent with the release of mitochondrial components in the cytoplasm in a case of m.8344A>G mutation (Patient 
37). Pseudocoloured areas indicated the major compartment bound by the OMM (green), and sub-compartments (red and 
blue). Adapted from Vincent et al. (2016b). 
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6.4.5 Nanotunnels 
“Nanotunnels” have previously been reported in studies using confocal fluorescent 
microscopy in rat cardiomyocytes (Huang et al., 2013) and also by TEM in cultured 
African grey monkey kidney cells (Bowes and Gupta, 2008). However, Vincent et 
al. (2016b) were the first to report mitochondrial nanotunnels in human skeletal 
muscle diseased or otherwise. Nanotunnels were found in three out of seven 
patients (P35, P36 and P40) (Figure 6.8 a and b). The average diameter of a 
nanotunnel was 62.3 ± 10.7 nm (Figure 6.8 c) and was similar in all three patients. 
The average nanotunnel length was 623 nm (range 206 nm to 2.3 µm). SBFSEM 
and three dimensional reconstruction of mitochondria connected by nanotunnels 
confirmed that they were thin tubular structures (Figure 6.8 d) and TEM images 
showed that nanotunnels lack cristae. 
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Figure 6.8 Nanotunneling and hyperbranching. (a-b) Examples of mitochondrial nanotunnels composed of both OMM and IMM 
but devoid of cristae in a patient with m.3243 A>G mutation (patient 40). (c) Variation in nanotunnel diameter, with each point 
representing the average of the largest and smallest diameters measured for individual nanotunnels across all subjects (n=26). 
(d) 3D reconstruction of three mitochondria connected via nanotunnels from a case of m.3243A>G (patient 40). (e-f) Examples 
of highly branched mitochondria (hyperfusion) from cases of m.3243A>G (patient 40). (g) Donut-shaped mitochondrion 
denoting self-fusion from a single mtDNA deletion patient (patient 35). (h) Three-dimensional reconstruction of donut shaped 
mitochondrion from a case of m.8344A>G (patient 39). Adapted from Vincent et al. (2016b).
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6.4.6 Hyperbranching and donut mitochondria 
A shift in mitochondrial dynamics towards greater mitochondrial fusion results in 
highly elongated and often branched mitochondria, this occurs in response to low  
levels of mitochondrial stress. For instance in the presence of m.3243A>G 
mutations up to 90% heteroplasmy mitochondria become increasingly elongated, 
however at mutational heteropmasy exceeding 90% the mitochondrial network 
fragments (Picard et al., 2014). Also, in aged skeletal muscle of mice mitochondria 
are found to be elongated in atrophied muscle fibres (Leduc-Gaudet et al., 2015). 
Highly branched mitochondria were observed in a case of m.3243A>G tRNALeu(UUR) 
with 21% heteroplasmy (patient 40) (Figure 6.8 e and f).  Donut-shaped 
mitochondria were also found in a patient with m.8344A>G tRNALys at 40% 
heteroplasmy (patient 39) (Figure 6.8 g and h). SBFSEM and three dimensional 
reconstruction supported the ring or toroid shape of the donut mitochondria (Figure 
6.8h), which may be produced by either self-fusion or “splitting” of a mitochondrion.  
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6.5 Discussion  
Mitochondrial ultrastructure is inexplicably linked to mitochondrial function 
(Mannella, 2006; Pernas and Scorrano, 2016). Initially electron microscopy studies 
identified ultrastructural abnormalities such as paracrystalline inclusions 
(Appendix 5), however a lot of early electron microscopy studies were completed 
before the understanding of molecular determinants of ultrastructure were known, 
which limits the potential interpretation.  However with the genetic revolution and 
the improvements in identifying genetic determinants of disease, a large 
percentage of patients now receive a diagnosis (Taylor et al., 2014). Therefore 
building on advances in genetic and molecular mitochondrial biology and imaging, 
the aim was to examine a small cohort of patients with genetically determined 
mitochondrial disease and assess the spectrum of ultrastructure present. 
Normal mitochondrial morphology is well classified in the literature and we were 
able to document similar mitochondrial morphology in two individuals with normal 
skeletal muscle and also in normal myofibres of patients, confirming the biopsy and 
imaging methods preserve mitochondrial ultrastructure. We also confirmed 
previous findings that normal ultrastructure includes cristae-cristae co-ordination 
between neighbouring mitochondria (Picard et al., 2015). It should also be noted 
that a mosaic distribution of mitochondrial ultrastructure was observed between 
individuals, between myofibres and within single myofibres which is consistent with 
what is seen with histology.  
 
6.5.1 Paracrystalline inclusions 
Although the patient sample size was small, PCI’s were identified in three patients 
and type I and type II PCIs were found to be mutually exclusive which is in 
agreement with previous reports (Hammersen et al., 1980). Of note two related 
patients with m.8344A>G tRNALys (mother and daughter, patients 37 and 38) had 
different types of PCIs, indicating that factors other than mtDNA mutation and 
nuclear background may be important determinates of disease phenotype. In order 
to determine specific conditions where PCIs form, a study in a larger disease 
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cohort would be necessary. However, it is worth noting that presence of PCIs 
correlated with severity of COX deficiency and lactic acidosis and also structurally 
with the presence of lineariSed IMM and concentric cristae.  
PCIs also appear more common in the SS mitochondria than the IMF 
mitochondria. Since PCIs are composed of crystalised mitochondrial creatine 
kinase (CK) (Eppenberger-Eberhardt et al., 1991), due to a compensatory 
upregulation of CK caused by a deficiency of the creatine phosphate shuttle 
activity. It seems likely that PCIs may result in patient tissue due to a reduction in 
ATP synthesis due to respiratory chain dysfunction, thus leading to an upregulation 
of CK synthesis and accumulation as PCIs. Since the upregulation required 
retrograde mitochondrial to nuclear signalling this may explain the preferential 
occurrence of PCIs in SS mitochondria. 
 
6.5.2 Linearised IMM 
Cristae with linearised membranes, altered electron density and rigid angular 
appearance were present in a single patient (Patient 37). These were commonly 
found in close proximity to mitochondria with PCIs and changes to both the 
membrane and matrix electron density. Changes to protein composition of the 
membrane or of the protein complex assembly could influence the shape of the 
IMM, in particular the ATP synthase, which determines the curvature of the 
membrane at the cristae junction (Strauss et al., 2008). Variation in the cardiolipin 
content of the IMM could also lead to changes in rigidity of the IMM (Jiang et al., 
2000; Weber et al., 2013; Phan and Shin, 2015). Interestingly these rigid lineariSed 
membranes regularly formed angles of ~120°. Previously hexagonal structures 
with membranes forming angles of 120° have been found in cardiolipid-containing 
phospholipid bilayer (Domènech et al., 2007), which could indicate that these 
abnormal membrane structures maybe due to changes in the membrane lipid 
composition.  
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6.5.3 Concentric cristae 
The presence of concentric cristae was noted in two related patients (P37 and 
P39), both harboring the m.8344A>G tRNALys mutation. This observation is similar 
to structures previously found in cultured human (HeLa) cells and yeast where the 
mitochondrial contact site and cristae organizing system (MICOS) components had 
been knocked down or knocked out resulting in concentric layering or stacking of 
the membrane (John et al., 2005; Rabl et al., 2009; van der Laan et al., 2012; 
Pfanner et al., 2014). Concentric cristae have also be found to form following 
abnormal ATP-synthase dimerization (Paumard et al., 2002). 
Measurements of the intra- and inter- cristae space demonstrate a significantly 
smaller size in mitochondria with concentric cristae compared to normal 
mitochondria. The width of both the intermembrane and intracristae spaces are 
tightly regulated by specific proteins and this regulation is believe to be of 
functional as well as structural importance (Mannella et al., 2013; Varanita et al., 
2015). Cristae junctions were not noted in these mitochondria, however this does 
not mean they are not present in another plane. However, based on the studies in 
model systems mentioned above, defects of the nuclear-encoded MICOS 
components or other proteins regulating the cristae junction may cause cristae 
junction dysfunction and result in the concentric cristae observed. Such mutations 
are unlikely to be the cause of these ultrastructural changes in mitochondrial 
myopathy patients, particularly those described here with mtDNA mutations. 
However, mitochondrial dysfunction may lead to protein damage via an increase in 
ROS, which would have the same affect. 
 
6.5.4 Compartmentalisation 
Mitochondria showing increased compartmentalisation, were found in two patients 
(P28 and P38). This increased compartmentalisation could be a product of hemi-
fusion i.e. OMM fusion in the absence of IMM fusion, therefore producing a single 
mitochondrion that has multiple matrix compartments (Zick et al., 2009). In support 
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of this hypothesis suppression of Opa1 homologue eat-3 in C. elegans causes a 
similar phenotype (Kanazawa et al., 2008). 
Further to this a distension of the OMM was noted with what appeared to be 
release of mitochondrial matrix content. This was observed without other changes 
to mitochondrial ultrastructure and therefore could be distinguished from 
mitochondrial swelling induced by opening of the permeability transition pore. 
Recent reports show that mitochondrial proteins (e.g. Prohitibin and Hsp60) and 
mtDNA (in its oxidised form) are released into the cell cytoplasm or systemic 
circulation (Zhang et al., 2010). This release of mitochondrial material acts as a 
damage associated mitochondrial protein (DAMP) and activates the inflammatory 
response pathways (Zhang et al., 2010). Similarly, release of mitochondrially 
derived vesicles have also been found to be a quality control mechanism in the 
cardiac system (Cadete et al., 2016).   
  
6.5.5 Nanotunneling 
Nanotunnels were first observed by transmission electron microscopy in African 
green kidney cells (Bowes and Gupta, 2008) and were subsequently named later 
upon visualisation using confocal microscopy in rat cardiomyocytes (Huang et al., 
2013). The first report of these structures in humans was in human skeletal muscle 
and relates to results presented here (Vincent et al., 2016b). Here nanotunnels 
were found  to be 62.3 ± 10.7 nm in diameter and 200 nm to 2.3 µm in length. In 
contrast others report diameters of 50 nm (Bowes and Gupta, 2008) and 90-120 
nm (Huang et al., 2013) respectively. Consistent with previous reports (Bakeeva et 
al., 1978; Fujioka et al., 2013) the nanotunnels observed here are double 
membrane structures lacking cristae. Consistent with their structure, live cell 
imaging demonstrates that nanotunnels are able to transport GFP targeted to both 
the mitochondrial matrix and also IMM (Huang et al., 2013). However, based on 
the diameter of nanotunnels here it is unlikely that a nucleoid containing mtDNA 
which is reported to average around 110 nm in diameter (Kukat et al., 2015), could 
be transported. Even so nanotunnels may be an effective method of 
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communication especially in skeletal muscle where mitochondrial movement is 
restricted (Huang et al., 2013).  
Live cell imaging has demonstrated that nanotunnels form in a KIF5B dependent 
manor, over a period of seconds (Wang et al., 2015). An alternative suggestion is 
that nanotunnels are in fact the results of stalled fission (Zhang et al., 2016), this 
may be supported by the similarity in diameter between the nanotunnels and 
restriction caused by dynamin Dnm1 during fission in yeast (Mears et al., 2011). 
An understanding of the function and conditions that initiate or prevent nanotunnel 
formation may offer new insights into the pathogenesis of mitochondrial myopathy. 
Nanotunnels are found here in three of seven patients, interestingly they were also 
found to be present in normal muscle without mitochondrial disease but not in the 
patients with the highest mutational heteroplasmy. However due to the small 
diameter of nanotunnels transmission electron microscopy is likely to provide an 
underestimate of the actual prevalence of nanotunnels, as such nanotunnels are 
analysed further, using SBFSEM in Chapter 7. 
 
6.5.6 Hyperbranching and donut mitochondria 
Increase in mitochondrial fusion or reduced fission results in mitochondrial 
elongation and hyperbranching. This switch in the balance between mitochondrial 
fission and fusion could be a response to mitochondrial stress (Shutt and McBride, 
2013), such as the dose-dependent response to m.3243A>G heteroplasmy 
demonstrated in cybrid cells (Picard et al., 2014). As such, hyperbranching 
witnessed here could therefore be indicators of stress due to respiratory chain 
dysfunction in patients with intermediate levels of mutational heteroplasmy (e.g. 
patient 40). 
Also observed here were donut mitochondria, formed by self-fusion events or 
mitochondrial splitting. Respiratory chain inhibition and oxidative stress have also 
been shown to cause similar mitochondrial morphology in vitro (Ahmad et al., 
2013) and are found to be present in the synaptic boutons in the brains of aged 
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rhesus monkeys and to correlate inversely with memory (Hara et al., 2014). As 
such the presence of Donut mitochondria may be an indicator of mitochondrial 
dysfunction and may be functionally relevant at the tissue or organism level. 
 
6.5.7 Limitations 
A number of limitations are important to remember when interpreting the data 
presented here. Firstly the aim of this investigation was to characterise the 
spectrum of mitochondrial ultrastructure in skeletal muscle. As such the methods 
for both sample collection and image capture reflect this. The samples were 
collected over sequential weeks in the mitochondrial clinic, yielding a small sample 
size with clinical and genetic heterogeneity.  A large number of images were 
captured and fibres with clear signs of disease pathology were targeted 
preferentially.  This means that although the methods yielded a large variety of 
different ultrastructural defects, the imaging strategy is not compatible with a 
quantitative assessment of the prevalence of these features, as such only a semi-
quantitative assessment is provided. Furthermore, the small sample size and the 
fact that some observations are made in a single patient prevents us from making 
deductions on specificity of these defects to a particular mtDNA mutation. 
 
6.5.8 Further work 
Although some features described above can be well linked with recent 
mitochondrial biology, a number of functional experiments to better understand 
other structures described would be useful. For instance Amoscato et al. (2014), 
recently described the use of imaging mass spectrometry to analyse the cardiolipin 
content of mitochondrial membranes in the brain. Such an investigation in the 
patients where we see concentrically organised or linear and electron dense 
cristae may answer questions as to whether it is a change in cardiolipin density. 
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In addition, it was hypothesised that similar to PCI formation due to lack of Creatine 
a reduction in ATP production may have a similar impact. As such it would also be 
interesting to see whether respiratory chain inhibition induces formation of PCI’s 
due to lack of ATP production. 
It may also be interesting to look for possible nuclear modifiers via patient exome 
sequencing that may impact on the ultrastructural defects observed. However, it 
seems highly likely that many of the ultrastructural defects are in fact secondary to 
dysfunction caused by the primary disease causing mutation. 
 
6.5.9 Conclusion 
The results presented here broaden knowledge of the ultrastructural abnormalities 
witnessed in mitochondrial myopathy. A number of the features presented here are 
novel (e.g. linearised cristae membranes), or have not previously been witnessed 
in human tissue (e.g. nanotunnels and donut mitochondria). Furthermore some of 
the features identified have previously been observed in model organisms or 
induced in vitro (e.g. concentric cristae), allowing me to hypothesise their 
mechanistic, functional or pathological relevance. As such this study provides a 
foundation on which future investigations can be planned. 
A larger-scale systematic assessment of mitochondrial ultrastructure using 
quantitative methods and a combination of TEM and serial block face scanning 
electron microscopy will be necessary to better understand the pathological 
relevance of these ultrastructural changes. Furthermore coupling this to molecular 
investigations such as whole exome studies may yield further insight into potential 
nuclear genetic modifiers to mitochondrial disease.
  Chapter 7 
214 
 
Chapter 7. Three-dimensional analysis of mitochondrial 
morphology in human skeletal muscle 
7.1 Introduction: 
7.1.1 Transmission electron microscopy and the limitations of two-dimensional 
electron microcopy 
Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) 
provide unrivalled resolution for visualising nanoscale structures and observing 
structural changes. However, as the scientific field has developed the demand for 
quantitative assessments over qualitative and observational studies is ever 
increasing. As such, TEM are commonly used to provide structural support to 
functional experimental findings. Alternatively, TEM sometimes allows the initial 
observation which guides the functional investigation but rarely forms the main 
component of an investigation. 
However TEM has a number of useful outcomes; i) deriving valuable quantitative 
information on the shape and size of biological structures, contributing to hypothesis 
testing, ii) visualising biological structures yielding hints of mechanisms for 
pathophysiological processes and iii) discovery of novel structures that generate 
insight into complex functions. This is particularly so where the questions being 
asked are about the length or width of a particular object e.g. the size of the 
intermembrane space or length of nanotunnels, as presented in Chapter 6. 
Furthermore, TEM has been used to quantitatively assess morphological differences 
between subsarcolemmal (SS) and intermyofibrillar (IMF) mitochondria, finding SS 
mitochondria to be rounder and IMF mitochondria more branched (Picard et al., 
2013). 
However, when the questions asked are about shape, area or perimeter, it has 
become increasingly apparent when the same tissue is observed in different 
orientations that measurements using two dimensional EM techniques, are often 
underestimates. A key example of this are observations of skeletal muscle 
mitochondria in transverse and longitudinal orientations. Here, findings suggest due 
to the complexity of the mitochondrial shape and branching (Leduc-Gaudet et al., 
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2015), that assessing mitochondrial morphology in two dimensions grossly 
underestimates the mitochondrial network connectivity. As such investigations using 
serial semi-thin sections on TEM have looked to reconstruct mitochondrial networks 
(Bakeeva et al., 1978; Kayar et al., 1988) and advances in technology have been 
sought to allow faster less human intensive, high-throughput, high-resolution imaging 
technologies (Escovitz et al., 1975; Denk and Horstmann, 2004). 
 
7.1.2  Volume electron microscopy (EM) and the advent of three-dimensional EM 
Traditionally three dimensional EM analysis has been performed by serial section 
transmission electron microscopy (ssTEM) (Bang and Bang, 1957). A rather 
painstaking and technically demanding technique ssTEM requires the investigator to; 
i) collect serial ultrathin sections for imaging by TEM without losing a section, ii) find 
the same area in each section and iii) orientate the images captured appropriately for 
reconstruction. Also commonly used is electron tomography which involves the 
imaging of a 200 nm to 1000 nm section by tilting the section up to ±70° within the 
path of the electron beam whilst imaging (McEwen and Marko, 2001).  This method 
allows a 2 nm axial resolution but similar to ssTEM, the ability to acquire larger 
volume stacks and the field of view are limited. 
Recent advances in technology have seen a surge of new methodologies for three 
dimensional nanoscale resolution imaging. These include array tomography, 
Automatic Tape-collecting Lathe Ultramicrotome (Hayworth et al., 2006) or Automatic 
Tape-collecting Ultramicrotome (Schalek et al., 2011) and finally serial block-face 
imaging techniques which include serial block-face SEM (SBFSEM) (Denk and 
Horstmann, 2004) and focused ion beam SEM (FIBSEM) (Escovitz et al., 1975). 
Serial block face techniques allow large volume imaging without the need for manual 
serial sectioning and alignment and thus allow much larger volumes to be imaged. 
An SBFSEM is essentially a microtome within an SEM, with a diamond knife cutting 
ultra-thin sections between imaging iterations. At present the maximum block-face of 
an SBFSEM sample is limited to approximately 800 µm2 in size but with much larger 
volume imaging possible than with previous technologies. The disadvantage of 
SBFSEM is that minimum section thickness is 25 nm in optimal specimens (Peddie 
  Chapter 7 
216 
 
and Collinson, 2014) and may be higher in non-optimal samples thus limiting the 
axial resolution. In comparison, FIBSEM uses a focused ion beam to mill away a 
layer of the block between imaging iterations, with the main advantage over SBFSEM 
being an increased maximum axial resolution to approximately 3 nm, however the 
process of ion beam milling is much slower than sectioning and as such SBFSEM is 
a fast way to acquire large data sets. SBFSEM is the method implemented here for 
large volume imaging at speed. In addition, the presence of an SBFSEM in the 
University’s Electron Microscopy Research Services allowed for in house processing 
and imaging and thus Dr Kathryn White and Dr Tracey Davies technical expertise. 
 
7.1.3  Three dimensional reconstructions of mitochondrial networks in mouse and 
human. 
Three dimensional reconstruction of mitochondria in healthy human skeletal muscle 
from focused ion beam scanning electron microscopy (FIBSEM) has recently been 
completed by (Dahl et al., 2015) , however no study has quantitatively assessed the 
mitochondrial network in three dimensions. The primary reason for this may be the 
lack of three-dimensional parameters to quantitatively assess the mitochondria 
compared to those already developed for two dimensional analysis (Koopman et al., 
2005; Picard et al., 2013). As such we do not know what constitutes “normal” when 
we discuss mitochondrial network morphology in human skeletal muscles, how 
variable “normal” is or how IMF and SS mitochondria vary.  
Although three dimensional quantitative analysis of human skeletal muscle 
mitochondria has not been completed mouse muscle mitochondria have been 
reconstructed and quantitatively assessed (Glancy et al., 2015). However, given that 
mouse skeletal muscle fibre-types differ from those found in human skeletal muscle 
(Gorza, 1990; Smerdu et al., 1994) intra–species differences in the mitochondrial 
morphology may be quite substantial. Furthermore research suggests that 
mitochondrial dynamics are a distinguishing feature between different fibre types in 
mice (Mishra et al., 2015), which implies that mitochondrial morphology is also likely 
to differ between fibre types of humans. 
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7.2 Aims of this investigation 
The first aim of this study was to develop a methodology for calculating mitochondrial 
complexity in three-dimensions and a validated approach to calculate the degree of 
branching. The purpose of this was to assess whether the mitochondrial network is 
anisotropic, that is it is more connected in one plane of the muscle fibre than the 
other. The second aim was to use this methodology to characterise the morphology 
(size, complexity and degree of branching) of mitochondria in skeletal muscle 
samples from patients with mitochondrial disease and healthy controls. 
 
7.3 Methodology: 
7.3.1 Patient cohort 
Patients were identified via the mitochondrial disease clinic in Newcastle over 12 
consecutive weeks and consented that part of their muscle biopsy be used for 
research. This study examines a group of six patients with genetically diagnosed 
mitochondrial disease; single large-scale mtDNA deletion (n = 2), m.8344A>G 
tRNALys (n = 3) and m.3243A>G tRNALeu(UUR) (n = 1). Patient details including genetic 
diagnosis plus relevant diagnostic and clinical information can be found in Error! 
eference source not found.. All work presented here was previously approved by the 
Newcastle and North Tyneside Local Research Ethics Committees (reference 
2002/205) and is now approved under Newcastle and North Tyneside Local 
Research Ethics Committees (reference 16NE/0267).  
Control muscle biopsies (controls 5-12) were collected during routine anterior 
cruciate ligament (ACL) surgery with prior informed consent. Ethical approval for 
collection of ACL biopsies was given by Newcastle and North Tyneside Local 
Research Ethics Committees (reference 12/NE/0395, project number 42). Age and 
gender of controls can be found in Table 2.6. 
 
7.3.2 Serial block face scanning electron microscopy 
Preparation of samples was completed as described in 2.12.2, by Drs Kathryn White 
and Tracey Davey. Fibres with a high mitochondrial content were selected from 
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cases with specific mitochondrial pathology and a series of serial images 
interspersed by 30 - 50 nm were captured at a magnification of 8,200x using the 
Gatan 3view system and digital micrograph software. 
 
7.3.3 IMOD three dimensional reconstruction 
Image stacks from Digital Micrograph (Gatan) were converted to MRC files and 25 to 
50 mitochondria per myofibre were reconstructed using IMOD image analysis 
software. Mitochondria were manually traced using the ‘sculpt’ drawing tool, after 
which a mesh and cap were applied using 1.5 as the flat criteria. After which surface 
area and volume inside the mesh were extracted. 
 
7.3.4 Mitochondrial volume density 
Mitochondrial volume density was calculated for each intermyofibrillar fibre by 
reconstructing all mitochondria in two sarcomeres (A-band to A-band). Several 
myofibres had poor orientation and A- and Z-bands were not clear and so 
mitochondrial volume density could not be accurately assessed. An additional object 
was created to measure the muscle volume of two sarcomeres and the total 
mitochondrial volume divided by the total muscle volume and multiplied by 100 to 
give mitochondrial volume density as a percentage. 
 
7.3.5 Quantification of mitochondrial complexity 
Mitochondrial complexity index (MCI) was calculated using Equation 7.1, where SA 
is surface area and V is volume. This equation was developed as a three-
dimensional equivalent to form factor (Koopman et al., 2005). Testing similar to that 
used by Koopman et al. (2005) was completed to validate the formula.                   
Equation 7.1 Mitochondrial complexity index (MCI) 
𝑀𝐶𝐼 = (
𝑆𝐴3/2
4𝜋𝑉
)
2
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7.3.6 Quantification of mitochondrial branching 
Mitochondrial branching was quantified to assess mitochondrial anisotropy in skeletal 
muscle. In order to do this each mitochondrion was assessed in two planes; 
transverse (or cross-section) (x,y) and longitudinal (x,z) and a ratio was calculated for 
the two giving the mitochondrial branching index (Equation 7.2). Transverse 
branching index (TBI) (Equation 7.3), was assessed by quantifying the total number 
of myofibrils bridged. In instances where a mitochondrion wraps around one myofibril 
the side with the largest value was taken as shown in Figure 7.1. Longitudinal 
branching index (LBI) (Equation 7.4) was assessed by adding up the total score for 
“boundaries bridged”, where a z-band or half sarcomere equates to a score of one 
and full sarcomere a score of two Figure 7.1. 
 
Equation 7.2 Mitochondrial branching index (MBI) 
𝑀𝐵𝐼 =
𝑇𝐵𝐼
𝐿𝐵𝐼
 
 
Equation 7.3 Transverse branching index (TBI) 
𝑇𝐵𝐼 = 1 + 𝑡𝑜𝑡𝑎𝑙 𝑚𝑦𝑜𝑓𝑖𝑏𝑟𝑖𝑙𝑠 𝑏𝑟𝑖𝑑𝑔𝑒𝑑 
 
Equation 7.4 Longitudinal branching index (LBI) 
𝐿𝐵𝐼 = 1 + 𝑡𝑜𝑡𝑎𝑙 𝑠𝑐𝑜𝑟𝑒 𝑓𝑜𝑟 𝑏𝑜𝑢𝑛𝑑𝑎𝑟𝑖𝑒𝑠 𝑏𝑟𝑖𝑑𝑔𝑒𝑑 
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Figure 7.1. Quantification of mitochondrial branching to assess anisotropy. (a) 
Mitochondrial branching index (MBI) = Transverse branching index (TBI) / 
Longitudinal branching index (LBI). In order to calculate MBI each mitochondrion is 
assessed first in the transverse orientation and then longitudinal orientation. As such 
any value greater than 1 indicates greater branching in the transverse orientation, 1 
equates to equivalent branching in both directions and less than 1 more branching in 
the longitudinal orientation. (b) Branching in transverse is assessed as TBI = 1 + the 
total length of all branches. The total length of branches is the sum of each myofibril 
“bridged”. In the event that a mitochondrion wraps around one myofibril as depicted 
the side with the greatest value is taken (i.e. this mitochondrion bridges three 
myofibrils.) (c) Branching in longitudinal orientation is assessed as LBI = 1 + total 
longitudinal boundaries bridged. Bridging of a z-band or half a sarcomere is valued 
as one, bridging of a full sarcomere is valued as 2. 
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7.3.7 Statistical analysis of mitochondrial morphology data 
A normality test was performed on all continuous data sets in Mini tab v17.1.0 and 
histograms plotted in Prism v7.0 (Graph Pad) to assess normality. All data sets were 
found not to be normally distributed as such a Cox-Box transformation was 
performed in Mini tab to try to normalise data and normality tests repeated. Volume 
was the only parameter that could be normalised, therefore  all parameters were 
assessed non-parametrically using a combination of tests performed in Prism v7.0 
(Graph Pad); Mann-Whitney test, Kruskal-Wallis test, one-way ANOVA and two-way 
ANOVA. Finally, linear regressions were plotted to assess the relationship of 
morphological parameters to each other and relevant clinical markers such as 
heteroplasmy, COX deficiency and NMDAS scores (Schaefer et al., 2006). Statistical 
significance was set at 0.05. 
Skewness and kurtosis were calculated in Prism v7.0. Skewness is a measure of 
symmetry of a distribution, with a symmetrical distribution having a skewness of 0, an 
asymmetrical distribution with a skew to the right (higher values) has a positive 
skewness and a skew to the left (lower values) has a negative skewness. Kurtosis is 
a measure of how well the distribution fits a Gaussian distribution. A Gaussian 
distribution will have a kurtosis of zero, a flatter distribution has a negative kurtosis 
and a more peaked distribution a positive kurtosis. 
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7.4 Results: 
7.4.1 Testing Mitochondrial Complexity Index 
Form factor is the parameter used to measure mitochondrial branching as assessed 
by two-dimension electron microscopy (Koopman et al., 2005). In order to develop a 
three dimensional equivalent metric, which was named the mitochondrial complexity 
index (MCI), we first replaced perimeter and area in the form factor formula with 
surface area and volume, respectively (Figure 7.2a). However when tested this 
formula was variable dependent on volume, which form factor is not. As such, the 
power to which surface area is raised had to be modified to make a formula that is 
pure shape descriptor and therefore does not change when volume increases but 
shape remains equal.  
In order to test this simulated three dimensional shapes made of 1 nm3 cubes were 
constructed and used to test MCI (Figure 7.2b), volume (Figure 7.2c), surface area 
(Figure 7.2d) and MCI (Figure 7.2e) were calculated for each object. Objects 1, 19 
and 20 are all the same shape and vary only in size, accordingly MCI is exactly the 
same for each of these. In comparison shapes 5, 10, 12 and 14 have none, one, two 
and three branches respectively and each have a slightly increased MCI. This 
therefore showed that MCI is a quantitative measure for three-dimensional 
mitochondrial branching that does not change dependent on size. Subsequently MCI 
was calculated for a range of reconstructed mitochondria to confirm that it 
appropriately increased as mitochondrial complexity increased. However, the overall 
increase in MCI did not reflect the apparent increase in mitochondrial complexity 
visually observed. As such a test in which MCI was squared and cubed was 
completed for a range of mitochondria to compare the values (Figure 7.3). The 
standard unmodified MCI did not appear to increase as dramatically as the shape 
changed and the cubed MCI formula showed too large an increase. Therefore the 
squared formula was selected as the most representative numerical assessment of 
mitochondrial complexity. 
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Figure 7.2. Mitochondrial Complexity index (MCI) was tested as a shape descriptor. 
(a) Conversion of form factor formula to three dimensions, giving MCI formula. (b) 
Various 3D shapes were generated consisting of 1x1x1 blocks. These were then 
tested by plotting: (c) surface area, (d) volume and (e) MCI. Plotting MCI for shapes 
in (b) validated that it is a three-dimensional measure of mitochondrial branching 
which does not take change if volume is increased without a change in shape (e.g. 1, 
19 and 20). 
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Figure 7.3. Modifying MCI formula to fit perceived increase in mitochondrial 
complexity. (A) However the change in MCI did not accurately reflect the increase in 
perceived complexity. Therefore, we transformed MCI by squaring and cubing the 
values and tested this on a sample of 8 mitochondria with varying complexities. This 
resulted in us selecting the formula MCI = ((SA3/2)/4𝜋V)2. Scale bar 1000 nm. (B) 
Final MCI formula. 
 
 
7.4.2 Intermyofibrillar and subsarcolemmal mitochondria comparison 
Similar to previous findings using TEM, comparison of SS and IMF mitochondria in 
images from SBF-SEM showed that IMF mitochondria are typically more branched 
than the smaller rounder SS mitochondria (Figure 7.4 a-c). Eight mitochondria 
representing the full range of volumes observed for IMF and SS mitochondria, 
presented in Figure 7.4d demonstrates a much wider range of volumes in the IMF 
mitochondria than the SS. Furthermore, other than the largest mitochondria 
presented for the SS group all the mitochondria are very simple in shape. The largest 
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SS mitochondria has a branch that reaches into the IMF area (red arrow), 6.1% of all 
SS mitochondria assessed (n = 573) had such protrusions into the IMF space. Such 
connections between SS and IMF mitochondria have previously been demonstrated 
in both mouse and human skeletal muscle (Picard et al., 2013; Dahl et al., 2015). 
The difference between IMF and SS mitochondria is further exemplified in Video 7.1 
(on CD provided), where the nucleus and all SS (red) and IMF (blue) mitochondria 
have been reconstructed. During the video the IMF mitochondria are made 
transparent so that projections from the SS mitochondria into the IMF space can be 
visualised. 
When IMF and SS mitochondrial populations were compared in the eight controls 
assessed, volume was typically higher in IMF mitochondria than in SS (Figure 7.4e). 
This difference was found to be significant in controls 5, 6, 11 and 12 (P = 0.0001) 
and control 10 (P = 0.0004). When MCI was compared SS mitochondria were found 
to be significantly less complex in all (P = 0.0001) but controls 8 and 10 (Figure 7.4f). 
Although the MCI mode was the same for IMF and SS mitochondria the IMF 
distribution was more skewed (Figure 7.4g) with higher skewness and kurtosis 
(skewness = 4.88, kurtosis = 37.09, n = 1201) than SS mitochondria (skewness = 
4.02, kurtosis =27.14, n = 344). Skewness and Kurtosis are explained in section 
7.3.7.  
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Figure 7.4 Mitochondria are highly variable and exist in two morphologically different 
subpopulations; subsarcolemmal (SS - Red) and intermyofibillar (IMF- Blue) 
mitochondria. (a) Low magnification electron micrograph of a myofibre in transverse 
orientation, with higher magnification images of (b) IMF and (c) SS mitochondria. 
Note the difference in size and shape. (d) Illustration of the volume spectrum of IMF 
and SS mitochondria with the smallest volume mitochondria on the left and largest on 
the right. The SS mitochondrion with the highest volume actually has a protrusion 
into the IMF area (red arrow), 6.1% of all (n = 573) SS mitochondria have such a 
protrusion. (e) Bar graph of MCI median and 95% confidence intervals for IMF (blue) 
and SS (red) mitochondria in controls 5 to 12. MCI is typically higher in IMF 
mitochondria. MCI is statistically significant between SS and IMF mitochondria and 
between controls (two-way ANOVA, P < 0.0001). A Mann-Whitney test for each 
control found significance (***, P = 0.0001) for all but C9 (n.s, p = 0.5382) and C10 (P 
= 0.9781). (f) Bar graph of volume median and 95% confidence intervals for IMF 
(blue) and SS (red) mitochondria in controls 5 to 12. Volume is typically higher in IMF 
mitochondria. A Mann-Whitney test for each control found significance (***, P = 
0.0001) for C5, C6, C11, C12 and (**, P = 0.0004) C10, but was not significant for C7 
(n.s, P = 0.591), C8 (n.s, P = 0.324) and C9 (P = 0.289). (g) Frequency histogram of 
IMF and SS volumes in (f). In order to demonstrate differences the graph was 
truncated at 0.5 and then the region above this included in a smaller graph with 
higher bin values. It can be noted that SS mitochondria and IMF mitochondria have 
approximately the same mode however a larger percentage of SS mitochondria are 
in the smaller bins with non above bin centre 0.9, whereas as small percentages of 
IMF mitochondria can be seen right up to bin centre 2. 
 
 
Video 7.1 The video can be found on the attached disk. This video shows one of the 
subsarcolemmal regions, fully reconstructed. This includes the nucleus (light blue), 
subsarcolemmal mitochondria (SS, red) and intermyofibrillar mitochondria (IMF, dark 
blue). The video pans through the full depth of the image stack in a transverse 
orientation, before rotating to a longitudinal orientation. The reconstruction then 
completes two full rotations in the y-axis one with all mitochondria present and one 
with just the SS mitochondria. Notice the projections from the SS mitochondria into 
the intermyofibrillar space. 
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7.4.3 Complexity of intermyofibrillar mitochondria 
The difference in size and morphology between IMF and SS mitochondria and the 
small spherical shape of the subsarcolemmal mitochondria was consistent with 
previous findings. What was more interesting was the number of very complex IMF 
mitochondria observed. Due to the lack of previous 3D analysis in human skeletal 
muscle the degree of connectivity assumed was largely based on TEM and SEM and 
thus underestimated the true complexity. The complexity of the IMF mitochondria in 
controls is illustrated in Figure 7.5. The images show reconstructions from control 
myofibres in both longitudinal and transverse orientations with annotations to 
demonstrate presence of the z-band. The mitochondria are highly complex in some 
fibres with a high degree of branching across the z-band. Branching can also be 
seen across the z-band and across the full sarcomere. 
  
  Chapter 7 
229 
 
 
Figure 7.5 Intermyofibrillar mitochondria exhibit complex morphology in controls. 
Figure shows a transverse and longitudinal view of resconstructed mitochondria in 
one fibre from controls 5, 6 and 12. Dashed lines in the longitudinal orientation 
represent location of the z-bands. Scale bar 1 µm. 
 
 
7.4.4 Variability of IMF MCI and volume within fibres, between fibres and between 
controls 
Comparison of MCI and volume for three fibres for each control demonstrated 
surprisingly high variability both between controls and between the three IMF fibres 
of the same control. Median  95% CI of the volume and MCI values were plotted for 
each IMF fibres of the controls to compare variability both within and between cases 
(Figure 7.6). For some controls all fibres are very similar (e.g. control 9), whereas 
others show a greater degree of variation (e.g. control 11). In addition in some cases 
the variability of MCI and volume in a single fibre is very small and in others much 
larger. This is clearer in Figure 7.7, where MCI and volume for the individual 
mitochondria in each IMF fibre in each control have been plotted for comparison. 
Control 7 fibre 1 and control 12 fibre 1 have very similar values with little variability 
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within the fibre. In comparison, control 5 fibre 2 and control 6 fibre 2 both have a high 
range of MCI values and thus are very variable. It should also be noted that the mean 
MCI for the three fibres for controls 6 and 12 were quite variable. This further 
demonstrates that the variability both within a fibre and between fibres of the same 
control is very variable in itself.  
 
 
Figure 7.6. Mitochondrial complexity (MCI) and volume are variable in the IMF 
mitochondria in the majority of patients. Mean and SEM of Volume against mean and 
SEM of MCI for each IMF myofibre coloured by control. Between fibre variability is 
small in some controls but larger in others (e.g. Control 11). This should be 
considered when interpreting control and patient data. 
  
Figure 6
Figure 2. Mitochondrial 
complexity (MCI) and 
volume are variable in the 
majority of patients. Mean 
and SEM of Volume against 
mean and SEM of MCI for 
each IMF muscle fibre 
coloured by control. Between 
fibre variability is small in some 
controls but larger in others 
(e.g. C7). This should be 
considered when interpreting 
control and patient data.
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Figure 7.7 Volume and MCI are variable within a single myofibre as well as between 
fibres. Comparison of (a) volume and (b) MCI for each mitochondrion in each the 
three IMF myofibres for the controls. Lines represent the mean for each fibre. Each 
data point represents one mitochondrion 
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7.4.5 Is there a relationship between mitochondrial volume density and MCI? 
It was hypothesised that MCI may increase in fibres where mitochondrial volume 
density was higher since the mitochondria would be in closer proximity and thus 
fusion events more likely. Mitochondrial volume density was assessed in each of the 
IMF myofibres as described in 7.3.4. When mitochondrial volume density was plotted 
against mean MCI of the myofibre, for all controls there was no significant correlation 
(R2 =0.09719, P = 0.1938) (Figure 7.8).The absence of relationship was even more 
evident when comparing single myofibres among individual subjects. 
 
 
Figure 7.8 Mitochondrial mass assessed over two sarcomeres from A-band to A-
band. Mitochondrial volume as a percentage of muscle volume was plotted against 
average MCI for each myofibre. The solid line indicates linear regression, and the 
dotted lines the 95% confidence interval. No assessment was made for control 5 (C5) 
and two fibres from control 10 (C10) due to the orientation of the myofibres. 
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7.4.6 How do patients with mtDNA mutations differ? 
A cohort of six patients with mtDNA mutations including; single large-scale mtDNA 
deletion (n = 1) m.8344A>G tRNALys (n = 3) and m.3243A>GLeu(URR) (n = 1). This 
cohort is small, furthermore there are a number of confounding variables that must 
be considered and make the patients difficult to interpret. These variables include, 
mtDNA mutation, heteroplasmy, level of respiratory chain defect and age. This is 
made more difficult given the morphological variability observed in the controls 
(Figure 7.9a) and in patients also (Figure 7.9b).  
Patients are colour coded based on the mtDNA mutation and ordered from left to 
right for patients 35 to 40. When compared to the combined control population using 
a Mann-Whitney test, patients 35, 37, 38 and 39 were significant. However, this is 
also the case if some of the controls are compared to the combined control 
population using a Mann-Whitney test, as such it is very difficult to make any firm 
conclusions from these data. 
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Figure 7.9 Mitochondrial volume is variable between controls and patients analysed. Patients are organised by genetic mutation: 
controls; C, single, large-scale mitochondrial DNA deletion; P35 and P36, m.8344A>G tRNALys: P37, P38 and P39, m.3243A>G 
tRNALeu(UUR); P40. (a) Intermyofibrillar mitochondrial volume of controls 5 to 12 showing individual values, median and 95% confidence 
intervals. A Kruskal-Wallis test indicates that the controls are significantly different (P < 0.0001). (b) Intermyofibrillar mitochondrial volume 
of combined control and patients 25 to 40 showing individual values, median and 95% confidence intervals. A Mann-Whitney test was 
used to compare each patient to the control population (***; P < 0.0001, * = 0.0295; n.s.; not significant). (c) Intermyofibrillar mitochondrial 
volume of combined controls and patients 35 to 40. Data was plotted as a percentage of mitochondria that fall into the 10th (small) and 
90th (large) percentile of the control population.
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It was expected that the most notable differences would be seen in the smallest and 
largest mitochondria. As such the tenth and ninetieth percentiles of the combined 
control population were used as a cut off to look at percentage of mitochondria that 
were either “small” (below the 10th percentile of controls) or “large” (above the 90th 
percentile of controls) respectively (Figure 7.9c). In doing so this made comparison 
of controls and patients easier. The first patient with a single mtDNA deletion (patient 
35) has approximately three times the number of small mitochondria than were 
detected in the control population and very few large mitochondria. In comparison, 
the second patient with a single mtDNA deletion (patient 36) is very similar to the 
control population and has a slightly smaller deletion and a slightly lower 
heteroplasmy level (18%) than patient 35 (20%). 
Within the patients analysed there are three related individuals with the m.8344A>G 
tRNALys mutation (Figure 7.10a). The mother (patient 38) was 50 years old with 63% 
mutational heteroplasmy and mild myopathy. Her first daughter (patient 37) was 21 
years old with 97% heteroplasmy, severe myopathy and exercise intolerance. In 
comparison her sister (patient 39) was 20 years old with 40% heteroplasmy and was 
asymptomatic. Patient 37 and her asymptomatic sister (patient 38), both had a much 
lower frequency of small mitochondria and the mother a marginally higher frequency 
of small mitochondria than was observed in the control population (Figure 7.9c). The 
opposite is observed for the large mitochondria and the asymptomatic sister had the 
highest frequency of large mitochondria with approximately four times that of the 
controls. Patient 37 had double the number of large mitochondria when compared to 
the controls whilst the mother had very few.  
When the EM micrographs and reconstructed models were compared for each of 
these individuals it was very apparent that both patient 37 and 38 had relatively 
simple mitochondria that are small and round (Figure 7.10b and c). In comparison, 
patient 39, the asymptomatic sister, with a moderate level of heteroplasmy, had 
some very complex mitochondria with large degrees of branching and nanotunnels 
(Figure 7.10d). This patient also had small round mitochondria isolated from the 
mitochondrial network. Together, a substantial portion of very complex and very small 
mitochondria contributed to a greater spread of both MCI and volume (Figure 7.10e 
and f). Interestingly the volume of patient 38 is less positively skewed than patient 37 
(skewness: patient 37 = 3.344 and patient 38 = 1.643), possibly suggesting that 
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some mitochondria in patient 37 are swollen, which is a common finding in 
mitochondrial myopathy. Finally, for the m.3243A>G tRNALeu(UUR) patient (patient 40), 
both small mitochondria and large mitochondria are marginally more frequent than 
controls.  
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Figure 7.10 A family variably affected with mitochondrial myopathy and m.8344A>G tRNALys show a high degree of variability in 
mitochondrial morphology. (a) Family tree showing; patient 38 affected mother (blue) with 63% heteroplasmy, 22% COX deficiency and 
mild myopathy, patient 37 the proband (orange) with 97% heteroplasmy, 97% COX deficiency myofibres and severe myopathy and 
exercise intolerance and patient 39 unaffected sister (green) with 40% heteroplasmy and some intermediate COX-deficient fibres. (b-d) 
Single slice from serial block face scanning electron microscopy (SBFSEM) and reconstruction of 50 mitochondria in an IMF region of 
myofibre for patients 37 (b), 38 (c) and 39 (d). Note the small round morphology in the mother and proband (b and c) and the branched 
mitochondria in the unaffected sister (d). Scale bars; 1 μm.
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MCI was also highly variable in both controls (Figure 7.11a) and patients (Figure 
7.11b). A Mann-Whitney test comparing patients to the combined control population 
found a significant difference in all patients. However, some but not all of the control 
cases also yielded this result when compared to the combined control population 
using a Mann-Whitney test. Similar to volume it was expected that the greatest 
changes would be observed at either end of the MCI spectrum. Therefore, the 10th 
and 90th percentiles of the MCI of the controls were used as cut offs to categorise 
patient mitochondria as simple (less than the 10th percentile of the control population) 
or complex (greater than the 90th percentile of the control population). This 
demonstrated that simple mitochondria, i.e. mitochondria that are more less 
branched and more round, are typically more frequent in patients than controls 
(Figure 7.11c). 
In the patients with single, large-scale mtDNA deletions (patient 35 and 36), patient 
36 was comparable to controls in frequency of simple and complex mitochondria, 
similar to results for volume (Figure 7.11c). Patient 35 also had a three times higher 
frequency of simple mitochondria than the control population, however the frequency 
of complex mitochondria was comparable to controls, a slight variation in the pattern 
observed with volume. This tends to indicate that the larger mitochondria in patient 
35 are likely large and branched rather than simple and swollen. 
In the three cases with the m.8344A>G tRNALys mutation, all patients had more 
simple mitochondria than the control population with patients 37 and 38; the proband 
and mother having the highest levels with approximately 70% and 80% of all 
mitochondria being classified as simple (Figure 7.11c). Of these three cases the 
symptomatic sister (patient 39) was the only patient to have complex mitochondria, 
with levels comparable to those of the control population. Finally, the m.3243A>G 
patient (patent 40) had an approximately six times higher frequency of simple 
mitochondria than the control population and very few simple mitochondria. 
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Figure 7.11 Mitochondrial complexity index (MCI) is variable between controls and patients analysed. Patients are organised by genetic 
mutation: controls; C, single, large-scale mitochondrial DNA deletion; P35 and P36, m.8344A>G tRNALys: P37, P38 and P39, m.3243A>G 
tRNALeu(UUR); P40. (a) Intermyofibrillar mitochondrial MCI of controls one to eight showing individual values, median and 95% confidence 
intervals. A Kruskal-Wallis test indicates that the controls are significantly different (p < 0.0001). (b) Intermyofibrillar mitochondrial MCI of 
combined control and patients one to six showing individual values, median and 95% confidence intervals. A Mann-Whitney test was 
used to compare each patient to the control population, all were significant (***; P < 0.0001, **; P = 0.0031). (c) Intermyofibrillar 
mitochondrial MCI of combined controls and patients 35 to 40. Data as plotted as a percentage of mitochondria that fall into the 10th 
(simple) and 90th (complex) percentile of the control population 
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7.4.7 Frequency of donut mitochondria and nanotunnels 
For each of the mitochondria reconstructed the number of nanotunnels and donut 
mitochondria were counted. For each of these counts the total was normalized to the 
number of mitochondria assessed giving number of nanotunnels or donut 
mitochondria per 100 mitochondria assessed. 
Donut mitochondria are those that have either fused back in on themselves or have 
split forming a ring shape. Once more these were found in both transverse and 
longitudinal orientations, and were in fact most commonly found in the longitudinal 
orientation. When the frequency was compared among all cases frequency of donut 
mitochondria had no clear trend in patients or controls (Figure 7.12a-c). However, it 
is difficult to draw robust conclusions on such a small sample size. The biological 
relevance and previous findings are discussed further in section 7.5.5.
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Figure 7.12 Donut mitochondria were observed in patients and controls. (a) Stack of serial block face scanning electron microscopy 
images showing a donut mitochondrion and (b) three dimensional reconstruction of the donut mitochondrion in (a). (c) Frequency of 
donut mitochondria per 100 mitochondria in combined controls (black) and patients 35-40 (left to right). Patients are organised by genetic 
mutation: controls; C5 to C12, single, large-scale mitochondrial DNA deletion; P35 and P36, m.8344A>G tRNALys: P37, P38 and P39, 
m.3243A>G tRNALeu(UUR); P40. A Mann-Whitney test was used to compare all controls (AC) and all patients (AP), no significant (n.s) 
difference was detected. Of the mitochondria that had nanotunnels (n = 241) and those that were donut mitochondria (n = 17), five had 
both. Scale bars; 500 nm.
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Nanotunnels were thin projections connecting two close or distant mitochondria 
(Figure 7.13 a and b). Nanotunnels were present in both the transverse and 
longitudinal orientation increasing the likelihood that the frequency would be 
underestimated by two dimensional assessments. When the frequency of 
nanotunnels was compared for all subjects, number of nanotunnels were generally                                                                                
low in controls, with the exception of control 6 (Figure 7.13c). In comparison 
frequency of nanotunnels was high in patients with the greatest number found in 
patient 39. Interestingly, the patients with m.8344A>G tRNALys and m.3243A>G 
tRNALeu(UUR) point mutations had higher levels of nanotunnels than those with large-
scale single deletions (patients 35 and 36). Although with such a small number of 
patients with point mutations we do not have the statistical power to test this. 
Because nanotunnels are newly discovered in human skeletal muscle, we attempted 
to derive some functional significance by analysing the correlation between the 
number of nanotunnels overserved and clinical parameters. Frequency of 
nanotunnels was plotted against key clinical and diagnostic parameters including 
percentage of COX deficiency (Figure 7.14a), heteroplasmy (Figure 7.14b) and 
NMDAS (Figure 7.14c), as well as MCI (Figure 7.14d). Regression lines 
demonstrated a lack of trend and significance. 
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Figure 7.13 Nanotunnels were observed in controls and patients but more frequenctly in patients. (a) Stack of serial block face scanning 
electron microscopy images showing a mitochondrion with a nanotunnel and (b) three dimensional reconstruction of the mitochondrion in 
(a). (c) Frequency of nanotunnels per 100 mitochondria in combined controls (black) and patients 35-40 (left to right). Patients are 
organised by genetic mutation: controls; C5 to C12, single, large-scale mitochondrial DNA deletion; P35 and P36, m.8344A>G tRNALys: 
P37, P38 and P39, m.3243A>G tRNALeu(UUR); P40. A Mann-Whitney test was used to compare all controls (AC) and all patients (AP) which 
are significantly different (p=0.01). 
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Figure 7.14 Regressions plotted for frequency of nanotunnels per 100 mitochondria. 
Number of nanotunnels plotted against (a) percentage COX-deficient fibres (R2 = 
0.002091, P = 0.88), (b) heteroplasmy (R2 = 0.052, p = 0.43), (c) NMDAS (R2 = 
0.08055, P = 0.33) and (d) MCI (R2 = 0.0090, P = 0.7467) 
 
7.4.8 Looking for trends that improve the understanding of disease pathology 
There were a number of confounding variables that needed to be considered when 
the patient data was interpreted, these included; mtDNA mutation, mutational 
heteroplasmy, degree of respiratory chain deficiency and age. As such it is helpful to 
look for correlations that may help yield a better understanding of the results. Plotting 
of MCI against heteroplasmy, percentage COX deficiency, age and also total 
NMDAS scores and NMDAS subscores for myopathy and exercise intolerance, 
yielded (Table 7.1) no strong or significant correlation (Figure 7.15). 
Interestingly, the pattern for heteroplasmy appears to take an adverted U shape. This 
would fit with previous findings and a hypothesis that fusion at low levels of 
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mutational heteroplasmy allows complementation but at higher levels of 
heteroplasmy the network fragments.   
 
 
 
Table 7.1 Total NMDAS and NMDAS subscores for exercise intolerance and 
myopathy for all patients, apart from patient 40, for whom these were unavailable 
Patient # Assessment time 
relative to biopsy 
NMDAS total Exercise 
intolerance 
Myopathy 
35 6 months pre-
biopsy 
21 0 2 
36 At biopsy 43 4 3 
37 1 year pre-biopsy 14.5 4 3 
38 At biopsy 9 0 2 
39 At biopsy 2 0 0 
40 N/A N/A N/A N/A 
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Figure 7.15 Average mitochondrial complexity index for the muscle fibres of each 
patient was regressed against (a) heteroplasmy (R2 = 0.0445, P = 0.0514) (b) 
percentage COX deficiency (R2 = 0.239, P = 0.325), (c) NMDAS exercise intolerance 
subscore (R2 = 0.00151, P = 0.951), (d) NMDAS myopathy subscore (R2 = 0.0406, P 
= 0.745) and (e) NMDAS total (R2 = 0.295, P = 0.344). Data for patient 40 was not 
plotted for c-e due to lack of NMDAS scores. 
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As the largest, but still very small, patient group the m.8344A>G patients were 
examined further for possible correlations. When MCI was regressed against COX-
deficiency (Figure 7.16a) and mutational heteroplasmy (Figure 7.16b) for the three 
m.8344A>G tRNALys patients, R squared values showed a strong relationship 
however neither heteroplasmy (R2 = 0.89, P = 0.056) or percentage COX deficiency 
(R2 = 0.61, P = 0.43) were significant. However, this should be interpreted with 
caution since these graphs include only a few data points and cannot really be used 
to draw conclusions, but were used to explore possible trends that may warrant 
investigation with a larger patient cohort. 
 
 
Figure 7.16 Mean MCI regressed against (a) percentage COX deficiency (R2 = 0.89, 
P = 0.056) and (b) heteroplasmy (R2 = 0.61, P = 0.43). Error bars are SEM.  
 
 
7.4.9 Assessing mitochondrial anisotropy 
COX deficiency in longitudinal skeletal myofibres is segmental and spreads slowly 
through the myofibre over time. The reason that short segments of COX deficiency 
are regularly observed and skeletal myofibres are rarely fully deficient is intriguing 
and has relevance for clinical pathology and disease progression. In order to test 
whether the mitochondrial network may be a limiting factor in the spread of 
respiratory chain deficiency, mitochondrial branching was assessed in the transverse 
and longitudinal planes and a ratio of the two calculated to quantitatively assess 
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mitochondrial anisotropy with a mitochondrial branching index (MBI).  It was 
hypothesised that mitochondrial branching would be greater in the transverse 
orientation possibly accounting for faster spread in this orientation (Figure 7.17a). 
Mitochondria that are equally branched in both directions will have an MBI of one. 
Mitochondria that exhibited more branching longitudinally had an MBI of less than 
one (e.g. Figure 7.17b) and those that were more branched in the transverse 
orientation had an MBI of greater than one (e.g. Figure 7.17c). This demonstrated 
that 48.7% of all mitochondria analysed are equally branched in both directions 
(Figure 7.17), 40.9% were more branched in the transverse orientation and only 
10.4% more branched longitudinally (Figure 7.17d). Taken together this suggests an 
approximately 4-fold greater degree of mitochondrial network connectivity across the 
plane of each z-band compared to the connections between mitochondria of different 
z-bands. This is noticeable upon visual assessment in some myofibres (e.g. Video 
7.2, on CD provided).  
 
Video 7.2 The video can be found on the attached disk. This video shows a full 
reconstruction of an intermyofibrillar serial block face scanning electron microscopy 
image stack. Each mitochondrion is in a different colour. The video starts in a 
transverse orientation and rotates 360 degrees in the x-axis. Then rotates to a 
transverse orientation before rotating in the y-axis. Notice the variation in 
mitochondrial shape and size and the organisation of mitochondria in layers at the z-
band. Also noticeable are nanotunnels connecting mitochondria at adjacent z-bands. 
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Figure 7.17 Anisotropy of branching may impact the spread of mtDNA mutations through skeletal myofibres. (a) Schematic 
demonstrating increased likelihood of mutation expansion in direction with greatest mitochondrial “network connectivity” or branching. (b) 
A reconstructed mitochondrion that was longer or more branched in the longitudinal orientation of the myofibre and (c) a reconstructed 
mitochondrion that was more branched in transverse orientation. (d) Mitochondrial branching indicator (Transverse branching 
indicator/Longitudinal branching indicator) in combined controls and patients. A value of less than 1 (orange) indicated greater branching 
in the longitudinal orientation of the myofibre, equal to 1 (green) indicated equivalent branching in both planes and greater than 1 (red) 
indicated more branching in the transverse plane of the myofibre. Note that the percentage of mitochondria that were more branched in 
the transverse orientation (40.9%) was greater than those more branched longitudinally (10.4%). Scale bars; (b) and (c) 1 μm and (d) 500 
nm.
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7.5 Discussion: 
Mitochondrial morphology is intrinsically linked to mitochondrial function, with 
numerous studies finding correlations between mitochondrial morphology and 
mitochondrial function and tissue function (Trushina et al., 2012; Hara et al., 2014; 
Picard et al., 2014; Leduc-Gaudet et al., 2015). Mitochondria become more fused at 
intermediate levels of mutational heteroplasmy (50-80%) and the network fragments 
at high levels of heteroplasmy (90%) (Picard et al., 2014). At the tissue level, 
frequency of donut mitochondria in synaptic boutons of aged rhesus monkeys 
inversely correlates with working memory (Hara et al., 2014). SS mitochondria are 
swollen and less circular and IMF mitochondria were longer and more branched in 
atrophied skeletal muscle fibres in mice (Leduc-Gaudet et al., 2015). 
Prior to this investigation three-dimensional assessment of human skeletal muscle 
mitochondria using electron microscopy had been restricted to one study in controls, 
which also completed quantitative mitochondrial volume density using confocal 
microscopy (Dahl et al., 2015). In addition, a study using FIBSEM to quantitatively 
assess mouse muscle mitochondrial morphology demonstrated a continuous 
mitochondrial reticulum (Glancy et al., 2015). 
 
7.5.1 Quantitative analysis of mitochondrial networks in three dimensions 
Due to the lack of previous quantitative assessment in three-dimensions, it was 
necessary to develop morphological parameters. Form factor which had already 
been developed and validated as a  two dimensional was modified to give a three 
dimensional branching indicator, which was subsequently validated. Testing of the 
Mitochondrial Complexity index (MCI), proved it to be the three dimensional 
equivalent of form factor and found it to be a valuable discriminating parameter when 
comparing both SS and IMF mitochondria. 
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7.5.2 Subsarcolemmal and intermyofibrillar mitochondrial are morphologically 
different 
Subsarcolemmal mitochondria were found to be less complex and have a smaller 
volume than intermyofibrillar mitochondria. Upon visual analysis the majority of 
subsarcolemmal mitochondria are spherical, with a small proportion having 
projections that reach into the IMF space or are fused to an IMF mitochondrion. This 
observation is in agreement with previous reports both in mouse (Picard et al., 2013) 
and humans (Dahl et al., 2015). 
 
7.5.3 Variability in mitochondrial morphology in control skeletal muscle 
Assessing mitochondrial morphology in control myofibres demonstrated unexpected 
variability within fibres, between fibres of the same individual and between controls. 
Although it is apparent that mitochondrial morphology is likely to be variable both 
between muscles with different oxidative capacities and tissues with different 
energetic demands, the variability of mitochondrial volume and branching observed 
here within a single myofibre was surprising.  
Since fibres were selected based on the mitochondrial mass within a fibre and fibre 
typing was not possible, it is possible that different fibre types were analysed. If so 
this may explain some of the variability observed, since fibre type has previously 
been demonstrated to alter mitochondrial morphology and dynamics (Dahl et al., 
2015; Mishra et al., 2015). In particular Dahl et al. (2015), demonstrates that type I 
fibres have a higher mitochondrial volume and tubular mitochondria are generally 
thicker, whilst Mishra et al. (2015) demonstrates that fusion events are more frequent 
in oxidative muscle fibres. 
Further to this when findings presented here in human skeletal muscle are compared  
to those of Glancy et al. (2015) in mouse skeletal muscle, there appear to be inherent 
differences between species. In mouse skeletal muscle the mitochondria form one 
reticular network with smaller isolated mitochondria being a rare occurrence and the 
overall mitochondrial volume density is greater.  This may be a consequence of the 
variation of mitochondrial fibre types in humans and mice (Gorza, 1990; Smerdu et 
al., 1994).  Alternatively, it could be a methodological artefact since, they implement 
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automatic segmentation of mitochondria by thresholding based on the pixel grey 
scale. Particularly for the subsarcolemmal mitochondria in images presented it looks 
like mitochondria that are not joined may have been artificially joined. 
However, Glancy et al. (2015) drop fixative on to the mouse muscle whilst the mouse 
is still alive. In comparison for human muscle biopsies there is typically up to an hour 
of ischemia following the biopsy prior to fixation. As such it should be considered that 
this could also be an artefact caused by the delay between biopsy and subsequent 
fixation of the tissue when we assess human samples. It is well known that 
mitochondria can change shape in seconds and that delay in fixation may result in a 
change in the structure observed on EM.  
Given the lower mitochondrial volume density in human skeletal muscle, it seems 
unlikely that the difference in mitochondrial morphology observed here is due to 
fixation artefact, since delayed fixation will only cause a fragmentation of the network 
not a change in total mitochondrial volume. Furthermore, clear variability is noted 
throughout the cases assessed with some exhibiting marked mitochondrial 
complexity and others very simple mitochondrial morphology and yet all biopsies 
were processed the identically. 
 
7.5.4 Mitochondrial morphology in mitochondrial myopathies 
A further novelty of this work was the comparison of mitochondrial three dimensional 
morphology in a cohort of mitochondrial myopathy patients to the control population. 
Although this included only a small group of patients thus making it difficult to 
interpret and draw conclusions, this provides grounding for future studies. In addition 
to the confounding variables considered previously (mtDNA mutation, heteroplasmy, 
percentage COX deficiency and age), there are also a number of other variables to 
consider. Due to variation in clinical severity as well as age some patients are likely 
to be more active than others, indeed some of the patients analysed have a degree 
of exercise intolerance (Table 7.1). Since exercise is known to promote mitochondrial 
biogenesis based on substantial research connecting level of exercise to both 
mitochondrial morphology and mitochondrial mass. 
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This work has also allowed the identification of morphological indicators of 
mitochondrial dysfunction and mitochondrial stress, in particular mitochondrial 
network fusion and fragmentation, nanotunnels and donut mitochondria. Nanotunnels 
and donut mitochondria were previously unobserved in human skeletal muscle. In 
addition, the data presented here provides a clearer picture than that presented in 
chapter 6, since we get a better idea of the true frequency and 3D shape of these 
structures. 
The mitochondrial network has been demonstrated to undergo stress induced 
mitochondrial fusion in response to low levels of mitochondrial stress or mutational 
heteroplasmy (Tondera et al., 2009; Shutt and McBride, 2013; Picard et al., 2014; 
Leduc-Gaudet et al., 2015). However, when mutational heteroplasmy is increased or 
stress exceeds a functional threshold the mitochondrial network appears to fragment 
likely due to loss of membrane potential and proteolytic cleavage of Opa1 (Ehses et 
al., 2009; Head et al., 2009). This appears to be supported by what is observed here 
in the m.8344A>G tRNALys trio, where both mother and daughter with 60% and 97% 
heteroplasmy respectively have fragmented mitochondrial networks whereas the 
sister with lower (40%) mutational heteroplasmy in fact shows greater mitochondrial 
network connectivity than the combined control population but similar or less than 
some controls (controls 6, 11 and 12) when compared individually. 
 
7.5.5 Donut mitochondria 
Donut or toroid mitochondria have been found to be a morphological marker of 
cellular stress and are found in cells during hypoxia (Liu and Hajnoczky, 2011) as 
well as being inducible via respiratory chain inhibition (Ahmad et al., 2013). They 
have been found to range in diameter from 0.5 – 2.4 µm with a nearly Gaussian 
distribution and to form by self-fusion due to increases in chemiosmotic pressure  
caused by opening of the permeability transition pore (PTP) and changes in the K+ 
conductance of the IMM (Long et al., 2015). This increase in pressure is relieved by 
mitochondrial swelling or donut formation (Long et al., 2015). Furthermore, toroid 
mitochondria return more easily to their initial morphology than swollen mitochondria 
so as well as a stress response it is also a protective mechanism (Liu and Hajnoczky, 
2011). Interestingly, frequency of donut mitochondria in presynaptic boutons of the 
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prefrontal cortex of aged rhesus monkey has also been found to correlate inversely 
with working memory (Hara et al., 2014) demonstrating that they may be associated 
with tissue dysfunction.  
Surprisingly, donut mitochondria were observed here in a small number of patients 
and controls and were not more prevalent in patients. In Chapter 6, donut 
mitochondria were observed in the transverse orientation, here using three-
dimensional reconstruction we observed that these actually appear more commonly 
in the longitudinal orientation. Thus three-dimensional EM techniques provides us 
with a clearer picture of both frequency, size and morphology of these toroid 
mitochondria. Quantitative measurements similar to those made by (Long et al., 
2015), need to be made to assess whether these measurements are in agreement. 
However, based on the available data for the frequency of donut mitochondria in 
controls and patients they are perhaps not a useful morphological abnormality for 
diagnostic purposes. 
 
7.5.6 Nanotunnels 
The first visualisation of a nanotunnel-like structure was in 2008 (Bowes and Gupta, 
2008) in African green monkey kidney cell, where transmission electron microscopy 
was used to demonstrate double membrane connections between mitochondria of 
roughly 50 nm in diameter. The term “nanotunnel” was introduced later by Huang et 
al. (2013). This study examined rat cardiomyocytes by live-cell confocal microscopy 
and found nanotunnel diameter to be 90-120 nm. In addition, measurements of 
nanotunnels in human skeletal muscle using TEM and reporting diameters of 62.3 ± 
10.7 nm are presented in Chapter 6 (Vincent et al., 2016b). Additionally, Bowes and 
Gupta (2008) found the length of the projections to be variable, Huang et al. (2013) 
report nanotunnels to span up to seven sarcomeres and findings presented in 
Chapter 6 (Vincent et al., 2016b) show lengths between 200 nm and 2.3 µm. Three-
dimensional analysis in this chapter finds nanotunnels more frequently than expected 
based on TEM analysis of the same patients in Chapter 6. 
Most interestingly, comparison of controls and patients demonstrates that nanotunnel 
are noticeably more frequent in patients than controls. This seems to implicate 
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nanotunnels as a stress response, which both increases the understanding of their 
relevance and raises further questions.  
Firstly, can nanotunnels transport mtDNA, thus allowing genetic complementation? 
Initial confocal live cell imaging demonstrated that nanotunnels can transport GFP 
localised to both the mitochondrial matrix and also the IMM. However, given that 
mammalian nucleoids are reported to have a uniform size of approximately 100 nm 
(Kukat et al., 2011), it is unlikely that nanotunnels could transport nucleoids. This 
suggests that the functional importance of nanotunnels is not complementation of 
mitochondria with nucleoid packaged mtDNA, but possibly proteins and RNA. 
In addition to this, are they only observed in skeletal and cardiac muscle where 
mitochondrial movement is restricted? It would make sense if nanotunnels were a 
morphological response to the fact that mitochondria are less motile in skeletal and 
cardiac muscle compared to other cells such as neurons where they are highly 
motile. If this were the case nanotunnels may function as an alternative 
communication method. In order to determine whether this is the case, studies similar 
to this one need to be performed in other tissues. In doing so it may be possible to 
find other morphological features with apparent tissue specificity. 
Based on previous findings nanotunnels are both highly dynamic and occur between 
distant mitochondria (Huang et al., 2013). As such the mechanism by which they 
form and whether there is a signalling involved to guide the projection of one 
mitochondrion to its target mitochondria should be investigated. Previous work has 
implicated a Kinesin family member 5B (Kif5b), a microtubule-dependent motor, 
dependent mechanism in their formation of nanotunnels between mitochondria that 
subsequently increase in diameter to form a fused network (Wang et al., 2015). A 
similar structure has also been reported in Alzheimer’s disease and is described as 
“mitochondria on a string”, these structures have been suggested to form from failed 
fission. This is supported by Lee et al. (2016) who find nanotunnel like structures 
form in a number of cell lines when treated with dynamin-2 siRNA. These two 
mechanisms seems to be distinct and produce similar structures. Which of these is 
being observed here or whether there are other mechanisms at work has yet to be 
determined. A number of projections from one mitochondrion not yet connected to a 
second mitochondrion were observed, this seemed to indicate that this is not the 
result of failed fission. 
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As to whether a signalling mechanism exists this seems very plausible but would 
require further investigation. Nanotunnels often form connections between two 
distant mitochondria passing other mitochondria in the process (Huang et al., 2013). 
As such, this could either be a random process and the nanotunnel fuses with the 
first mitochondrion it contacts or alternatively and perhaps more likely a signalling 
mechanism guides the nanotunnel projection to its intended target. This hypothesis is 
perhaps more appealing if we consider the that tube-like membranous 
communication mechanisms are known to occur in bacteria (Dubey and Ben-
Yehuda, 2011), as are chemoattractant cell to cell signalling mechanisms (Brown and 
Berg, 1974). Furthermore chemoattractant signalling has been found to drive filipodia 
formation and tunnelling nanotube communication between cells (Gerdes et al., 
2013). 
 
7.5.7 Mitochondrial anisotropy affects spread of mtDNA mutations and respiratory 
chain deficiency 
In skeletal muscle COX-deficiency is found to be segmental when examined 
longitudinally (Matsuoka et al., 1992; Elson et al., 2002; Bua et al., 2006) and to 
expand over time (Lopez et al., 2000). The restricted spread of respiratory chain 
deficiency throughout the full length of the myofibre is of functional and clinical 
relevance to mitochondrial myopathy, skeletal muscle ageing and neuromuscular 
diseases for which respiratory deficiency is seen to varying degrees. Results 
presented here found that the mitochondrial network in human skeletal muscle is 
anisotropic with greater branching across the transverse myofibre than longitudinally. 
As such, this may explain the segmental histological pattern of COX-deficiency since 
mtDNA mutations and respiratory deficiency are likely to spread quicker along the 
path of least resistance (the transverse orientation) than longitudinally where there 
are fewer mitochondrial connections.  When considered in the context of 
investigations into mechanisms of clonal expansion, (explored in detail in Chapter 5), 
this further suggests that the mechanism by which mtDNA mutations clonally expand 
may differ dependent of the tissue architecture and mitochondrial network 
morphology.  
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7.5.8 Limitations: 
This study has a number of limitations that must be considered. Primarily the control 
and patient biopsies are taken from different muscles which may impact on the fibre 
type distribution and lead to differences in mitochondrial morphology. Furthermore, 
all patients are female, whilst only three of the eight controls are female and 
oestrogen levels have been known to affect mitochondrial morphology (Hara et al., 
2014). In addition when muscle biopsies are taken there is always a delay between 
the removal of the muscle biopsy from the leg muscle and its subsequent fixation 
which may induce artefacts when mitochondrial morphology is examined. Time of 
biopsy is also found to be an important variable when assessing mitochondrial 
morphology in liver (Jacobi et al., 2015) and may also be important to consider in 
skeletal muscle. Finally activity levels of the controls and patients biopsied are likely 
to impact results since mitochondrial mass is known to increase with exercise 
(Holloszy, 1967). 
Finally, when trying to correlate mitochondrial morphology with heteroplasmy, these 
results are potentially confounded by the fact that we are using heteroplasmy based 
on muscle homogenate mtDNA rather than single cell. Unfortunately using the 
present technique, the correlation with single cell heteroplasmy is not possible and 
therefore limits how we interpret the data. 
 
7.5.9 Further work 
Due to the large data set acquired here, it would be interesting to apply analysis 
methods used on large data sets like those acquired from metabolomics. As such the 
intention is to use the online web tool MetaboAnalyst v3.0 (Xia et al., 2015), to 
generate a model and see if it is possible to identify key morphological discriminators 
to identify patients and controls. 
Primarily an experiment comparing fixation protocols typically used in for electron 
microscopy in rodents with methods used here should be completed. This should 
elucidate whether the differences observed between mice and human muscle is a 
species related difference or an artifact induced by fixation delay. 
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Studies in mice could also be performed to assess the effect of exercise and 
metabolic state on the mitochondrial morphology. In addition, super resolution or 
expansion microscopy could be used to assess the mitochondrial morphology in the 
context of respiratory chain function and fibre type.  
Another possibility is to try to correlate single cell heteroplasmy for known mtDNA 
mutations with mitochondrial morphology. This could be attempted using probes for 
mutant and wild type mtDNA in combination with expansion microscopy. This would 
hopefully allow us to assess the relative proportions of wild-type and mutant mtDNA 
as well as the morphology of the mitochondrial network with nanoscale resolution. 
 
7.5.10 Conclusion: 
This work developed methodology for three-dimensional quantification of 
mitochondrial branching and morphology. MCI was used in combination with volume, 
which provided the first quantitative assessment of mitochondrial morphology and 
network organisation in human skeletal muscle at EM resolution. Furthermore, it 
confirmed two dimensional findings that in muscle SS mitochondria are smaller and 
rounder than IMF mitochondria and reports that SS and IMF mitochondria interact 
(Picard et al., 2013; Dahl et al., 2015). 
The data demonstrated unexpected variation both within fibres of the same control 
and among the control population, which lead to questions of whether fibre type, 
levels of activity and metabolic state may be confounding variables. 
Interestingly, low levels of m.8344A>G tRNALys heteroplasmy presents with a 
hyperfused mitochondrial network, while high heteroplasmy results in fragmented 
mitochondria. This supports findings and suggestions by Picard et al. (2014) that 
mitochondria initially form a hyperfused and branched network at low levels of stress 
but fragment when stress exceeds a certain threshold. 
Nanotunnels appear to be more frequent in patients but also appear to have a weak 
trend with age, which may suggest that these are a mitochondrial stress response. 
However, the presence of donut mitochondria, which are known to be a 
morphological indicator of mitochondrial stress, do not differ between patients and 
controls. 
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Finally, the data demonstrates anisotropy of the mitochondrial network which may 
have significance when we consider how mtDNA mutations and respiratory chain 
deficiency spread throughout the myofibre. Also data gathered here finds that the 
mitochondrial network is more connected along the numbers z-bands of skeletal 
myofibres than between z-bands. This may impact the spread of mitochondrial DNA 
mutations and respiratory chain deficiency and explain segmental respiratory chain 
deficiency inn skeletal myofibres of ageing and disease.  
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Chapter 8. Discussion 
Skeletal muscle is one of the most energetically demanding tissues within the body, as such 
it is understandable that mitochondrial dysfunction in the skeletal muscle is linked to 
neuromuscular disease and ageing. Skeletal muscle respiratory chain deficiency arises in a 
mosaic pattern (Johnson et al., 1983; Sciacco et al., 1994), is segmental along the myofibre 
and is concomitant with mtDNA mutations (Wanagat et al., 2001; Bua et al., 2006; Herbst et 
al., 2007). However, the mechanisms by which the mtDNA mutations accumulate and the 
factors governing this accumulation and spread of respiratory chain deficiency are not fully 
understood. As such, the work presented here aimed to improve the understanding of the 
mechanisms and pathological significance of mitochondrial dysfunction in skeletal muscle. 
 
8.1 Major findings and future work 
8.1.1 Levels of respiratory chain deficiency are higher in patients with Dysferlin mutations 
than age matched controls 
Investigations into mitochondria in dysferlinopathy have previously reported COX-
deficiency, paracrystalline inclusions and reduced complex I, II and IV activities (Gayathri et 
al., 2011; Liu et al., 2016). The findings presented in Chapter 3 demonstrate a higher level 
of mitochondrial respiratory chain deficiency in muscle of patients with DYSF mutations than 
age matched controls. Although the underlying cause of the dysfunction is not fully 
elucidated, the potential relevance or role of Ca2+ homeostasis in disease pathogenesis, 
warrants further investigation. Fluorescence imaging of patient myoblasts to detect 
fluorescence intensity of Rhod2/AM (mitochondrial Ca2+ concentration) and Fluo3 
(cytoplasmic Ca2+ concentration), as previously described (Csordás and Hajnóczky, 2003). 
Furthermore, since increases in Ca2+ concentration are known to disrupt the mitochondrial 
network and induce mitochondrial swelling (Chappell and Crofts, 1965), an electron 
microscopy investigation of the mitochondrial ultrastructure and morphology would also be 
valuable. SBFSEM, three-dimensional reconstruction of mitochondrial networks and 
quantitative morphological measures developed in Chapter 7, may be interesting to apply 
to the dysferlin patients. However, this would need to be approached in a new cohort of 
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patients since neither EM prepped muscle blocks nor myoblasts are available for the 
patients included here. 
 
8.1.2 Mitochondrial mass is reduced in myofibrillar myopathy 
Previously, research characterising mitochondrial dysfunction in myofibrillar myopathy has 
demonstrated respiratory chain deficiency, presence of mtDNA deletions and a change in 
the positioning of IMF mitochondria to the periphery of the cell (Reimann et al., 2003; 
Schroder et al., 2003; Claeys et al., 2008; Dold et al., 2012; Henderson et al., 2013). 
However, no quantitative assessment of respiratory chain deficiency has been performed 
and so far no attempts have been made to link the mitochondrial changes observed, to the 
protein aggregates which accumulate as the hallmark of MFM. 
As such, the most interesting finding from work presented in Chapter 4 is that all 
mitochondrial proteins assayed (NDUFB8, MTCOI and VDAC1) are reduced in a large 
percentage of MFM skeletal myofibres. Attempts to correlate this with the presence of 
protein aggregates, however, showed no correlation. This suggests that the aggregation of 
proteins does not cause the reduction in mitochondrial mass, but does not provide answers 
as to the underlying cause of mitochondrial dysfunction. 
Since the reduction of mitochondrial mass must result from a shift in the balance of 
mitochondrial biogenesis and mitophagy, quantifying key markers for both pathways may 
help to elucidate the pathological mechanisms.  In addition, previous studies have indicated 
a shift in the ratio of IMF/SS mitochondria (Claeys et al., 2008; Winter et al., 2016).  
Therefore, application of the methodologies developed in Chapter 7 to patients with 
myofibrillar myopathy may be useful to understand the effect that aggregates containing 
desmin, have on mitochondrial positioning and morphology.  Unfortunately, samples 
processed for diagnostic EM were only available for a few patients and were mainly found 
to contain fatty tissue rather than muscle. Examining more biopsies in this manner and 
implementing the TEM, SBFSEM and reconstruction protocols, as described in this thesis, 
might provide further insight into the changes in mitochondrial volume density, positioning 
and morphology. 
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8.1.3 There is a much larger spectrum of ultrastructural changes in mitochondrial myopathy 
than previously reported 
Previously, EM had been used only on small cohorts or in case studies and is at present 
commonly used to provide supportive data, rather than to generate the foundation of the 
results for an investigation (see review in Appendix 5). As such, a comprehensive, study of 
mitochondrial ultrastructure in skeletal muscle biopsies, from patients with mitochondrial 
myopathy was missing. 
In doing this study, a wide range of ultrastructural changes were observed, some of which 
can already be linked to biological findings in model organisms (e.g. concentric cristae and 
MICOS (John et al., 2005; Rabl et al., 2009) and donut mitochondria (Long et al., 2015). In 
addition, a number of other changes have not yet been fully investigated but have led to 
novel hypotheses and new avenues for investigation. One example is the presence of 
linearised cristae membranes. It is hypothesised that a change in membrane composition 
leads to linearised and electron dense cristae. This hypothesis requires an examination of 
membrane composition and, in particular, the percentage of cardiolipin present in the IMM 
of mitochondria with linearised and normal cristae. This could be achieved using imaging 
mass spectrometry as previously reported (Amoscato et al., 2014). 
In addition, for paracrystalline inclusions the biological make up has already been identified, 
and in vitro conditions for their development determined (Eppenberger-Eberhardt et al., 
1991). However, understanding how and why they develop in myopathic conditions requires 
further investigation. 
 
8.1.4 Nanotunnels are more frequent in patient muscle biopsies than controls 
A recently described and, as yet, not well characterised structure, the nanotunnel, was 
identified for the first time in human skeletal muscle in Chapter 6 and Chapter 7. Previous 
investigations have provided information about the dimensions and lifetime of these 
structures in rodent models, and also about the movement of matrix and IMM located 
proteins (Bowes and Gupta, 2008; Huang et al., 2013). Measurement of nanotunnel 
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diameters, made for the first time in human skeletal muscle (Chapter 6), allow predictions of 
the function and capacity of nanotunnels as a communicative mechanism. However, further 
work is required to investigate the mechanisms by which these nanotunnels form and the 
physiological conditions that promotes them. In particular, findings in Chapter 7 
demonstrate that they are much more common in patients compared to controls. By 
understanding the conditions under which they form, a better understanding of their 
functional capacity can be gleaned.  
Nanotunnels are intriguing structures and their presence and potential relevance to 
mitochondrial pathology in skeletal muscle raises a number of questions that necessitate 
further investigation. First, are nanotunnels specific to skeletal muscle due to reduced 
mitochondrial motility? EM investigations in other tissues will be necessary to answer this. 
Second, is the membrane composition of nanotunnels similar to the two mitochondria it 
connects? This question might be investigated using imaging mass spectrometry 
(Amoscato et al., 2014). Third, what controls their formation and are there multiple ways by 
which similar structures form? Work so far has partly elucidated two possible mechanisms, 
of which a microtubule dependent formation fits best with observations in mitochondrial 
myopathy. However, characterisation of this process and the machinery involved will be 
important future steps. Fourth, is there a signal that promotes their formation, or an “SOS” 
signal that guides them to the target mitochondria? This final question is perhaps the most 
intriguing and yet most difficult to investigate, possibly requiring some inspiration from the 
microbiology world, where similar mechanisms of cell-to-cell communication are observed.  
 
8.1.5 Clonal expansion appears to start as a perinuclear niche 
Previous investigations into the mechanism of clonal expansion have focused on a number 
of key questions. First, some studies have aimed to understand whether the process by 
which mtDNA deletions accumulate is random (Elson et al., 2001), or if dysfunctional 
mitochondria are actively selected for (de Grey, 1997). Second, others have investigated 
the presence of a replicative advantage (Hayashi et al., 1991; Moraes et al., 1999; Diaz et 
al., 2002; Campbell et al., 2014; Gitschlag et al., 2016), allowing smaller genomes to 
accumulate faster. Finally, a number of studies have aimed to investigate compensatory 
  Chapter 8 
 
264 
 
mechanisms that may lead to the accumulation of mtDNA deletions (Kowald and Kirkwood, 
2014; Gitschlag et al., 2016; Lin et al., 2016).  
However, what these studies have not considered to date is whether the tissue-specific 
cytoarchitecture and the location of the initial deletion event is an important factor. Work 
presented here aimed to identify the first observable regions of respiratory chain deficiency 
and to consider the multinucleated myofibres, the lack of motility of mitochondria and the 
connectivity of the mitochondrial network as factors in the clonal expansion of mtDNA 
deletions in skeletal muscle. 
Results in Chapter 5 indicate that mtDNA deletions arise in the subsarcolemmal 
mitochondria causing an initial focus of respiratory chain deficiency. Investigation 
demonstrated close proximity of COX-deficient foci to myonuclei and found that both 
deletion level and mitochondrial mass appear to be increased in the perinuclear niche 
compared to the remainder of the fibre. This is suggestive of mito-nuclear signalling, 
facilitated by the close proximity to the nucleus, promoting mitochondrial biogenesis. 
However, evidence for the upregulation of mitochondrial biogenesis markers and an exact 
signalling pathway has not been elucidated. There are a number of possible signalling 
pathways that may be implicated and should be investigated.  
As such proposed further work would include examining levels of mitochondrial biogenesis 
and mitophagy markers as well as intermediates in the AKT and JNK pathways which have 
been shown to be implicated in the mammalian UPRmt (Pellegrino et al., 2013). As proposed 
by the perinuclear niche hypothesis, the suspicion is that upregulation of mitochondrial 
biogenesis will be the main driving force behind the propagation of mtDNA deletions, 
however it will be interesting to investigate whether this occurs through the UPRmt and the 
AKT pathway which upregulates Nrf1 transcription (Pellegrino et al., 2013). In addition, this 
mechanism is currently only investigated for mtDNA deletions and may also be applicable to 
mtDNA point mutations. Therefore, once the signalling pathways and mechanisms have 
been elucidated, examining these in a cohort of patients with mtDNA point mutations will be 
an important next step. 
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8.1.6 Mitochondrial network morphology is highly variable 
Quantification of mitochondrial morphology has previously been underestimated by the use 
of two dimensional EM techniques and so far newer, three-dimensional EM, volume 
imaging techniques have only been quantitatively applied to skeletal muscle mitochondria in 
mice (Glancy et al., 2015). This thesis includes the first quantitative assessment of three-
dimensional mitochondrial morphology in human skeletal muscle and highlights striking 
variability within fibres, between fibres and between individuals in the control population.  In 
addition, when compared to previous work in mice (Glancy et al., 2015), it highlights a large 
difference in both mitochondrial network connectivity and mitochondrial volume density that 
should be considered when implementing mouse models for studies into human disease. 
A cohort of mitochondrial myopathy patients were also investigated and compared to 
controls, with results from three related patients with the same mutation suggesting 
fragmentation of the mitochondrial network at higher levels of heteroplasmy followed by 
swelling of mitochondria with further increases in heteroplasmy. This is intriguing and fits 
with previous observations of mitochondrial dynamics in cybrids with variations in 
heteroplasmy (Picard et al., 2014). 
Further work, to understand whether an initial increase in fusion occurs at lower levels of 
heteroplasmy prior to fragmentation of the mitochondrial network should be completed. In 
addition, increasing the number of patients with each mutation and comparing between the 
mtDNA genetic defects may allow us to elucidate whether there is a heteroplasmy threshold 
for these changes in morphology and whether this differs between patients. Limitations in 
the present experimental design however, necessitate consideration of other techniques 
such as expansion microscopy, which allow functional assessment of the respiratory chain 
alongside mitochondrial morphology and may also allow us to probe for known mtDNA 
mutations. In addition to this, analysis as performed on metabolomics datasets may yield 
further insight into changes in mitochondrial morphology in healthy and diseased muscle. 
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8.1.7 The skeletal muscle mitochondrial network is anisotropic 
Only one previous study visualises the mitochondrial network in human skeletal muscle at 
nanoscale resolution (Dahl et al., 2015). In this study the analysis is restricted to 
characterising the interaction of SS and IMF mitochondria, and as such, no characterisation 
of mitochondrial branching orientation has been completed.  
Therefore, the finding that the mitochondrial network is substantially more branched in the 
transverse plane than the longitudinal is both novel as well as interesting, even more so 
when we consider the potential pathological significance of this. Segmental respiratory 
chain deficiency has been a hallmark of mitochondrial myopathy and ageing alike, yet an 
explanation for why this deficiency does not propagate rapidly along the length of the fibre 
has been lacking. 
However, this finding could be the missing link to explain this. In theory, in order for mtDNA 
mutations and dysfunctional respiratory chain proteins to spread there must be at least a 
transient connection of the mitochondria network. Therefore, the large degree of 
connectivity in the transverse plane may allow a relatively quick spread of mtDNA mutations 
and respiratory chain deficiency across the myofibre. In comparison, the smaller number of 
connections along the fibre may hinder spread in this direction, thus giving rise to segmental 
deficiency in the longitudinal orientation. 
Contrary to this, imaging from mice with photoactivatable mitochondria demonstrates that 
fusion events are more frequent in the longitudinal orientation within the myofibre (Eisner et 
al., 2014). This may, however, be an artefact of the imaging process or due to differences 
between the two species, possibly due to fibre type variations and differences in 
mitochondrial volume density. In order to assess this, similar live imaging would need to be 
completed for human skeletal muscle fibres. Since this is not possible, the closest 
representation may be the generation of a skeletal muscle organoid from human myoblasts 
(Shansky et al., 1997). This would allow live cell study of human samples whilst replicating 
the cytoskeletal structure of developed myofibres, which it has been demonstrated in this 
thesis is an important factor to consider when designing experiments. 
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8.2 Final conclusion 
This work provides a number of novel insights into mitochondrial involvement in 
neuromuscular disease pathology. Key findings include: the reduction of mitochondrial 
mass in myofibrillar myopathy, increased respiratory chain deficiency in some patients with 
dysferlinopathy, the spectrum of mitochondrial ultrastructural defects in mitochondrial 
myopathy, the anisotropic nature of the skeletal muscle mitochondria, the perinuclear 
origins of mtDNA deletions and their clonal expansion due to retrograde signalling and 
mitochondrial biogenesis. In addition to these findings, I believe that this work highlights the 
importance of considering tissue-specific and species-specific differences when 
investigating the mechanisms governing mitochondrial pathogenesis. On top of these 
differences, the changes that occur during myogenesis, both to cell structure and the 
mitochondria, also pose a number of challenges to the investigation of skeletal muscle 
mitochondrial pathology. Despite this, many questions are left to be answered and although 
each proposed experiment will have its limitations, in combination these will hopefully 
advance the understanding of the molecular mechanisms governing disease pathology and 
provide insight to develop informed and targeted treatments. 
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Chapter 9. Appendices 
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Appendix 1 Newcastle Adult Mitochondrial Disease scale (NMDAS) 
questionnaire. As used to assess mitochondrial disease severity and progression 
in the Newcastle Mitochondrial disease cohort.  
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THE NEWCASTLE 
 
MITOCHONDRIAL DISEASE ADULT SCALE  
 
(NMDAS) 
 
 
Name:                        ________________   
 
Date of birth:            ________________ 
 
 
 
Age at assessment:   ________________ 
 
Date of assessment:     ________________ 
 
 
 
Checklist – please tick off when completed. 
 
 
 Height:  ____________ 
 
 FVC  -  1st attempt ____________   
 
 FVC  - 2nd  attempt ____________   
 
 FVC  - 3rd  attempt ____________ % Predicted ___________ 
 
 
 
                 Raw Score      Scaled Score  Centile 
 
 SF-12v2 self completion questionnaire ________ ________ ________ 
 
 WTAR reading test (1 minute)  ________ ________ ________ 
 
 Symbol Search (2 minutes)    ________ ________ ________ 
 
 Speed of comprehension test (2 minutes)   ________ ________ ________ 
 
                 Disease score (sections I-III)_______ 
       SF-12v2 Quality of Life score (section IV)_______
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Section I- Current Function 
Rate function over the preceding 4 week period, according to patient and/or caregiver interview only. The 
clinician’s subjective judgement of functional ability should not be taken into account.  
 
 
1. Vision with usual glasses or contact lenses 
 
0. Normal. 
1. No functional impairment but aware of worsened acuities. 
2. Mild - difficulty with small print or text on television.  
3. Moderate - difficulty outside the home (eg bus numbers, road signs or shopping). 
4. Severe - difficulty recognising faces. 
5. Unable to navigate without help (eg carer, dog, cane).  
 
2. Hearing with or without hearing aid  
 
0. Normal. 
1. No communication problems but aware of tinnitus or deterioration from prior ‘normal’ hearing. 
2. Mild deafness (eg missing words in presence of background noise). Fully corrected with hearing aid. 
3. Moderate deafness (eg regularly requiring repetition). Not fully corrected with hearing aid.   
4. Severe deafness - poor hearing even with aid (see 3 above). 
5. End stage - virtually no hearing despite aid. Relies heavily on non-verbal communication (eg lip 
reading) or has cochlear implant. 
 
 
3. Speech  
 
0. Normal. 
1. Communication unaffected but patient or others aware of changes in speech patterns or quality. 
2. Mild difficulties - usually understood and rarely asked to repeat things. 
3. Moderate difficulties - poorly understood by strangers and frequently asked to repeat things. 
4. Severe difficulties - poorly understood by family or friends. 
5. Not understood by family or friends. Requires communication aid. 
 
    
4. Swallowing  
 
0. Normal. 
1. Mild - sensation of solids ‘sticking’ (occasional). 
2. Sensation of solids ‘sticking’ (most meals) or need to modify diet (eg avoidance of steak/salad). 
3. Difficulty swallowing solids - affecting meal size or duration. Coughing, choking or nasal 
regurgitation infrequent (1 to 4 times per month) but more than peers. 
4. Requires adapted diet - regular coughing, choking, or nasal regurgitation (more than once per week). 
5. Requiring enteral feeding (eg PEG). 
 
 
5. Handwriting 
 
0. Normal. 
1. Writing speed unaffected but aware of increasing untidiness. 
2. Mild – Has to write slower to maintain tidiness/legibility. 
3. Moderate – Handwriting takes at least twice as long or resorts to printing (must previously have used 
joined writing). 
4. Severe – Handwriting mostly illegible. Printing very slow and untidy (eg ‘THE BLACK CAT’ takes in 
excess of 30 seconds). 
5. Unable to write. No legible words. 
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6. Cutting food and handling utensils (irrespective of contributory factors – eg weakness, coordination, 
cognitive function etc. This is also true for questions 7-10) 
  
0. Normal. 
1. Slightly slow and/or clumsy but minimal effect on meal duration. 
2. Slow and/or clumsy with extended meal duration, but no help required.      
3. Difficulty cutting up food and inaccuracy of transfer pronounced. Can manage alone but avoids 
problem foods (eg peas) or carer typically offers minor assistance (eg cutting up steak). 
4. Unable to cut up food. Can pass food to mouth with great effort or inaccuracy. Resultant intake 
minimal. Requires major assistance. 
5. Needs to be fed. 
 
 
7. Dressing  
     
0. Normal. 
1. Occasional difficulties (eg shoe laces, buttons etc) but no real impact on time or effort taken to dress. 
2. Mild – Dressing takes longer and requires more effort than expected at the patient’s age. No help 
required. 
3. Moderate - Can dress unaided but takes at least twice as long and is a major effort. Carer typically 
helps with difficult tasks such as shoe laces or buttons. 
4. Severe – Unable to dress without help but some tasks completed unaided. 
5. Needs to be dressed. 
 
 
8. Hygiene  
     
0. Normal. 
1. Occasional difficulties only but no real impact on time or effort required. 
2. Mild – hygienic care takes longer but quality unaffected. 
3. Moderate - bathes and showers alone with difficulty or needs bath chair / modifications. Dextrous 
tasks (eg brushing teeth, combing hair) performed poorly. 
4. Severe - unable to bathe or shower without help. Major difficulty using toilet alone. Dextrous tasks 
require help. 
5. Dependent upon carers to wash, bathe, and toilet. 
 
 
9. Exercise Tolerance  
       
0. Normal. 
1. Unlimited on flat - symptomatic on inclines or stairs. 
2. Able to walk < 1000m on the flat. Restricted on inclines or stairs - rest needed after 1 flight (12 steps). 
3. Able to walk < 500m on the flat. Rest needed after 8 steps on stairs. 
4. Able to walk < 100m on the flat. Rest needed after 4 steps on stairs. 
5. Able to walk < 25m on the flat. Unable to do stairs alone.    
 
 
10. Gait stability  
 
0. Normal. 
1. Normal gait - occasional difficulties on turns, uneven ground, or if required to balance on narrow base. 
2. Gait reasonably steady. Aware of impaired balance. Occasionally off balance when walking. 
3. Unsteady gait. Always off balance when walking. Occasional falls. Gait steady with support of stick 
or person.         
4. Gait grossly unsteady without support. High likelihood of falls. Can only walk short distances (< 10m) 
without support.  
5. Unable to walk without support. Falls on standing.  
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Section II – System Specific Involvement 
Rate function according to patient and/or caregiver interview and consultation with the medical notes. Each 
inquiry should take into account the situation for the preceding 12 month period only, unless otherwise stated 
in the question.  
 
 
1. Psychiatric  
 
0. None. 
1. Mild & transient (eg reactive depression) - lasting less than 3 months. 
2. Mild & persistent (lasting more than 3 months) or recurrent. Patient has consulted GP.  
3. Moderate & warranting specialist treatment (e.g. from a psychiatrist) - eg. bipolar disorder or 
depression with vegetative symptoms (insomnia, anorexia, abulia etc).  
4. Severe (eg self harm - psychosis etc). 
5. Institutionalised or suicide attempt. 
 
 
2. Migraine Headaches During the last 3 months, how many days have headaches prevented the patient from 
functioning normally at school, work, or in the home? 
 
0. No past history. 
1. Asymptomatic but past history of migraines. 
2. One day per month. 
3. Two days per month. 
4. Three days per month. 
5. Four days per month or more. 
 
 
3. Seizures 
 
0. No past history. 
1. Asymptomatic but past history of epilepsy. 
2. Myoclonic or simple partial seizures only. 
3. Multiple absence, complex partial, or myoclonic seizures affecting function or single generalised 
seizure. 
4. Multiple generalised seizures. 
5. Status epilepticus. 
 
 
4. Stroke-like episodes (exclude focal deficits felt to be of vascular aetiology)  
 
0. None. 
1. Transient focal sensory symptoms only (less than 24 hours). 
2. Transient focal motor symptoms only (less than 24 hours). 
3. Single stroke-like episode affecting one hemisphere (more than 24 hours). 
4. Single stroke-like episode affecting both hemispheres (more than 24 hours).  
5. Multiple stroke-like episodes (more than 24 hours each). 
 
 
5. Encephalopathic Episodes 
 
0. No past history. 
1. Asymptomatic but past history of encephalopathy. 
2. Mild - single episode of personality or behavioural change but retaining orientation in 
time/place/person. 
3. Moderate - single episode of confusion or disorientation in time, place or person. 
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4. Severe – multiple moderate episodes (as above) or emergency hospital admission due to 
encephalopathy without associated seizures or stroke-like episodes.  
5. Very severe - in association with seizures, strokes or gross lactic acidaemia.  
 
 
6. Gastro-intestinal symptoms  
 
0. None. 
1. Mild constipation only or past history of bowel resection for dysmotility. 
2. Occasional symptoms of ‘irritable bowel’ (pain, bloating or diarrhoea) with long spells of normality. 
3. Frequent symptoms (as above) most weeks or severe constipation with bowels open less than 
once/week or need for daily medications. 
4. Dysmotility requiring admission or persistent and/or recurrent anorexia/vomiting/weight loss. 
5. Surgical procedures or resections for gastrointestinal dysmotility. 
 
 
7. Diabetes mellitus 
 
0. None. 
1. Past history of gestational diabetes or transient glucose intolerance related to intercurrent illness. 
2. Impaired glucose tolerance (in absence of intercurrent illness). 
3. NIDDM (diet).  
4. NIDDM (tablets). 
5. DM requiring insulin (irrespective of treatment at onset). 
 
        
8. Respiratory muscle weakness 
 
0. FVC normal (≥ 85% predicted). 
1. FVC < 85% predicted. 
2. FVC < 75% predicted. 
3. FVC < 65% predicted. 
4. FVC < 55% predicted. 
5. FVC < 45% predicted or ventilatory support for over 6 hours per 24 hr period (not for OSA alone). 
 
  
9. Cardiovascular system 
 
0. None. 
1. Asymptomatic ECG change. 
2. Asymptomatic LVH on echo or non-sustained brady/tachyarrhythmia on ECG. 
3. Sustained or symptomatic arrhythmia, LVH or cardiomyopathy. Dilated chambers or reduced 
function on echo. Mobitz II AV block or greater. 
4. Requires pacemaker, defibrillator, arrhythmia ablation, or LVEF < 35% on echocardiogram.                                                        
5. Symptoms of left ventricular failure with clinical and/or x-ray evidence of pulmonary oedema or 
LVEF < 30% on echocardiogram. 
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Section III – Current Clinical Assessment 
Rate current status according to examination performed at the time of assessment 
 
 
1. Visual acuity with usual glasses, contact lenses or pinhole. 
 
0. CSD ≤ 12   (ie normal vision - 6/6, 6/6 or better). 
1. CSD ≤ 18  (eg 6/9, 6/9). 
2. CSD ≤ 36   (eg 6/12, 6/24). 
3. CSD ≤ 60  (eg 6/24, 6/36). 
4. CSD ≤ 96  (eg 6/60, 6/36). 
5. CSD ≥ 120   (eg 6/60, 6/60 or worse).  
         
 
2. Ptosis  
 
0. None. 
1. Mild ptosis - not obscuring either pupil. 
2. Unilateral ptosis obscuring < 1/3 of pupil. 
3. Bilateral ptosis obscuring < 1/3 or unilateral ptosis obscuring > 1/3 of pupil or prior unilateral surgery. 
4. Bilateral ptosis obscuring > 1/3 of pupils or prior bilateral surgery.  
5. Bilateral ptosis obscuring >2/3 of pupils or >1/3 of pupils despite prior bilateral surgery. 
 
 
3. Chronic Progressive External Ophthalmoplegia  
 
0. None. 
1. Some restriction of eye movement (any direction). Abduction complete. 
2. Abduction of worst eye incomplete.  
3. Abduction of worst eye below 60% of normal.  
4. Abduction of worst eye below 30% of normal.   
5. Abduction of worst eye minimal (flicker).  
 
 
4. Dysphonia/Dysarthria  
 
0. None. 
1. Minimal - noted on examination only. 
2. Mild – clear impairment but easily understood.  
3. Moderate – some words poorly understood and infrequent repetition needed. 
4. Severe – many words poorly understood and frequent repetition needed. 
5. Not understood. Requires communication aid. 
 
 
5. Myopathy 
    
0. Normal. 
1. Minimal reduction in hip flexion and/or shoulder abduction only (eg MRC 4+/5). 
2. Mild but clear proximal weakness in hip flexion and shoulder abduction (MRC 4/5). Minimal 
weakness in elbow flexion and knee extension (MRC 4+/5 - both examined with joint at 90 degrees). 
3. Moderate proximal weakness including elbow flexion & knee extension (MRC 4/5 or 4 -/5) or 
difficulty rising from a 90 degree squat. 
4. Waddling gait. Unable to rise from a 90 degree squat (=a chair) unaided.  
5. Wheelchair dependent primarily due to proximal weakness.  
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6. Cerebellar ataxia   
 
0. None. 
1. Normal gait but hesitant heel-toe. 
2. Gait reasonably steady. Unable to maintain heel-toe walking or mild UL dysmetria. 
3. Ataxic gait (but walks unaided) or UL intention tremor & past-pointing. Unable to walk heel-toe - falls 
immediately.  
4. Severe - gait grossly unsteady without support or UL ataxia sufficient to affect feeding. 
5. Wheelchair dependent primarily due to ataxia or UL ataxia prevents feeding. 
 
 
7. Neuropathy  
 
0. None. 
1. Subtle sensory symptoms or areflexia. 
2. Sensory impairment only (eg glove & stocking sensory loss). 
3. Motor impairment (distal weakness) or sensory ataxia. 
4. Sensory ataxia or motor effects severely limit ambulation. 
5. Wheelchair bound primarily due to sensory ataxia or neurogenic weakness. 
 
 
8. Pyramidal Involvement  
 
0. None. 
1. Focal or generalised increase in tone or reflexes only. 
2. Mild focal weakness, sensory loss or fine motor impairment (eg cortical hand). 
3. Moderate hemiplegia allowing unaided ambulation or dense UL monoplegia. 
4. Severe hemiplegia allowing ambulation with aids or moderate tetraplegia (ambulant). 
5. Wheelchair dependant primarily due to hemiplegia or tetraplegia. 
 
 
9. Extrapyramidal  
 
0. Normal. 
1. Mild and unilateral. Not disabling (H&Y stage 1). 
2. Mild and bilateral. Minimal disability. Gait affected (H&Y stage 2).  
3. Moderate. Significant slowing of body movements (H&Y stage 3) 
4. Severe. Rigidity and bradykinesia. Unable to live alone. Can walk to limited extent (H&Y stage 4). 
5. Cannot walk or stand unaided. Requires constant nursing care (H&Y stage 5). 
     
 
10. Cognitition  
 
Patients undergo testing using WTAR, Symbol Search and Speed of Comprehension Test. 
 
0. Combined centiles 100 or more. 
1. Combined centiles 60 - 99 
2. Combined centiles 30 - 59 
3. Combined centiles 15 - 29 
4. Combined centiles 5 - 14 
5. Combined centiles 4 or below. 
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WORD CARD 
      
      1.    again       26.  conscientious 
     2.    address       27.  homily 
      3.    cough       28.  malady 
      4.    preview       29.  subtle 
     5.    although      30.  Fecund 
      6.    most       31.  Palatable 
     7.    excitement      32.  Menagerie 
    8.    know       33.  obfuscate 
 9.    plumb       34.   liaison 
 10.  decorate      35.  exigency 
 11.  fierce       36.  xenophobia 
 12.  knead       37.  ogre  
 13.  aisle       38.  scurrilous   
 14.  vengeance      39.  ethereal  
 15.  prestigious      40.  paradigm  
 16.  wreathe       41.  perspicuity 
 17.  gnat       42.  plethora  
 18.  amphitheatre      43.  lugubrious   
 19.  lieu       44.  treatise 
 20.  grotesque      45.  dilettante 
 21.  iridescent      46.  vertiginous 
 22.  ballet       47.  ubiquitous 
 23.  equestrian      48.  hyperbole 
 24.  porpoise      49.  insouciant 
 25.  aesthetic      50.  hegemony 
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                                           WTAR Word List – UK pronunciation guide 
Say, I will show you some words that I will ask you to pronounce.  Place the WTAR Word Card in front of the examinee.  As you point to the card, say, Beginning with the first word on the list, 
pronounce each word aloud.  Start with this word (point to item 1), and go down this column, one after the other, without skipping any.  When you finish this column, go to the next column 
(point to the second column).  Pronounce each word even if you are unsure.  Do you understand?  When you are sure that the examinee understands the task, say, Ready? Begin. 
  Item Pronunciation  Score (0,1)   Item  Pronunciation  Score (0,1) 
1 again  ah-GEHN ah-Gain or uh-GEHN or uh-GAIN   26 Conscientious con-shee-EN-shss   
2 address ah-DRESS or uh-DRESS   27 homily HOM-ih-lay or HOM-ih-lee   
3 cough kawf or kof   28 malady MAL-uh-day or MAL-uh-dee   
4 preview PREE-vyue   29 subtle SUH-tl   
5 although awl-THO   30 fecund FE-cund or FEE-cund   
6 most Mohst   31 palatable PAL-ah-tuh-bul or PAL-uh-tuh-bul    
7 excitement eck-SITE-munt or ik-SITE-munt   32 menagerie meh-NA-juh-ree   
8 know noh or no   33 obfuscate OB-fuh-skate   
9 plump Plum   34 liaison lee-AY-zon or lee-AY-zn   
10 decorate DEK-oh-rate or DEK-uh-rate   35 exigency eks-IH-jen-say or eks-IH-jen-see   
11 fierce fee-us or feerss   36 xenophobia zen-oh-FO-bee-uh   
12 knead need   37 ogre OH-gur   
13 aisle iyle   38 scurrilous SKUR-ih-lus or SKUR-uh-lus   
14 vengeance VEN-jnss   39 ethereal ih-THEE-ree-ul or ih-THEER-ee-ul   
15 prestigious pre-STIJ-us or pre-STEEJ-us   40 paradigm PAH-rah-dime   
16 wreathe reeTH   41 perspicuity per-spuh-KYEW-uh-tee   
17 gnat nat   42 plethora PLETH-oh-rah or PLETH-eh-rah   
18 amphitheatre AM-fih-thee-uh-ter   43 Lugubrious loo-GOOB-ree-uss or loo-GOO-bree-uss   
19 lieu loo or l(y)oo   44 treatise TREE-tiz or TREET-iz   
20 grotesque gro-TESK   45 dilettante DILL-ih-tan-tay or DILL-uh-tahnt   
21 iridescent ihr-ih-DESS-unt or ihr-uh-DESS-unt   46 vertiginous ver-TIDJ-in-iss   
22 ballet BA-lay or ba-LAY or bal-ay   47 ubiquitous you-BIC-wuh-tiss or you-BIC-wuh-tus   
23 equestrian eh-KWESS-tree-un or ih-KWESS-tree-un   48 hyperbole hy-PER-bul-lay or hy-PUR-bul-lay   
24 propoise PAW-pss or POR-opyz (scots)   49 insouciant in-SOO-see-yunt   
25 aesthetic ess-THET-ik or ees-THET-ik   50 hegemony heh-GEM-o-nee or heh-JEM-o-nee or HEH-geh-mon-ee   
      WTAR Raw Score    
      WTAR Standard Score    
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Response Booklet            2 minutes to complete 
 
Symbol Search  Ricerca di Simboli Symbol Sek  Hledání symbolů 
Symbòles  Símbolos  Symboler  Hl’andanie symbolov 
Symboltest  Pesquisa de simbolos Merkintinnistus 
Symbolletnign  Figuren Vergelijken 
 
 
 
Sample Items 
       ∟ <  ~  
 
   ∩     ~        
 
~  ∟  ∩   
Yes No 
Yes No 
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                       The Speed of Comprehension Test    VersionA   
 
             
                        Many of the things we do rely on ‘common sense’,  
                           a knowledge of the world and an ability to make use 
                           of such knowledge.  This test looks at the speed and  
                           accuracy with which people can use such informa- 
                           tion.  It consists of a series of sentences, about half 
                           of which are true and half false.  The true sentences  
                           are all obviously true, e.g. ;dogs have four legs’, or 
                           ‘birds have wings’.  The false sentences are made up 
                            by combining two true sentences.  ‘dogs have wings’, 
                            or ‘birds have four legs’.  While the true sentences 
                            may not be all quite as obvious at this, there are no  
                            trick questions.  If you do find a question that you  
                            really cannot answer, mark it with a ‘?’. 
 
                            Work as quickly as you can without making errors, 
                            and put a tick against sentences which are true and  
                            a cross against those which are false.  Are there any 
                            questions? 
 
                            Then try the following at your own speed, but do not 
                             turn over until you are given the signal to begin the  
                             main test. 
 
                             Practice 
                              
                              P1   Rats have teeth 
                              P2   Nuns are made in factories 
                              P3   Ants are living creatures 
                              P4   Tractors grow in gardens  
                              P5    Pythons move around searching for food 
                              P6    Desks wear clothes 
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1 Admirals are people  
2 Footstools are small  
3 Beef steaks can be bought in shops 
4 Dragonflies have wings  
5 Grapes are people 
6 Grass snakes move around searching for food  
7 Prime Ministers have feathers 
8 Bishops wear clothes 
9 Bedroom slippers are made in factories 
10 Beavers have strong teeth  
11 Forks are manufactured goods 
12 Architects can be bought in shops 
13 Prime Ministers hold a political office 
14 Vans grow in gardens  
15 Pliers are found in tool chests 
16 Tomato soup is a liquid  
17 Admirals have fins 
18 Wives often have husbands 
19 Beef steaks are footwear 
20 Grapes come from plants  
21 Wives are made in factories 
22 Beer lives in trees 
23 Penguins are living creatures 
24 Dragonflies are manufactured goods 
25 Haddocks are fish 
26 Beer is an alcoholic drink 
27 Bishops are islands 
28 Architects undergo a long training  
29 Tomato soup moves around searching for food 
30 Vans are vehicles 
31 Haddocks have wheels 
32 Footstools wear clothes 
33 Pencils undergo a long training 
34 Fish and chips move around searching for food 
35 Climbing boots are made in factories 
36 Gin is sold by butchers 
37 Potatoes can be eaten  
38 Can – openers are said to have loud voices 
39 Fish and chips are fried 
40 Mothers are parents 
41 Crows are in charge of ships 
42 U.S Presidents have feathers  
43 Grass snakes come from pigs  
44 Corporals are people  
45 U.S Presidents hold a political office 
46 Popes wear clothes 
47 Drills are found in tool chests 
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48 Trucks grow in gardens  
49 Popes are footwear 
50 Corporals come from calves 
51 Pliers are made in factories 
52 Forks have feet 
53 Carrots come from cattle 
54 Wives can be bough in shops 
55 Roses grow in gardens 
56 Beavers are manufactured goods 
57 Radishes can be bough in shops 
58 Wool comes from sheep  
59 Books are vegetables 
60 Tomato soup is people 
61 Haddocks are a liquid 
62 Biscuits can be eaten 
63 Snails are make from apples 
64 Radishes are furniture 
65 Books can be bought in shop 
66 Grass snakes have shops 
67 Penguins are birds  
68 Vans wear clothes 
69 Pliers have a profession  
70 Wool have handles  
71 Grass snakes are living creatures  
72 Spoons are used for eating soup  
73 Mothers are part if the family  
74 Crows are a liquid 
75 Pineapples are used for storage  
76 Drills have a profession  
77 Sharks are good swimmers 
78 Trucks wear clothes 
79 Biscuits come in long strands  
80 Hammers are found in tool chests 
81 Oranges are furniture 
82 Pencils are made in factories  
83 Squirrels are manufactures goods 
84 Carrots ca be eaten  
85 Cobras serve on city councils 
86 U.S Presidents are made in factories  
87 Can-openers have feet 
88 Bees move around searching for food 
89 Potatoes are cooked 
90 Gin is alcoholic 
91 Gin moves around searching for food 
92 Can-openers are kitchen utensils 
93 Popes are people 
94 Roses deliver sermons 
95 Beef steaks crawl on their bellies 
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96 Oranges can be eaten  
97 Climbing boots live in monasteries 
98 Ladles are kitchen utensils  
99 Pineapples are fruit 
100Trucks carry loads 
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                          Your Health and Well-Being 
 
_________________________________________ 
 
 
This Survey asks for you views about your health.  This information will help keep track of 
how you feel and how well you are able to do you usual activities.  Thank you for completing this 
survey. 
 
For each of the following questions, please tick the one box that best describes your answer. 
 
 
 
1.    In general, would you say your health is: 
               
            _____________________________________________________ 
               Excellent        Very good         Good           Fair            Poor   
                 ▼              ▼             ▼          ▼          ▼ 
                  □             □            □          □          □ 
 
 
 
2.  The Following questions are about activities you might do during a typical day.  Does your 
health now limit you in these activates? If so, how much? 
 
 
                                                                                              Yes,         Yes,        No, not 
                                                                                           limited      limited     limited 
                                                                                             a lot         a little       at all 
                                                                                               ▼          ▼          ▼ 
A      Moderate activities, such as moving a table, pushing  
        A vacuum cleaner, bowling or playing golf………………□..........□……...□ 
 
B       Climbing several flights of stairs………………………… □…...  □……...□ 
 
 
 
 
 
3.  During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of your physical health. 
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                                           All of        Most of       Some of       A little of       None of 
                                         the time      the time      the time       the time         the time 
                                             ▼            ▼            ▼             ▼             ▼ 
 
A   Accomplished less than 
    you would like………… □………□………□………..□………□ 
 
b  Were limited in the kind 
    of work or other activities..□………□………□………..□………□ 
 
 
4. During the part 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of any emotional problems (such as 
feeling depressed or anxious)? 
 
                                                                     
                                          All of        Most of       Some of       A little of       None of 
                                         the time      the time      the time       the time         the time 
                                             ▼            ▼            ▼             ▼             ▼ 
 
A  Accomplished less than 
    you would like………… □………□………□………..□………□ 
 
b  Did work or other  
activities less carefully 
than usual …………………□………□………□………..□………□ 
 
 
 
5.  During the past 4 weeks, how much did pain interfere with your normal work (including 
both work outside the home and housework)? 
 
    ______________________________________________________________ 
  
            Not at all       A little bit       Moderately       Quite a bit       Extremely  
                   ▼             ▼              ▼               ▼              ▼ 
              □         □          □           □          □ 
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6.  These questions are about how you feel and how things have been with you during the past 4 
weeks.  For each question, please give the one answer that comes closest to the way you have 
been feeling.  How much of the time during the past 4 weeks… 
 
                                                                                                                                                                  
                                         All of        Most of       Some of       A    little of       None of                                                                                                                                             
                                        the time      the time      the time       the time         the time 
                                             ▼            ▼            ▼             ▼             ▼ 
 
A  Have you felt calm & 
    Peaceful?.............................□………□………□………..□………□ 
 
B   Did you have a lot of 
     Energy?..............................□………□………□………..□………□   
 
C    Have you felt  
     Downhearted & low……..□………□………□………..□………□ 
 
 
 
7.  During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friend’s relatives, etc.)? 
 
______________________________________________________________ 
  
            Not at all       A little bit       Moderately       Quite a bit       Extremely  
                   ▼             ▼              ▼               ▼              ▼ 
              □         □          □           □          □ 
 
 
 
    Thank you for completing these questions!
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Appendix 2   “Dysferlin  mutations and Mitochondrial Dysfunction”. Vincent et al. (2016).  
Manuscript published in Neuromuscular disorders. 
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Appendix 3   “Mitochondrial dysfunction in myofibrillar myopathy”. Vincent et al. (2016).  
Manuscript published in Neuromuscular disorders. 
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Appendix 4   “The  spectrum of Mitochondrial Ultrastructral Defects in Mitochondrial 
Myopathy”. Vincent et al. (2016).  Manuscript published in Neuromuscular disorders. 
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Appendix 5: Results from a systematic review of literature of electron microscopy studies 
(n = 135) in skeletal muscle of patients with confirmed mitochondrial myopathy. 
*Age at biopsy for EM study 
AV: Atrioventricular 
CPEO: Chronic progressive external opthalmoplegia 
IMF: Intermyofibrillar 
KSS: Kearns-sayer syndrome 
MELAS: Mitochondrial encephalomyopathy, lactic acidosis and stoke-like episodes 
mtDNA: Mitochondrial DNA 
MERRF: Myoclonic epilepsy and ragged red fibres 
N.S.: Not specified 
PCI: Paracrystalline inclusion 
PEO: progressive external opthalmoplegia 
RRF: Ragged-red fibers 
SS: Subsarcolemmal 
1: common large-scale deletion, 4977bp in length between two 13-bp direct repeats at 
positions m.13447-13459 and m.8470-8482. 
Genetic diagnostic methodology: aRestriction site mutation assay; bSouthern blot, cPCR, 
dSanger sequencing, eRFLP, fSolid phase mini sequencing, gSequencing, hNext 
generation sequencing, iNot specified.
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Author 
(Year) 
Muscle Age* Clinical Genetics Ultrastructural abnormality 
van 
Wijngaarden 
et al. (1967)  
Deltoid and 
gastrocnemius 
15 years [Pediatric] 
Myopathy without 
muscle atrophy, 
deltoid muscle 
weakened, 
paresis of pelvic 
muscles (n=1). 
N.S. Matrix swelling and electron lucent mitochondria; 
clumped and filamentous, small osmiophilic dense 
bodies present in mitochondrial matrix; larger electron-
dense round granules or irregularly shaped inclusions 
of moderately electron dense granular material. 
(Afifi et al., 
1972) 
N.S. 19 years Hypermetabolic 
“mitochondrial” 
disease. 
Substantial 
muscle 
weakness (n=1). 
N.S. Osmiophilic inclusions of variable size and density 
within mitochondria; dense inclusions replacing most 
of the cristae, with cristae reduced to a thin circular 
rim at the periphery of affected mitochondria.  
(Hudgson et 
al., 1972)  
Peroneus 
longus and 
biceps 
35 years 
(proband) 
and 12 
years 
(niece). 
Familial 
“mitochondrial” 
myopathy. Facial 
and ocular, 
pectoralis major 
and bicep 
weakness, 
considerable 
lower limb 
weakness (n=2). 
Dominant 
inheritance; 
high 
penetrance; 
maternal 
transmission. 
Mutation N.S. 
Giant mitochondria measuring up to 3 µm containing 
concentric cristae and small electron-dense 
inclusions; mitochondria with “parking-lot” type 
inclusions between inner and outer mitochondrial 
membranes; mitochondrial with six layers with 
periodicity between both their transverse and axial 
cristae of approximately 75 A. 
(Adachi et al., 
1973) 
Ocular muscles 37 years CPEO, cerebella 
ataxia and 
N.S. Enlarged mitochondria with parallel or concentric 
cristae. 
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cardiomyopathy 
(n=1). 
Deltoid 37 years 
(same 
individual 
as above) 
CPEO, cerebella 
ataxia and 
cardiomyopathy 
(n=1). 
N.S. Unusually large mitochondria ranging from 5-8 µm in 
greatest diameter with cristae usually located at the 
periphery of the organelle and rectangular inclusions; 
cross sections of the PCI structures disclosed well-
organized arrays of tubules oriented in parallel rows 
with a diameter of 70-80 A, with a lumen of 30-40 A, 
and interspace between the tubules of 20-30 A, 
arranged in a helical pattern; abnormal mitochondria 
almost completely replaced by dense rectangular 
inclusions and occasionally showed complete 
transition to crystalline structures obscuring the 
original mitochondrial morphology. 
(Shibasaki et 
al., 1973) 
Deltoid 60 years Late onset 
myopathy; 
marked atrophy 
of shoulder girdle 
and proximal 
upper limb, pelvic 
and proximal 
lower limb 
muscles; mild 
atrophy of distal 
lower limb 
muscles (n=1). 
N.S. Elongated, giant mitochondria up to 5 µm in greatest 
diameter, particularly in the SS region; PCIs including 
lattice pattern, four-fold array, or amorphous form. 
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(Crosby and 
Chou, 1974) 
Left bicep 10 years [Pediatric] Leigh 
disease (n=1). 
N.S. Enlarged mitochondria (in cross section); whirled 
cristae membranes; electron dense spheroid bodies; 
electron-lucent mitochondrial matrix spaces; complex, 
convoluted membrane systems; PCI within cristae 
membrane. 
(Black et al., 
1975) 
Anterior tibialis 
or Quadriceps 
30 years Mitochondrial 
disorder, RRFs, 
and ptosis (n=1). 
N.S. Enlarged mitochondria with “wavy” cristae and central 
electron dense granular material; round dense 
osmiophilic inclusions; occasional lipid inclusions and 
concentric cristae. 
(Karpati et 
al., 1975) 
Quadriceps 11 years [Pediatric] KSS 
biopsied before 
and after 
Carnitine 
supplementation 
(n=1). 
N.S. PCI; concentric cristae; swollen mitochondria. 
(McLeod et 
al., 1975) 
Quadriceps 
(vastus lateralis) 
27 years Mitochondrial 
myopathy (n=1). 
N.S. PCI with parallel bands of amorphous material 
surrounded by a membrane; mitochondria with 
“empty” electron-lucent spaces; amorphous material 
between the mitochondrial membranes; mitochondria 
containing “empty space” surrounded by double 
membranes. 
(Bastiaensen 
et al., 1979) 
Ocular and 
skeletal 
>30 years 
[review] 
PEO plus. N.S. [Review] Aggregates of swollen mitochondria with 
parallel or concentric cristae. 
(Linden and 
Ansink, 1979) 
Gastrocnemius 11 years [Pediatric] KSS. 
Ptosis, mental 
and physical 
N.S. PCI; large mitochondria. 
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retardation, 
dysarthria (n=1). 
(Fitzsimons 
and Tyer, 
1980) 
Left deltoid 10 and 17 
years 
Mitochondrial 
myopathy. 
Myopathy, 
scoliosis, 
respiratory 
failure. (n=2) 
N.S. Rectangular inclusions, PCI, amorphous material and 
concentric cristae in mitochondria. 
(Fukuhara et 
al., 1980) 
Quadriceps 
femoris 
21 years MERRF. 
Myoclonic jerk, 
seizures, 
hypotonia, ataxia 
(n=1). 
N.S. Electron-lucent homogenous matrix space; enlarged 
mitochondria; markedly proliferated IMM; PCIs. 
(Land et al., 
1981) 
 
Left deltoid 14 years [Pediatric] 
Mitochondrial 
myopathy, 
opthalmoplegia 
(n=1). 
N.S. Mitochondria with “finger-print” like patterns (i.e., 
densely packed parallel cristae); concentric cristae. 
(Shah et al., 
1982) 
Quadriceps N.S. KSS, 
polymyositis, 
neurogenic 
atrophy, 
mitochondrial 
myopathy. 
N.S. PCIs (30-45 nm long and 22-23 nm wide); round or 
oval swollen mitochondria; presence of various 
inclusions; densely packed or tubular cristae 
formation; concentric cristae or “lamellar bodies”; 
parallel destruction of cristae and presence of 
amorphous material. 
(Holliday et 
al., 1983) 
N.S. 18 and 26 
years 
Mitochondrial 
myopathy, 
N.S. Rectangular or curvilinear PCIs composed of four 
parallel lamina within a boundary membrane. 
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encephalopathy 
(n=2). 
(Mitsumoto et 
al., 1983) 
Deltoid 11 to 49 
years 
(m=34.5) 
CPEO with RRF 
(n=8). 
N.S. Mitochondria with absent cristae; irregular vacuoles; 
PCIs; concentric cristae; dark inclusion; whirl 
formation. 
(Müller-
Höcker et al., 
1983) 
N.S. N.S. PEO (n=8). N.S. Enlarged mitochondria with high cristae content; 
concentric cristae and PCIs. 
(Prick et al., 
1983) 
N.S. 2 and 5 
years 
[Pediatric] Alper’s 
disease (n=2). 
N.S. Aggregates of enlarged mitochondria with PCIs in SS 
region. 
(Sarnat et al., 
1983) 
Quadriceps 
femoris, deltoid, 
extensor 
digitorum longus 
of the forearm 
(post mortem) 
3 weeks 
and 4 
months 
[Pediatric] 
Mitochondrial 
myopathy, 
cerebro-hepato 
renal (Zellweger) 
syndrome (n=2). 
N.S. Electron dense granules in mitochondrial matrix; 
myelin figures, degeneration and other degenerative 
changes (e.g. membrane rupture) to mitochondria. 
(Sengers et 
al., 1983) 
Quadriceps 4 years [Pediatric] 
Mitochondrial 
myopathy, 
carnitine 
deficiency (n=1). 
N.S. Large mitochondria with densely packed or whirled 
cristae; granular or fibrillary electron dense material in 
intercristal space. 
(Hayes et al., 
1984) 
Intercostal 
muscle 
20 years Mitochondrial 
myopathy, 
bilateral ptosis, 
muscle bulk 
normal, mild 
N.S. SS mitochondria with concentric cristae and 
inclusions; central droplets of neutral or osmiophilic 
lipid or areas of central necrosis. 
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diffuse weakness 
(n=1). 
(Kennaway et 
al., 1984) 
N.S. 17 years Mitochondrial 
myopathy, lactic 
acidosis (n=1). 
N.S. Abnormally large mitochondria some with PCIs. 
(Bresolin et 
al., 1985) 
Quadriceps 2, 3, 6 and 
7 months 
[Pediatric] 
Mitochondrial 
myopathy, 
hypertonia and 
severe limb 
weakness, 
tendon and 
pharyngeal 
weakness absent 
(n=1). 
N.S. Large mitochondria with irregular or concentric tubular 
cristae. 
(Müller-
Höcker et al., 
1985) 
N.S. 12 years [Pediatric] 
Mitochondrial 
myopathy, 
excercise 
induced muscle 
weakness and 
pain, tachycardia 
and dyspnoea 
(n=1). 
N.S. Swollen mitochondria with PCIs. 
(Niebrój-
Doblosz et 
al., 1985) 
Biceps brachii 
and quadriceps 
7 years [Pediatric] KSS. 
Biceps and 
quadriceps 
N.S. Giant mitochondria; PCIs; concentric cristae. 
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weakness, 
mental 
retardation, 
progressive limb 
weakness (n=1). 
(Fischer et 
al., 2006) 
Quadriceps 17 years Mitochondrial 
enchephalomyop
athy, seizures, 
myoclonic 
contractures, 
retarded motor 
and speech 
development 
(n=1). 
N.S. Small mitochondria with swollen matrix; concentric 
cristae or “concentric laminated bodies”.  
(Lehmann et 
al., 1986) 
Deltoid 44 years Myopathy with 
rimmed vacuoles, 
mild shoulder 
girdle weakness, 
exercise 
intolerance (n=1). 
N.S. PCIs of Type I and II. 
(Stadhouders 
and Sengers, 
1987) 
N.S. N.S. Mitochondrial 
myopathy (KSS, 
MELAS, MERRF) 
N.S. [Review] PCIs and concentric cristae; suggests model 
of PCI formation; classify 2 types of PCI (Type I, Type 
II); suggests different types of PCI for different fibre 
types. 
(van Ekeren 
et al., 1987) 
N.S. 6 days Hereditary 
mitochondrial 
hypertrophic 
N.S. Mitochondria with vesicular inclusions; matrix crystals. 
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cardiomyopathy 
(n=1). 
(Colombo et 
al., 1988) 
Left quadriceps 27 years Mitochondrial 
occuloskeletal 
myopathy (n=1). 
N.S. PCIs; globular dense bodies; cristae running 
concentrically.  
(Dias-Tosta, 
1988) 
N.S. N.S. CPEO. Sporadic 
muscle 
weakness 
(n=10), familial 
isolated 
myopathy (n=9), 
myopathy with 
retinopathy, 
cerebellar ataxia, 
or peripheral 
neuropathy 
(n=15). 
N.S. PCIs; concentric cristae; “parking lot” and “intramural 
type” inclusions. 
(Federico et 
al., 1988) 
Quadriceps N.S. LHON (n=3). N.S. Enlarged mitochondria with PCIs. 
(Mizusawa et 
al., 1988) 
Rectus femoris 
or tibialis 
46 and 48 
years 
Familial 
mitochondrial 
myopathy, pptic 
atrophy, muscle 
wasting, 
weakness (n=2). 
N.S. Aggregates of mitochondria with PCIs; electron dense 
globular bodies; concentric cristae. 
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(Kim et al., 
1989) 
Left deltoid 53 years CPEO. Mild 
proximal limb 
weakness (n=1) 
N.S. PCIs; irregularly orientated cristae. 
(Paulus et al., 
1989) 
Left quadriceps 33 years Mitochondrial 
encephalomyopa
thy with 
perivacuolar 
inclusions, 
bilateral hearing 
loss, seizures, 
cerebral atrophy, 
moderate muscle 
atrophy (n=1). 
N.S. Small osmiophilic rod-like inclusions; piles within 
round or oval vacuoles (perivacuolar inclusions). 
(Rivner et al., 
1989) 
N.S 25 years KSS. Cerebellar 
and cortical 
atrophy, mild 
ataxia and 
generalised 
weakness of 
proximal and 
distal muscles 
(n=1). 
N.S. Deformed internal architecture; PCI arrays; concentric 
cristae or “cristae arranged circumferentially”. 
(Suzuki et al., 
1989) 
Quadriceps 35 years Mitochondrial 
encephalomyopa
thy, general 
muscle atrophy, 
psychiatric 
N.S. Enlarged mitochondria with PCIs. 
  Appendices 
 
330 
 
disturbance 
(n=1). 
(Arruda et al., 
1990) 
Quadriceps 32 and 34 
years 
Mitochondrial 
myopathy with 
myoclonic 
epilepsy. 
Myoclonic jerks 
and seizures 
(n=2). 
N.S. Enlarged mitochondria. 
(Haginoya et 
al., 1990) 
Quadriceps 
(vastus femoris) 
8-43 years 
(m=25) 
MERRF and 
MELAS. Mixed, 
myoclonic 
seizure, ataxia, 
stroke-like 
episodes, ptosis 
(n=3). 
N.S. Aggregated mitochondria in areas of segmental COX 
deficiency. 
(Korenke et 
al., 1990) 
 
N.S. 2 weeks - 
9 years 
(m=2 
years) 
[Pediatric] 
Mitochondrial 
myopathy. 
Mixture; 
respiratory 
insufficiency, 
hypotonia, motor 
retardation and 
feeding problems 
(n=8). 
N.S. Abnormally small and large mitochondria; PCIs; 
polymorphy; altered cristae. 
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(Schapira et 
al., 1990) 
Quadriceps 
(vastus lateralis) 
14 years Mitochondrial 
myopathy. 
Weakness of 
limbs and trunk, 
high CK. 
Defect in 
protein 
transport? 
Molecular 
cause N.S. 
Disordered “labyrinth” cristae with electron dense and 
granular inclusions. 
(Sumegi et 
al., 1990) 
N.S. 45 days [Pediatric] COX 
deficiency. 
N.S. Swollen mitochondria, and often “tennis-racket” like 
mitochondria (swollen at one end); mitochondria with 
honeycomb cristae. 
(Takeda et 
al., 1990) 
Extraocular 
muscles 
14 to 30 
years 
(m=20) 
MELAS and 
MERRF. Mixed 
symptoms (n=3). 
N.S. Mitochondria of irregular shape with tubule-vesicular 
cristae; morphological changes more prominent in 
MELAS than MERRF. No PCI. 
(Kim et al., 
1991) 
N.S. 16 and 22 
years 
Mitochondrial 
myopathy. 
Severe 
respiratory 
dysfunction, mild 
myopathy. 
N.S. Sickle shaped mitochondria containing curvilinear PCI, 
regular PCIs. 
(McKelvie et 
al., 1991) 
Quadriceps 
(vastus lateralis) 
48 years 
(n=1) 
KSS. 
Opthalmoplegia, 
limb weakness, 
ataxia (n=1). 
3.5Kb single 
mtDNA 
deletioni 
PCIs in subsarcolemmal aggregates of mitochondria. 
(Letellier et 
al., 1992) 
 
Deltoid 1 week to 
4 months 
(m=2 
months) 
[Pediatric] 
Mitochondrial 
myopathy. 
Mixture of 
symptoms (n=6). 
N.S. Enlarged and swollen mitochondria. 
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(Linda et al., 
1992) 
 
N.S. N.S. Mitochondrial 
myopathy. 
MELAS (n=3), 
Marinesco-
Sjogren 
syndrome (n=7) 
and KSS (n=2). 
mtDNA 
mutations N.S. 
PCIs; pleoconial mitochondria; enlarged 
“megamitochondria”; thickening, unfolding, and 
parallelization of cristae; concentric cristae or 
“concentric lamellar cristae”; augmented matrix space; 
amorphous inclusion bodies. 
(Modi et al., 
1992) 
Biceps brachii 20 years Mitochondrial 
myopathy. 
Proximal 
myopathy, 
cardiomyopathy, 
bilateral deafness 
and ptosis. 
N.S. Laminated PCIs. 
(Telerman-
Toppet et al., 
1992) 
N.S. 8 weeks [Pediatric] COX 
deficiency and 
mtDNA depletion 
(n=1). 
N.S. PCIs; abnormal spatial arrangement of mitochondrial 
cristae. 
(Angelini et 
al., 1993) 
Biceps and 
quadriceps 
19 and 25 
years 
Hypertrophic 
cardiomyopathy 
with 
mitochondrial 
myopathy. 
Weakness in 
upper limb girdle 
muscles and 
Gower’s signs 
and waddling 
Dystrophin and 
mtDNA 
deletions ruled 
out. Cause 
N.S.i 
Enlarged mitochondria with irregular cristae. 
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gait, no 
cerebellar 
abnormalities 
(n=2). 
(Coquet et 
al., 1993) 
N.S. 15 and 17 
years 
MERRF. 
Myoclonic jerks, 
epileptic 
seizures, ataxia, 
deafness, lower 
limb weakness 
(n=2). 
m.8344A>Ga 
tRNALys 
PCIs; concentric cristae. 
(Reichmann 
et al., 1993) 
Biceps brachii 53 years KSS. Mild 
generalized 
muscle 
weakness and 
exercise 
intolerance, 
diabetes, slowly 
progressive 
ataxia (n=1). 
Multiple 
deletionsb 
(causative 
mutation N.S.)  
PCIs; concentric cristae.  
(Ionasescu et 
al., 1994) 
Quadriceps 
(vastus lateralis) 
9 years [Pediatric] 
MERRF. 
Progressive 
proximal 
weakness (n=1). 
m.15990A>Ga 
tRNAPro 
PCIs. 
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(Norby et al., 
1994) 
Quadriceps 
(vastus 
medialis) 
15 years [Pediatric] KSS.  
Epileptic 
seizures, ataxia, 
myopathy (n=1). 
11Kb single 
mtDNA 
deletionb 
Enlarged mitochondria with PCIs. 
(Stadhouders 
et al., 1994) 
N.S. N.S. CPEO, KKS, 
MELAS 
N.S. PCIs (Types I and II). 
(Gilbert and 
Emms, 1996) 
N.S. 21 months Pearson’s 
syndrome. 
Pancreatic 
atrophy, enlarged 
kidneys, 
metabolic 
acidosis, high 
blood lactate and 
hypomagnesemi
a (n=1). 
N.S. Aggregated SS and IMF mitochondria; concentric 
cristae, enlarged mitochondria with disrupted 
membranes; central follicular (granular) matrix. 
(Melberg et 
al., 1996) 
Quadriceps 
(vastus lateralis) 
or bicularis oculi 
16 to 63 
years 
(m=52 
years) 
Dominant PEO. 
Ocular myopathy, 
hypogonadism 
(n=14). 
Dominant 
genetic cause 
N.S. 
Densely packed cristae; size variation; longitudinally 
or circular cristae; crystalloid-like alterations. 
(Toscano et 
al., 1996) 
N.S. 73 to 75 
years 
(m=74 
years) 
Late-onset 
mitochondrial 
neuropathy. 
Muscle 
weakness and 
cramps, ataxia, 
No mtDNA 
mutations 
foundb,c. 
Genetic cause 
N.S. 
PCIs, enlarged or bizarrely shaped mitochondria. 
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exercise 
intolerance (n=3). 
(van 
Domburg et 
al., 1996) 
Soleus, 
quadriceps, 
ocular rectus 
superior  
25 to 36 
years 
(m=30 
years) 
CPEO plus. 
Ocular myopathy, 
encephalomyopa
thy, sensory 
neuropathy, 
ataxia, 
polyneuropathy 
(n=6). 
No evidence of 
maternal 
inheritance, 
common point 
mutations and 
deletions ruled 
outi. Genetic 
cause N.S. 
PCIs, mitochondria with deranged cristae; concentric 
cristae. 
(Wada et al., 
1996) 
Quadriceps 
femoris 
11 weeks [Pediatric] 
Mitochondrial 
myopathy. 
Muscular 
hyoptonia, 
profound 
acidosis, difficulty 
suckling, no 
muscle 
weakness (n=1). 
N.S. Enlarged mitochondria with sparse cristae; concentric 
cristae. 
(Heiman-
Patterson et 
al., 1997) 
N.S. 4 to 63 
years 
(m=28 
years) 
Family with 
mitochondrial 
myopathy. 
Exercise 
intolerance, 
proximal lower 
limb weakness in 
mtDNA 
deletions and 
common point 
mutations ruled 
out, a number 
of non-
pathogenic 
point mutations 
Uneven and electron dense cristae; globular 
inclusions. 
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first decade of life 
(n=11). 
foundd. 
Genetic cause 
N.S. 
(Kim and Chi, 
1997) 
Deltoid 22 and 23 
years 
KSS. Neck and 
proximal limb 
weakness, 
severe ptosis, AV 
block. 
Single mtDNA 
deletion1,c 
PCIs, enlarged mitochondria with distorted cristae. 
(Smith et al., 
1997) 
Quadriceps N.S. Mother of 
MELAS patient, 
with insulin 
dependent 
diabetes (n=1). 
m.3243A>Ga 
tRNALeu 
Pleomorphic mitochondria; concentric cristae; 
electron-dense bodies. 
(Takahashi et 
al., 1998) 
Quadriceps 
femoris 
9 months [Pediatric] Leigh 
disease. 
Generalized 
hypotonia at 
birth, apnea 
attacks, irregular 
breathing, poor 
head control 
(n=1). 
m.8993T>Ga 
MT-ATP6 
Variably sized mitochondria; aberrant cristae. 
(Castro-Gago 
et al., 1999) 
Deltoid Fetus Hydranencephali
c-hydrocephalic 
syndrome in 
association with 
mitochondrial 
Common 
mtDNA point 
mutations and 
deletions ruled 
Enlarged SS mitochondria; abnormal cristae (honey-
comb-like). 
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encephalomyopa
thy. 
outi. Genetic 
cause N.S. 
(Kyriacou et 
al., 1999) 
 
N.S. 6 days to 
10 years 
(m=2 
years) 
[Pediatric] 
Mitochondrial 
enchephalomyop
athy. Hypotonia 
and psychomotor 
retardation (n=5), 
multisystemic 
(n=2), Pearson 
syndrome (n=1), 
Leigh disease 
(n=1).  
(Adult) Myalgia 
and proximal limb 
weakness (n=8), 
PEO (n=3). 
N.S. Pleomorphic mitochondria; simplified cristae; vesicular 
cristae. 
(Melegh et 
al., 1999) 
N.S. 5 months Mitochondrial 
enchephalomyop
athy. Myoclonic 
jerk, 
uncoordinated 
eye movement 
(n=1). 
Multiple 
mtDNA 
deletionsb. 
Nuclear 
mutation N.S. 
Enlarged mitochondria with no or few cristae. 
(Carta et al., 
2000) 
Quadriceps 
(rectus medialis) 
48 years CPEO (n=1) Single common 
mtDNA 
deletion1,b 
PCIs; “onion-like” concentric cristae, “ghost-like” 
mitochondria (devoid of cristae). 
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(Makino et 
al., 2000) 
 
N.S. N.S. Leigh syndrome. 
Hypotonia, 
necrotic lesions 
in basal ganglia 
and brainstem 
(n=1). 
m.8993T>Ga 
MT-ATP6 
Enlarged mitochondria. 
(Wang et al., 
2000) 
N.S. 9 years No prominent 
muscle 
weakness or 
hypotonia, but 
wobbling gait 
early on. 
Proximal limb 
myopathy 1 
month prior to 
biopsy (n=1).  
N.S. Loss of matrix and cristae. 
(De Kremer 
et al., 2001) 
N.S N.S. [Pediatric] Barth-
syndrome like 
disorder, marked 
muscle 
weakness. 
m.3243A>Gd 
tRNALeu 
Round swollen mitochondria; fine fibrillary matrix; 
poorly define cristae. 
(Higashikata 
et al., 2001) 
Biceps brachii 80 years MELAS. 
Cardiomyopathy. 
m.3243A>Ga  
tRNALeu 
Aggregates of enlarged mitochondria with PCIs. 
(Rollins et al., 
2001) 
N.S. 1 to 70 
years 
(m=12.5 
years) 
Mitochondrial 
cytopathy 
(n=113) 
Mutation of  
“maternal 
inheritance” 
N.S. 
PCI; enlarged mitochondria. 
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(Vogel, 2001) N.S. N.S. Mitochondrial 
myopathy 
N.S. [Review] Swollen, elongated, devoid of cristae, PCIs. 
(Fagiolari et 
al., 2002) 
N.S. 27 to 73 
years 
(m=55 
years) 
CPEO (n=7), 
PEO and ptosis 
(n=7), myopathy 
(n=1). 
Multiple 
mtDNA 
deletionsb due 
to ANT1 
mutation – 
p.114A>P and  
p.98L>Pi 
Mitochondrial proliferation and PCIs. 
(Fillano et al., 
2002) 
N.S. 2 to 12 
years 
(m=7 
years) 
HEADD 
syndrome 
(hypotonia, 
epilepsy, autism, 
and 
developmental 
delay) (n=3) 
Multiple 
mtDNA 
deletionsc 
(nuclear cause 
N.S.) or 7.4Kb 
single mtDNA 
deletionc 
Stacked cristae; electron dense deposits. 
(Kim et al., 
2002) 
Biceps brachii 18 Years MERRF. 
Myoclonic 
epilepsy, 
myopathy, ataxia, 
dysarthria (n=1). 
m.8344A>Ge 
tRNALys 
PCI; concentric cristae. 
(Marín-
García et al., 
2002) 
N.S. 15 years PEO (n=1) Multiple 
mtDNA 
deletionsb 
Vacuolated cristae; variation in size and morphology. 
(Nevo et al., 
2002) 
Quadriceps 11 to 26 
months 
[Pediatric] 
Mitochondrial 
myopathy. Motor 
TK2 mutation 
causing 
Pleomorphic mitochondria; enlarged mitochondria; 
concentric cristae or “concentric lamellae”. 
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(m=16 
months) 
deterioration, 
dyspneic, muscle 
weakness, 
bilateral ptosis. 
mtDNA 
depletioni 
(Kyriakides et 
al., 2003) 
 
N.S. 6 days to 
18 months 
(m=6 
months, 
n=19), 19 
to 75 years 
(m=42 
years, 
n=14) 
Mitochondrial 
encephalomyopa
thies: myopathic, 
multisystemic or 
CPEO. Pediatric 
(n=19) and adult 
(n=14). 
N.S. Mitochondrial dysmorphology more common in 
children than adults and vice versa. 
(Uusimaa et 
al., 2003) 
N.S. 10 months Alpers-
Huttenlocher-like 
disease (n=1) 
 
m.7706G>Ad 
MT-COII 
Enlarged mitochondria; variable shape and size. 
(Mierau et al., 
2004) 
Quadriceps 8 years [Pediatric] Lactic 
acidosis, 
proximal 
weakness, 
cognitive delay.  
N.S. PCIs; enlarged or abnormally small; concentric 
cristae; parking lot type inclusions; spherical electron 
dense inclusions. 
(Patterson, 
2004) 
N.S. 16 years KSS. 5Kb mtDNA 
deletionf 
PCIs. 
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(Carta et al., 
2005) 
Quadriceps 
(rectus medialis) 
42 to 75 
years 
(m=63 
years) 
CPEO and LHON 
(n=3) 
Single common 
mtDNA 
deletion1,i 
“Ghost” mitochondrial profiles (lack of cristae) with 
partial to complete matrix emptying rearrangement of 
the cristae with an “onion ring-like” appearance  
(Coulbault et 
al., 2005) 
N.S. 10 months [Pediatric] 
Psychomotor 
retardation, 
failure to thrive, 
hypotonia, 
hepatocellular 
dysfunction, 
thrombocytopeni
a. Multiple organ 
failure (lethal) 
(n=1). 
m.5693T>Ce, 
tRNAASN 
PCIs; stacked cristae. 
(Dinopoulos 
et al., 2005) 
Quadriceps 1 to 15 
months 
(n=9 
months) 
[Pediatric] 
Hypotonia, 
myoclonic 
epilepsy, 
cardiomyopathy, 
psychomotor 
regression, 
failure to thrive, 
lactic acidosis 
(mixed) (n=4). 
NDUFS2 
c.237T>C, 
NDUFS8  
c.236C>T and 
c.302G>A, 
NDUFVI  
c.175C>X and 
c.1268C>T 
mutations (CI)i 
Concentric cristae or “concentric laminated bodies”; 
osmiophilic mitochondria. 
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(Enns et al., 
2005) 
Quadriceps 
(vastus 
lateralis)  
and deltoid 
6 weeks to 
5 years 
(m=1.5 
years) 
Electron 
transport chain 
abnormalities, 
RRFs. (n=7) 
N.S. Enlarged mitochondria; swelling with electron-lucent 
matrix space; proliferation of mitochondria; elongated 
and branched.  
(Güçer et al., 
2005) 
N.S. 4 months 
and 9 
years 
[Pediatric] 
Seizures, ptosis, 
failure to thrive, 
high serum 
lactate and 
pyruvate, RRF 
(n=2). 
Single common 
mtDNA 
deletion1,b 
Increased matrix density and cristae; SS mitochondrial 
accumulation. 
(Karppa et 
al., 2005) 
Quadriceps 
(vastus lateralis) 
or tibialis 
anterior 
16 to 70 
years 
(m=45 
years) 
MELAS m.3243A>Gi 
tRNALeu 
PCIs (Types I and II); variation in size and 
ultrastructure. 
(Kyriacou et 
al., 2005) 
N.S. 6 days to 
18 years 
(median= 
4 years, 
n=31) and 
19 to 75 
years 
(median= 
46 years, 
n=17) 
Mitochondrial 
encephalomyopa
thy (n=48). 
N.S. Elongated and enlarged mitochondria more common 
in children than adults; subsarcolemmal aggregation 
of mitochondrial (RRF) more common in adults. 
(Pulkes et al., 
2005) 
N.S. 16 and 23 
years 
MERRF. 
Proximal upper 
m.7472_insCi  
tRNASer 
Type 2 fibres larger and dense matrix components 
and contain either or both type 1 or 2 crystalline intra-
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and lower limb 
weakness, 
ataxia, seizures 
and myoclonus 
(n=2).  
  
membranous inclusions. Type 1 myofiber 
mitochondria, have many large and abnormal forms, 
show a more orderly arrangement of their cristae, a 
lesser quantity of less dense matrix, and only type 1 
intra-membranous crystalline inclusions. 
(Stenqvist et 
al., 2005) 
Quadriceps 
(vastus 
lateralis)  
10 years [Pediatric] 
MELAS. Mild 
central and 
cortical brain 
atrophy, 
encephalopathy, 
no mention of 
myopathy (n=1). 
m.3271T>Cf 
tRNALeu 
Dense granular inclusions, parallel cristae arrays, 
open matrix spaces. 
(Zeharia et 
al., 2005) 
 
N.S. 19 years Mitochondrial 
myopathy (n=1). 
Autosomal 
recessive 
PUS1d 
PCIs. 
(Cardaioli et 
al., 2006) 
Quadriceps 31 years Deafness, mental 
retardation, brain 
atrophy (n=1). 
m.7472insCe  
tRNAser (UCN) 
and 
m.7472A>Ce  
tRNAser (UCN) 
Swollen mitochondria with reduced cristae and PCIs. 
(Deschauer 
et al., 2006) 
N.S. 66 years Exercise 
intolerance, 
walking difficulty, 
muscle cramps, 
m.622G>Ad 
tRNAPhe 
Enlarged mitochondria with PCIs. 
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hearing 
impairment, mild 
myopathy and 
peripheral 
neuropathy 
(n=1). 
(Miles et al., 
2006) 
N.S. 2 weeks to 
21 years 
(median=2
.7 years) 
KSS (n=4), Leigh 
syndrome (n=2), 
lethal infantile 
COX deficiency 
(n=2), MERRF 
(n=1), 
encephalopathy 
with (n=72) and 
without myopathy 
(n=46). 
N.S. PCIs; abnormal patterns of cristae; concentric cristae 
or “circular cristae” and fingerprint cristae; abnormal 
matrix density. 
(Saneto and 
Bouldin, 
2006) 
N.S. 11 years [Pediatric] 
Muscle 
weakness, 
hypercarbia, 
lactic acidosis, 
absent deep 
tendon reflexes, 
respiratory 
difficulty (n=1). 
m.3243A>Gi 
tRNALeu 
Enlarged rounded mitochondria; distorted cristae; 
electron dense inclusions. 
(Thajeb et al., 
2006) 
N.S. 65 years Oculopharangyl 
somatic 
myopathy, 
Single mtDNA 
deletionc,d and 
homoplasmic 
“Parking lot” type PCIs. 
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bilateral ptosis 
and difficulty 
swallowing (n=1). 
m.5814T>Cd 
tRNACys 
 
(Wabbels et 
al., 2007) 
M. levator 
palpebrae, 
and/or the M. 
orbicularis oculi 
4 to 81 
years 
(m=40 
years) 
Adult/child 
Ptosis/CPEO 
(n=21).  
N.S. PCIs; concentric and wavy cristae; pleomorphy; 
intermitochondrial granules. 
(Perry and 
Sladky, 2008) 
Quadriceps 3 days [Pediatric] 
Sengers 
syndrome. 
Bilateral ptosis, 
hypotonia, trace 
reflexes, skeletal 
muscle myopathy 
and 
cardiomyopathy 
(n=1). 
N.S. Diffuse dysmorphic mitochondria. 
(Pronicki et 
al., 2008) 
Quadriceps 
(vastus 
lateralis)  
9 months 
to 12 years 
(m=3.5 
years) 
[Pediatric)] Leigh 
Syndrome. Motor 
regression, 
bulbar 
symptoms, 
difficulty walking, 
hypotonia, failure 
to thrive, 
floppiness, 
disturbed eye 
SURF1i 
mutation 
Enlarged or elongated mitochondria; dark matrix with 
densely packed, concentric lamellae cristae; 
mitochondrial matrix displaced by amorphous granular 
material; small electron-dense osmiophilic granules. 
  Appendices 
 
346 
 
movement 
(n=21). 
(Yerdelen et 
al., 2008) 
Biceps brachii 38 years KSS. Delayed 
motor and mental 
development, 
arrhythmia (n=1).  
N.S. PCIs; swollen mitochondria with few electron dense 
cristae; osmiophilic and electron-dense structures. 
(Abu-Amero 
et al., 2009) 
N.S. 34 years MELAS (n=1) No mtDNA 
mutations or 
POLG 
mutations. 
Genetic cause 
N.S. 
Mitochondria with parallel cristae and PCIs, 
osmiophilic inclusions and mitochondrial vacuoles. 
(DeBrosse et 
al., 2009) 
Deltoid 67 years CPEO. Ptosis, 
mild upper limb 
weakness, mild 
memory difficulty 
and imbalance 
(n=1). 
N.S. PCIs; dystrophic mitochondria. 
(Yau et al., 
2009) 
Quadriceps 14 years [Pediatric] KSS, 
short stature, 
mental 
deficiency, lower 
limb weakness, 
mild ataxic gait 
(n=1).  
Single 7.2Kb 
mtDNA 
deletionc 
PCIs; irregular structure and cristae; central core-like 
fibres (IMF mitochondrial depletion). 
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(Ali et al., 
2010) 
Triceps brachii 62 years CPEO. Diplopia, 
no muscle 
weakness (n=1). 
Single mtDNA 
deletion1,b,c,d 
PCIs (Type I); swollen rounded mitochondria. 
(Ascaso et 
al., 2010) 
N.S. 48 years KSS. Bilateral 
ptosis, proximal 
muscle 
weakness and 
RRFs (n=1). 
Single mtDNA 
deletion1b,c,d 
Large atypical mitochondria; round electron dense 
bodies. 
(Cardenas 
and Amato, 
2010) 
N.S. 14 years [Pediatric] Alpers 
disease. 
Neuropathalogica
l degeneration of 
cerebral grey 
matter (n=1). 
POLG 
mutations 
(compound 
heterozygous)  
c.911T>G (p. 
L304R), 
c.1174C>G 
(p.L392V)  and 
a duplication 
(pR1081dup)f 
Reduced mitochondrial content, absence of cristae, 
vacuolization. 
(Chi et al., 
2010) 
Quadriceps 1 month to 
15 years 
(median=1
5 months, 
n=69) 
[Pediatric] Leigh 
disease (n=6).  
m.8993T>G 
(n=3) MT-
ATP6, 
m.8993T>C 
MT-ATP6 
(n=1), 
m.10191T>C 
MT-ND3 (n=1) 
and 
Tubular cristae; swollen mitochondrial accumulation; 
variable shapes; concentric “whirl” cristae; inclusion 
bodies. 
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m.8344A>G 
(n=1)c,d,e 
[Pediatric] 
MELAS (n=4). 
m.3243A>G 
tRNALeu 
(n=4)c,d,e 
[Pediatric] 
Pearson 
syndrome (n=1) 
6 Kb mtDNA 
deletion 
(n=1)c,d,e 
Mixed 
mitochondrial 
disease (n=58) 
Genetic cause 
N.S. 
(Han et al., 
2010) 
Rectus femoris 4 to 48 
years 
(m=N.S) 
Spinocerebellar 
ataxia type 7. 
Unsteady gait, 
visual problems, 
cerebellum and 
brain stem 
atrophy (n=34). 
SCA7 
mutationc CAG 
repeat 
Mitochondrial with tubular or absent cristae. 
(Herrero-
Marti et al., 
2010) 
 
N.S. 50 years MELAS MERRF 
overlap (n=1)  
m.5521G>Ag 
tRNATrp 
PCIs. 
(Lang et al., 
2010) 
Ocular medial 
rectus 
47 and 67 
years 
CPEO, ptosis, 
exercise 
intolerance and 
Multiple 
mtDNA 
deletionsi 
Enlarged mitochondria; hypertrophic concentric 
lamellar cristae. 
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mild myopathy 
(n=2). 
(nuclear 
mutation not 
defined) 
(Baskin et al., 
2011) 
N.S. 9 years Mitochondrial 
myopathy. 
Myopathic 
findings by 
electromyograph
y, deafness, 
ocular and 
neurological 
findings (n=1). 
NPHS3g 
mutation 
Abnormal mitochondrial shape and cristae patterns. 
(Cenacchi et 
al., 2011) 
 
Quadriceps, 
Tricep, deltoid 
19 to 79 
years 
(m=56 
years) 
Mitochondrial 
myopathy (=14). 
N.S. Accumulation of SS mitochondria; rounded, 
elongated, or cup-shaped mitochondria; abnormally 
large or “mega-mitochondria”; concentric cristae; lipid-
dense; PCIs in matrix. 
(Conway et 
al., 2011) 
gastrocnemius 29 years MELAS. 
Seizures, hearing 
loss (n=1). 
m.3243A>Gi 
tRNALeu 
Abnormally arranged cristae and aberrant electron 
density. 
(Schaaf et 
al., 2011) 
N.S. 3 and 8 
years 
Optic nerve 
atrophy, 
hypotonic, ataxia 
(n=2). 
OPA1 mutation  
c.2708_2711de
lTTAG 
(p.V903GfsX3) 
and 
c.1146A>G 
(p.I382M)d 
Mitochondrial with dense osmiophilic bodies. 
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(Blakely et 
al., 2012) 
Quadriceps 21 years Neuropathy and 
leukoencephalop
athy, walking 
difficulties, distal 
numbness, 
muscle wasting 
of hands and 
distal lower limbs 
(n=1). 
MPV17 
mutationd 
causing 12.5Kb 
mtDNA 
deletionc 
Enlarged, “parking lot” type inclusions. 
(Bostan et 
al., 2012) 
Deltoid 52 years Ptosis, ataxia, 
neuropathy, 
gastroparesis, 
myopathy (n=1).  
POLG 
mutationi 
PCIs. 
(Gotz et al., 
2012) 
N.S. 5 days [Pediatric] Fatal 
neonatal lactic 
acidosis (n=1). 
m.7453G>Ad 
tRNASer 
Enlarged and swollen mitochondria, concentric 
cristae. 
(Kendall, 
2012) 
Multiple N.S. Multiple 
mitochondrial 
disorders. 
N.S. [Review] Previous reports suggest electron 
microscopy is not a good diagnostic tool. However 
other sources report the frequency of 30-44% of 
aberrant mitochondrial morphology in pediatric 
mitochondrial disease and conclude its usefulness. 
(Pfeffer et al., 
2012) 
Levator 
palpebrae 
34 to 72 
years 
(m=52 
years) 
CPEO (n=8) POLG1 (n=1), 
single mtDNA 
deletion (n=4), 
multiple 
mtDNA 
Large mitochondrial aggregates, pleomorphism, 
various inclusions. 
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deletion (n=1, 
NS (n=2)b,c,e  
(Roefs et al., 
2012) 
Orbicularis 46 to 64 
years 
(m=58 
years) 
Progressive 
bilateral ptosis 
and generalised 
muscle 
weakness (n=3). 
Single mtDNA 
deletionb,c 
Enlarged mitochondria; densley packed parallel 
cristae; electron dense inclusions. 
(Baric et al., 
2013) 
Deltoid 17 years Elevated CK, 
mild myopathy in 
brachial muscles. 
m.5522G>Ac,g 
tRNATrp 
Swollen globular looking mitochondria, occasional 
branching and angular OMM. 
(Lopez et al., 
2013) 
Tibialis anterior 22 years [Pediatric] Fatal 
infantile 
mitochondrial 
DNA depletion 
(n=1). 
TK2 
mutationc,g 
Elongated mitochondria with PCIs. 
(Lu and 
Huang, 2013) 
Biceps brachii 1 to 13 
years 
(m=8 
years) 
MELAS (n=6) m.3243A>Gi 
tRNALeu 
Globualar looking mitochondrial shape elongated with 
swollen regions and PCIs. 
(Nolte et al., 
2013) 
N.S. 16 and 17 
years 
Seizures, 
myoclonic jerk, 
PEO (n=2). 
POLG1  
c.2243G>C 
(p.W748S) and 
c.1879C>T 
(p.R627W)g 
Elongated mitochondria with “globoid” inclusions 
(amorphous lipid-like); SS mitochondrial accumulation 
or “aggregates”. 
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(Polimeno et 
al., 2013) 
N.S. N.S. Mitochondrial 
myopathy (other 
symptoms N.S.). 
N.S. PCIs; mitochondria assuming bizarre and/or giant 
forms. 
(Siriwardena 
et al., 2013) 
N.S. 15 months Sengers 
syndrome (n=1) 
AGK mutationg Pentagonal mitochondrial crystals with a dense outer 
layer. 
(Yuan et al., 
2013) 
N.S. 51 and 54 
years 
RRF, rimmed 
vacuoles, muscle 
weakness in 
facial, cervical 
and proximal 
muscles, wasting 
of shoulder girdle 
(n=2). 
m.8344A>Gd 
tRNALys 
PCIs; Mitochondrial proliferation, concentric cristae. 
(Zhao et al., 
2013) 
Biceps brachii 66 years CPEO, RRF and 
diffuse muscle 
weakness 
(n=1)g. 
Large 4Kb 
mtDNA 
mutation 
PCIs. 
(Chen et al., 
2014) 
N.S. 44 years CPEO, ptosis, 
diplopia, bulbar 
paresis, 
inflammatory 
myopathy, neck 
muscle 
weakness (n=1). 
Single mtDNA 
deletion1,h 
PCIs preferentially in SS mitochondria. 
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(Hopmann et 
al., 2014) 
N.S. 72 years Mitochondrial 
myopathy, 
muscle atrophy 
and proximal 
weakness of 
arms trunk and 
legs (n=1). 
Multiple 
mtDNA 
deletionsb,c 
“Parking lot” inclusions; swollen aggregated 
mitochondria; loss of cristae. 
(Chatfield et 
al., 2015) 
N.S. 2 months Mild 
enchephalomyop
athy, diffusion of 
the perirolandic 
white matter 
(n=1). 
HSD10 
mutationg  
c.740A>G  
(p.N247S) 
Loss of cristae; swollen vacuolated mitochondria. 
(Nozuma et 
al., 2015) 
N.S. 32 and 76 
years 
Mitochondrial 
myopathy, limb 
weakness and 
general fatigue, 
high CK, myalgia 
(n=2). 
16 non-
pathogenic 
mtDNA 
alterationsi: 
Pathogenic 
N.S. 
Accumulation of mitochondria, vacuolated 
mitochondria. 
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